



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A01H 1/00, C07H 21/04, C07K 14/00, C12N 5/04, 5/10, C12P 19/34, C12Q 1/68		A1	(11) International Publication Number: WO 98/30083 (43) International Publication Date: 16 July 1998 (16.07.98)
(21) International Application Number: PCT/US98/00615		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 9 January 1998 (09.01.98)		Published <i>With international search report.</i>	
(30) Priority Data: 08/781,734 10 January 1997 (10.01.97) US			
(71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612 (US).			
(72) Inventors: SHEN, Kathy; 44228 Country Club Drive, El Macero, CA 95618 (US). MEYERS, Blake; 904 Drake Drive, Davis, CA 95616 (US). MICHELMORE, Richard, W.; 36757 Russel Boulevard, Davis, CA 95616 (US).			
(74) Agents: EINHORN, Gregory, P. et al.; Townsend and Townsend and Crew LLP, 8th floor, Two Embarcadero Center, San Francisco, CA 94111 (US).			

(54) Title: RG NUCLEIC ACIDS FOR CONFERRING DISEASE RESISTANCE TO PLANTS

(57) Abstract

The present invention provides RG nucleic acids and proteins which confer disease resistance to plants. The nucleic acids can be used to produce transgenic plants resistant to pests. Antibodies to proteins of the invention are also provided.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

RG NUCLEIC ACIDS FOR CONFERRING DISEASE RESISTANCE TO PLANTS

5

10 The present application is a continuation-in-part application ("CIP") of U.S. Patent Application Serial No. ("USSN") 08/781,734, filed January 10, 1997. The aforementioned application is explicitly incorporated herein by reference in its entirety and for all purposes.

15 This invention was made with Government support under Grant Nos. 92-37300-7547 and 95-37300-1571, awarded by the United States Department of Agriculture.

15 The Government has certain rights in this invention.

FIELD OF THE INVENTION

20 The present invention relates generally to plant molecular biology. In particular, it relates to nucleic acids and methods for conferring pest resistance in plants. particularly lettuce.

BACKGROUND OF THE INVENTION

Recently, several resistance genes have been cloned by several groups from 25 several plants. Many of these genes are sequence related. The derived amino acid sequences of the most common class, *RPS2*, *RPM1* (bacterial resistances in *Arabidopsis* (Mindrinos *et al.* *Cell* 78:1089-1099 (1994)); Bent *et al.* *Science* 265:1856-1860 (1994); Grant *et al.*, *Science* 269:843-846 (1995)), *L6* (fungal resistance in flax; Lawrence, *et al.*, *The Plant Cell* 7:1195-1206 (1995)), and *N*, (virus resistance in tobacco; Whitham, *et al.*, *Cell* 78:1101-1115 (1994); and U.S. Patent No. 5,571,706), all contain leucine-rich 30 repeats (LRR) and nucleotide binding sites (NBS).

The NBS is a common motif in several mammalian gene families encoding signal transduction components (e.g., *Ras*) and is associated with ATP/GTP-binding sites.

The NBS is a common motif in several mammalian gene families encoding signal transduction components (e.g., *Ras*) and is associated with ATP/GTP-binding sites.

LRR domains can mediate protein-protein interactions and are found in a variety of proteins involved in signal transduction, cell adhesion and various other functions. LRRs are leucine rich regions often comprising 20-30 amino acid repeats where leucine and other aliphatic residues occur periodically. LRRs can function extracellularly or intracellularly.

Since the onset of civilization, plant diseases have had catastrophic effects on crops and the well-being of the human population. Plant diseases continue to effect enormous human and economic costs. An increasing human population and decreasing amounts of arable land make all approaches to preventing and treating plant pathogen destruction critical. The ability to control and enhance a plant's protective responses against pathogens would be of enormous benefit. Tissue-specific and temporal control of mechanisms responsible for plant cell death would also be of great practical and economic value. The present invention fulfills these and other needs.

What is needed in the art are plant disease resistance genes and means to create transgenic disease resistance plants, particularly in lettuce. Further, what is needed in the art is a means to DNA fingerprint cultivars and germplasm with respect to their disease resistance haplotypes for use in plant breeding programs. The present invention provides these and other advantages.

SUMMARY OF THE INVENTION

The present invention provides isolated nucleic acid constructs. These constructs comprise an RG (resistance gene) polynucleotide which encodes an RG polypeptide having at least 60% sequence identity to an RG polypeptide selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, and an RG4 polypeptide. RG1, RG2, RG3, RG4, and the like, represent individual "RG families." Each "RG family," as defined herein, is a group of polypeptide sequences that have at least 60% amino acid sequence identity. Individual members of an RG family, *i.e.*, individual species of the genus, typically map to the same genomic locus. The invention provides for constructs comprising nucleotides encoding the RG families of the

invention, which can include sequences encoding a leucine rich region (LRR), and/or a nucleotide binding site (NBS), or both.

The invention provides for an isolated nucleic acid construct comprising an RG polynucleotide which encodes an RG polypeptide having at least 60% sequence identity to an RG polypeptide from an RG family selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, an RG4 polypeptide, an RG5 polypeptide, and an RG7 polypeptide. In alternative embodiments, the nucleic acid construct comprises an RG polynucleotide which encodes an RG polypeptide comprising an leucine rich region (LRR), or, an RG polypeptide comprising a nucleotide binding site (NBS). The nucleic acid construct can comprise a polynucleotide which is a full length gene. In another embodiment, the nucleic acid construct encodes a fusion protein.

In one embodiment, the nucleic acid construct comprises a sequence encoding an RG1 polypeptide. The RG1 polypeptide can be encoded by a polynucleotide sequence selected from the group consisting of SEQ ID NO:1 (RG1A), SEQ ID NO:2 and SEQ ID NO:137 (RG1B), SEQ ID NO: 3 (RG1C), SEQ ID NO:4 (RG1D), SEQ ID NO:5 (RG1E), SEQ ID NO:6 (RG1F), SEQ ID NO:7 (RG1G), SEQ ID NO:8 (RG1H), SEQ ID NO:9 (RG1I), and SEQ ID NO:10 (RG1J).

In another embodiment, the nucleic acid construct comprises a sequence encoding an RG2 polypeptide. The RG2 polypeptide can be encoded by a polynucleotide sequence selected from the group consisting of: SEQ ID NO:21 and SEQ ID NO:27 (RG2A); SEQ ID NO:23 and SEQ ID NO:28 (RG2B); SEQ ID NO:29 (RG2C); SEQ ID NO:30 (RG2D); SEQ ID NO:31 (RG2E); SEQ ID NO:32 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:34 (RG2H); SEQ ID NO:35 (RG2I); SEQ ID NO:36 (RG2J); SEQ ID NO:37 (RG2K); SEQ ID NO:38 (RG2L); SEQ ID NO:39 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104 (RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W).

In other embodiments, the nucleic acid construct comprises a RG3 sequence (SEQ ID NO:68) encoding an RG3 polypeptide (SEQ ID NO:138) (RG3). In other embodiments, the nucleic acid construct comprises an RG4 sequence (SEQ ID NO:69) encoding an RG4 polypeptide (SEQ ID NO:139) (RG4).

5 In other embodiments, the nucleic acid construct comprises a RG5 sequence (SEQ ID NO:134) encoding an RG5 polypeptide (SEQ ID NO:135). The RG5 polypeptide can be encoded by a polynucleotide sequence as set forth in SEQ ID NO:134.

10 The invention also provides for a nucleic acid construct which comprises an RG7 sequence encoding an RG7 polypeptide. The RG7 polypeptide can be encoded by a polynucleotide sequence as set forth in SEQ ID NO:136.

15 In further embodiments, the nucleic acid construct can further comprise a promoter operably linked to the RG polynucleotide. In alternative embodiments, the promoter can be a plant promoter; a disease resistance promoter; a lettuce promoter; a constitutive promoter; an inducible promoter; or, a tissue-specific promoter. The nucleic acid construct can comprise a promoter sequence from an RG gene linked to a heterologous polynucleotide.

20 The invention also provides for a transgenic plant comprising a recombinant expression cassette comprising a promoter operably linked to an RG polynucleotide. The expression cassette can comprise a plant promoter or a viral promoter; the plant promoter can be a heterologous promoter. In one embodiment, the transgenic plant is lettuce. In alternative embodiments, the transgenic plant comprises an expression cassette which includes an RG polynucleotide selected from the group consisting of SEQ ID NO:1 (RG1A); SEQ ID NO:2 and SEQ ID NO:137 (RG1B); SEQ ID NO:3 (RG1C); SEQ ID NO:4 (RG1D); SEQ ID NO:5 (RG1E); SEQ ID NO:6 (RG1F); SEQ ID NO:7 (RG1G);
25 SEQ ID NO:8 (RG1H); SEQ ID NO:9 (RG1I) and SEQ ID NO:10 (RG1J); SEQ ID NO:21 and SEQ ID NO:27 (RG2A); SEQ ID NO:23 and SEQ ID NO:28 (RG2B); SEQ ID NO:29 (RG2C); SEQ ID NO:30 (RG2D); SEQ ID NO:31 (RG2E); SEQ ID NO:32 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:34 (RG2H); SEQ ID NO:35 (RG2I); SEQ ID NO:36 (RG2J); SEQ ID NO:37 (RG2K); SEQ ID NO:38 (RG2L); SEQ ID NO:39 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104

(RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W); SEQ ID NO:68 (RG3); SEQ ID NO:69 (RG4); SEQ ID NO:134 (RG5); or SEQ ID NO:136 (RG7).

The invention provide for a transgenic plant comprising an expression cassette comprising an RG polynucleotide which can encode an RG1 polypeptide selected from the group consisting of SEQ ID NO:11 (RG1A), SEQ ID NO:12 (RG1B), SEQ ID NO:13 (RG1C), SEQ ID NO:14 (RG1D), SEQ ID NO:15 (RG1E), SEQ ID NO:16 (RG1F), SEQ ID NO:17 (RG1G), SEQ ID NO:18 (RG1H), SEQ ID NO:19 (RG1I), or SEQ ID NO:20 (RG1J); or, an RG2 polypeptide selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W); an RG4 polypeptide as set forth by SEQ ID NO:72; an RG5 polypeptide with a sequence as set forth by SEQ ID NO:135; or, an RG7 polypeptide.

The invention also provides for a method of enhancing disease resistance in a plant, the method comprising introducing into the plant a recombinant expression cassette comprising a promoter functional in the plant and operably linked to an RG polynucleotide sequence. In this method, the plant can be a lettuce plant; and, the RG polynucleotide can encode an RG polypeptide selected from the group consisting of an RG1 polypeptide selected from the group consisting of SEQ ID NO:11 (RG1A), SEQ ID NO:12 (RG1B), SEQ ID NO:13 (RG1C), SEQ ID NO:14 (RG1D), SEQ ID NO:15 (RG1E), SEQ ID

NO:16 (RG1F), SEQ ID NO:17 (RG1G), SEQ ID NO:18 (RG1H), SEQ ID NO:19 (RG1I), or SEQ ID NO:20 (RG1J); or, an RG2 polypeptide selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:72; SEQ ID NO:74; SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W). In this method, the promoter can be a plant disease resistance promoter, a tissue-specific promoter, a constitutive promoter, or an inducible promoter.

The invention also provides for a method of detecting RG resistance genes in a nucleic acid sample, the method comprising: contacting the nucleic acid sample with an RG polynucleotide to form a hybridization complex; and, wherein the formation of the hybridization complex is used to detect the RG resistance gene in the nucleic acid sample. In this method, the RG polynucleotide can be an RG1 polynucleotide, an RG2 polynucleotide, an RG3 polynucleotide, an RG4 polynucleotide, an RG5 polynucleotide or an RG7 polynucleotide. In this method, the RG resistance gene can be amplified prior to the step of contacting the nucleic acid sample with the RG polynucleotide, and, the RG resistance gene can be amplified by the polymerase chain reaction. In one embodiment, the RG polynucleotide is labeled.

The invention further provides for an RG polypeptide having at least 60% sequence identity to a polypeptide selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, an RG4 polypeptide, an RG5 polypeptide, and an RG7 polypeptide.

A further understanding of the nature and advantages of the present invention may be realized by reference to the remaining portions of the specification, the figures and claims.

5 All publications, patents and patent applications cited herein are hereby expressly incorporated by reference for all purposes.

DETAILED DESCRIPTION OF THE INVENTION

This invention relates to families of RG genes, particularly from *Lactuca sativa*. Nucleic acid sequences of the present invention can be used to confer resistance in 10 plants to a variety of pests including viruses, fungi, nematodes, insects, and bacteria. Sequences from within the RG genes can be used to fingerprint cultivars or germplasm for the presence of desired resistance genes. Promoters of RG genes can be used to drive 15 heterologous gene expression under conditions in which RG genes are expressed. Further, the present invention provides RG proteins and antibodies specifically reactive to RG 20 proteins. Antibodies to RG proteins can be used to detect the type and amount of RG protein expressed in a plant sample.

The present invention has use over a broad range of types of plants, including species from the genera *Cucurbita*, *Rosa*, *Vitis*, *Juglans*, *Fragaria*, *Lotus*, *Medicago*, *Onobrychis*, *Trifolium*, *Trigonella*, *Vigna*, *Citrus*, *Linum*, *Geranium*, *Manihot*, *Daucus*, *Arabidopsis*, *Brassica*, *Raphanus*, *Sinapis*, *Atropa*, *Capsicum*, *Datura*, *Hyoscyamus*, *Lycopersicon*, *Nicotiana*, *Solanum*, *Petunia*, *Digitalis*, *Majorana*, *Ciahorium*, *Helianthus*, *Lactuca*, *Bromus*, *Asparagus*, *Antirrhinum*, *Heterocallis*, *Nemesis*, *Pelargonium*, *Paniceum*, *Pennisetum*, *Ranunculus*, *Senecio*, *Salpiglossis*, *Cucumis*, *Browalia*, *Glycine*, *Pisum*, *Phaseolus*, *Lolium*, *Oryza*, *Zea*, *Avena*, *Hordeum*, *Secale*, *Triticum*, and, *Sorghum*. In particularly preferred embodiments, species from the family 25 *Compositae* and in particular the genus *Lactuca* are employed such as *L. sativa* and such subspecies as *crispa*, *longifolia*, and *asparagina*.

The nucleic acids of the present invention can be used in marker-aided selection. Marker-aided selection does not require the complete sequence of the gene or 30 precise knowledge of which sequence confers which specificity. Instead, partial sequences can be used as hybridization probes or as the basis for oligonucleotide primers to amplify nucleic acid, e.g., by PCR. Partial sequences can be used in other methods, such as to

follow the segregation of chromosome segments containing resistance genes in plants. Because the RG marker is the gene itself, there can be negligible recombination between the marker and the resistance phenotype. Thus, RG polynucleotides of the present invention provide an optimal means to DNA fingerprint cultivars and wild germplasm with respect to their disease resistance haplotypes. This can be used to indicate which germplasm accessions and cultivars carry the same resistance genes. At present, selection of plants (e.g., lettuce) for resistance to some diseases is slow and difficult. But linked markers allow indirect selection for such resistance genes. Moreover, RG markers also allow resistance genes to be identified and combined in a manner that would not otherwise be possible. Numerous accessions have been identified that provide resistance to all isolates of downy mildew (*Bremia lactucae*). However, without molecular markers it is impossible to combine such resistances from different sources. The nucleic acid sequences of the invention provide for a fast and convenient means to identify and combine resistances from different sources. The RG markers of the invention can also be used to identify recombinants that have new combinations of resistance genes in *cis* on the same chromosome.

In addition, RG markers may allow the identification of the Mendelian factors determining traits, such as field resistance to downy mildew. Once such markers have been identified, they will greatly increase the ease with which field resistance can be transferred between lines and combined with other resistances.

In another application, primers to RG sequences can be also designed to amplify sequences that are conserved in multiple RG family members. This gives genetic information on multiple RG family members. Alternatively, one or more primers can be made to sequences unique to a single resistance gene genus or a single RG specie. This allows an analysis of individual family groups (an RG genus) or an individual family member (a specie). Primers made to individual RGs at the edge of each cluster can be used to select for recombinants within the cluster. This minimizes the amount of linkage drag during introgression. Classical and molecular genetics has shown that pest resistance genes tend to be clustered in the genome. Pest resistance loci comprise arrays of genes and exhibit a variety of complex haplotypes rather than being simple alternate allelic forms. Pest resistance is conferred by families, or genuses, of related RG sequences, individual members, or species, of which have evolved to have a different specificity.

Oligonucleotide primers can be designed that amplify members from multiple haplotypes, or genuses, or amplify only members of one genus, or only amplify an individual specie. This will provide codominant information and allow heterozygotes to be distinguished from homozygotes.

5 Further, comparison of RG sequences will allow a determination of which sequences are critical for resistance and will ultimately lead to engineering resistance genes with new specificities. Resistance gene sequences were not previously available for lettuce. Marker-aided selection will greatly increase the precision and speed of breeding for disease resistance. Transgenic approaches will allow pyramiding of resistance genes
10 into a single Mendelian unit, transfer between sexually-incompatible species, substitute for conventional backcrossing procedures, and allow expression of other genes in parallel with resistance genes.

15 The RG polynucleotides also have utility in the construction of disease resistant transgenic plants. This avoids lengthy and sometimes difficult backcrossing programs currently necessary for introgression of resistance. It is also possible to transfer resistance polynucleotides between sexually-incompatible species, thereby greatly increasing the germplasm pool that can be used as a source of resistance genes. Cloning of multiple RG sequences in a single cassette will allow pyramiding of genes for resistance against multiple isolates of a single pathogen such as downy mildew or against multiple
20 pathogens. Once introduced, such a cassette can be manipulated by classical breeding methods as a single Mendelian unit.

25 Transgenic plants of the present invention can also be constructed using an RG promoter. The promoter sequences from RG sequences of the invention can be used with RG genes or heterologous genes. Thus, RG promoters can be used to express a variety of genes in the same temporal and spatial patterns and at similar levels to resistance genes.

Nucleic acids of the Invention and Their Preparation

RG Polynucleotide Families

30 The present invention provides isolated nucleic acid constructs which comprise an RG polynucleotide. In alternative embodiments, the RG polynucleotide is at least 18 nucleotides in length, typically at least 20, 25, or 30 nucleotides in length, more

typically at least 100 nucleotides in length, generally at least 200 nucleotides in length, preferably at least 300 nucleotides in length, more preferably at least 400 nucleotides in length, and most preferably at least 500 nucleotides in length.

5 In particularly preferred embodiments, the RG polynucleotide encodes a RG protein which confers resistance to plant pests. This RG protein can be longer, equivalent, or shorter than the RG protein encoded by an RG gene. In various embodiments, an RG polynucleotide can hybridize under stringent conditions to members of an RG family (an RG genus); *e.g.*, it can hybridize to a member of the RG1 RG family, such as an RG1 polynucleotide selected from the group consisting of: SEQ ID NO:1 (RG1A); SEQ ID NO:2 and SEQ ID NO:137 (RG1B); SEQ ID NO:3 (RG1C); SEQ ID NO:4 (RG1D); SEQ ID NO:5 (RG1E); SEQ ID NO:6 (RG1F); SEQ ID NO:7 (RG1G); SEQ ID NO:8 (RG1H); SEQ ID NO:9 (RG1I) and SEQ ID NO:10 (RG1J).

10

15 In other embodiments, the polynucleotide can also hybridize under stringent conditions to a member of the RG2 family; such as an RG2 polynucleotide selected from the group consisting of: SEQ ID NO:21 and SEQ ID NO:27 (RG2A); SEQ ID NO:23 and SEQ ID NO:28 (RG2B); SEQ ID NO:29 (RG2C); SEQ ID NO:30 (RG2D); SEQ ID NO:31 (RG2E); SEQ ID NO:32 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:34 (RG2H); SEQ ID NO:35 (RG2I); SEQ ID NO:36 (RG2J); SEQ ID NO:37 (RG2K); SEQ ID NO:38 (RG2L); SEQ ID NO:39 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104 (RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W).

20

25

30 In alternative embodiments, each RG2 gene can also include an AC15 sequence which hybridizes under stringent conditions to a polynucleotide selected from the group consisting of: SEQ ID NO:56 (AC15-2A); SEQ ID NO:57 (AC15-2B); SEQ ID NO:58 (AC15-2C); SEQ ID NO:59 (AC15-2D); SEQ ID NO:60 (AC15-2E); SEQ ID NO:61 (AC15-2G); SEQ ID NO:62 (AC15-2H); SEQ ID NO:63 (AC15-2I); SEQ ID

NO:64 (AC15-2J); SEQ ID NO:65 (AC15-2L); SEQ ID NO:66 (AC15-2N); SEQ ID NO:67 (AC15-2O).

In other embodiments, an RG polynucleotide can hybridize under stringent conditions to an RG3 (SEQ ID NO:68), an RG4 (SEQ ID NO:69), and RG5 (SEQ ID NO:135), and an RG7 (SEQ ID NO:137), RG family member.

The present invention further provides nucleic acid constructs which comprise an RG polynucleotide which encodes RG polypeptides from various RG families; such as an RG polypeptide having at least 60% sequence identity to an RG polypeptide selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, and RG4 polypeptide, and RG5 polypeptide, and an RG7 polypeptide.

Exemplary RG1 polypeptides have the sequences shown in SEQ ID NO:2 (RG1A), SEQ ID NO:4 (RG1B), SEQ ID NO:6 (RG1C), SEQ ID NO:8 (RG1D), SEQ ID NO:10 (RG1E), SEQ ID NO:12 (RG1F), SEQ ID NO:14 (RG1G), SEQ ID NO:16 (RG1H), SEQ ID NO:20 (RG1J). Exemplary RG2 polypeptides have the sequences shown in SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W).

An exemplary RG3 polypeptide has the sequence shown in SEQ ID NO:138. An exemplary RG4 polypeptide has the sequence shown in SEQ ID NO:139. RG polynucleotides will have at least 60% identity, more typically at least 65% identity, generally at least 70% identity, and preferably at least 75% identity, more preferably at least 80% identity, and most preferably at least 85%, 90%, or 95% identity at the deduced amino acid level. The regions where substantial identity is assessed can be inclusive or exclusive of the nucleotide binding site or the leucine rich region.

Vectors and Transcriptional Control Elements

The invention, providing methods and reagents for making novel species and genuses of RG nucleic acids described herein, further provides methods and reagents for expressing these nucleic acids using novel expression cassettes, vectors, transgenic plants and animals, using constitutive and inducible transcriptional and translational *cis*- (e.g., promoters and enhancers) and *trans*-acting control elements.

The expression of natural, recombinant or synthetic plant disease resistance polypeptide-encoding or other (i.e., antisense, ribozyme) nucleic acids can be achieved by operably linking the coding region a promoter (that can be plant-specific or not, constitutive or inducible), incorporating the construct into an expression cassette (such as an expression vector), and introducing the resultant construct into an *in vitro* reaction system or a suitable host cell or organism. Synthetic procedures may also be used.

Typical expression systems contain, in addition to coding or antisense sequence, transcription and translation terminators, polyadenylation sequences, transcription and translation initiation sequences, and promoters useful for transcribing DNA into RNA. The expression systems optionally at least one independent terminator sequence, sequences permitting replication of the cassette *in vivo*, e.g., plants, eukaryotes, or prokaryotes, or a combination thereof, (e.g., shuttle vectors) and selection markers for the selected expression system, e.g., plant, prokaryotic or eukaryotic systems. To ensure proper polypeptide expression under varying conditions, a polyadenylation region at the 3'-end of the coding region can be included (see Li (1997) *Plant Physiol.* 115:321-325, for a review of the polyadenylation of RNA in plants). The polyadenylation region can be derived from the natural gene, from a variety of other plant genes, or from T-DNA (e.g., using *Agrobacterium tumefaciens* T-DNA replacement vectors, see e.g., Thykjaer (1997) *Plant Mol. Biol.* 35:523-530; using a plasmid containing a gene of interest flanked by *Agrobacterium* T-DNA border repeat sequences; Hansen (1997) "T-strand integration in maize protoplasts after codelivery of a T-DNA substrate and virulence genes," *Proc. Natl. Acad. Sci. USA* 94:11726-11730.

To identify the promoters, the 5' portions of the clones described here are analyzed for sequences characteristic of promoter sequences. For instance, promoter sequence elements include the TATA box consensus sequence (TATAAT), which is usually 20 to 30 base pairs upstream of the transcription start site. In plants, further

upstream from the TATA box, at positions -80 to -100, there is typically a promoter element with a series of adenines surrounding the trinucleotide G (or T) N G (see, e.g., Messing, in *Genetic Engineering in Plants*, pp. 221-227, Kosage, Meredith and Hollaender, eds. 1983). If proper polypeptide expression is desired, a polyadenylation region at the 3'-end of the RG coding region should be included. The polyadenylation region can be derived from the natural gene, from a variety of other plant genes, or from viral genes, such as T-DNA.

The nucleic acids of the invention can be expressed in expression cassettes, vectors or viruses which are transiently expressed in cells using, for example, episomal expression systems (e.g., cauliflower mosaic virus (CaMV) viral RNA is generated in the nucleus by transcription of an episomal minichromosome containing supercoiled DNA, Covey (1990) *Proc. Natl. Acad. Sci. USA* 87:1633-1637). Alternatively, coding sequences can be inserted into the host cell genome becoming an integral part of the host chromosomal DNA.

Selection markers can be incorporated into expression cassettes and vectors to confer a selectable phenotype on transformed cells and sequences coding for episomal maintenance and replication such that integration into the host genome is not required. For example, the marker may encode biocide resistance, such as antibiotic resistance, particularly resistance to chloramphenicol, kanamycin, G418, bleomycin, hygromycin, or herbicide resistance, such as resistance to chlorosulfuron or Basta, to permit selection of those cells transformed with the desired DNA sequences, see for example, Blondelet-Rouault (1997) *Gene* 190:315-317; Aubrecht (1997) *J. Pharmacol. Exp. Ther.* 281:992-997. Because selectable marker genes conferring resistance to substrates like neomycin or hygromycin can only be utilized in tissue culture, chemoresistance genes are also used as selectable markers *in vitro* and *in vivo*. See also, Mengiste (1997) "High-efficiency transformation of *Arabidopsis thaliana* with a selectable marker gene regulated by the T-DNA 1' promoter," *Plant J.* 12:945-948, showing that the 1' promoter is an attractive alternative to the cauliflower mosaic virus (CaMV) 35S promoter for the generation of T-DNA insertion lines, the 1' promoter may be especially beneficial for the secondary transformation of transgenic strains containing the 35S promoter to exclude homology-mediated gene silencing.

5

The endogenous promoters from the RG genes of the present invention can be used to direct expression of the genes. These promoters can also be used to direct expression of heterologous structural genes. The promoters can be used, for example, in recombinant expression cassettes to drive expression of genes conferring resistance to any number of pathogens or pests, including fungi, bacteria, and the like.

10

Constitutive Promoters

In construction of recombinant expression cassettes, vectors, transgenics, of the invention, a promoter fragment can be employed to direct expression of the desired gene in all tissues of a plant or animal. Promoters that drive expression continuously under physiological conditions are referred to as "constitutive" promoters and are active under most environmental conditions and states of development or cell differentiation. Examples of constitutive promoters include those from viruses which infect plants, such as the cauliflower mosaic virus (CaMV) 35S transcription initiation region; the 1'- or 2'- promoter derived from T-DNA of *Agrobacterium tumefaciens*; the promoter of the tobacco mosaic virus; and, other transcription initiation regions from various plant genes known to those of skill. See also Holtorf (1995) "Comparison of different constitutive and inducible promoters for the overexpression of transgenes in *Arabidopsis thaliana*," *Plant Mol. Biol.* 29:637-646.

15

Inducible Promoters

20

Alternatively, a plant promoter may direct expression of the plant disease resistance nucleic acid of the invention under the influence of changing environmental conditions or developmental conditions. Examples of environmental conditions that may effect transcription by inducible promoters include pathogenic attack, anaerobic conditions, elevated temperature, drought, or the presence of light. Such promoters are referred to herein as "inducible" promoters. For example, the invention incorporates the drought-inducible promoter of maize (Busk (1997) *supra*); the cold, drought, and high salt inducible promoter from potato (Kirch (1997) *Plant Mol. Biol.* 33:897-909).

25

Embodiments of the invention also incorporate use of plant promoters which are inducible upon injury or infection to express the invention's plant disease resistance (RG) polypeptides. Various embodiments include use of, *e.g.*, the promoter for a tobacco (*Nicotiana tabacum*) sesquiterpene cyclase gene (EAS4 promoter), which is expressed in wounded leaves, roots, and stem tissues, and upon infection with microbial pathogens (Yin

30

(1997) *Plant Physiol.* 115(2):437-451); the ORF13 promoter from *Agrobacterium rhizogenes* 8196, which is wound inducible in a limited area adjacent to the wound site (Hansen (1997) *Mol. Gen. Genet.* 254:337-343); the Shpx6b gene promoter, which is a plant peroxidase gene promoter induced by microbial pathogens (demonstrated using a fungal pathogen, see Curtis (1997) *Mol. Plant Microbe Interact.* 10:326-338); the wound-inducible gene promoter wun1, derived from potato (Siebertz (1989) *Plant Cell* 1:961-968); the wound-inducible *Agrobacterium pmas* gene (mannopine synthesis gene) promoter (Guevara-Garcia (1993) *Plant J.* 4:495-505).

Alternatively, plant promoters which are inducible upon exposure to plant hormones, such as auxins, are used to express the nucleic acids of the invention. For example, the invention can use the auxin-response elements E1 promoter fragment (AuxREs) in the soybean (*Glycine max L.*) (Liu (1997) *Plant Physiol.* 115:397-407); the auxin-responsive *Arabidopsis GST6* promoter (also responsive to salicylic acid and hydrogen peroxide) (Chen (1996) *Plant J.* 10: 955-966); the auxin-inducible parC promoter from tobacco (Sakai (1996) 37:906-913); a plant biotin response element (Streit (1997) *Mol. Plant Microbe Interact.* 10:933-937); and, the promoter responsive to the stress hormone abscisic acid (Sheen (1996) *Science* 274:1900-1902).

Plant promoters which are inducible upon exposure to chemicals reagents which can be applied to the plant, such as herbicides or antibiotics, are also used to express the nucleic acids of the invention. For example, the maize In2-2 promoter, activated by benzenesulfonamide herbicide safeners, can be used (De Veylder (1997) *Plant Cell Physiol.* 38:568-577); application of different herbicide safeners induces distinct gene expression patterns, including expression in the root, hydathodes, and the shoot apical meristem. Coding sequence can be under the control of, *e.g.*, a tetracycline-inducible promoter, *e.g.*, as described with transgenic tobacco plants containing the *Avena sativa L.* (oat) arginine decarboxylase gene (Masgrau (1997) *Plant J.* 11:465-473); or, a salicylic acid-responsive element (Stange (1997) *Plant J.* 11:1315-1324. Using chemically- (*e.g.*, hormone- or pesticide-) induced promoters, harvesting of fruits and plant parts would be greatly facilitated. A chemical which can be applied to the transgenic plant in the field and induce expression of a polypeptide of the invention throughout all or most of the plant would make a environmentally safe defoliant or herbicide. Thus, the invention also provides for transgenic plants containing an inducible gene encoding for the RG

polypeptides of the invention whose host range is limited to target plant species, such as weeds or crops before, during or after harvesting.

Abscission promoters are activated upon plant ripening, such as fruit ripening, and are especially useful incorporated in the expression systems (e.g., expression 5 cassettes, vectors) of the invention. In some embodiments, when a plant disease resistant polypeptide-encoding nucleic acid is under the control of such a promoter, rapid cell death, induced by expression of the invention's polypeptide, can accelerate and/or accentuate abscission, increasing the efficiency of the harvesting of fruits or other plant parts, such as cotton, and the like. Induction of rapid cell death at this time would accelerate separation 10 of the fruit from the plant, greatly augmenting harvesting procedures. See, e.g., Kalaitzis (1997) *Plant Physiol.* 113:1303-1308, discussing tomato leaf and flower abscission; Payton (1996) *Plant Mol. Biol.* 31:1227-1231, discussing ethylene receptor expression regulation during fruit ripening, flower senescence and abscission; Koehler (1996) *Plant Mol. Biol.* 31:595-606, discussing the gene promoter for a bean abscission cellulase; Kalaitzis (1995) 15 *Plant Mol. Biol.* 28: 647-656, discussing cloning of a tomato polygalacturonase expressed in abscission; del Campillo (1996) *Plant Physiol.* 111:813-820, discussing pedicel breakstrength and cellulase gene expression during tomato flower abscission.

Tissue-Specific Promoters

Tissue specific promoters are transcriptional control elements that are only 20 active in particular cells or tissues. Plant promoters which are active only in specific tissues or at specific times during plant development are used to express the nucleic acids of the invention. Examples of promoters under developmental control include promoters that initiate transcription only in certain tissues, such as leaves, roots, fruit, seeds, ovules, pollen, pistils, or flowers. Such promoters are referred to as "tissue specific". The 25 operation of a promoter may also vary depending on its location in the genome. Thus, an inducible promoter may become fully or partially constitutive in certain locations.

For example, a seed-specific promoter directs expression in seed tissues. Such promoters may be, for example, ovule-specific, embryo-specific, endosperm-specific, integument-specific, seed coat-specific, or some combination thereof. A leaf-specific 30 promoter has been identified in maize, Busk (1997) *Plant J.* 11:1285-1295. The ORF13 promoter from *Agrobacterium rhizogenes* exhibits high activity in roots (Hansen (1997) *supra*). A maize pollen-specific promoter has been identified in maize (Guerrero (1990)

Mol. Gen. Genet. 224:161-168). A tomato promoter active during fruit ripening, senescence and abscission of leaves and, to a lesser extent, of flowers can be used (Blume (1997) *Plant J.* 12:731-746). A pistol specific promoter has been identified in the potato (*Solanum tuberosum* L.) SK2 gene, encoding a pistil-specific basic endochitinase (Ficker (1997) *Plant Mol. Biol.* 35:425-431). The Blec4 gene from pea (*Pisum sativum* cv. 5 *Alaska*) is active in epidermal tissue of vegetative and floral shoot apices of transgenic alfalfa, making it a useful tool to target the expression of foreign genes to the epidermal layer of actively growing shoots. The activity of the Blec4 promoter in the epidermis of the shoot apex makes it particularly suitable for genetically engineering defense against insects 10 and diseases that attack the growing shoot apex (Mandaci (1997) *Plant Mol Biol.* 34:961-965).

The invention also provides for use of tissue-specific plant promoters include a promoter from the ovule-specific *BEL1* gene described in Reiser (1995) *Cell* 15 83:735-742, GenBank No. U39944. Suitable seed specific promoters are derived from the following genes: *MAC1* from maize, Sheridan (1996) *Genetics* 142:1009-1020; *Cat3* from maize, GenBank No. L05934, Abler (1993) *Plant Mol. Biol.* 22:10131-1038; the gene encoding oleosin 18kD from maize, GenBank No. J05212, Lee (1994) *Plant Mol. Biol.* 26:1981-1987; viviparous-1 from *Arabidopsis*, Genbank No. U93215; the gene encoding oleosin from *Arabidopsis*, Genbank No. Z17657; *Atmyc1* from *Arabidopsis*, Urao (1996) 20 *Plant Mol. Biol.* 32:571-576; the 2s seed storage protein gene family from *Arabidopsis*, Conceicao (1994) *Plant* 5:493-505; the gene encoding oleosin 20kD from *Brassica napus*, GenBank No. M63985; *napA* from *Brassica napus*, GenBank No. J02798, Josefsson (1987) *JBL* 26:12196-1301; the napin gene family from *Brassica napus*, Sjodahl (1995) 25 *Planta* 197:264-271; the gene encoding the 2S storage protein from *Brassica napus*, Dasgupta (1993) *Gene* 133:301-302; the genes encoding oleosin a, Genbank No. U09118, and, oleosin B, Genbank No. U09119, from soybean; and, the gene encoding low 30 molecular weight sulphur rich protein from soybean, Choi (1995) *Mol Gen. Genet.* 246:266-268. The tissue specific E8 promoter from tomato is particularly useful for directing gene expression so that a desired gene product is located in fruits. Other suitable promoters include those from genes encoding embryonic storage proteins.

One of skill will recognize that a tissue-specific promoter may drive expression of operably linked sequences in tissues other than the target tissue. Thus, as

used herein a tissue-specific promoter is one that drives expression preferentially in the target tissue, but may also lead to some expression in other tissues as well.

The invention also provides for use of tissue-specific promoters derived from viruses which can include, *e.g.*, the tobamovirus subgenomic promoter (Kumagai (1995) *Proc. Natl. Acad. Sci. USA* 92:1679-1683; the rice tungro bacilliform virus (RTBV), which replicates only in phloem cells in infected rice plants, with its promoter which drives strong phloem-specific reporter gene expression; the cassava vein mosaic virus (CVMV) promoter, with highest activity in vascular elements, in leaf mesophyll cells, and in root tips (Verdaguer (1996) *Plant Mol. Biol.* 31:1129-1139).

In some embodiments, the nucleic acid construct will comprise a promoter functional in a specific plant cell, such as in a species of *Lactuca*, operably linked to an RG polynucleotide. Promoters useful in these embodiments include RG promoters. In additional embodiments, the nucleic acid construct will comprise a RG promoter operably linked to a heterologous polynucleotide. The heterologous polynucleotide is chosen to provide a plant with a desired phenotype. For example, the heterologous polynucleotide can be a structural gene which encodes a polypeptide which imparts a desired resistance phenotype. Alternatively, the heterologous polynucleotide may be a regulatory gene which might play a role in transcriptional and/or translational control to suppress, enhance, or otherwise modify the transcription and/or expression of an endogenous gene within the plant. The heterologous polynucleotide of the nucleic acid construct of the present invention can be expressed in either sense or anti-sense orientation as desired. It will be appreciated that control of gene expression in either sense or anti-sense orientation can have a direct impact on the observable plant characteristics.

Modifying and Inhibiting RG Gene Expression

The invention also provides for RG nucleic acid sequences which are complementary to the RG polypeptide-encoding sequences of the invention; *i.e.*, antisense RG nucleic acids. Antisense technology can be conveniently used to modify gene expression in plants. To accomplish this, a nucleic acid segment from the desired gene is cloned and operably linked to a promoter such that the anti-sense strand of RNA will be transcribed. The construct is then transformed into plants and the antisense strand of RNA is produced. In plant cells, it has been shown that antisense RNA inhibits gene expression by preventing the accumulation of mRNA which encodes the enzyme of interest, *see, e.g.*,

Sheehy (1988) *Proc. Nat. Acad. Sci. USA* 85:8805-8809; Hiatt et al., U.S. Patent No. 4,801,340.

5 Antisense sequences are capable of inhibiting the transport, splicing or transcription of RG-encoding genes. The inhibition can be effected through the targeting of genomic DNA or messenger RNA. The transcription or function of targeted nucleic acid can be inhibited, *e.g.*, by hybridization and/or cleavage. One particularly useful set of inhibitors provided by the present invention includes oligonucleotides which are able to either bind RG gene or message, in either case preventing or inhibiting the production or function of RG. The association can be through sequence specific hybridization. Such 10 inhibitory nucleic acid sequences can, for example, be used to completely inhibit a plant disease resistance response. Another useful class of inhibitors includes oligonucleotides which cause inactivation or cleavage of RG message. The oligonucleotide can have enzyme activity which causes such cleavage, such as ribozymes. The oligonucleotide can be chemically modified or conjugated to an enzyme or composition capable of cleaving the 15 complementary nucleic acid. One may screen a pool of many different such oligonucleotides for those with the desired activity.

Antisense Oligonucleotides

20 The invention provides for with antisense oligonucleotides capable of binding RG message which can inhibit RG activity by targeting mRNA. Strategies for designing antisense oligonucleotides are well described in the scientific and patent literature, and the skilled artisan can design such RG oligonucleotides using the novel reagents of the invention. In some situations, naturally occurring nucleic acids used as 25 antisense oligonucleotides may need to be relatively long (18 to 40 nucleotides) and present at high concentrations. A wide variety of synthetic, non-naturally occurring nucleotide and nucleic acid analogues are known which can address this potential problem. For example, peptide nucleic acids (PNAs) containing non-ionic backbones, such as N-(2-aminoethyl) glycine units can be used. Antisense oligonucleotides having phosphorothioate linkages can also be used, as described in WO 97/03211; WO 96/39154; Mata (1997) *Toxicol Appl Pharmacol* 144:189-197; Antisense Therapeutics, ed. Agrawal (Humana Press, Totowa, 30 N.J., 1996). Antisense oligonucleotides having synthetic DNA backbone analogues provided by the invention can also include phosphoro-dithioate, methylphosphonate,

phosphoramidate, alkyl phosphotriester, sulfamate, 3'-thioacetal, methylene(methylimino), 3'-N-carbamate, and morpholino carbamate nucleic acids, as described herein.

Combinatorial chemistry methodology can be used to create vast numbers of oligonucleotides that can be rapidly screened for specific oligonucleotides that have appropriate binding affinities and specificities toward any target, such as the sense and antisense RG sequences of the invention (for general background information, see, e.g., Gold (1995) *J. of Biol. Chem.* 270:13581-13584).

Inhibitory Ribozymes

The invention provides for with ribozymes capable of binding RG message which can inhibit RG activity by targeting mRNA. Strategies for designing ribozymes and selecting the RG-specific antisense sequence for targeting are well described in the scientific and patent literature, and the skilled artisan can design such RG ribozymes using the novel reagents of the invention. Ribozymes act by binding to a target RNA through the target RNA binding portion of a ribozyme which is held in close proximity to an enzymatic portion of the RNA that cleaves the target RNA. Thus, the ribozyme recognizes and binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to cleave and inactivate the target RNA. Cleavage of a target RNA in such a manner will destroy its ability to direct synthesis of an encoded protein if the cleavage occurs in the coding sequence, or, preventing transport of the message from the nucleus to the cytoplasm. After a ribozyme has bound and cleaved its RNA target, it is typically released from that RNA and so can bind and cleave new targets repeatedly.

Catalytic RNA molecules or ribozymes can also be used to inhibit expression of any plant gene. It is possible to design ribozymes that specifically pair with virtually any target RNA and cleave the phosphodiester backbone at a specific location, thereby functionally inactivating the target RNA. In carrying out this cleavage, the ribozyme is not itself altered, and is thus capable of recycling and cleaving other molecules, making it a true enzyme. The inclusion of ribozyme sequences within antisense RNAs confers RNA-cleaving activity upon them, thereby increasing the activity of the constructs. The design and use of target RNA-specific ribozymes is described, e.g., in Haseloff (1988) *Nature* 334:585-591.

In some circumstances, the enzymatic nature of a ribozyme can be advantageous over other technologies, such as antisense technology (where a nucleic acid

molecule simply binds to a nucleic acid target to block its transcription, translation or association with another molecule) as the effective concentration of ribozyme necessary to effect a therapeutic treatment can be lower than that of an antisense oligonucleotide. This potential advantage reflects the ability of the ribozyme to act enzymatically. Thus, a single 5 ribozyme molecule is able to cleave many molecules of target RNA. In addition, a ribozyme is typically a highly specific inhibitor, with the specificity of inhibition depending not only on the base pairing mechanism of binding, but also on the mechanism by which the molecule inhibits the expression of the RNA to which it binds. That is, the inhibition is caused by cleavage of the RNA target and so specificity is defined as the ratio 10 of the rate of cleavage of the targeted RNA over the rate of cleavage of non-targeted RNA. This cleavage mechanism is dependent upon factors additional to those involved in base pairing. Thus, the specificity of action of a ribozyme can be greater than that of antisense oligonucleotide binding the same RNA site.

The enzymatic ribozyme RNA molecule can be formed in a hammerhead 15 motif, but may also be formed in the motif of a hairpin, hepatitis delta virus, group I intron or RNaseP-like RNA (in association with an RNA guide sequence). Examples of such hammerhead motifs are described by Rossi (1992) *Aids Research and Human Retroviruses* 8:183; hairpin motifs by Hampel (1989) *Biochemistry* 28:4929, and Hampel (1990) *Nuc. Acids Res.* 18:299; the hepatitis delta virus motif by Perrotta (1992) *Biochemistry* 31:16; 20 the RNaseP motif by Guerrier-Takada (1983) *Cell* 35:849; and the group I intron by Cech U.S. Pat. No. 4,987,071. The recitation of these specific motifs is not intended to be limiting; those skilled in the art will recognize that an enzymatic RNA molecule of this invention has a specific substrate binding site complementary to one or more of the target gene RNA regions, and has nucleotide sequence within or surrounding that substrate 25 binding site which imparts an RNA cleaving activity to the molecule.

Sense Suppression

Another method of suppression is sense suppression. Introduction of 30 nucleic acid configured in the sense orientation has been shown to be an effective means by which to block the transcription of target genes. For an example of the use of this method to modulate expression of endogenous genes see, Napoli et al., *The Plant Cell* 2:279-289 (1990), and U.S. Patent No. 5,034,323.

Cloning of RG Polypeptides

Synthesis and/or cloning of RG polynucleotides and isolated nucleic acid constructs of the present invention are provided by methods well known to those of ordinary skill in the art. Generally, the nomenclature and the laboratory procedures in recombinant DNA technology described below are those well known and commonly employed in the art. Standard techniques are used for cloning, DNA and RNA isolation, amplification and purification. Generally enzymatic reactions involving DNA ligase, DNA polymerase, restriction endonucleases and the like are performed according to the manufacturer's specifications. These techniques and various other techniques are generally performed according to Sambrook *et al.*, *Molecular Cloning - A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, (1989).

The isolation of RG genes may be accomplished by a number of techniques. For instance, oligonucleotide probes based on the sequences disclosed here can be used to identify the desired gene in a cDNA or genomic DNA library. To construct genomic libraries, large segments of genomic DNA are generated by random fragmentation, e.g. using restriction endonucleases, and are ligated with vector DNA to form concatemers that can be packaged into the appropriate vector. To prepare a cDNA library, mRNA is isolated from the desired organ, such as roots and a cDNA library which contains the RG gene transcript is prepared from the mRNA. Alternatively, cDNA may be prepared from mRNA extracted from other tissues in which RG genes or homologs are expressed.

The cDNA or genomic library can then be screened using a probe based upon the sequence of a cloned RG gene such as the genes disclosed herein. Probes may be used to hybridize with genomic DNA or cDNA sequences to isolate homologous genes in the same or different plant species.

Those of skill in the art will appreciate that various degrees of stringency of hybridization can be employed in the assay; and either the hybridization or the wash medium can be stringent. As the conditions for hybridization become more stringent, there must be a greater degree of complementarity between the probe and the target for duplex formation to occur. The degree of stringency can be controlled by temperature, ionic strength, pH and the presence of a partially denaturing solvent such as formamide. For example, the stringency of hybridization is conveniently varied by changing the polarity of the reactant solution through manipulation of the concentration of formamide within the range of 0% to 50%.

Alternatively, the RG nucleic acids of the invention can be amplified from nucleic acid samples using a variety of amplification techniques, such as polymerase chain reaction (PCR) technology, to amplify the sequences of the RG and related genes directly from genomic DNA, from cDNA, from genomic libraries or cDNA libraries. PCR and other *in vitro* amplification methods may also be useful, for example, to clone nucleic acid sequences that code for proteins to be expressed, to make nucleic acids to use as probes for detecting the presence of the desired mRNA in samples, for nucleic acid sequencing, or for other purposes.

Oligonucleotides can be used to identify and detect additional RG families and RG family species using a variety of hybridization techniques and conditions. Suitable amplification methods include, but are not limited to: polymerase chain reaction, PCR (PCR PROTOCOLS, A GUIDE TO METHODS AND APPLICATIONS, *ed.* Innis, Academic Press, N.Y. (1990) and PCR STRATEGIES (1995), *ed.* Innis, Academic Press, Inc., N.Y. (Innis)), ligase chain reaction (LCR) (Wu (1989) *Genomics* 4:560; Landegren (1988) *Science* 241:1077; Barringer (1990) *Gene* 89:117); transcription amplification (Kwoh (1989) *Proc. Natl. Acad. Sci. USA* 86:1173); and, self-sustained sequence replication (Guatelli (1990) *Proc. Natl. Acad. Sci. USA*, 87:1874); Q Beta replicase amplification and other RNA polymerase mediated techniques (e.g., NASBA, Cangene, Mississauga, Ontario); see Berger (1987) *Methods Enzymol.* 152:307-316, Sambrook, and Ausubel, as well as Mullis (1987) U.S. Patent Nos. 4,683,195 and 4,683,202; Arnheim (1990) *C&EN* 36-47; Lomell *J. Clin. Chem.*, 35:1826 (1989); Van Brunt, *Biotechnology*, 8:291-294 (1990); Wu (1989) *Gene* 4:560; Sooknanan (1995) *Biotechnology* 13:563-564. Methods for cloning *in vitro* amplified nucleic acids are described in Wallace, U.S. Pat. No. 5,426,039.

The degree of complementarity (sequence identity) required for detectable binding will vary in accordance with the stringency of the hybridization medium and/or wash medium. The degree of complementarity will optimally be 100 percent; however, it should be understood that minor sequence variations in the probes and primers may be compensated for by reducing the stringency of the hybridization and/or wash medium as described earlier.

In some preferred embodiments, members of this class of pest resistance genes can be identified by their ability to be amplified by PCR primers based on the sequences disclosed here. Appropriate primers and probes for identifying RG sequences

from plant tissues are generated from comparisons of the sequences provided herein. See, e.g., Table 1. For a general overview of PCR see *PCR Protocols: A Guide to Methods and Applications*. (Innis, M, Gelfand, D., Sninsky, J. and White, T., eds.), *Academic Press*, San Diego (1990), incorporated herein by reference.

5 Briefly, the first step of each cycle of the PCR involves the separation of the
nucleic acid duplex formed by the primer extension. Once the strands are separated, the
next step in PCR involves hybridizing the separated strands with primers that flank the
target sequence. The primers are then extended to form complementary copies of the
target strands. For successful PCR amplification, the primers are designed so that the
10 position at which each primer hybridizes along a duplex sequence is such that an extension
product synthesized from one primer, when separated from the template (complement),
serves as a template for the extension of the other primer. The cycle of denaturation,
hybridization, and extension is repeated as many times as necessary to obtain the desired
amount of amplified nucleic acid.

15 In the preferred embodiment of the PCR process, strand separation is
achieved by heating the reaction to a sufficiently high temperature for an sufficient time to
cause the denaturation of the duplex but not to cause an irreversible denaturation of the
polymerase (see U.S. Patent No. 4,965,188). Template-dependent extension of primers in
PCR is catalyzed by a polymerizing agent in the presence of adequate amounts of four
20 deoxyribonucleotide triphosphates (typically dATP, dGTP, dCTP, and dTTP) in a reaction
medium comprised of the appropriate salts, metal cations, and pH buffering system.
Suitable polymerizing agents are enzymes known to catalyze template-dependent DNA
synthesis.

25 Polynucleotides may also be synthesized by well-known techniques as described in the technical literature. See, e.g., Carruthers *et al.*, *Cold Spring Harbor Symp. Quant. Biol.* 47:411-418 (1982), and Adams *et al.*, *J. Am. Chem. Soc.* 105:661 (1983). Double stranded DNA fragments may then be obtained either by synthesizing the complementary strand and annealing the strands together under appropriate conditions, or by adding the complementary strand using DNA polymerase with an appropriate primer sequence.
30

The present invention further provides isolated RG proteins encoded by the RG polynucleotides disclosed herein. One of skill will recognize that the nucleic acid encoding a functional RG protein need not have a sequence identical to the exemplified genes disclosed here. For example, because of codon degeneracy a large number of nucleic acid sequences can encode the same polypeptide. In addition, the polypeptides encoded by the RG genes, like other proteins, have different domains which perform different functions. Thus, the RG gene sequences need not be full length, so long as the desired functional domain of the protein is expressed.

The resistance proteins are at least 25 amino acid residues in length.

Typically, the RG proteins are at least 50 amino acid residues, generally at least 100, preferably at least 150, more preferably at least 200 amino acids in length. In particularly preferred embodiments, the RG proteins are of sufficient length to provide resistance to pests when expressed in the desired plants. Generally then, the RG proteins will be the length encoded by an RG gene of the present invention. However, those of ordinary skill will appreciate that minor deletions, substitutions, or additions to an RG protein will typically yield a protein with pest resistance characteristics similar or identical to that of the full length sequence. Thus, full-length RG proteins modified by 1, 2, 3, 4, or 5 deletions, substitutions, or additions, generally provide an effective degree of pest resistance relative to the full-length protein.

The RG proteins which provide pest resistance will typically comprise at least one of an LRR or an NBS. Preferably, both are present. LRR and/or NBS regions present in the RG proteins of the present invention can be provided by RG genes of the present invention. In some embodiments, the LRR and/or NBS regions are obtained from other pest resistance genes. See, e.g., Yu *et al.*, *Proc. Natl. Acad. Sci. USA*, 93: 11751-11756 (1996); Bent *et al.*, *Science*, 265: 1856-1860 (1994).

Modified protein chains can also be readily designed utilizing various recombinant DNA techniques well known to those skilled in the art. For example, the chains can vary from the naturally occurring sequence at the primary structure level by amino acid substitutions, additions, deletions, and the like. Modification can also include swapping domains from the proteins of the invention with related domains from other pest resistance genes.

Pests that can be targeted by RG genes and proteins of the present invention include such bacterial pests as *Erwinia carotovora* and *Pseudomonas marginalis*. Fungal pests which can be targeted by the present invention include *Bremia lactucae*, *Marssonina panaitianiana*, *Rhizoctonia solani*, *Olpidium brassicae*, root aphid, *Sclerotinia sclerotiorum* and *S. minor*, and *Botrytis cinerea* which causes gray mold. RG genes also provide resistance to viral diseases such as lettuce and turnip mosaic viruses.

Fusion Proteins

RG polypeptides can also be expressed as recombinant proteins with one or more additional polypeptide domains linked thereto to facilitate protein detection, 10 purification, or other applications. Such detection and purification facilitating domains include, but are not limited to, metal chelating peptides such as polyhistidine tracts and histidine-tryptophan modules that allow purification on immobilized metals, protein a domains that allow purification on immobilized immunoglobulin, and the domain utilized 15 in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA). The inclusion of a cleavable linker sequences such as Factor Xa or enterokinase (Invitrogen, San Diego CA) between the purification domain and plant disease resistant polypeptide 20 may be useful to facilitate purification. One such expression vector provides for expression of a fusion protein comprising the sequence encoding a plant disease resistant polypeptide of the invention and nucleic acid sequence encoding six histidine residues followed by thioredoxin and an enterokinase cleavage site (e.g., see Williams (1995) 25 *Biochemistry* 34:1787-1797). The histidine residues facilitate detection and purification while the enterokinase cleavage site provides a means for purifying the desired protein(s) from the remainder of the fusion protein. Technology pertaining to vectors encoding fusion proteins and application of fusion proteins are well described, see e.g., Kroll (1993) *DNA Cell. Biol.*, 12:441-53.

Antibodies Reactive to RG Polypeptides and Immunological Assays

The present invention also provides antibodies which specifically react with RG proteins of the present invention under immunologically reactive conditions. An antibody immunologically reactive with a particular antigen can be generated *in vivo* or by 30 recombinant methods such as selection of libraries of recombinant antibodies in phage or similar vectors. "Immunologically reactive conditions" includes reference to conditions which allow an antibody, generated to a particular epitope of an antigen, to bind to that

epitope to a detectably greater degree than the antibody binds to substantially all other epitopes, generally at least two times above background binding, preferably at least five times above background. Immunologically reactive conditions are dependent upon the format of the antibody binding reaction and typically are those utilized in immunoassay

5 protocols.

"Antibody" includes reference to an immunoglobulin molecule obtained by *in vitro* or *in vivo* generation of the humoral response, and includes both polyclonal and monoclonal antibodies. The term also includes genetically engineered forms such as chimeric antibodies (e.g., humanized murine antibodies), heteroconjugate antibodies (e.g., 10 bispecific antibodies), and recombinant single chain Fv fragments (scFv). The term "antibody" also includes antigen binding forms of antibodies (e.g., Fab', F(ab')₂, Fab, Fv, rIgG, and, inverted IgG). See, Pierce Catalog and Handbook, 1994-1995 (Pierce Chemical Co., Rockford, IL). An antibody immunologically reactive with a particular antigen can be generated *in vivo* or by recombinant methods such as selection of libraries 15 of recombinant antibodies in phage or similar vectors. See, e.g., Huse *et al.* (1989) *Science* 246:1275-1281; and Ward, *et al.* (1989) *Nature* 341:544-546; and Vaughan *et al.* (1996) *Nature Biotechnology*, 14:309-314.

Many methods of making antibodies are known to persons of skill. A number of immunogens are used to produce antibodies specifically reactive to an isolated 20 RG protein of the present invention under immunologically reactive conditions. An isolated recombinant, synthetic, or native RG protein of the present invention is the preferred immunogens (antigen) for the production of monoclonal or polyclonal antibodies.

The RG protein is then injected into an animal capable of producing 25 antibodies. Either monoclonal or polyclonal antibodies can be generated for subsequent use in immunoassays to measure the presence and quantity of the RG protein. Methods of producing monoclonal or polyclonal antibodies are known to those of skill in the art. See, e.g., Coligan (1991) *Current Protocols in Immunology* Wiley/Greene, NY; and Harlow and Lane (1989) *Antibodies: A Laboratory Manual* Cold Spring Harbor Press, NY); Goding (1986) *Monoclonal Antibodies: Principles and Practice* (2d ed.) Academic Press, 30 New York, NY.

Frequently, the RG proteins and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide

variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionucleotides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents teaching the use of such labels include U.S. 5 Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241.

The antibodies of the present invention can be used to screen plants for the expression of RG proteins of the present invention. The antibodies of this invention are also used for affinity chromatography in isolating RG protein.

10 The present invention further provides RG polypeptides that specifically bind, under immunologically reactive conditions, to an antibody generated against a defined immunogen, such as an immunogen consisting of the RG polypeptides of the present invention. Immunogens will generally be at least 10 contiguous amino acids from an RG polypeptide of the present invention. Optionally, immunogens can be from regions 15 exclusive of the NBS and/or LRR regions of the RG polypeptides. Nucleic acids which encode such cross-reactive RG polypeptides are also provided by the present invention. The RG polypeptides can be isolated from any number plants as discussed earlier. Preferred are species from the family *Compositae* and in particular the genus *Lactuca* such as *L. sativa* and such subspecies as *crispa*, *longifolia*, and *asparagina*.

20 "Specifically binds" includes reference to the preferential association of a ligand, in whole or part, with a particular target molecule (i.e., "binding partner" or "binding moiety") relative to compositions lacking that target molecule. It is, of course, recognized that a certain degree of non-specific interaction may occur between a ligand and a non-target molecule. Nevertheless, specific binding, may be distinguished as mediated 25 through specific recognition of the target molecule. Typically specific binding results in a much stronger association between the ligand and the target molecule than between the ligand and non-target molecule. Specific binding by an antibody to a protein under such conditions requires an antibody that is selected for its specificity for a particular protein. The affinity constant of the antibody binding site for its cognate monovalent antigen is at 30 least 10^7 , usually at least 10^8 , preferably at least 10^9 , more preferably at least 10^{10} , and most preferably at least 10^{11} liters/mole. A variety of immunoassay formats are appropriate for selecting antibodies specifically reactive with a particular protein. For

example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically reactive with a protein. See Harlow and Lane (1988) *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, New York, for a description of immunoassay formats and conditions that can be used to determine specific reactivity. The 5 antibody may be polyclonal but preferably is monoclonal. Generally, antibodies cross-reactive to such proteins as RPS2, RPM1 (bacterial resistances in *Arabidopsis*, L6 (fungal resistance in flax, PRF (resistance to *Pseudomonas syringae* in tomato), and N, (virus resistance in tobacco), are removed by immunoabsorption.

Immunoassays in the competitive binding format are typically used for 10 cross-reactivity determinations. For example, an immunogenic RG polypeptide is immobilized to a solid support. Polypeptides added to the assay compete with the binding of the antisera to the immobilized antigen. The ability of the above polypeptides to compete with the binding of the antisera to the immobilized RG polypeptide is compared to the immunogenic RG polypeptide. The percent cross-reactivity for the above proteins is 15 calculated, using standard calculations. Those antisera with less than 10% cross-reactivity with such proteins as RPS2, RPM1, L6, PRF, and N, are selected and pooled. The cross-reacting antibodies are then removed from the pooled antisera by immunoabsorption with these non-RG resistance proteins.

The immunoabsorbed and pooled antisera are then used in a competitive 20 binding immunoassay to compare a second "target" polypeptide to the immunogenic polypeptide. In order to make this comparison, the two polypeptides are each assayed at a wide range of concentrations and the amount of each polypeptide required to inhibit 50% of the binding of the antisera to the immobilized protein is determined using standard techniques. If the amount of the target polypeptide required is less than twice the amount 25 of the immunogenic polypeptide that is required, then the target polypeptide is said to specifically bind to an antibody generated to the immunogenic protein. As a final determination of specificity, the pooled antisera is fully immunosorbed with the immunogenic polypeptide until no binding to the polypeptide used in the immunosorption is detectable. The fully immunosorbed antisera is then tested for reactivity with the test 30 polypeptide. If no reactivity is observed, then the test polypeptide is specifically bound by the antisera elicited by the immunogenic protein.

Production of transgenic plants of the invention

Isolated nucleic acid constructs prepared as described herein can be introduced into plants according techniques known in the art. In some embodiments, the introduced nucleic acid is used to provide RG gene expression and therefore pest resistance in desired plants. In some embodiments, RG promoters are used to drive expression of desired heterologous genes in plants. Finally, in some embodiments, the constructs can be used to suppress expression of a target endogenous gene, including RG genes.

To use isolated RG sequences in the above techniques, recombinant DNA vectors suitable for transformation of plant cells are prepared. Techniques for transforming a wide variety of higher plant species are well known and described in the technical and scientific literature. See, for example, Weising *et al. Ann. Rev. Genet.* 22:421-477 (1988).

A DNA sequence coding for the desired RG polypeptide, for example a cDNA or a genomic sequence encoding a full length protein, will be used to construct a recombinant expression cassette which can be introduced into the desired plant. An expression cassette will typically comprise the RG polynucleotide operably linked to transcriptional and translational initiation regulatory sequences which will direct the transcription of the sequence from the RG gene in the intended tissues of the transformed plant.

Such DNA constructs may be introduced into the genome of the desired plant host by a variety of conventional techniques. For example, the DNA construct may be introduced directly into the genomic DNA of the plant cell using techniques such as electroporation, PEG poration, particle bombardment and microinjection of plant cell protoplasts or embryogenic callus, or the DNA constructs can be introduced directly to plant tissue using ballistic methods, such as DNA particle bombardment. Alternatively, the DNA constructs may be combined with suitable T-DNA flanking regions and introduced into a conventional *Agrobacterium tumefaciens* host vector. The virulence functions of the *Agrobacterium tumefaciens* host will direct the insertion of the construct and adjacent marker into the plant cell DNA when the cell is infected by the bacteria.

Transformation techniques are known in the art and well described in the scientific and patent literature. The introduction of DNA constructs using polyethylene glycol precipitation is described in Paszkowski *et al. Embo J.* 3:2717-2722 (1984).

Electroporation techniques are described in Fromm *et al.* *Proc. Natl. Acad. Sci. USA* 82:5824 (1985). Ballistic transformation techniques are described in Klein *et al.* *Nature* 327:70-73 (1987).

5 *Agrobacterium tumefaciens*-mediated transformation techniques are well described in the scientific literature. See, for example Horsch *et al.* *Science* 233:496-498 (1984), and Fraley *et al.* *Proc. Natl. Acad. Sci. USA* 80:4803 (1983). Although 10 *Agrobacterium* is useful primarily in dicots, certain monocots can be transformed by *Agrobacterium*. For instance, *Agrobacterium* transformation of rice is described by Hiei *et al.*, *Plant J.* 6:271-282 (1994). A particularly preferred means of transforming lettuce is described in Michelmore *et al.*, *Plant Cell Reports*, 6:439-442 (1987).

15 Transformed plant cells which are derived by any of the above transformation techniques can be cultured to regenerate a whole plant which possesses the transformed genotype and thus the desired RG-controlled phenotype. Such regeneration techniques rely on manipulation of certain phytohormones in a tissue culture growth medium, typically relying on a biocide and/or herbicide marker which has been introduced together with the RG nucleotide sequences. Plant regeneration from cultured protoplasts is described in Evans *et al.*, *Protoplasts Isolation and Culture, Handbook of Plant Cell Culture*, pp. 124-176, Macmillan Publishing Company, New York, 1983; and Binding, 20 *Regeneration of Plants, Plant Protoplasts*, pp. 21-73, CRC Press, Boca Raton, 1985. Regeneration can also be obtained from plant callus, explants, organs, or parts thereof. Such regeneration techniques are described generally in Klee *et al.* *Ann. Rev. of Plant Phys.* 38:467-486 (1987).

25 The methods of the present invention are particularly useful for incorporating the RG polynucleotides into transformed plants in ways and under circumstances which are not found naturally. In particular, the RG polypeptides may be expressed at times or in quantities which are not characteristic of natural plants.

30 One of skill will recognize that after the expression cassette is stably incorporated in transgenic plants and confirmed to be operable, it can be introduced into other plants by sexual crossing. Any of a number of standard breeding techniques can be used, depending upon the species to be crossed.

The present invention further provides methods for detecting RG resistance genes in a nucleic acid sample suspected of comprising an RG resistance gene. The means by which the RG resistance gene is detected is not a critical aspect of the invention. For example, RG resistance genes can be detected by the presence of amplicons using RG resistance gene specific primers. Additionally, RG resistance genes can be detected by assaying for specific hybridization of an RG polynucleotide to an RG resistance gene. In some embodiments, the RG resistance gene can be amplified prior to the step of contacting the nucleic acid sample with the RG polynucleotide.

In a typical detection method, the nucleic acid sample is contacted with an RG polynucleotide to form a hybridization complex. The hybridization complex may be detected directly (e.g., in Southern or northern blots), or indirectly (e.g., by subsequent primer extension during PCR amplification). The RG polynucleotide hybridizes under stringent conditions to an RG polynucleotide of the invention. Formation of the hybridization complex is directly or indirectly used to indicate the presence of the RG resistance gene in the nucleic acid sample.

Detection of the hybridization complex can be achieved using any number of well known methods. For example, the nucleic acid sample, or a portion thereof, may be assayed by hybridization formats including but not limited to, solution phase, solid phase, mixed phase, or *in situ* hybridization assays. Briefly, in solution (or liquid) phase hybridizations, both the target nucleic acid and the probe or primer are free to interact in the reaction mixture. In solid phase hybridization assays, probes or primers are typically linked to a solid support where they are available for hybridization with target nucleic in solution. In mixed phase, nucleic acid intermediates in solution hybridize to target nucleic acids in solution as well as to a nucleic acid linked to a solid support. In *in situ* hybridization, the target nucleic acid is liberated from its cellular surroundings in such as to be available for hybridization within the cell while preserving the cellular morphology for subsequent interpretation and analysis. The following articles provide an overview of the various hybridization assay formats: Singer *et al.*, *Biotechniques* 4(3):230-250 (1986); Haase *et al.*, *Methods in Virology*, Vol. VII, pp. 189-226 (1984); Wilkinson, "The theory and practice of *in situ* hybridization" In: *In situ Hybridization*, Ed. D.G. Wilkinson. IRL Press, Oxford University Press, Oxford; and *Nucleic Acid Hybridization: A Practical Approach*, Ed. Hames, B.D. and Higgins, S.J., IRL Press (1987).

The effect of the modification of RG gene expression can be measured by detection of increases or decreases in mRNA levels using, for instance, Northern blots. In addition, the phenotypic effects of gene expression can be detected by measuring nematode, fungal, bacterial, viral, or other pest resistance in plants. Suitable assays for determining pest resistance are well known. Michelmore and Crute, *Trans. Br. mycol. Soc.*, 79(3): 542-546 (1982).

The means by which hybridization complexes are detected is not a critical aspect of the present invention and can be accomplished by any number of methods currently known or later developed. RG polynucleotides can be labeled by any one of several methods typically used to detect the presence of hybridized nucleic acids. One common method of detection is the use of autoradiography using probes labeled with ^3H , ^{125}I , ^{35}S , ^{14}C , or ^{32}P , or the like. The choice of radioactive isotope depends on research preferences due to ease of synthesis, stability, and half lives of the selected isotopes. Other labels include ligands which bind to antibodies labeled with fluorophores, chemiluminescent agents, and enzymes. Alternatively, probes can be conjugated directly with labels such as fluorophores, chemiluminescent agents or enzymes. The choice of label depends on sensitivity required, ease of conjugation with the probe, stability requirements, and available instrumentation. Labeling the RG polynucleotide is readily achieved such as by the use of labeled PCR primers.

The choice of label dictates the manner in which the label is bound to the probe. Radioactive probes are typically made using commercially available nucleotides containing the desired radioactive isotope. The radioactive nucleotides can be incorporated into probes, for example, by using DNA synthesizers, by nick translation with DNA polymerase I, by tailing radioactive DNA bases to the 3' end of probes with terminal deoxynucleotidyl transferase, by treating single-stranded M13 plasmids having specific inserts with the Klenow fragment of DNA polymerase in the presence of radioactive deoxynucleotides, dNTP, by transcribing from RNA templates using reverse transcriptase in the presence of radioactive deoxynucleotides, dNTP, or by transcribing RNA from vectors containing specific RNA viral promoters (e.g., SP6 promoter) using the corresponding RNA polymerase (e.g., SP6 RNA polymerase) in the presence of radioactive ribonucleotides rNTP.

5 The probes can be labeled using radioactive nucleotides in which the isotope resides as a part of the nucleotide molecule, or in which the radioactive component is attached to the nucleotide via a terminal hydroxyl group that has been esterified to a radioactive component such as inorganic acids, *e.g.*, ³²P phosphate or ¹⁴C organic acids, or esterified to provide a linking group to the label. Base analogs having nucleophilic linking groups, such as primary amino groups, can also be linked to a label.

10 Non-radioactive probes are often labeled by indirect means. For example, a ligand molecule is covalently bound to the probe. The ligand then binds to an anti-ligand molecule which is either inherently detectable or covalently bound to a detectable signal system, such as an enzyme, a fluorophore, or a chemiluminescent compound. Enzymes of interest as labels will primarily be hydrolases, such as phosphatases, esterases and glycosidases, or oxidoreductases, particularly peroxidases. Fluorescent compounds include fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, etc. Chemiluminescers include luciferin, and 2,3-dihydropthalazinediones, *e.g.*, luminol.

15 Ligands and anti-ligands may be varied widely. Where a ligand has a natural anti-ligand, namely ligands such as biotin, thyroxine, and cortisol, it can be used in conjunction with its labeled, naturally occurring anti-ligands. Alternatively, any haptenic or antigenic compound can be used in combination with an antibody.

20 Probes can also be labeled by direct conjugation with a label. For example, cloned DNA probes have been coupled directly to horseradish peroxidase or alkaline phosphatase, (Renz. M., and Kurz, K. (1984) A Colorimetric Method for DNA Hybridization. *Nucl. Acids Res.* 12: 3435-3444) and synthetic oligonucleotides have been coupled directly with alkaline phosphatase (Jablonski, E., *et al.* (1986) Preparation of Oligodeoxynucleotide-Alkaline Phosphatase Conjugates and Their Use as Hybridization Probes. *Nuc. Acids. Res.* 14: 6115-6128; and Li P., *et al.* (1987) Enzyme-linked Synthetic Oligonucleotide probes: Non-Radioactive Detection of Enterotoxigenic *Escherichia Coli* in Faecal Specimens. *Nucl. Acids Res.* 15:5275-5287).

Definitions

30 Units, prefixes, and symbols can be denoted in their SI accepted form. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation, respectively. The

headings provided herein are not limitations of the various aspects or embodiments of the invention which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification as a whole.

5 As used herein, the term "plant" includes reference to whole plants, plant organs (e.g., leaves, stems, roots, etc.), seeds and plant cells and progeny of same. The class of plants which can be used in the methods of the invention is generally as broad as the class of higher plants amenable to transformation techniques, including both monocotyledonous and dicotyledonous plants.

10 As used herein, "pest" includes, but is not limited to, viruses, fungi, nematodes, insects, and bacteria.

15 As used herein, "heterologous" is a nucleic acid that originates from a foreign species, or, if from the same species, is substantially modified from its original form. For example, a promoter operably linked to a heterologous structural gene is from a species different from that from which the structural gene was derived, or, if from the same species, one or both are substantially modified from their original form.

20 As used herein, "RG gene," alternatively referred to as "RLG gene," is a gene encoding resistance to plant pests, such as viruses, fungi, nematodes, insects, and bacteria, and which hybridizes under stringent conditions and/or has at least 60% sequence identity at the deduced amino acid level to the exemplified sequences provided herein. RG genes encode "RG polypeptides," alternatively referred to as "RLG polypeptides," which can comprise LRR motifs and/or NBS motifs. The RG polypeptides encoded by RG genes have at least 55% or 60% sequence identity, typically at least 65% sequence identity, preferably at least 70% sequence identity, often at least 75% sequence identity, more preferably at least 80% sequence identity, and most preferably at least 90% sequence identity at the deduced amino acid level relative to the exemplary RG sequences provided herein. The term "RG family" or "RG family genus" or "genus" includes reference to a group of RG polypeptide sequence species that have at least 60% amino acid sequence identity, and, the nucleic acids encoding these polypeptides. The individual species of a genus, i.e., the members of a family, typically are genetically mapped to the same locus.

25 30 As used herein, "RG polynucleotide" includes reference to a contiguous sequence from an RG gene of at least 18, 20, 25, 30, 40, or 50 nucleotides in length, up to

at least about 100 or at least about 200 nucleotides in length. In some embodiments, the polynucleotide is preferably at least 100 nucleotides in length, more preferably at least 200 nucleotides in length, most preferably at least 500 nucleotides in length. Thus, RG polynucleotide may be a RG gene or a subsequence thereof.

5 As used herein, "isolated," when referring to a molecule or composition, such as, for example, an RG polypeptide or nucleic acid, means that the molecule or composition is separated from at least one other compound, such as a protein, other nucleic acids (e.g., RNAs), or other contaminants with which it is associated *in vivo* or in its naturally occurring state. Thus, an RG polypeptide or nucleic acid is considered isolated
10 when it has been isolated from any other component with which it is naturally associated, e.g., cell membrane, as in a cell extract. An isolated composition can, however, also be substantially pure. An isolated composition can be in a homogeneous state and can be in a dry or an aqueous solution. Purity and homogeneity can be determined, for example, using analytical chemistry techniques such as polyacrylamide gel electrophoresis (SDS-
15 PAGE) or high performance liquid chromatography (HPLC).

The term "nucleic acid" or "nucleic acid molecule" or "nucleic acid sequence" refers to a deoxyribonucleotide or ribonucleotide oligonucleotide in either single- or double-stranded form. The term encompasses nucleic acids, *i.e.*, oligonucleotides, containing known analogues of natural nucleotides which have similar or
20 improved binding properties, for the purposes desired, as the reference nucleic acid. The term also includes nucleic acids which are metabolized in a manner similar to naturally occurring nucleotides or at rates that are improved thereover for the purposes desired. The term also encompasses nucleic-acid-like structures with synthetic backbones. DNA backbone analogues provided by the invention include phosphodiester, phosphorothioate,
25 phosphorodithioate, methylphosphonate, phosphoramidate, alkyl phosphotriester, sulfamate, 3'-thioacetal, methylene(methylimino), 3'-N-carbamate, morpholino carbamate, and peptide nucleic acids (PNAs); see Oligonucleotides and Analogues, a Practical Approach, edited by F. Eckstein, IRL Press at Oxford University Press (1991); Antisense Strategies, Annals of the New York Academy of Sciences, Volume 600, Eds. Baserga and
30 Denhardt (NYAS 1992); Milligan (1993) *J. Med. Chem.* 36:1923-1937; Antisense Research and Applications (1993, CRC Press). PNAs contain non-ionic backbones, such as N-(2-aminoethyl) glycine units. Phosphorothioate linkages are described in WO

97/03211; WO 96/39154; Mata (1997) *Toxicol Appl Pharmacol* 144:189-197. Other synthetic backbones encompassed by the term include methyl-phosphonate linkages or alternating methylphosphonate and phosphodiester linkages (Strauss-Soukup (1997) *Biochemistry* 36:8692-8698), and benzylphosphonate linkages (Samstag (1996) *Antisense Nucleic Acid Drug Dev* 6:153-156). The term nucleic acid is used interchangeably with gene, cDNA, mRNA, oligonucleotide primer, probe and amplification product. Unless otherwise indicated, a particular nucleic acid sequence includes the complementary sequence thereof.

The term "exogenous nucleic acid" refers to a nucleic acid that has been isolated, synthesized, cloned, ligated, excised in conjunction with another nucleic acid, in a manner that is not found in nature, and/or introduced into and/or expressed in a cell or cellular environment other than or at levels or forms different than the cell or cellular environment in which said nucleic acid or protein is found in nature. The term encompasses both nucleic acids originally obtained from a different organism or cell type than the cell type in which it is expressed, and also nucleic acids that are obtained from the same cell line as the cell line in which it is expressed. invention.

The term "recombinant," when used with reference to a cell, or to the nucleic acid, protein or vector refers to a material, or a material corresponding to the natural or native form of the material, that has been modified by the introduction of a new moiety or alteration of an existing moiety, or is identical thereto but produced or derived from synthetic materials. For example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise expressed at a different level, typically, under-expressed or not expressed at all. The term "recombinant means" encompasses all means of expressing, *i.e.*, transcription or translation of, an isolated and/or cloned nucleic acid *in vitro* or *in vivo*. For example, the term "recombinant means" encompasses techniques where a recombinant nucleic acid, such as a cDNA encoding a protein, is inserted into an expression vector, the vector is introduced into a cell and the cell expresses the protein. "Recombinant means" also encompass the ligation of nucleic acids having coding or promoter sequences from different sources into one vector for expression of a fusion protein, constitutive expression of a protein, or inducible expression of a protein, such as the plant disease resistant, or RG. polypeptides of the invention.

The term "specifically hybridizes" refers to a nucleic acid that hybridizes, duplexes or binds to a particular target DNA or RNA sequence. The target sequences can be present in a preparation of total cellular DNA or RNA. Proper annealing conditions depend, for example, upon a nucleic acid's, such as a probe's length, base composition, and the number of mismatches and their position on the probe, and can be readily determined empirically providing the appropriate reagents are available. For discussions of nucleic acid probe design and annealing conditions, see, *e.g.*, Sambrook and Ausubel.

The terms "stringent hybridization," "stringent conditions," or "specific hybridization conditions" refers to conditions under which an oligonucleotide (when used, for example, as a probe or primer) will hybridize to its target subsequence, such as an RG nucleic acid in an expression vector of the invention but not to a non-RG sequence.

Stringent conditions are sequence-dependent. Thus, in one set of stringent conditions an oligonucleotide probe will hybridize to only one specie of the genus of RG nucleic acids of the invention. In another set of stringent conditions (less stringent) an oligonucleotide probe will hybridize to all species of the invention's genus but not to non-RG nucleic acids. Longer sequences hybridize specifically at higher temperatures. Stringent conditions are selected to be about 5⁰C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength, pH, and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium (if the target sequences are present in excess, at T_m, 50% of the probes are occupied at equilibrium). Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, *i.e.*, about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30⁰C for short probes (e.g., 10 to 50 nucleotides) and at least about 60⁰C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Often, high stringency wash conditions preceded by low stringency wash conditions to remove background probe signal. An example of medium stringency wash conditions for a duplex of, *e.g.*, more than 100 nucleotides, is 1x SSC at 45⁰C for 15 minutes (see Sambrook for a description of SSC buffer). An example low stringency wash for a duplex of, *e.g.*, more than 100 nucleotides, is 4-6x SSC at 40⁰C for 15 minutes. a signal to noise ratio of 2x (or higher) than that observed for an unrelated

probe in the particular hybridization assay indicates detection of a "specific hybridization." Nucleic acids which do not hybridize to each other under stringent conditions can still be substantially identical if the polypeptides which they encode are substantially identical. This can occur, *e.g.*, when a nucleic acid is created that encodes for conservative substitutions. Stringent hybridization and stringent hybridization wash conditions are different under different environmental parameters, such as for Southern and Northern hybridizations. An extensive guide to the hybridization of nucleic acids is found in, *e.g.*, Sambrook, Tijssen (1993) *supra*.

As used herein "operably linked" includes reference to a functional linkage between a promoter and a second sequence, wherein the promoter sequence initiates and mediates transcription of the DNA sequence corresponding to the second sequence. Generally, operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame.

In the expression of transgenes one of skill will recognize that the inserted polynucleotide sequence need not be identical and may be "substantially identical" to a sequence of the gene from which it was derived. As explained herein, these variants are specifically covered by this term.

In the case where the inserted polynucleotide sequence is transcribed and translated to produce a functional RG polypeptide, one of skill will recognize that because of codon degeneracy, a number of polynucleotide sequences will encode the same polypeptide. These variants are specifically covered by the term "RG polynucleotide sequence". In addition, the term specifically includes those full length sequences substantially identical (determined as described herein) with an RG gene sequence which encode proteins that retain the function of the RG protein. Thus, in the case of RG genes disclosed here, the term includes variant polynucleotide sequences which have substantial identity with the sequences disclosed here and which encode proteins capable of conferring resistance to nematodes, bacteria, viruses, fungi, insects or other pests on a transgenic plant comprising the sequence.

Two polynucleotides or polypeptides are said to be "identical" if the sequence of nucleotides or amino acid residues, respectively, in the two sequences is the same when aligned for maximum correspondence, as described below. The term

"complementary to" is used herein to mean that the complementary sequence is identical to all or a specified contiguous portion of a reference polynucleotide sequence.

The terms "sequence identity," "sequence similarity" and "homology" refer to when two sequences, such as the nucleic acid and amino acid sequences or the polypeptides of the invention, when optimally aligned, as with, for example, the programs PILEUP, BLAST, GAP, FASTA or BESTFIT (see discussion, *supra*). "Percentage amino acid/nucleic acid sequence identity" refers to a comparison of the sequences of two polypeptides/nucleic acids which, when optimally aligned, have approximately the designated percentage of the same amino acids/nucleic acids, respectively. For example, "60% sequence identity" and "60% homology" refer to a comparison of the sequences of two RG nucleic acids or polypeptides which, when optimally aligned, have 60% identity. For example, in one embodiment, nucleic acids encoding RG polypeptides of the invention comprise a sequence with at least 50% nucleic acid sequence identity to SEQ ID NO:1. In other embodiments, the RG polypeptides of the invention are encoded by nucleic acids comprising a sequence with at least 50% sequence identity to SEQ ID NO:1, or, are encoded by nucleic acids comprising SEQ ID NO:1, or, have at least 60% amino acid sequence identity to the polypeptide of SEQ ID NO:2.

"Percentage of sequence identity" is determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.

The term "substantial identity" of polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 55% or 60% sequence identity, generally at least 65%, preferably at least 70%, often at least 75%, more preferably at least 80% and most preferably at least 90%, compared to a reference sequence using the programs described above (preferably BESTFIT) using standard parameters. One of skill will recognize that these values can be appropriately adjusted to determine corresponding

identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning and the like. Substantial identity of amino acid sequences for these purposes normally means sequence identity of at least 55% or 60%, preferably at least 70%, more preferably at least 80%, and most preferably at least 95%. Polypeptides having "sequence similarity" share sequences as noted above except that residue positions which are not identical may differ by conservative amino acid changes. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.

Another indication that nucleotide sequences are substantially identical is if two molecules hybridize to each other under appropriate conditions. Appropriate conditions can be high or low stringency and will be different in different circumstances. Generally, stringent conditions are selected to be about 5°C to about 20°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Typically, stringent wash conditions are those in which the salt concentration is about 0.02 molar at pH 7 and the temperature is at least about 50°C. However, nucleic acids which do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This may occur, *e.g.*, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code.

Nucleic acids of the invention can be identified from a cDNA or genomic library prepared according to standard procedures and the nucleic acids disclosed here used as a probe. Thus, for example, stringent hybridization conditions will typically include at least one low stringency wash using 0.3 molar salt (*e.g.*, 2X SSC) at 65°C. The washes

are preferably followed by one or more subsequent washes using 0.03 molar salt (e.g., 0.2X SSC) at 50°C, usually 60°C, or more usually 65°C. Nucleic acid probes used to identify the nucleic acids are preferably at least 100 nucleotides in length.

As used herein, "nucleotide binding site" or "nucleotide binding domain" ("NBS") includes reference to highly conserved nucleotide-, *i.e.*, ATP/GTP-, binding domains, typically included in the "kinase domain" of kinase polypeptides, such as a kinase-1a, kinase 2, or a kinase 3a motif, as described herein. For example, the tobacco N and Arabidopsis RPS2 genes, among several recently cloned disease-resistance genes, share highly conserved NBS sequence. Kinase NBS subdomains further consist of three subdomain motifs: the P-loop, kinase-2, and kinase-3a subdomains (Yu (1996) *Proc. Acad. Sci. USA* 93:11751-11756). As discussed in detail herein, examples include the *Arabidopsis* RPP5 gene (Parker (1997) *supra*), the *A. thaliana* RPS2 gene (Mindrinos (1997) *supra*), and the flax L6 rust resistance gene (Lawrence (1995) *supra*) which all encode proteins containing an NBS; and Mindrinos (1994) *Cell* 78:1089-1099; and Shen (1993) *FEBS* 335:380-385. Using the teachings disclosed and incorporated herein and standard nucleic acid hybridization and/or amplification techniques, one of skill can identify members having NBS domains, including any of the genus of NBS-containing plant disease resistant polypeptides of the invention.

As used herein, "leucine rich region" ("LRR") includes reference to a region that has a leucine content of at least 20% leucine or isoleucine, or 30% of the aliphatic residues: leucine, isoleucine, methionine, valine, and phenylalanine, and arranged with approximate repeated periodicity. The length of the repeat may vary in length but is generally about 20 to 30 amino acids. An LRR-containing polypeptide typically will have the canonical 24 amino acid leucine-rich repeat (LRR) sequence, which is present in different proteins that mediates molecular recognition and/or interaction processes; as described in Bent (1994) *Science* 265:1856-1860; Parker (1997) *Plant Cell* 9:879-894; Hong (1997) *Plant Physiol.* 113:1203-1212; Schmitz (1997) *Nucleic Acids Res.* 25:756-763; Hipskind (1996) *Mol. Plant Microbe Interact.* 9:819-825; Tornero (1996) *Plant J.* 10:315-330; Dixon (1996) *Cell* 84:451-459; Jones (1994) *Science* 266:789-793; Lawrence (1995) *Plant Cell* 7:1195-1206; Song (1995) *Science* 270:1804-1806; as discussed in further detail *supra*. Using the teachings disclosed and incorporated herein and standard nucleic acid hybridization and/or amplification techniques, one of skill can

identify polypeptides having LRR domains, including any member of the genus of LRR-containing RG polypeptides of the invention.

The term "promoter" refers to a region or sequence determinants located upstream or downstream from the start of transcription and which are involved in 5 recognition and binding of RNA polymerase and other proteins to initiate transcription. A "plant promoter" is a promoter capable of initiating and/or regulating transcription in plant cells; see also discussion on plant promoters, *supra*.

The term "constitutive promoter" refers to a promoter that initiates and helps control transcription in all tissues. Promoters that drive expression continuously 10 under physiological conditions are referred to herein as "constitutive" promoters and are active under most environmental conditions and states of development or cell differentiation; see also detailed discussion, *supra*.

The term "inducible promoter" refers to a promoter which directs transcription under the influence of changing environmental conditions or developmental 15 conditions. Examples of environmental conditions that may effect transcription by inducible promoters include anaerobic conditions, elevated temperature, drought, or the presence of light. Such promoters are referred to herein as "inducible" promoters; see also detailed discussion, *supra*.

The term "abscission-induced promoter" or "abscission promoter" refers to a 20 class of promoters which are activated upon plant ripening, such as fruit ripening, and are especially useful incorporated in the expression systems (*e.g.*, expression cassettes, vectors) of the invention. When the plant disease resistant polypeptide-encoding nucleic acid is under the control of an abscission promoter, rapid cell death, induced by expression 25 of the invention's polypeptide, accelerates and/or accentuates abscission of the plant part, increasing the efficiency of the harvesting of fruits or other plant parts, such as cotton, and the like; see also detailed discussion, *supra*.

The term "tissue-specific promoter" refers to a class of transcriptional control elements that are only active in particular cells or tissues. Examples of plant 30 promoters under developmental control include promoters that initiate transcription only (or primarily only) in certain tissues, such as roots, leaves, fruit, ovules, seeds, pollen, pistils, or flowers; see also detailed discussion, *supra*.

As used herein "recombinant" includes reference to a cell, or nucleic acid, or vector, that has been modified by the introduction of a heterologous nucleic acid or the alteration of a native nucleic acid to a form not native to that cell, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.

As used herein, a "recombinant expression cassette" or "expression cassette" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements which permit transcription of a particular nucleic acid in a target cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the recombinant expression cassette portion of the expression vector includes a nucleic acid to be transcribed, and a promoter.

As used herein, "transgenic plant" includes reference to a plant modified by introduction of a heterologous polynucleotide. Generally, the heterologous polynucleotide is an RG structural or regulatory gene or subsequences thereof.

As used herein, "hybridization complex" includes reference to a duplex nucleic acid sequence formed by selective hybridization of two single-stranded nucleic acids with each other.

As used herein, "amplified" includes reference to an increase in the molarity of a specified sequence. Amplification methods include the polymerase chain reaction (PCR), the ligase chain reaction (LCR), the transcription-based amplification system (TAS), the self-sustained sequence replication system (SSR). A wide variety of cloning methods, host cells, and *in vitro* amplification methodologies are well-known to persons of skill.

As used herein, "nucleic acid sample" includes reference to a specimen suspected of comprising RG resistance genes. Such specimens are generally derived, directly or indirectly, from lettuce tissue.

The term "antibody" refers to a polypeptide substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments or synthetic or recombinant analogues thereof which specifically bind and recognize analytes and antigens, such as a genus or subgenus of polypeptides of the invention, as described *supra*.

It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.

5

EXAMPLES

The following examples are offered to illustrate, but not to limit the claimed invention.

Example 1

10 Example 1 describes the use of PCR to amplify RG genes from lettuce.

Multiple primers with low degeneracy, particularly at the 3' end, were designed based on the sequences of two known resistance genes from tobacco and flax.

DNA Templates

15 Lettuce genomic DNA was extracted from cultivar Diana and a mutant line derived from cultivar Diana using a standard CTAB protocol. To generate cDNA templates, RNA was isolated from cultivar Diana and the mutant following standard procedures; first strand cDNA was synthesized using Superscript reverse transcriptase from 1 Φ g total RNA as specified by the manufacturer (Life Technologies). BAC (bacterial artificial chromosome) clones from the *Dm3* region were isolated from a BAC library of 20 over 53,000 clones using marker AC15 that was known to be closely linked to *Dm3*. Bacterial plasmids containing clones of *L6* and *RPS2* were used as positive controls.

PCR with degenerate oligonucleotide primers

25 Oligonucleotide primers were designed based on conserved motifs in the nucleotide binding sites (NBS) of *L6*, *RPS2*, and *N*. Eight primers were made corresponding to the GVGKTT motif in the sense direction; each had 64-fold degeneracy. Six primers were made to the GPLAL motif in the anti-sense direction; with either 16 or 256-fold degeneracy (Table 1).

30 Oligonucleotides included 14-mer adaptors of (CUA)₄ at the 5' end of the sense primers and (CAU)₄ at the 5' end of the antisense primers to allow rapid cloning of the PCR products into pAMP1 (Life Technologies).

PCR amplification was performed in 50 μ l reaction volume with 1 μ M of each of a pair of sense and antisense primers. The templates were denatured by heating to 94EC for 2 min. This was followed by 35 cycles of 30 sec at 94EC, 1 min at 50EC, 2 min at 72EC, with a single final extension of 5 min at 72EC. 25 ng of genomic DNA or cDNA was used. BAC clones as templates required less. The final dNTP concentration was 0.2 mM; MgCl₂ was 1.5 mM.

Forty-eight combinations of sense and antisense primers were tested on a panel of nine templates consisting of two genomic DNA samples, two cDNA preparations, three BAC clones and plasmids containing *L6* and *RPS2* as positive controls.

Amplification from *L6* and *RPS2* resulted in fragments of 516 and 513 respectively. Seven combinations of primers resulted in fragments of approximately this size with multiple templates (Table 2). Primers that gave RLG products were: PLOOPAA, PLOOPAG, PLOOPGA, PLOOPGG, PLOOPAC, GLPL3, GLPL4.

15

20

(Intentionally left blank)

25

Table 1

DEGENERATE PRIMER SEQUENCES for NBS PCR

Sense primers based on GVGKTT amino acid sequence from L6, N and rps2 PLOOP motif:

PLOOPAG 5' GGN GTN GGN AAA ACG AC 3'

PLOOPAA 5' GGN GTN GGN AAA ACA AC 3'

PLOOPAT 5' GGN GTN GGN AAA ACT AC 3'

PLOOPAC 5' GGN GTN GGN AAA ACC AC 3'

PLOOPGG 5' GGN GTN GGN AAG ACG AC 3'

PLOOPGA 5' GGN GTN GGN AAG ACA AC 3'

PLOOPGT 5' GGN GTN GGN AAG ACT AC 3'

PLOOPGC 5' GGN GTN GGN AAG ACC AC 3'

Antisense primers based on GPLAL amino acid sequence:

GPLL1 5' AGN GCN AGN GGN AGG CC 3'

GPLL2 5' AGN GCN AGN GGN AGA CC 3'

GPLL3 5' AGN GCN AGN GGN AGT CC 3'

GPLL4 5' AGN GCN AGN GGN AGC CC 3'

GPLL5 5' AAN GCC AAN GGC AAA CC 3'

GPLL6 5' AAN GCC AAN GGC AAT CC 3'

TABLE 2. Characteristics of RLGs isolated from lettuce.

	Template	Primers	Number ^a	Size ^b (bp)	Copy number ^c	Dm linkage
5	RLG1 genomic DNA	PLOOPGA+GLPL6	6/6	522		DM4, DM13
	cDNA	PLOOPGA+GLPL6	1/5			
	genomic DNA	PLOOPAA+GLPL6	5/5			
	cDNA	PLOOPAA+GLPL6	1/1			
10	RLG2 BACH8	PLOOPGG+GLPL3	3/3	510		DM1, Dm3
	RLG3 gemonic DNA	PLOOPGA+GLPL4	3/6	461		Dm5 Dm8
15	RLG4 genomic DNA	PLOOPGA+GLPL4	1/6	524		

^a Number of RLG sequences out of total number of clones sequenced.

^b Size of fragment amplified from the nucleotide bindind domain.

^c Estimated copy number from genomic Southern blot analysis and numbers of clones in the BAC library.

Example 2

Example 2 describes the genetic analysis used to obtain a preliminary indication of the linkage relationships of the amplified products and known clusters of resistance genes.

Bulked segregant analysis was performed to obtain a preliminary indication of the linkage relationships of the amplified products and known clusters of resistance genes. DNA from individuals were pooled for each susceptible and resistant bulk.

Amplified products were then mapped by RFLP analysis from our intraspecific mapping population. Resistances from four clusters of resistance genes as well as over six hundred markers have now been mapped on this population. Linkage analysis was done using JIONMAP or MAPMAKER mapping programs. Due to a suppression of recombination in the *Dm3* region, sequences were mapped relative to *Dm3* using a panel of deletion mutants that provided greater genetic resolution than the mapping population (Anderson *et al.* 1996).

All blots were washed twice at 63EC in 2x SSC/1% SDS for 20 min, followed by one wash at 63EC in 1x SSC/0.1% SDS for 10 or 30 min.

Most of the RLG sequences were analyzed by bulked segregant analysis (BSA) using pools of resistant and susceptible individuals for each of the four clusters of resistance genes. In genomic Southern analyses, all the RLGs revealed numerous fragments of varying intensity. The numbers of bands was highly dependent of the stringency of hybridization. BSA demonstrated that RLG1 was linked to the *Dm4,7* and *Dm13* clusters. Segregation analysis confirmed this linkage.

RLG2 was derived from BAC H8 that was known to be from the *Dm3* region. BSA with RLG2 demonstrated that the polymorphic bands that distinguished the parents of our mapping population mapped to the *Dm1,Dm3* cluster. Several bands absolutely cosegregated with *Dm1* or *Dm3*. To provide finer genetic resolution, RLG2 was also mapped using a panel of *Dm3* deletion mutants. A number of fragments were missing in largest deletion mutant demonstrating that several RLG2 family members are physically located very close to *Dm3*. No fragment was missing in all deletion mutants; however, this is not unexpected as there is extensive duplication within the region.

15

Example 3

Example 3 describes the screening of a bacterial artificial chromosome library.

Over 53,000 BAC clones containing lettuce genomic DNA were screened with two of the amplified products. High density filters each containing 1536 clones were hybridized to ³²P labelled probes. Filters were washed at 65EC with 40 mM Na₂PO₄/0.1% SDS for 5 min followed by 20 min in the same solution.

To isolate additional RLG sequences we screened our genomic BAC library. Clones were identified that hybridized to RLG1 and RLG2. Nearly all the clones that hybridized to RLG2 also hybridized to marker AC15 that had already been shown by deletion mutant analysis to be clustered around *Dm3*. This provided further evidence for clustering of RLG2 sequences.

Using primers conserved within each family, part of the NBS was amplified from each unique BAC clone and sequenced. This revealed that members within each family varied from 64% identical at the deduced amino acid level. The most divergent members only weakly cross-hybridized to each other. Currently, RLG sequences are

considered to be part of the same family of sequences if they are at least 55% identical at the deduced amino acid level and map to the same region of the chromosome.

Example 4:

5 Example 4 describes the cloning, identification, sequencing and characterization of RG polynucleotide sequences; including use of RG sequences from plasmid and PCR products.

Doubled stranded plasmid DNA clones and PCR products were sequenced using an ABI377 automated sequencer and fluorescently labelled di-deoxy terminators.

10 Sequences were assembled using Sequencher (Genecodes), DNASTar (DNASTar) and Genetics Computer Group (GCG, Madison, WI) software. Database searches were performed using BLASTX and FASTA (GCG) algorithms.

15 Sequences flanking the NBS region for RLG2 and for some of RLG1 were obtained by a series of IPCR and the products sequenced directly. IPCR worked less well for RLG1. Therefore RLG1 was subcloned from a BAC clone into pBSK (Stratagene) and the double stranded plasmid sequenced by long range sequencing.

20 Initially, a total of 30 clones were sequenced. Three of these seven primer combinations yielded sequences that comprised continuous open reading frames with sequence identity to the NBS of known resistance genes. Seven out of 10 clones amplified from genomic DNA with the primer pair PLOOPGA/GLP6 were 522 bp long; they were identical to each other and named RLG1. All six clones amplified from genomic DNA or cDNA using the primers PLOOPAA/GLP6 were similar/the same as RLG1. All three clones sequenced from BAC clone H8 were 510 bp long, identical to each other but different from RLG1 and were therefore designated RLG2. The 11 clones sequenced from 25 four other primer combinations had no similarity to any NBS motifs and therefore were not studied further. Therefore, sequencing resulted in the identification of clones containing NBS motifs representing four RLG sequences.

30 Comparison of the deduced amino acid sequences of RLG1 and RLG2 to those of known resistance genes revealed that RLG1 and RLG2 are as similar to each other as they are to resistance genes from other species and that this is the same level of identity shown between the known resistance genes (Table 3). The percent identity (upper quadrant) and percent identity (lower quadrant) were determined using the MEGALIGN

routine of the DNASTAR package. Identity refers to the proportion of identical amino acids; identity refers to the proportion of identical and similar amino acids and takes into account substitutions of amino acids with similar chemical characteristics. RG1 and RG2 are as similar to each other and to cloned resistance genes as cloned resistance genes from a variety of species are to each other. L6, resistance to *Melampsora lini* in flax (Lawrence *et al.*, 1995). N, resistance to tobacco mosaic virus in tobacco (Whitham *et al.*, 1994). PRF, required for resistance to *Pseudomonas syringae* in tomato. RPS2, resistance to *Pseudomonas syringae* in *Arabidopsis thaliana* (Bent *et al.*, 1994; Mindrinos *et al.*, 1994). RPM1, resistance to *Pseudomonas syringae* pv. *maculicola* in *A. thaliana* (Grant *et al.*, 1995). The initial RG1 and RG2, sequences were amplified from lettuce using degenerate primers.

15 **Table 3**

IDENTITIES OF

RESISTANCE GENE HOMOLOGUES

		RG1	RG2	RG3	RG4	N gene	RPS2
	Lettuce	RG1	***	22.7	15.0	29.2	25.4
	Lettuce	RG2		***	32.2	21.6	22.7
	Lettuce	RG3			***	17.2	15.0
20	Lettuce	RG4				***	32.8
	Tobacco	N gene				44.3	22.7
	<i>Arabidopsis</i>	RPS2				***	21.6

25

The regions homologous to the primers are included in this analysis as the genomic sequences for RLG1 and RLG2 were determined by IPCR. Interestingly, the genomic sequences for RLG1 exactly matched that of the primers used.

30 To obtain further evidence that we had amplified resistance genes, we amplified the regions flanking the NBSs of RLG1a and RLG2a by IPCR of BAC clones. These products were then directly sequenced without cloning to minimize the introduction of PCR artifacts. Sequence analysis of the 5' regions failed to detect any homology to known resistance genes. However, the sequence of the 3' region contained leucine-rich

repeats (LRRs). When this sequence was used to search GENBANK using BLASTX, it detected identity to the *Arabidopsis* resistance gene, *RPS2*. This region does not contain as regular LRRs as in some resistance genes; however, the repeat structure seems to be consistent with that of the flax resistance gene, *L6*. Therefore, the presence of an LRR 5 region is further evidence that the sequences we amplified using degenerate oligonucleotide primers are probably resistance genes.

The sequences of the IPCR products also provided the genomic sequences of the regions complementary to the sequences of the degenerate oligonucleotide primers. The genomic sequences for RLG1 were identical to one of the primers in the mixture. 10 The RLG sequences are resistance genes as supported by three criteria: the presence of multiple sequence motifs characteristic of resistance genes, genetic cosegregation with known resistance genes, and their existence as clustered multi-gene families. The presence of LRR regions in a similar position relative to the NBS as in cloned resistance genes provides stronger evidence than relying solely sequence similarity between NBS regions. 15 The clustering of RLG sequences at the same position as the known clusters of resistance genes make them strong candidates for encoding resistance genes. The hybridization patterns and genetic distribution of the RLG sequences are similar to that of cloned resistance genes in other species. Most of these hybridize to small multigene families and preliminary genetic evidence indicates that they are clustered in the genome. Therefore, 20 the degenerate primers that we designed from other resistance genes seemed to have been specific enough to amplify resistance genes rather than P-loop containing proteins in general.

25

(intentionally left blank)

30

SEQID No:1

RLG1A
[Strand]

1 ATCGTAAACCGTTCGACGAG ANCCTGCCCCCTTCATC TTTTGTCAATATGTCATATTTC TCATNNATTNTGCCACATNT
 81 AATTTTGTGGTTATTTTAA TTAATTTTTATTCACATGT CATTATGAGTTTTCTAT TTTATTGAGTTTCACATAAT
 161 ATTTAAATGTAATAACAATA AATGCAATTATTTTCTT TAAATAAACGCTATAATAAT ATAGATTAATAACATATAAT
 241 ACATAGGTTAACCTATATA ATACATAATGTCATCCCCAG TTATTTTATAATGTCATCC TTAAATTATTTATTTAT
 321 TTATTAGAGTAGATGATCTT TGAGATATTTAAATTTAA TTGTTCAAAATTTAAATTA TTAAATATCCACAAATTGAG
 401 ATAAAATAAAAAAATGGN CCCACCAATTAGTCACATCACT TTTCAGCTCATAAATATCG TGAGTATTCTCCCTCGTTTC
 481 CACCCCTATCAATATTCACCA GCGAATGACAGACTCTACG GCGTTTCTGAATTTCGCGTTTC CGACACTGTTCAATTGAAGGA
 561 GATAATAATCAAATGGAGC TGCTCAATGTCATTGCTG ATGAAAGGTGAATTGTATGT GAAGANAAATGTCAGCGATCN
 641 ATCTCCATCCGGAACCCACC ACATTATCAGTGTACCCACCA ACCACTCAAAACGGYGGAA GTAGRRAKACWRAAAAGTC
 721 TGAAGAATAGATTATTTTG TCCTCATGGGCTGACTGAGG AGCGGGTTAGTTCATCATT TTCTTTAAATCTTTTATCTT
 801 TCGGTCCATCGAATTTCATC ATCGACAAAGAAGTTCACCT TCGCAATGTTTAAACA ATTTTTAAATCTTTTATCTT
 881 TCGTTGAAACTCCCTCAATT GCAACTTGCACATTGCAACT TTGGGCCCAACAAATTGAG AGGGCGGTAAATTAAATCCCA
 961 CATATTCAGTAAACATA ATTCAAATGCACTCTGTC ATCCATTCAATCAACATCTC TTGATAATTGAAATCATTC
 1041 CGCTTCATCCATTTCATCCA CATCTATACTATATTCCTG CTCCTATCATATAAAACGAT GGCTGAAATCGTTCTTCTG
 1121 CTTCTTGACAGTGGTGTGTT GAAAAGCTGGCATYTGAAGC TTGAGAAAGATTGTTGCT CCAAAAGAATGAAATCTGAG
 1201 CTAAAGAAATTGAGGAGAC ATTAGACCAAATCCAAGATC TGCTTAACGATGCTTCCAG AAGGAAGTAACAAATGAAAC
 1281 CGTTAAAAGATGGCTGAATG ATCTCCAACATTGGCTTAT GACATAGACGACCTACTTGA TGATTTGCAACTGAAGCTG
 1361 TTCAACGTGAGTTGACCGAG GAGGGTGGAGCCTCCCTCAG TATGGTAAGAAAACAAATCC CAAGTTGTCACAAAGTTTC
 1441 TCACAAAGTAATAGGATGCA TGCCAAAGTTAGATGATATTG CCACCAAGGTTACAAGAAACTG GTAGAGGCAAAATAATCT
 1521 TGGTTTAAGTGTGATAACAT ATGAAAAGCCAAAAATTGAA AGGTATGAGGGCTTTGGT AGATGAAAGCGGTACTGTC
 1601 GACGTGAGAGTGTAAAGAAA AATTGCTGGAGAACGCTGTT GGGGGATAAAAGATGAATCAG GGAGTCAAAACCTCAGC
 1681 GTGCCCCATAGTTGCTATGGG TGGAGTTGGTAAAAACACTC TAGCTAGACTTTGATGAT GAAAAGAAATGAAAGGATCA
 1761 CTTCGAAACTCAGGGCTTGGG TTGTTGTTCTGATGAGTTC AGTGTCCCAATATAAGCAG AGTTATTATCAATCTGTA
 1841 CTGGGGAAAAGAAGGAGTTT GAAGACTTAAATCTGCTTCA AGAAGCTCTAAAGAGAAAC TTAGGAACAGCTATTCTA
 1921 ATAGTTTGGATGATGTTG TGCTGAAAGCTATGGTATT GGGAGAAAATTAGTGGGCCCCA TTCTTGGGGGCTCTCTGG
 2001 AAGTAGATAATCATGACAA CTGGAAAGGGCAATTGCTC AGAAAGCTGGGCTTTCTCA TCAAGACCTCTGGAGGGTC
 2081 TATCACAAAGATGATGCTTGT TCTTGTGTCACACGCC ATTGTTGTAACAAACTTGT ATTACATCAACACTAAGG
 2161 CCACATGGAGAACTGTTGT GAAGAAATGATGGCTTAC CTCTAGCTTAAAGAACACTT GGAAGGTTATTAAGGACAAA
 2241 AACAGACGGGAAACAATGGA AGGGAGCTGTTGGATAGTGGAG ATATGAGGGTAGGAAAGAG CGATGAGATTGTTCCGGCTC
 2321 TTGACTAAAGCTACATGAT CTTCCTGCCCTTGAAGCT RTTGTGTCATATGCTCT TGTTCCTCAAGGACTATGAG
 2401 TTGTCAGGGAGGATGTTGAT TCTATTGTCAGGGAGAAGG GGTGTTGCAACCAACTC AYAAACAAGTCACAGC
 2481 TTGGGTCTTGAATTTTTAA AAGAGTTGTCAGRTCR TTGTTCAACATGCTCTAA TTRCAAATCSTTGTGTA
 2561 TGCATGACCTAATGATGAT TTGGCTACATTGTTGCTGG AGAATTTTTCAAGGTTAG ACATAGAGATGAAAGGAA
 2641 TTGAGGATGSAATCTTGGG RAAGCACCGCATATGTCAT TTGTATGAGRATTACATA GGTTACAAAARGTTGAGGCC
 2721 ATTTAGAGGGAGCTAAAAATT TGAGAACATTTTAGCATG TCTGTTGGGGTGGTAGAAGA TTGGAAGATGTTTACTTAT
 2801 CAAACAGGTCTTGTGAC WTACTTCGAAATTACCAATT GTTAAGGGTCTRAKTTGA TTRRTCTTAYAATAASYRAG
 2881 GTACCCAAATCGTSCGTAG TATGAACSCATTGGGTATC TTAACATCTACWGAAACTTWA ATCACMCATTACCGGAAWA
 2961 TKTCTGCAATCTTATAATT TACARACCCCTGATGTTCT TGGCTGAMATTAGTTAA KITGCCCAARACCTTCTCAA
 3041 ASCCTTAAATTTCGASCAT TTGACATGGGGRTACTCC KAANTTAAARAACATGCCCT TARGGATTGGGARTTGAAAA
 3121 ARTCTCACAATTCTCTTGG TAAACATTGGCATAGCAATTAA CCGAGCTTAAAGAACCTGCA AAYCTCCATTGGAAAATTG
 3201 TATTGGGGGTGGGAAAAA TGGAAAATGCMGTTGGGATTC ACGTTAACGCAACTTGTCT AAAAAGGTTWAATGARITA
 3281 NAAACTGGRWTGGGGGTGA TAAATTAAATGTTTCCCAA ATGGGAAACACTTGAAGAAAAGA AGTCCCTCAATGAAAGTGTG
 3361 CTCAATAGGTACTCTAA AAAACCCAAATTATGTCAT TAGGGGGTATAGAGTTTCCA AATTGGGTGGTTTCACTAA
 3441 GGGTTCTGAAACTAGAGAT GTGTTCATGGTGTATGAAAA AGANTTTTACGTTAGTTTC ATCAATCACCAAGTGGAAA
 3521 TAGATGATAATTTCAGGGC TACTGATGAGATGTTGGAGAG GTATGATAGGGTTCTTGGG GCGGTAGAAGAAATAAGCAT
 3601 CCATTCTGTAAATGAAATAA GATATTTGTTGGGAAATCAGAA CGAGAGGCAAGTAAGGTTCT TATGAATTAAAGAAGTTGG
 3681 ATTAGGTGAAATGTTGAAA TTGGTGTGAGTTAGGGGAGAA AAAGGAGGATAATCATAATA TTAATAGTGGGACCACTA
 3761 ACATCTTGTAGGAGTTGAA TGTATGAGGATGTAACAGCT TGGACCATGGCAGGTGTCCA GATAGCATGGAGATTGTA
 3841 TATGCAATGTTGAGCTAA TAAACATGGCTCTTCTCCA ACAGGAGGAGGACAGAAGAT CAAGTCACCTTACCATCACTG
 3921 ATTGCAAGAAGCTTGGAA GAGGAGTTGGGAGGACGAGA GAGGACAAGAGTGTCTTATAA ACTCAAAATGCAAGATGCTT
 4001 GAATCAAGTGTAGATATACGTA TGGGCCAAATCTGAAATCTA TCAGTGAATTGAGTTGCTTCA ATTCAACCTGAACAGATTATA
 4081 TATATCACAATGTCGGAGTR TGGAGTCATTCTGACCAT GAGTGGCCAAATCTCACCTC CTTAACAGATCGAAGGAGAG
 4161 GACAGCGATTTCGTCAGCAA CGGTTACGATTGACTGGCC GTGTTTTT

SEQ ID NO: 2

RLG1B

[Strand]

1 AACCGTTCGT ACGAGAACCG CTGTCCTCTC CTTCCCTGAA TATAATGATA AGAAAAAATA TGATTAAGG
 71 TTTAAATCCA AAATCCATTAA TTCCACCGGT GATATGATGC ACTAGCTGTA GTATGAAAA ACAGTATTAT
 141 AAATGCTAAC CAAAACAGCA GCTAAGAAC AATATAAAATGTTTGAA TCGTCCTTC TCCGTACAQT
 211 CATTTCCTCC AAATCCCTAT CATTTCATACA TACAAGTGCT CCCATATTAG GTTTTCACTA TAAGCAATGG
 281 CTGAAATCCT TGGTCTGCG TTCTTTCGGG TGTTCTTGA AAAGCTTGCT TCTGAAGGCT TGAAGAGGGT
 351 TGCTTGCTCC AAAGTAATTG ACAAAGGAGCT CGAGAAATTG AATAGCTCAT GAATCAATAT AAAAGCTCTG
 421 CTCATGATG CTTCTCAGAA GGAAATAAGT AAGGAAGCTG TTAAGAATG GTGAAATGCT CTTCAACATT
 491 TGCCCTACGA CATAAGATGAT CTACTTGGCG ATTTGGCAAC CAAAGCTATC CATCGTAAGT TCTCTGAGGA
 561 ATACGGGGCC ACCATCAACA AGGTACGAAA GTTAAATTCCA TCTTGTTCCT CTAGTTTGTCA AAGTACTAAG
 631 ATGCGCAACA AGATACATAA TATTACCGC AAGTTACAAG AACTATTAGA AGAGAGAAAT AATCTTGGAT
 701 TATGTGAAAT TGGTGAAGC CGAAAACCTC GAAATAGAAA ATCAGAGACC TCTNTGCTAG ATCCATCTAG
 771 TATTGTGGA CGCACAGATG ATAAGGAAGC GTGCTCTC AAGCTATATG AACCATGTGA TAGRAACTTT
 841 AGCATCTGTC CNATAGTTGG TATGGGTGGG TTAGATAAGA CCACTTTAGG TAGACTTTTG TATGATNAAA
 911 TGCAAGTGAA GGATCACTTC GAACCTCAAGG CGTGGGTTTG TGTTTCTGAT GAGTTTGATA TCTTCGGTAT
 981 AAGCAAAACC ATTTGCAAT CGATAGAGGG GGGAAACCAA GAGTTTAAGG ATTTAAATCT GCTTCAGGTG
 1051 GCTTTAAAGG AGAAAATCTC AAAGAAACCG TTTCTTGTG TTCTTGATGA TGTATGGAGC GAGAGCTATA
 1121 CTGATTTGGG AATTCTAGAA CGTCCATTTC TAGCAGGAGC ACCAGGAAGT AAAGTAATCA TCACAAACCG
 1191 CAAGTTGTCG TTGCTAAACC AATTGGGTC A TGATCAACCA TACCAATTGT CTGATTGTC ACATGACAAT
 1261 GCTCTATCCT TATTTTGTCA ACACGCATTG GGTGTAATAA GCTTGTGATC ACATCCGATA CTTAAACCCAC
 1331 ATGGTGAAGG TATTTGTGAA AAATGTGATG TTTGCCATT GGCTTGTGATT GCACTTGGGA GGTTATTGAG
 1401 GACAAAAGA GATGAGGAAG AATGGAAGGA ACTATTGAAT AGTGGAGATAT GGAGGTTAGG AAAGAGAGAT
 1471 GAGATTTTC CGGYTCTTAG ACTAAGCTAT AATGATCTTT CTGCTCTT GAAGCAGTTG TTGCTATATT
 1541 GCTCCTGTT CCCAAAGAC TATGTTGTC ACAAGGAGAA GTTGATTTA TTATGGATGG CAGAAGGGTT
 1611 TTTGCAACAT GAAAATACAA ACAAGTCAAT GGAACGCTTA GNTCTTGAAT ATTTTGACGA CTGTTGTCA
 1681 AGGTCTTTT TTCAACATGC ACTCGATGAC AAATGTTGTG TTGTTGTCGA CGACCTCATG AATGACTTGG
 1751 CCACATCTGT TGCTGGAGAT TATTTTTAA GATTAGACAT TGAAATGAAA AAGGAAGCTT TGGAAAAATA
 1821 CCGACATATG TCATTTGTT GTGAGAGTTA CATGGTTAC AAAAGGTTCG AACCATTAA AGGAGCTAAA
 1891 AAATTGAGAA CTTCTTAGC AATGCTGTT GGGATGATAA AAAGTTGGAC AACATTTCAC TTATCAAATA
 1961 AGGTCTTGA TGACTTACTT CACGAATTAC CATTGTTGAG AGTCTAAGT TTGAGTTATC TTAGCATCAA
 2031 GGAGGTACCT GAAATAATAG GCAATTGAA ACACCTGGG TATCTTAATT TATCACACAC GAGTATCACA
 2101 CATTTCACAG AAAATGCTG CAATCTTAC AACTTACAA CATTGATCCT TTGTTGCTGT TGTTTATAA
 2171 CCAAGTTTCC CAAACACTTC TTAAAGCTTA GAAATTACG GCATTGGAC ATTAGCGATA CTCCCGTTT
 2241 GAAGAAGATG TCCCTGGGG A TTGGTGAATT GAAGAACCTA CACACYCTCT CCAAGCTCAT TATTGGAGGT
 2311 GAAATGAC TAAACGAGCT TAAGAACTTA CAAAATCTCC ATG

RLG1b - Diana
[Strand]

1 TACTACTACT AGAATTCCGGT GTTGGTAAGA CGACTCTAGC TAGACTTTTG TATGAGGAAA TGCAAGGGAA
71 GGATCACTTC GAACTTAAGG CGTGGGTATG TGTTTCTGAT GAGTTTGATA TCTTCATAT AAGCAAAATT
141 ATCTTACAAT CGATAGGTGG TGGAAACCAA GAATTTACGG ACTTAAACCT GCTTCGAGTA GCTTTAAAAG
211 AGAAGATCTC AAAGAAAAG^a TTTCTTCCTG TTCTTGATGA TGTTTGGAGT GAAAGCTATA CCGATTGGGA
281 AATTNTAGAA CGCCCCATTTC TTGCAGGGGC ACCTTGAAGT AAGATTATTA TCACCACCCG GAAGCTGTCA
351 TTGTTAAACA AACTCGGTTA CAATCAACCT TACAACCTTT CGGTTTGTCT ACATGAGAAT GCTTTGTCTT
421 TATTCTGTCA GCATGCATTG GGTGAAGATA ACTTCAATTG ACATCCAACA CTTAAACCAC ATGGCGAGG
491 TATTGTGAA AAATGTGATG G^aTTGCCATT GGCATTGTG ACATGATGAT GATG

SEQ ID 137

SEQ ID NO:3
RLGIC
[Strand]

1 TCCCGTGC^A CGTNTATCAT TCAGAAGNGC CCAAAGACCA NAGATNTGTT TAANGNTGNT TNTCAGAAGG
71 AAGTATTGA TGAAGCTGTN AAAAGATGGC TGATTGATNT CCAACAATTG GCTTACGACA CTGANGACNA
141 ACTTGATGAT NTGCGAACAG AAGCTATTCA TCGTGAGTTG ATCCGTGAAA CTGGAGCTTC CNCCAGCATG
211 GTAAGRAACC TAATCCCAAG TTGTTGCACA AGTTTCTCAC AAAGTAATAG GATGCATGCC AGGTTAGATG
281 ATATTGCCGC TAAGT^NACAA GAACTGGTAG AGGCAGAAAAA TAATCTTGGT TPAAGTGTGA TAACATACGA
351 AAAACCCAAA ATTGAAAGAG ATGAGGCGTN TTGTTGAGAT GCAAGTGGTA TCATTGGACG TGAAGATGAT
421 AAGAAAAAAAT TGCCTTCAGAA GCTGTTGGGG GATACTTATG AATCAAGTAG TCAAAACTTC AACATCGTGC
491 CCATAGTTGG TATGGGTGGG GTAGGTAAAAA CAACTCTAGC TAGACTTTG TATGATGAAA AAAAAGTGAA
561 GGATCACTTC GAACTCAGGG TTGTTGGTTTG TGTTTCTGAT GAGTTCACTG TTCCCAATAT AAGCAGAGTT
631 ATCTATCAAT CTGTGACTGG TGAAAACAAA GAATTGCGAG ATTTAAATCT GCTTCAAGAA GCCCCTAAAG
701 AGAAACTTCA GAACAAACTA TTCTTAATAG TTTTAGATGA TGATGGTCT GAAAGCTATG GTGATTGGGA
771 GAAATTAGTG GCCCCATTTC ATGCTGGGAC TTCTGGAAGT AGAATAATCA TGACTACTCG GAAGGGAGCAA
841 TTACTCAAAC AGCTGGGTTT TTCTCATGAA GACCCCTCTGC ATAGTATAGA CTCCCTGCAA CGTCTATCAC
911 AAGAAGATGC TTTGTCTTTG TTTTCTCAAC ACGCATTTGG TGTACCTAAC TTTGATTAC ATCCAACACT
981 AAGGCCATAT GGGGAAACAGT TTGTGAAAAA ATGTGGGGGA TTGCCTTGG CCTTGT

SEQ ID NO:4
RLGID
[Strand]

1 CNTACCCITTC TACGAGATCG CTGTCCCTCC TCGATCTGCT TAACGATGCT TCCCAGAAGG AAGTNACTAA
71 TGAAGCCGTT AAAAGATGGC TGAATGATCT CCAACATTG GCTTATGACA TANACGACCT ACTTGATGAT
141 CTTGGCAGACAS AAAGCTTATIC NTCSTGAGTT GACCGANGAA GGTGGAGCCT CCACCACTAT GGTAAGAAA
211 CTAATCCCAA GTTGTGAC AAGTTTCTCA CAAAGTTATA GGATGCATGC CAAGTTAGAT GATATTGCCA
281 CCAGGTTACA AGAACTGGTA GAGGCAAAAA ATAATCTTGG TTTAAGTGTG ATAACATATG AAAAGCCCAA
351 AATTGAAAGG TATGAGGCAT CTTGGTAGA CGAAAGTGGT ATTTTTGGAC GTTNAAGATGA TNAGAAAAAA
421 TTGATGGAGA AGCTGTGGA GGATAAAAGAT GAATCCGGAG TCNAAACTTC AGCATCCTGC CCATAATTGG
491 TATGGGTGGA GTTGGCNAAA CAACTCTAGC TAGACTCTTG TTGATGAAA AGACAGTGAA GGATCACTTC
561 GAACTCAGGG CTTGGGTTTG TGTTTCTGAT GAATTCAAGTA TTCTCAACAT AAGCAAAGTT ATCTATCAAT
631 CTGTGACCGG GGAAAAGAAA GAGTTTGAAG ACTTAAATCT GCTTCAGAA GCTCTTAGAG GGAAACTACA
701 AAACAAACTA TTCTAAATAG TTTGGATGA TGTATGGTCG GAAAGCTATG GTGATTGGGA GAAATTAGTG
771 GGCCCCTTTC ATGCTGGGAC TTCTGGAAGT AGAATAATCA TGACTACTCG GAAGGAGCAA TTACTCAAAC
841 AGTTGGGTTT TTCTCATCAA GACCCCTCTGC GTTGTATAGA CTCCCTGCCAA CGTCTATCAC AAGATGATGC
911 TTGTCCTTG TTGCTCAAC ACGCATTGG TGWCCA

RL1E
[Strand]

1 TCTAGCTAGA CTTTTGTATG ACGAGATGCA AGAGAAGGAT CACTTCGAAC TCAAGGCGTG GGTTTGTGTT
71 TCTGATGAGT TTGATATATT CAATATAAGC AAAATTATT TCCAATCGAT AGGAGGTGGA AACCAAGAAT
141 TTAAGGACTT AAATCTCCCTT CAAGTAGCTG TAAAAGAGAA GATTTCAAAG AAACGATTTTC TACTTGTCT
211 TGATGATGTT TGGAGTGAAA GCTATGCGGA TTGGGAAATT CTGGAACGCC CATTTCCTTC AGGGGCAGCC
281 GGAAGTAAAAA TTATCATGAC GACCCGGAAG CAGTCATTGC TAACCAAACG CGGTTACAAAG CAACCTTACA
351 ACCTTTCCGT TTGTCACAT GACAGTGCTC TCTCTTTATT CTGTCAGCAT GCATTGGGTG AAGATAACTT
421 CGATTCACTA CCAACACTTA AACCACATGG CGAAGGCATT GTTGAAAAAT GTGCT

SEQ ID NO:5

RLG1F
[Strand]

1 ATTTTCNGCT CAAACAAAN AAAAGCAATG GCTGAAATCT TTCTTCNGC ATTCTAGACC AGTATTCTTT
71 GAAAAGNTGG CTTCCTGAAGC CTTGAAGAAG ATCGCTCGCT TCCATCGGAT TGATTTCTGAG CTCAAGAAAC
141 TGAAGAGGTC ATTAATCCAG ATCAGATCTG TGCTTAATGA TGCTTCTGAG AACGAAATAA GTGATGAAGC
211 TGTTAAAGAA TGCGTGAATG GTCTCCAAAC TTTGCTTAC GACATAGACC ACCTACTTGA TGATTTGGCA
281 ACGGAACTA TGCGATCGTGA GTTGACCCAC GGATCTGGAG CCTCCACCAAG CTTGTAAGAA AGATAATCCC
351 AACTTGTGAC ACAGATTTCT CACTAAGTAG TAAGATCGCT AACAGTTAG ATAATATTAC CATCAAGTTA
421 CAAGAAGTGG TAGAGGAAAA AGATAATCTT GGCTTAAGTGTG TGAAGGGTGA AAGCCAAAAA CATACCAACA
491 GAAGATTACA GACCTCTTTC GTAGATGCAT CTAGCATTAT TGGCTGTGAA GGTGATAAGG ATGCATTGCT
561 CCATAAGCTG CTGGAGGATG AACCAAGTGA TAGAAACTTT ACCATCGTCC CAATAGTTGG TATGGGTGGT
631 GTGGGTAAAGA CGACTCTAGC TAGACTTTTG TAGACGGAGA TCCAAGAGAA GGATCACTTC GAACTCAAGG
701 CGTGGGTTTG TGTTTCTGAT GAGTTTGATA TCTTCATAAT AACCAAAGTT ATCTTCCAAT CGATAGGTGG
771 TGGARACCAA GAATTTAAGG ACTTTAAATCT CCTTCAAGTA CCTGTAAGAG AGAAGATTTC AAAGAACGA
841 TTTCCTTYYTG TTCTGGATGA TGTTTGGAGT GAAAGCTATA CAGAATGGGA ATTCTAGCA CGTCCTTTTC
911 TTGCRGGGGC ACCAGGAAGT AAGATTATCA TGACGACCCG GAAGTTGTCC TTGCTAACCA AACTCGGTTA
981 CAATCAACCT TACAACCTTT CSGTTTGTG ACATGATAAT GCTYTGCTT TATTCTGTCA GCAYGCATTG
1051 GGTGAAGATA ACTTCGATTC ACATCCAACA CTTAAACCCAC ASGGTGAAGAAG TATTGTTGAA AAATGTGACG
1121 GTTTEACCATT GGCTTTRATT GCACTTGGGA GRTTGTGAR GACAAAAACA GATGAGGAAG AATGGAARGA
1191 AGTGTGAAAT AGTGAATAT GGGGGTCAGG AAAGGGAGAT GAGATTGTT CGGCTCTTAA ACTAAGCTAC
1261 AATGATCTCT CTGCTCTTTT GAAGAAGTTG TTTCATACT GCTCCCTGTT CCCAAAAGAC TATGTGTTCG
1331 ATAAGGAGGA GTTGTGTTTG TTGTTGGATGG CAGAAGGGTT TTGTCACCAA TCAACCACAA GCAAGTCBAT
1401 GGAACGCTTG GGHCATGAAG GTTTTGATGA ATTGTGTCA AGATCATTTT TTCAACATGC CCCGTATGCC
1471 AAATCGATGT TTGTGATGCA TGACCTGATG AATGACTTGG CHACATCIGT TGCTGGAGAT TTTTTTCAA
1541 GGATGGACAT TGAGATGAAG AARGAATTAA GGAAGGAAGC TTGSAAG YAYCGCCATA TGTCAWTGTT
1611 TTGTGAKGAT TACATGGTAKK ACAAAAGGTT CRAGCCATTs ACAAGGGAGCT AG

SEQ ID No: 6

RLG1G
[Strand]

1 GTGAAGGATC ACTTCGAACT CAGGGCTTGG GTTTGTGTTT CTGATGAATT TAATATCCTC AATATAAGCA
71 AAGTAATTAA TCAATCTGTA ACCGGGGAAA AAAAGGAGTT TGAAGACTTA AATCTGCTTC AAGAAGCTCT
141 TAAAGAAAAAA CTTTGGAAATC AGTTATTCT AATAGTTCTG GATGATGTGT GGTCTGAAAG CTATCGTGAT
211 TGGGAGAAAT TAGTGGGCCCTT TTTTTTTCG GGGTCTCTG GAAGTATGAT TATCATGACA ACTCGGAAAG
281 AGCAATTGCC AAGAAAGCTG GGTTTCTTC ATCAAGACCC TTTCAGAAGGT CTATCACATG ACGATGCTTT
351 GTCTTGTGTT GCTCAACACG CATTGGTGT ACCA

SEQ ID NO: 7

RLGIH
[Strand]

1 TCTAGCTAGA CTTTTGTATG AGGAAATGCA AGGGAAAGGAT CACTTCGAAC TCAAGGCGTG GGTATGTGTT
71 TCTGATGAGT TTGATATCTT CAATATAAGC AAAATTATCT TACAATCGAT AGGTGGGTGGA AACCAAGAAT
141 TTACGGACTT AAACCTGCTT CAAGTAGCTT TAAAAGAGAA GATCTCAAAG AAAAGATTTC TTCTTGTTC
211 TGATGATGTT TGGAGTGAAA GCTATACCGA TTGGGAAATT CTAGAACGCC CATTTCCTTGC AGGGGCACCT
281 GGAAGTAAGA TTATTATCAC CACCCGGAAAG CTGTCATTGT TAAACAAACT CGGTTACCAT CAACCTTACA
351 ACCTTTGGT TTGTCACAT GAGAATGCTT TGTCCTTATT CTGTCACCAT GCATTGGGTG AAGATAACTT
421 CAATTACACAT CCAACACTTA AACCACATGG CGAAGGTATT GTGAAAAAT GTGAT

SEQ ID NO: 8

RLGLI
[Strand]

1 TCTAGCTAGA CTTGTTGATG ATGAGATGCA AGAGAAGGAT CACTTTGAAC TCAAGGCGTG GGTATGTGTT
71 TCTGATGAGT TTGATATATT CAATATAAGC AAAATTATTT TCCAATCGAT AGGAGGTGGA ACCAAGAAT
141 TTAAGGACTT AACCTCCCTT CAAGTAGCTG TAAAAGAGAA GATTTTAAG AAACGATTTC TTCTTGTCT
211 TGACGACGTT TGGAGTGAAA GCTATGCCGA TTGGGAAATT NTGGAACGCC CATTTCCTTGC AGGGGCAGCC
281 GGAAGTAAAAA TTATCATGAC AACCCGAAAG CAGTCATTGC TAACCAAACG CGGTTACAAG CAACCTTACA
351 ACCTTTCCGT TTGTCACAT GACAGTGCTC TGTCTTTATT CTGTCAGCAT GCATTTGGTG AAGGTAACTT
421 CGATTACAT CCAACACTTA AACCACATGG CGAAGGCATT GTTGAAAAAT GTGCTGGATT GCCATTGGCA
491 TTGTCGACA

SEQ ID NO. 9

RLGLJ
[Strand]

1 TACTACTACT AGAATTCCGGT GTTGGTAAGA CGAactCTAGC TAGACTTTTG TATGAGGAAA TGCAAGGGAA
71 GGATCCTCTTC GAACTTAAGG CGTGGGTATG TGTTTCTGAT GAGTTTGATA TCTTCATAT AAGCAAAATT
141 ATCTTACAAT CGATAGGTGG TGGAAACCAA GAATTTACGG ACTTAAACCT GCTTCGAGTA GCTTTAAAAG
211 AGAAGATGTC AAAAGAAAGA TTTCCTCTTG TTCTTGATGA TGTTTGGAGT GAAAGCTATA CCGATTGGGA
281 AATTMTAGAA CGCCCATTTTC TTGCAGGGGGC ACCTGGAAGT AAGATTATTA TCACCCACCCG GAAGCTGTCA
351 TTGTTAAACA AACTCGGTTA CAATCAACCT TACAACCTTT CGGTTTGTCA ACATGAGAAT GCTTGTCTT
421 TATTCTGTCA GCATGCATTG GGTGAAGATA ACTTCAATTG ACATCCAACA CTTAAACCAC ATGGCGnAGG
491 TATTGTTGAA AAATGTGATG GattGCCATT GGCATTGTCG ACATGATGAT GATG

SEQ ID NO.:10

RLGIA a.a.

IVTVRTR?LSLLHLLSYVIFS?I?PH?ILWLF.INFYSTCHFMSFSILLSFT.YLNVITINAYLFFFK.THIIYR
LKSYNT.VKLI.YICSSPVYLYVSSLIYLLFIY.SR.SL.Y.KFNLFKI.NY..SHNLNKKNGPTISPSLFQLUNIV
SILLRFHPNQYFQRMRTDSYGVSEFAFRHCSLKEIINQMELLQCSLLMKGELYVK?MSA?LHPEPTTLSV
YHQTQNNGGSR?T?KS.RIDYFCPHGLTEERV.FIIFL?KNYRSIEFLHRQRSFTSQCFVKQFLIFLSFR.NS
SIATCNLQLLGPQICGGR.FNPHIHCKQ.FKSISVHPIHQHLLIIIIHASSISSTSILYSLLSY.TMAEIVLS
AFLTUVFEKLA?EALKKIVRSKRIESELKKLKETLDQIQDLLNDASQKEVTNEAVKRWLNDLQHLAYDID
DLDD?ATEAV?RELTEEGGASSSMVRKLIPSCCTSFSQSNSRMHAKLDDIATRLQELVEAKNNLGLSVI
TYEKPKIERYEASLVDESGTVGREDDKKKLEKLLGDKDESGSQNFSIVPIVGMGGVGKTTLARILLYDEK
KVKDHFELRAWCVSDEFSPNISRVYQSVTGEKKEFEDLNLLQEAALKERNQLFLIVLDDWSESY
GDWEKLVGPFLAGSPGSRIIMTRKEQLLRKLGFSHQDPLEGLSQDDALSLFAQHAFGVPNFDSHPTLR
PHGELFVKKCDGLPLALRTLGRLLRTKDEEQWKELLDSEIWRLGKSDEIVPALRLSYNDLSA?LKLLFA
YCSLFPKDYEFDKEELLLWMAEGFLHQPT?NKSQRLGLEYF?ELLSRSFFQHAPN?KSLFVMHDLMND
LATFVAGEFFSRLDIEMKKEFRM?SLEKHRHMSFVCE?YIGYK?FEPFRGAKNLRTFLASGVVVEDWK
MFYLSNKVLND?LQDPLLLRVL?L?L?I??VP??VGSM?HLRYLNLS?T?IHLPE??CNLYNLQTLIV
SGC?YLV?LPKTF?LKNL?HFDMR?TP?LKNMPL?IGELK?LQTLF?NIGIAITELKNL?NLHGK?CIGG
LGKMENAVGCTLSELVSKV?.?NW??G..ICFPKWEHLKKSSMK.CLIMVL?KKP?IMSIGGIEFPN
WGSLRVSETRDVFMVYEK?CFT.FHQSPSGK.MIFSG?TDEMWRGMI?LGAVEEISIHSCEIRYLWE
SEAEASKVLMNLKKLDLGECECNLVSLGEKKEDNHNINSGSSLTSFRRILNVWRCNSLEHICRCPDMSMENLY
MHMCDS?TSVSFPTGGGQKIKSLTITDCKLSEELGGRERTRVLNSKMQMLESVDIRNWPNLKSISEL
SCFIHLNRLYISNCPS?ESFPDHELPNLTSLDRRRGQRFSYERLRFDWPSF

SEQ ID NO:11

RLG1B a.a.

NRSYENRCPLLIVI...EKI.LKV.IQNPLFHR.YDALAVVCKNSIINANQNSS.ETI.IMV.IVLSPYTHFFQIPII
HTYKCSHIRFSLAMAEILGSAFFAVFFEKLASEALKRVACSKVIDKELEKLNSS.INIKALLNDASQKEIS
KEAVKEWLNALQHLPYDIDDLGLATKAIHRKFSEEGATINKVRKLIPSCFSSLSSTKMRNKHNTS
KLQELLEERNNLGLCEIGESRKLRNRKSETS?LDPSSIVGRTDDKEALLKLYEPCDRNFSILPIVGMGGL
DKTTLGRLLYD?MQVKDHFELKAWCVSDEFDFIFGISKTIFESIEGGNQEKFDLNLLQVALKEKISKKRFL
VWDDVVWSESYTDWEILERPFLAGAPGSKVITTRKLSLLNQLGHQDQYQLSDLSHDNALSLFCQHAFG
VNSFDSDHPILKPHGEGIVEKCDGLPLALIALGRLLRTKRDDEEWKELLNSEIWRLGKRDEIIP?LRLSYND
LSASLKQLFAYCSLFPKDYVNKEKLILLWMAEGFLHNENTNKSMERL?LEYFDDLLSRSSFFQHALDDKS
LFVHDLMNDLATSVAGDYFLRLDIEMKKEALEKYRHMSVCESYMVYKRFEPPKGAKKLRTFLAMPV
GMIKSWTTFYLSNKVLDLLHELPLLRVLSLSYLSIKEVPEIIGNLKHRYLNLSHTSITHLPENVCNLYN
LQTLILGCCFITKFPNNFLKLRNLRHLDISDTP.GLKKMSSGIGELKNLHTLSKLIIGGENRLNELKNLQNL
H

SEQ ID NO:12

RLG 1c aa.

SRAT?IIQK?PKT?D?F????QKEVIDEAVKRWLID?QQLAYDT?D?LDD?ATEAIHRELJRETGAS?S
MVRKLIPSCCTSFSQSNSRMHARLDDIAAK?QELVEAKNNLGLSVITYEKPKIERDEA?LVDASGIIGRED
DKKKLLQKLLGDTYESSSQNFNIVPIVGMGGVGKTLARLLYDEKKVKDHFELRVWVCSVDEFSPVNIS
RVYQSVTGENKEFADLNLLQEALKEKLQNKLFLIVLDDWSESYGDWEKLVGPFHAGTSGSRIIMTTR
KEQLLKQLGFSHEDPLHSIDSLQRQLSQEDALSLFSQHAFGVPNFDSHPTLRPYGEQFVKKCGGLPLAL

SEQ ID NO:13

RLG ID

?T?LRDRCPSSICLMLPRRK?LMKPLDG.MISNIWLMT?TTYLMILQ?KAI??ELT?EGGASTSMVRK
LIPSCCTSFSQSYRMHAKLDDIATRLQELVEAKNNLGLSVITYEKPKIERYEASLVDESGIFGR?DD?KK
LMEKLLEDKDESGVKLQHLPiGMGGVG?TTLARLLFDEKTVKDHFELRAWCVSDEFSILNISKVIYQS
VTGEKKEFEDLNLLQEARRGKLQNKLFLIVLDDWWSESYGDWEKLVGPFHAGTSGSRIIMTRKEQLLK
QLGFSHQDPLRCIDSLQRLSQDDALSLFAQHAFG?

SEQ ID NO: 14

RLGIE

LARLLYDEMQEKDHFELKAW/CSVDEFDFNISKIIFQSIGGGNQEFKDLNLLQAVKEKISKKRFLLVLD
DVWSESYADWEILERPFLAGAAGSKIMTRKQSLLTKLGYKQPYNLSVLSHDSALSLFCQHALGEDNF
DSHPTLKHGEKCA

SEQ ID No: 15

RLG1F

FSA?NK?KQWLKSFF?HSRPVFFEK?ASEALKKIAFHRIDSELKKLKRSLIQIRSVLNDASEKEISDEA
VKEWLNGLQHLSYDIDDLDDLATETMHRELTTDLEPPPACCKDNPTCCTDFSLSSKMRNKLDNITIKL
QELVEEKDNLGLSVKGESPCKHTNRRRLQTSVDASSIIIGREGDKDALLHKLLEDEPSDRNFSIVPIVGMMG
VGKTLARLLYDEMQUEKDHFELKAWCVSDEFDIFNISKVIFQSIGGG?QEFKDLNLLQAVKEKISKKR
FL?VLDDWSESYTEWEILARPFLAGAPGSKIIMTRKLSLLTKLGYNQPYNLSVLSHDNALSLFCQHA
LGEDNFDShPTLKP?GESIVEKCDGLPLALIALGRLL?TKTDEEEWKEVLNSEIWGSGKGDEIVPALKLS
YNDLSASLKKLFAYCSLFPKDYVFDKEELLLWMAEGFLHQSTTSKSMERLGHEGFDELLSRFFQHAPD
AKSMFVMHDLMNDLATSVAGDFFSRMDIEMKKEFRKEAL?K?RHMS?VC?DYMV?KRF?P?TRS.

SEQ ID NO.:16

RLG16

VKDHFELRAWCVSDEFNILNISKVIYQSVTGEKKEFEDLNILLQEALKEKLWNQLFLIVLDDVWSESYR
DWEKLVGPFFSGSPGSMIIMTRKEQLPRKLGFPHQDPLQGLSHDDALSLFAQHAFGVP

SEQ ID No: 17

RLG 1 +

LARLLYEEMQGKDHFELKAWCVSDEFDFNISKIILQSIGGGNQEFTDLNLLQVALKEKISKKRFLVLD
DWSESYTDWEILERPFLAGAPGSKIIITRKLSLLNKLGYNQPYNLSVLSHENALSLFCQHALGEDNFN
SHPTLKPHGEGIVEKCD

SEQ ID NO: 18

RLGI

LARLVYDEMQEKDHFELKAWCVSDEFDFNISKIIFQSIGGGNQEFKDLNLLQAVKEKILKKRFLVLD
DWSESYADWEI?ERPFLAGAAGSKIIMTRKQSLLTGYKQPYNLSVLSHDSALSLFCQHALGEGNF
DSHPTLKPHGEGIVEKCAGLPLALST

SEQ ID NO: 19

RLG 15

EFGVGKTLARLLYEEMQGKDHFELKAWCVSDEFDFNISKIILQSIGGGNQEFTDLNLLRVALKEKISK
KRFLLVLDVWSESYTDWEI?ERPFLAGAPGSKIIITRKLSSLNLGYNQPYNLSVLSHENALSLFCQH
ALGEDNFSHPTLKPHG?GIVEKCDGLPLALS

SEQ ID NO: 20

SEQ ID NO: 21
RLG 2A

1 TTNACACCCTT AAATTCCTCA CCTGNGGGGA CAAAAACCTA AAAATGGTCC ATAATGCNCA AATCAGNAAG
 71 GTTGAAAGCTCTAAGTTT TTNACCTCCA NCTGATGCNC NNCTCTCTA AAGTTCANAT CCAAGCTTGC
 141 CCTCCAACTC TANCCCTTC AATGGCACCT CTTCTCTTC AAAAGCACAC AAGAACACTT TCAAGCTCA
 211 CCACACTCAC ACAAGCTCTA GAACNAGGGT TAGGGCACAT TTAGGGTTTT GCTCTCTGGA AATGGTGTCT
 281 AAAAGTGAGG CCATAATGTT CCTTATATATAA GGCTCCTCTC CACAATTAGG CTTTCAATCT GAACGTANTA
 351 CGCCCAGTGT ACACATATGGT ACGCCCAACG TACTCCGTAG TCTCCCGTCA AAAAATACAC TCATGAGTAC
 421 GCGAACGTA CTTTCCCTTA CGCCCAGCGT ACTCAAAAGC CAAACATTCT TTCAAGGGAC TAATTTGAC
 491 AACTTGAGGA AAGAAAAGGA TCAAAGANAT ATACTTGAAT TCCGGGATGT TACAATGAAG TTGAAACCTT
 561 GGCTAAAGAA TAAATTGGT TGTTGGAGGC GTTGGCTGAG CAAGCAACAA GGGTAAAATT CGTAATCTAC
 631 AAATGGTGT ATTTCCTPATT TCTTCTTATT ATTTCCTTGT ATTACGGGT AGTTTTTTT TCTTACAAAAA
 701 AATATTAAGG TTGATAAAGT ATAGCCACTA AAATTGACTT TTTCCTAAAC ATAATGTCAA ATGGTGCCTA
 771 TATGTATCAT GTTGTATTAN ATAATGAATA TGATGATNCT GTTCTATTAA ANCCGAAAAA ATTATCTAAT
 841 GATTTTATAT TGGAAACAC AGTTTGATTT TTGNGCTAA TATAATCAAA TCCNCTTTG TNIGGGAGGT
 911 GGATAAAATGT CGTAAATTAA ACAAGATGT TTTCACCTTG AAGGGTNTGG AAAGGTGAA AAAAGTTAAA
 981 ATGATAAAAT GTTACACAA ATGTTGTATC CGACTGTAAT TTATGTTAA GGATNATTGT ATTAAATTTG
 1051 TGATATATAG TAAGCATAAA TATTTAGAAT TGTGACTTAA ATTPTATAAGT TATNCNAACT GGATTGAAAC
 1121 ATTTTGATA TANATTAGGA ATGAAAATGCA GCAACCCCTAA CATACTTATC TTGGTAGTT TGGTTATTAT
 1191 ATTTTCTTTA NAATATAGAA NCATCCCCTT ATTTTAAACC CATATTGTGG ACGGACTTGA ATAAATGGGA
 1261 AAAATGTACCT TTGCTTATTTA GCACAAAAAA ATTATAAAAA TGACATTGC TATTTCAGCAC AAACAAAAAA
 1331 AAAAACCTTA TCCCTTTTGC ATTAGGTCAAC AAAGAAATAT AAAATGGGAA ATGTGTTGCT ATTTAATGCA
 1401 CTAAAAAGAAA CTATTTTGCC TTATTTAAAC CGGGTAAACCC AATAGAAAAA TGGAAAGTACA TTGTCATTAA
 1471 GCATGAAAAA AAATAACTTT CCATTTTG CATCCGGTCA CAATAATAGA AAAATGAAAG TACGTGCTA
 1541 TTAGCGAAA CTAACTTCTT TTTCCTTGT TGGCCTCGT TCATAAAATA TAGACTAAAA TACGTGTT
 1611 TTACATTTT AATACATTGA ATGCTAT CCACATGTTA TTCTTATAAA AGGGAAATGT ATTAACTTAA
 1681 TTCTTGTATT CTTGGCTTC TTCTTGTAC CCACAAATCCTCCTTATCC TCTTATCCAA CTAAAATAAT
 1751 GAAAACCTATA TTCCCTCCAT TGAGGATG TTATAAATTGTT TTATGCAA AAAGTGT
 1821 TTGTTAAGTA GATTAACGAG ATTCACTTTT CAGCATTGTTA CGAGAAGTTC ATCCATCTT TGGATATGAA
 1891 GTGCCAGGCCA AGTTCTTTAA CATGGAATAT GAGGTCCTA TATGCTAAA AAATAGCAA TGAGAAATT
 1961 TTAAATTTGG ATCCCCATAA AAGAAAATTG TTAAATGGTT GTTTTAATAT TGGTCAATGT GTCCACCGGA
 2031 TGAGCTTAAT ACTAGTTTAT AAGGGTAAAC GGTGGGTTTG GTGGGCCCAT TTATCTTTAT TATTTCTAAA
 2101 AGTCAGATT AGTAAAAAA TAAATACCAT AAGGATAAAA ATTCATTTTA TTGTTACCGA
 2171 AGACCAAAAGT TGTTAAGGGG CTTTTGTTT TTGTTGAA GAGCTGTGCA ACCACTTTG TCTCCGCC
 2241 ACAGACAAACG TCCAGACATA TGCCCTCGCA GAGTGTGTTG TTGTTGAAAG TGCCAGACCC
 2311 CTGGCGGAGG TCATCTCGGC GCATATATGTC GTCACTGTCT TCAAAGGTCT
 2381 AAAAAAAAGG GACCACCGGT TTTTTTTTTT TTTTTTCTC TTCTCTGTGTA
 2451 CTTTATGACA TGAAATTAAAG TTGAAAAT TAATTATTT CAACAGCTGT
 2521 CTTCTGGTTG CAGACTGTGG ACATTTGGTC CACCTCTCT ACCCGAGAGA
 2591 ACTGCAGACA TTTGGCTTC AAATAAAACAA ACATCACCTA ATTTCGACTAC
 2661 AACAAAAAAAGG AGTTGAAAC ACAGTTCCTT ATTTCCTCCAT ATCCAGGGC
 2731 AATTTTGTGTT CGGTAGATC AGTTCTCAAA TTTCACCGG GTAAAGTGT
 2801 AAAGGTTTGA ANGTAACCTTC CAAACTGAAN CAANAATCGA TATGAAGTAT
 2871 TGAAGGAAATC AGCTGGAGGT TGGGGAAATCG AGCTTCACT ATTAAAGGTA
 2941 GGTACCGTCA TATATCAAAT TGCGTGTGTT TTGGAATGAA AAAAGCATGC
 3011 ACGGTATATG ACATATTTAT AGTTACTGAT ACAAATTAT GATAATTG
 3081 CGTACTTCAA CAAATGTAA TAGTTTTGT GAGTCTATCT ATGTATTG
 3151 ATTGTACTAG TAATTCGAA AAGTCTTTA AATAATTTTT CTGTTTATAAA
 3221 CATCTAATAT TAAATAGAAT GTATCTGATA TTGAAATTAAT GTCTTAAATG
 3291 TTACTAATGC CTAATTATTA GTTCTCTAAC AATAATTTTT AATTCCTGTT
 3361 AATCCATGA TTACCTTTA AATTAACCA AAAATGACCA TAAATAAATA
 3431 CCCCCGGCAT GCCCAATGTC TAAATATTCT TGATGTTTT GCTTTTCCCT
 3501 ATTCTGGAGA GTTTCATACA AAAAAATTTC AAGAAGAAG
 3571 TTCTTAAATT ATGTTATTAAC TTACAAGCAT TTTTACAGG ATCCATGGTT
 3641 TTGAAACTAG ATTGGGACTT TTGCCCCCTGA TGATTCATAA GATATTG
 3711 AAAGTGGTGA ATAGAAAAGAG CAAGTGAATC CAGATATAGT ATTGGTAATA
 3781 ATGTTAAAC TGGTAGAAA ATTGTTTTAA TTGAAATTT AGGTGTTG
 3851 ATAACTAATT AGTTATGCTA AATAGTTATA AAGAACAAAC AACTCGTAGT
 3921 CCTCTTGGTA CCAAACCTAA TTATAACAAAT TTGAATATC ATTCCTCTGCA
 3991 TTATCTCAT GTCTAAATT GCCACAAGTT TATTTCTATA GTCATATTGG ATTATGAAAG GACTATT
 4061 ACCAACTACA TCTTACTTT ATGGCCAAAG CTAATACAAT CCGACTAAAC TAAAGGATTC TAGGATGCAT

SEQ ID NO:21
RLG 2A cont.

4131 ATAGTTTGCT CCCCGATTAT AGATTTCTAT CTAATTGTC TATTGACTA ATTTAGGTGC CACCACAAGT
4201 AAATTCCTGA AATGGATGTC GTTAATGCCA TTCTTAAACC AGTGTGCGAG ACTCTCATGG TACCCGTTAA
4271 GAAACACATA GGGTACCTCA TTCTCTGCAG GCAATATATG AGGGAAATGG GTATCAAAT GAGGGGATTG
4341 AATGCTACAA GACTTGGTGT CGAAGAGGCC GTGAACCGGA ACATAAGCAA CCAGCTTGAG GTTCCAGCCC
4411 AAGTCAGGGG TTGGTTTGAAGA GAAGTAGGAA AGATCAATGC AAAAGTGGAA ATTTTCCCTA GCGATGTTGG
4481 CAGTTGTTTC AATCTTAAGG TTAGACACGG GGTGCGAAAG AGAGCCTCCA AGATAATIGA CGACATCGAC
4551 AGTGTCACTGA GAGAACACTC TATCATCATT TGGAAATGATC ATTCCTATTCC TTTAGGAAGA ATTGATTCCA
4621 CGAAAGCCTC CACCTCAATA CCATCAACCG ATCATCATGA TGAGTTCCAG TCAAGAGAGC AAACCTTCAC
4691 AGAACGACTA AACGCACTCG ATCCTAACCA CAAATCCCAC ATGATAGCCT TATGGGAAT GGGCGGAGTG
4761 GGGAAAGACGA CAATGATGCA TCGGCTCAA AAGGTTGTGA AAGAAAAGAA ATATGTTTAAT TTTATAATTG
4831 AGGGTGTGT AGGGGAAAAAA ACAGACCCCA TTGCTATTCA ATCAGCTGTG GCAGATTAC TAGGTATAGA
4901 GCTCAATGAA AAAACTAAC CAGCAAGAAC TGAGAAAGCTT CGGAAATGGT TTGTTGGACAA TTCTGGTGGT
4971 AAGAAAGATCC TAGTCTCATCG CGGAGATGTA TGGCAGTTTG TGATATTGGT TTAAGTCCIT
5041 TACCAAATCA AGGTGTCGAC TTCAAGGTGATC AGCAGACAAA GATGTTTGCATC CTGAGATGGG
5111 AGCTGAAGTT AATTCACATT TTAAATGTGAA ATATGTTATAA GAACAGAAAG CACAAAGTTT ATTCCACCAA
5181 TTATAGAAA TTTCGGATGAA TGTTGATCCT GAGCTCCATA ATATAGGAGT GAATATTGTA AGGAAGTGTG
5251 GGGGTCTACC CATTGCCATA AAAACCATGG CGTGTACTCT TAGAGGAAAA AGCAAGGATG CATGGAAGAA
5321 TGCACCTCTT CGTTTAGAGC ACTATGACAT TGAAAATATT GTTAATGGAG TTTTTAAAT GAGTTACGAC
5391 AATCTCCAAG ATGAGGGAGAC TAAATCCACC TTTTTGCTTT GTGGAATGTA TCCCGAARAC TTTGATATTG
5461 TTACCGAGGA GTTGGTGTGAGG TATGGATGGG GTTGAATT ATTAAAAAAA NIGTATACTA TAGGAGAAGC
5531 AAGAACCAGG CTCACACAT GCATTCGAGCG GCTCATTCAT ACAAAATTGT TGATGGAAGT TGATGATGTT
5601 AGGTGCTCATCA AGATGCCATCA TTCTGGTCTG GTTGAATTGTA TTCTAAAGTC GAGCATGCTT
5671 CCATTGTCAA CCTAGTAAAT ACACATAGT GGCATGCAAC TAATATGCAAC GACTCTGTA AAAGACTTTC
5741 ATTAACATGC AAGGGTATGT CTAAGTTTCC TACAGACCTG AATTTTCCAA ACCTCTCCAT TTTGAAACCTT
5811 ATGCATGAAAG ATATATCATT GAGGTTTCCC AAAAACATTG ATGAGAAAT GGAGAAAGCTT GAGGTTATAT
5881 CCTATGATAA AAIGAAATAT CCATTCGTTCC TCAATGTTCC GTCAACCTTC GCGTGTGTC
5951 TCTACATAAA TGCTCGTTAG TGATGTTGAA CTGCTCTGAT ATTGGAATTC TGTCGAATCT AGAAAGTGT
6021 AGCTTTGCTG ATTCTGCCAT TGACCGGTG CTTTCCACAA TCGGAAAGTT GAAGAAGCTA AGGCTACTGG
6091 ATTTGACGAA TTGTTATGGT GTTCTGTATAG ATAATGGTGT TTAAAAAAA TTGGTCAAAC TGGAGGAGCT
6161 CTATATGCA GTGGTGTGATC GAGGTCGAA GGCATTTAGC CTCAACAGATG ATAACTGCAA GGAGATGGCA
6231 GAGCTCTCAA AAAGATATTG TGCAATTAGAA CTTGGAGTCT TGAAAACCGA TGCTCAACCA AAGAATATGT
6301 CATTGAGAA GCTACAACGA TTCCAGATCT CTTGGGGCG CTATTTATAT GGAGATTCCA TAAAGAGTAG
6371 GCACTCGTAT GAAAACACAT TGAAAGTTGTT CTTGAAAAA GTGGAATTAT TGGAAGCTCG AATGAACGAG
6441 TTGTTAAGA AAACAGAGGT TTATGTTTA AGTGTGGGAG ATATGAATGA TCTTGAAGAT ATTGAGGTTA
6511 AGTCATCCTC ACAACTTCCTT CAATCTCTT CGTCAACAA TTAAAGACTC TTGTCGTTT CAAAGTGTG
6581 AGAGTTGAAA CACTTCTICA CACCTGGTGT TGCACAAACT TTAAAAAACG TTGAGCATCT TGAAGTTAC
6651 AAATGTGATA ATATGGAAGA ACTCATACTG AGCAGGGGTA GTGAAGAAGA GACGATTACA TTCCCCAACG
6721 TGAAGTTTTT ATCTTTGTTGTT GGGCTACCAA AGCTATCGGG TTGTTGCGAT AATGTCAAAA TAATTGAGCT
6791 ACCACAACTC ATGGGTTGGG AACTTGACGA CATTCCAGGT TTCAACAGCA TATATCCAT GAAAAGTTT
6861 GAAACATTAA TTGTTGTGAA GGAAGAGGT AAATAAAATT TTAAATGCTA ATACATTACA AAGGATCTTT
6931 TCAGTTAAAT CTTCAAAAT ATATTGTAAT TTGATTTGTT GGGGTATTAT TGTTGGATGG GACTTAAAT
7001 AAATGATTAT CTTGCAGGTT CTGATTCCTA AGTTAGAGAA ACTGCAATGTT AGTAGTATGTT GGAATCTGAA
7071 GGAGATATGG CCTTGCAGAAT TTAATATGAG TGAGGAAGTT AAGTTCAAGAG AGATTAAGT GAGTAACCTG
7141 GATAAGCTTG TGAATTGTT TCCGCACAAG CCCATATCTC TGCTGCACTA TCTTGAAGAG TTAAAGTC
7211 AGAATTGTTG TTCCATTGAA TCGTTATTCA ACATCCATTG GGATTTGTTT GGTGCAACTG GAGATGAATA
7281 CAACACAGT GGTGTAAGAA TTATTAAGT GATCAGTTG GATAAGCTTG TGAATCTCTT TCCACACAAAT
7351 CCCATGCTCA TACTGCATCA TCTTGAAGAG CTTGAAGTCG AGAATTGTTG TTCCATTGAA TCGTTATICA
7421 ACATTGACTT GGATTTGCT GGTGCAATTG GGCAGAAGA CAACAGCCTC AGCTTAAGAA ACATCAAAGT
7491 GGAGAATTAA GGGAAAGCTAA GANAGGTGTG GAGGATAAAA GTGGAGATA ACTCTCGTCC CCTGTTCTAT
7561 GGCTTCAAT CTGTTGAAAG CATAAGGGTT ACNAAATGTN AGAAGTTTAG AAATGTATTIC ACACCTACCA
7631 CCACAAATTAA TAATCTGGGG GCACATTGTTG AGATTCATC AGATGACTCG GGAGAAAACA GGGGAAATGA
7701 CGAACCGGAA GAGAGTAGCC ATGAGCAAGA GCAGGTAGG ATTCAATT CACTGCTTTA ATTAATGATT
7771 AAGCTCTGC TTTTGAATA AAAAGGGAC AAACATTTC ATGACTTAAT GTAGCAATAC AAGTCATGTA
7841 TAAGAGTGCAC CAACTCTTIT TTATTTATAA AATGACTACA AAATATTGTTT TTTCATTAGA GATCATGTT
7911 AAATGTGACT AATTTTCTAT CACCTAATT TAGTGTATAA ATCTTTATAA ATGTCACTAG TTACTTTCA
7981 GTAAAATAAC AAATTTAATA AATTATCAAC AAAAGCCTC AACTAAAAAA ATCCCACAAAC CGCTAATAAT
8051 TTAAAATAAA AGGATTTAAC ATCTAATAG AACATTGTTT TTCTAAACA TGATTGGAC CAAATATCAC
8121 CAGCAACTCA AGTTGGAAAT CGATTCACT TAAAACCTGA CCAGCATAAT TAGATAGATG AGAGTTGAAG
8191 CTAAAGTGCC TATATAAGTT CGTTCTGATCT TTTTCTGAA TCTTGTGATGC AAGTTGAATG ATTTCTCT

RLG 2A cont.

8261 TCAAAATTGA TAAAAATCTA CATTATAAAG AGACTAGCTT GAAAAAAAAT GGTCTAGGTG GGTCTTGGGT
 8331 TCTGGTAGAT GAAGATGGAA GGGGAGAGTA TGATTTCAAA GACACAACAC ATCCTTCATT TTATTATT
 8401 ATTATTATTA TTATTTTTG ATATCTTGCT CATATTGTT ACAGATAGT GAGGTCTATT AATCTTTTA
 8471 AATATATAAA AAAATAATA ACATAATGA GAAAATAAA TAAAGAATAA ATTAATAAGG GCACATAAGT
 8541 CTTTTAGGT AAGACAAGGA CAAACACCGC AACAAAAATA AACAGTAGGG ACCATCCGAT TTAAAAAAA
 8611 TAATTAGGGA CCAAAAACAT AAATTCCCCC AAACCATAGG GACCATTCAT GTAAATTACT CTTACTTTC
 8681 GTTTTGTCA TATTGGGTA ACTATTTTT TGTACACAT CTAGGTAACG AACTTGTTGA AGTGTCCCA
 8751 TTTAGGATGT GACCTACTAC AACCGATCAT AATAGTCATA TGTGAACACT TCCAACAAC TTATTACTTA
 8821 GGTGTGTACA AAAAAACAAT AGTTACCATG ATGTGAACAT ACTGAAAAAT TAATTACCTT AGCAAGTTAT
 8891 TTTCCCTTTT AGGTGTATG GAAACAGTTC CGTGAGACCG TGACTTGGAT GGTAGATAAA TTAGTAAAC
 8961 TTAACCCCTTC AATTAACCTA CCTTTTTCTT ATTAACCTAA TTCAACCTA AATTCTGATT CTGTTTGAA
 9031 AGTAAGTTGC ATCTTTATTT TGTATTATTC TTGTGTCATA GGATCCCTAG CATCTTTAA TAATTATT
 9101 GAAGGTGAA GATCCAACTA TTTTAATCT GTGGCATTT TCCATCATTT GCAACTGTTT CTGAAAAAA
 9171 AAATACCTAA AATCAAATA ACCATTTCA AATCCAAAAT TATAAGAGAG AATTGTAAAAT GGACATGGAA
 9241 TCATAAATCA TTAACACAGT TCAGTAAACA AGTGTGTAAT TACATTTCTT GCTGTGCAGA TTGAAATTCT
 9311 ATCAGAGAAA GAGACATTAC AAGAAGCCAC TGACAGTATT TCTAATGTTG TATTCCTCATC CTGTCATG
 9381 CACTTTTC ATAACCTCCA GAAACTTATA TTGAACAGAG TAAAGGAGT GGAGGTGGTG TTGAGATAG
 9451 AGAGTGAGAG TCCAACAAGT AGAGAATTGG TAACAACCTCA CCATAACCAA CAACAACCTA TTATACCTCC
 9521 CRACCTCCAG GAATTGATTC TATGGAATAT GGACAACATG AGTCATGTGT GGAAGTGCAG CAACGGAAT
 9591 AAATTCCTCA CTCTTCCAAA ACAACAATCA GAATCCCCAT TCCACAAACCT CACAACCTA AAAATTATGT
 9661 ATTGCAAAAG CATTAGTAC TTGTTTCTCCT CTCTCATGGC AGAACTTCTT TCCAACCTAA AGCATATCAA
 9731 GATAAGAGAG TGTGATGGTA TTGGAGAAAGT TGTGTTCAAC AGAGATGATG AGGATGAAGA AATGACTACA
 9801 TTTACATCTA CCCACACAAAC CACCACTTGT TTCCCTAGTC TTGATTCTCT CACTCTAAGT TTCCCTGGAGA
 9871 ATCTGAAGTG TATTGGTGGG GGTGGTGCCCA AGGATGAAGG GAGCAATGAA ATATCTTCA ATAATACCCAC
 9941 TGCAACTACT GCTGTTCTTG ATCAATTGTA GGTATGTTT GTACATATTTC AATTATTTAT TTAATTTCCT
 10011 TTTTATTG CAATATTCTA TAAATAATAC ATTATTATACC CACTATATACTA AGATAATAAT TACCTAGAGG
 10081 GATGGATGCT ATGACACAGC TGCTACACTT CAGAAACTCT AGTAAGGGCA GTTATGGAAG TTCAATAAAA
 10151 TGATAATGGC ATCTTTTGAT GGGTAATATA GGCAATTAAAT GTTTTATTTG TGTTAAAGCA GTATTTAGCA
 10221 AGTACTGGCC AGTAGGAGAG GAGAATATCA CCTTTTGTGA AATCTGGTC ATTGTACCCA GAATTTAGTT
 10291 AAATGTAACA TTTTATGAT CAGGGTCTAT CAGGTGACAG ATATTGTAGA ATAGAACAAAT ATATAATATC
 10361 ACCCAAACCT ATTTCCTCTA AGGTATTCT GTTAAATAATG TGCTTCTCTG TTTTCAINGA ATTNGCATT
 10431 GTATATTITA GGTGTTAAAG TGATTTTNTC TTCAATAAAAT CCCGAATTTA ATTAAAAAAA AAAAACAAA
 10501 AGTACATTTC TGATGTGGAG AGCACTGGTA TCACATTGTA TATAAAAAGC TTGATTGTTGA ATTAACCTTC
 10571 TTATACAAAAA GTTGTGTATA TAGTTTAATT AGTTTACAT CATTTCCTCA TGTGGTGTG CAGTTGTCIG
 10641 AAGCAGGTGG TGTTCCTTGG AGCTTATGCC AATACGCTAG AGAGATGAGA ATAGAACATCT GCAATGCAATT
 10711 GTCAAGTGTAA ATTCCATGTT ATGCAGCAGG ACAAAATGCAA AAGCTGAAGG AGAGGACAGC GATTCTCGTA
 10781 CGAACGGTTA CGATTGACT GGCGTCGTT TTACA

SEQ ID NO: 21

RLGIA a.a.

MDVVNAILKPVETLMVPVKKHIGYLISCRQYMREMGIKMRGLNATRLGVEEHVNRNISNQLEVPAQV
RGWFEEVGKINAKVENFPSDVGSCFNLKVRHGVGKRASKIIEDIDSVMREHSIIWNDHSIPLGRIDSTK
ASTSIPSTDHHDEFQSREQTFTEAALNADPNHKSHMIALWGMGGVGKTTMMHRLKKVKEKKMFNFII
EAVVGEKTDPIAQSAVADYLGIELNEKTPARTEKLRKWFVDNSGGKKILVILDDVVQFVDNDIGLS
PLPNQGVDFKVLLTSRDKDVCTEMGAEVNSTFNVKMLIETEAQSLFHQFIEISDDVDPELHNIGVNIVRK
CGGLPIAKTMACTLRGKSKDAWKNALLRLEHYDIEIVNGVFKMSYDNLQDEETKSTFLCGMYPE?FD
ILTEELVRYGWGLKLFKK?YTIGEARTPLNTCIERLIHTNLLMEVDDVRCIKMHDLVRAFVLDMSKVEH
ASIVNHSNTLEWHADNMHDSCRKRLSLTCKGMSKFPTDLKFPNLSILKLMHEDISLRFPKNFYEEIMEKLE
VISYDKMKYPLLSSPQCSVNLRFHLHKCSLVMFDCSCIGNLSNILEVLSFADSADRLPSTIGKLKKLR
LLDLTNCYGVRIDNGVLKKLVLEELYMTVDRGRKAISLTDDNCKEMAERSKDIYALELEFFENDAQPK
NMSFEKLQRFQISVGRYLYGDSIKSRHSYENTLKVLEKGELLEARMNEFLKKTEVLCISVGDMNDLEDIE
VKSSSQLQSSSFNNLRLVWVKCAELKHFFPGVANTLKKLEHLEVYKCDNMEELIRSRGSEEETITFP
KLKFLSLCGLPKLGLCDNVKIIELPQLMELELDDIPGFTSIYPMKKFETFSLLKEEVLIPKLEKLHVSSM
WNLKEIWPCEFNMSEEVKFREIKVSNCDKLVNLFPHKPISLLHHLEELKVKNCGSIESLFNIDLDCAGAIGQEDNSISLRNI
KDEYNNSGVRIIKVISCDKLVNLFPHPMSILHHLEEEVENCGSIESLFNIDLDCAGAIGQEDNSISLRNI
KVENLGKLR?VWRIKGGDNSRPLVHGFAQVESIRVTKC?KFRNVFTPTTTFNLGALLEISIDDCGENR
GNDSESESSHEQEQQIEILSEKETLQEATDSISNVVFPSCLMHSFHNLQKLILNRVKGVENVFEIESPSTS
RELVTTHHNQQQPIILPNLQELILWNMDNMSHVWKCSNWNKFFTLPKQQSESPFHNLTTIKIMYCKSIKY
LFSPLMAELLSNLKHIKIRECDGIGEVVSNRDEDEEMTTFTSTHTTTLFPSLDSLTLISFLNLIKCIIGGG
GAKDEGSNEISFNNTTATTAVLDQFEVCFVHIQLFI.

SEQ ID NO:22

RLG 2B

SEQ ID NO: 23

1 AGTTTTTTTT TTIICCAATA TCCATTATA TGCATTAT TCTGAAATA ATTTTATCAA AACGCAGGAA
 71 ACAATGTAGA ATAATACTGG TATAATTAAAT TATATAAAGT TATTAGGCAG AAATCTTGG GCTACTATAA
 141 TTTAATTATC ATAATTGAA AATCATCAA TTGTATTCCA TGTTATTTA TGTTATCAGA TAATTAAATAA
 211 TATGTGGGCC ACACAAATCC ACATCATCG ACACCCACC TTATTGTCGG CTACCTCACC ACTTGCATGA
 281 TCCCGACATC TTICCAACCC CACCGACGAC TTGGGGCTC CTTAATATAT CAATTATTTT CTGTAAGTAT
 351 TTATTGCTG AAATGTGTA TGICATTATA CCTTTTCTC AATATATACA GAAACATAAA TTTAAATGA
 421 AATTCAACTG CGTTTCATTC TTGATTAAA AAAAAAGACT GTACTGTTGT CAATATTATA CTTATAACCT
 491 GATTAATTAA TTAAAGCGTA ATTGCATAAT TTGCATTAGG TTGTAATTAA GTGTTTATA GGGAGGGTGA
 561 GGGTCACCGG GAATCAAAGC ACTTATGTA AAGCAGGGGA AATACAAAAA ATTTACTCGA AACAAATTIT
 631 ATTCAATTAA AGTGAGATAA TAATGTTCTG ATTAGATTAT GAGAAGCTAGG AGATTTAAGT GATATATCCC
 701 ATTTAAAGA AATGCACTTA TTAAATTGG ATCTCTTGTG ATGACAAAAA TTAACTCGTG ACAGGTTATA
 771 TATCATATAC AAAATGAGTG GCTATGCTT CGCTTCCAA AAAGCAATTAA TAGTTATACT ACACCTACAA
 841 ATTTTAAAGG GGGTTAAACA TATGAAATAA TTGATAAGT AATTATATAA ATATGCATT AACCTCTAA
 911 AGAAAAATGCT ACTAAGCTTG GACCATCTCA GAATTACATA CATACCCCTC CCTCAAAAAA AGATTCGTAT
 981 ATATCAGTC ATTGGCATT CATTCTTTC TCACATTCA TAGTTCTATT CTCAAAAAAT TCGAGTTCTC
 1051 GTATTCTAA GGAAGATCG AAGAGACTGT TCACACAGGT ACTCTCTTTT ATTTATTGAT TCACATTCA
 1121 ATATGTTATT GTTTCTTGTG TTAAATGGTT CGTCAGTCTA ACTGGCCTTG CTGATTAAA TTCTTCACT
 1191 TTCTTCCACG GATTTTTAA ATATTAGTT TGTAATGAA CAATGGTGA AGGAAAGAAA CATGGGAGTC
 1261 TTTCTAAG TAAACCTAGA TACTTTAGTT ATAAGGGTAT ATGCTAAAAT GAACTATGCC CATTACCTT
 1331 TGCTTTCTC TTACTTTTT AGTTTTAGA ATCCAAGTT TCATATGTAT CTGATGTTG GAGAAGATA
 1401 GGCATTAGAA AGGTAAGGA CGTACATAAA ATTGATTAAT TAGTGAATGT TCTTTGATAT CATTATTTT
 1471 ACTCTCTAA AAAGCATATA GATCAAACAC AAATIGCTAC TIGTTAGTGT ACAACTCTG ACTTAAATAAT
 1541 GTTAATATC AAGATTCTCT TGATTTCAC TATTTCCTAA CCGAACAAAGC TCACTAAAAT CTCATATTGC
 1611 TTTGAGTCIG AGTGGTTTAT ATTGGGGTT TTACATTTAA TTGGGGTGC ATGAATGTGA AAATAGACTG
 1681 CTTATTGATT CTGGTGTGTT CATTGAGTGT ATTTCATTA TTACTACCTT ACAATTGCT CAGTGATAGA
 1751 TTTCATTA TTGCTAATT CGGTGCTC TAAATATGTA GGAGCTACTA AAAGCAAAA TATCGAGCAA
 1821 TGCGGACCC AACGGGGATT GCTGGTGCCTA TTATTAACCC AATTGCTCAG ACGGCCTTGG TTCCCGTTAC
 1891 GGACCAAGTA GGCTACATGA TTTCCTGCAG AAAATATGTG AGGGTCATGC AGATGAAAAT GACAGAGTTG
 1961 AATACCTCAA GAATCAGTGT AGAGGAACAC ATTACCCCGA ACACAAGAAA TCATCTTCAG TTCCATCTCA
 2031 AACTAAGGA TGTTGGACC AAGTAGAAGG GATCAGAGCA ATGTGGAAA ACTTTCCGAT TGATGTCATC
 2101 ACTTGTGTTGA GTCTCAGGAT CAGGGCACAAG CTGGACAGA AAGCCTTCAG GATAACTGAG CAGATTGAAA
 2171 GTCTAACGAG ACAACTCTCC CTGATCAGTT GGACTGATGA TCCAGTTCTY CTAGGAAGAG TTGGTTCCAT
 2241 GAATGCATCC ACCCTCTGAT CATTAAAGTA TGATTCTCCA TCAGAGAGA AAATTTTAC ACAAGCACTA
 2311 ATAGCACTCG AACCCAAACCA AAAATTCCAC ATGGTAGCCT TTGTGGGGAT GGGGGAGTGG GGGAAAGACTA
 2381 GAATGATGCA AAGGCTGAAG AAGGCTGTT AAGAAAAGAA ATTTGTTAAT TATATTGTTG GGGCAGTTAT
 2451 AKGGGAAAAG ACGGACCCCT TTGCCCCATCA AGAAGCTATA GCAGATTACC TCGGTATACA ACTCAATGAA
 2521 AAAACTAAGC CAGCAAGAGC TGATAAGCTT CGTGAATGGT TCAAAAAGAA TTCAAGATGGA GGTAAGACTA
 2591 AGTTCCTCAT AGTACTTTGAC GATGTTTGGC ATTAGTTGTA TCTTGAAGAT ATTGGGTTAA GTCCCTTTCC
 2661 AAATCAGGT GTCTGCTTCAGGTTT GACATCACCGA GACTCACAAAG TTGCACTAT GATGGGGTTT
 2731 GAAGCTTAATT CAATTATTTAA CGTGGGCTT CTAACGAAAG CAGAACGCTCA AAGTCTGTTG CAACAAATTG
 2801 TAGAACTTC TGAGCCCGAG CTCCAGAGA TAGGAGAGGA TATCGTAAGG AAGTGTGCG GTCTACCTAT
 2871 TGCCATAAAA ACCATGGCAT GTWCTCTTAG AAATAAAAGA AAGGATGCT GGAAGGATGCG ACTTTCCGCG
 2941 ATAGAGCACT ATGACATTCA CAATGTTGCC CCCAAAGTCT TTGAAACAGG CTACCCAAAT CTCCAAGAAG
 3011 AGGAGACTAA ATCCACTTTT TTAAATGTTGCT GTTGTGTTCC CGAAGACTTC GATAATTCTA CTGAGGAGTT
 3081 GATGAGGTAT GGATGGGCT TGAAGCTATT TGATAGAGTT TATACGATTA GAGAACGAG AACCAAGGCTC
 3151 AACACCTGCA TTGAGCGACT GGTGCAGACA AATTGTTAA TTGAAAGTGA TGATGTTGGG TGTCACCAAGA
 3221 TGCATGATCT GGTCCGTGCT TTGTTTTGG GTATGTTTTC TGAAAGTCAG CATGCTTCTA TTGTCACCA
 3291 TGGTAAATG CCTGGGTGCC CTGATGAAAA TGATATGATC GTGCACTCTT GCAAAAGAAT TTCAATTAAACA
 3361 TGCAAGGGTA TGATTGAGAT TCCAGTACAG CTCAGTTTC CTAAACTAAC GATTTGAAA CTATGCAATG
 3431 GAGATTAAGTC GCTAAGGTTT CCTCAAGACT TTATGAGG AATGGAAAAG CTCCAGTTA TATCATACGA
 3501 TAAAATGAG TACCCATTGTC TTCTTCTGGC ACCTCGATGC TCCACCAACA TTGGGGTGCCT TCATCTCACT
 3571 GAATGTTCAT TAAAGATGTT TGATTGCTCT TCTATCGGAA ATCTATCGAA TCTGGAAGTG CTGAGCTTTG
 3641 CAAATTCTCA CATTGAATGG TTACCTTCCA CAGTCAGAAA TTAAAGAAG CTAAGGTTAC TTGATCTGAG
 3711 ATTTTGTGAT GGTCTCCGTA TAGAACACGG TGCTTGTAAA AGTTTGTCA AACTTGAAGA ATTTTATAATT
 3781 GGAGATGTCAT CTGGGTTTAT AGATGATAAC TGCAATGAGA TGGCAGAGCG TTCTTACAAC TTCTCTGCA
 3851 TAGAACTCGC GTTCTTTAAT AACAAAGGTG AAGTGGAAAAT TATGTCATTG GAGAATCTTG AACGATTCAA
 3921 GATCTCAGTG GGATGCTCTT TTGATGAAAAT TATCAATATG AGTAGCCACT CATAACGAAA CATGTTGCAA
 3991 TTGGTGAACCA ACAAAGGTGA TGTATTAGAC TCTAAACTTA ATGGGTTATT TTTGAAAACA GAGGTGCTTT
 4061 TTTTAAGTGT GCATGGCATG AATGATCTTG AAGATGTTGA GTGGAAGTCG ACACATCTA CTCACTCTC

RLG 2B cont.

SEQ ID NO: 23

4131 TTCAATTCTGC AATTTAAAAG TTCTTATTAT TTCAAAGTGT GTAGAGTTGA GATACTTTT CAAACTCAAT
 4201 CTTGCAAAACA CTTTGTCAAG ACTTGAGCAT CTAGAAGTTT GTGAATGTGA GAATATGGAA GAACTCATAAC
 4271 ATACTGGAAT TGGGGGTGTG GGAGAAGAGA CAATACATT CCCTAAGCTG AAGTTTTTAT CTTGAGTCA
 4341 ACTACCGAAG TTATCAAGTT TGTGCCATAA TGTCAACATA ATGGGCTAC CACATCTCGT AGACTTGATA
 4411 CTTAAGGGCA TTCCAGGTTT CACAGTCATT TATCCGAGA ACAAGTTGCG AACATCTAGT TTGTTGAAGG
 4481 AAGGGGTAGA TATATGTTCT TTATGTTAAT ACAATTAAA TAATATTTC AACCAAATT TCATAATATA
 4551 TCTGTAAATT GATTGTATGA TGTTGTTATG TTTATATGTG GCTATTAAGG GATGATTATT TTGCAAGGTTG
 4621 TGATTCCTAA GTTGGAGACA CTCAAATTG ATGACATGGA GAACTTAGAA GAAATATGGC TTGCAAGTCA
 4691 TAGTGGAGGT GAGAAAGTTA AGTTGAGAGC GATTAAGTG AGTAGCTGTG ATAAGCTTGT GAATCTATT
 4761 CCGCGCAATC CCATGTCCT CTTGCATCAT CTGCAAGAGC TTACAGTCGA GAATTGCGGT TCCATTGAGT
 4831 CGTTATTCAA CATTGACATTG GATTGTGCG GTGCAATTGG AGAAGAAGAC AACAAAGAGCC TCTTAAGAAG
 4901 CATCAACGTG GAGAATTAG CGAAGCTAAG AGAGGTGTTG AGGATAAAAG GTGCAGATAA CTCTGATCTC
 4971 ATCAACGGTT TCAAGCTGT TGAAAGCTA AAGATTGAAA ATGTAAGAG GTTTAGAAAT ATATTACAC
 5041 CTATCACCGC CAATTTTTAT CTGGAGGCAC TTTTGGAGAT TCAGATAGAA GGTTGCGGAG GAAATCACGA
 5111 ATCAGAAGAG CAGGTAAACGC TTTCAATTTC ACTTCTTAA TPAATTAAAGG ACTAAGCTCC TGTTTTTG
 5181 ATAATTAAGA GGTGGGATGA CTAAACTTGG GCATCACAAAT TGCAACAAAAT TGTTACAAAC CATGAAACGT
 5251 TCAAACCATT TCTTGAATTAGGTTTCAAT ACAAGTCATT CTTAAATTATG CTTTAATTATT TTTTATATT
 5321 TATGTATCAA CATGATTTTT CATTAGAGAT CATTATTATA ATAGTAAGTT TAAAGCAATT TAAATCAGAA
 5391 CTAATTCTAA CTTTAGCTAA TAAATCGTTA TAAATGTTAA TAATTACTTT TTAGTGAAT AAGCAACGG
 5461 TTTATAAAGT TAACAACCTTAAATGCTATT CTTAAACAAA AAAACTTTGG TTCAAGAAAA CCGCAATTCA
 5531 AGATAACTAA AATAAAATAA TTGACATTC ACTAAGAGCA TTTTTTTTC TAAATATGAT TGCAAAATGAA
 5601 TAAATCTTAA ATTATACAG AAAATTCTT TATATATGTT ATACAAAATT TACAAATTGA AATTGGATAT
 5671 GTTAATTAAC GGTTTATAAT TCTGGTATCA CAAAGGGATA TATAATAAAAA TATTATTTTC TGTAGTCATT
 5741 TGTAATTGTA CTAGTTTATA ACCCGTGGGA ACCATGAGTT CTAAAATTAG TTAAACTTTTC ATAATAAAAA
 5811 TTATTAATTAA TTATTAATTAA TAAATAAATT ATTATTAAG AGATATATCA AAAATTAAA GTTATTATAA
 5881 CTTCAATTAA AACATATAAT TAGAAAAATT ATGACATATAA CTTCTGCAC TCTCTTGTAT AAATGAG
 5951 AAGCTATTAG TATATTTCTA ATCAAGTCAC AACCTAATGA ACCCTATATA ATTGGTGAAT AACTCAATT
 6021 GCATTAGGTT TTAAGAGTC CCAAATTCAA AGAATAATCC ATGCTTTCA TTACCACTAT GGAGAAAATA
 6091 TTTCTTGT TTAATGAAA TGAAAACAAA CATTCAAACCTT AATTGTTGCT TATTAACCA AAGACCCATT
 6161 ACTTAGCCAA GAGTTTAACA AAAAAAAATT ACATTCACTG ATCATTATTTC ATGACTAGAT ATATATGAAC
 6231 ATGAAAGGAG TTGTTATAGA AAATATAATC ATAGATATTTC ACACATAACTT CAGGGAAATT CTCAAAATAA
 6301 CCAAGTTATT CAAGAAATTAA CATCCAAGTC AACCAAAGAG AAGTTTAGCC TAGCATGGCT AAACCTCAAGA
 6371 AACCTTAAATA AGGATTAGAA GTACCAAAAC TGTAGTAAGA ATCACAGTAA AAGATGATGT TGTCTTGT
 6441 GTTCTTCTAA GTTCTTCAAG TCTCCAGTT CTCTTAATAA TGCAACAGG AGCCATTAAA TTGATGT
 6511 TTGATCCCTT CAAAGCTGC ACCAACCTTC CTTAAATAAC ACTCAAAGCA AAAATGACAA ARTGCCCTGA
 6581 AGGACCCCTAT GTGGGTGCGCT TGGGGGGCTG GAGCTGCATA CGAAAGGTCT TTGTCCTTG TGAGGGTGAT
 6651 GTTGTGCGGG ATAGCTTGTG GCATGCTTCC CGCGGGTTCA CGCACATGTG CACAGGTGAT GCATGGTGTG
 6721 TCGGTCTTGT AGTTTTGAGC CTCCGATGCT TAGTCCACTT GGGCCAAATTC GAGTCCAATC AGCTTATAAC
 6791 CCATTTTCTT TCAAGTTATC TTCAAGTTA GCGCAATTG GCTTCTCCAA ATCATCCATA ACTTCACAGA
 6861 ATGCCCGTT CTCCTTAAATC CCGGATGCA AATTATCTC CCGTCCTCAT TTTAAGCAAG ATACCACCTT
 6931 CTTCATGCTT CATCCATCAA TAGTACACTT CATGATCAT CTCTACTAGT TTTTGTGTC ACAAATCCCT
 7001 GTTGTCTTCC AAATTAAATT ATCTCATTTA GTTCCCCGTT CCGCTACTTT CCTTAAATT TGGAAATTAAAG
 7071 CTCAGAGAAA TATTAAGTAC CCGAAATGGT CATAAAATT ACAAAGGAA AAATGATGAA AGATTAAC
 7141 AATGATGAAAC GAAATATGCT AAAATAGACT ATAAATGAA GTAAATTATC TGAAATTATC GCACCTCCGAC
 7211 CACCTTATG GCTTGTAGTC CACCCACCTC TCATCTTTC TACCAATATG CGATGGAAAC ATCATTAATT
 7281 AAGCCAAAAA GCTAACATAT AAGGGTTAG TGACAAAGGT AAGTACTAA GATGAAAATA ATCCATT
 7351 CTTGTCTTCA CACAACACAC ACATAGGGGC AGACGTAGGA TTCAAGAGA CAGATTGTTG GTGGCACATA
 7421 AGTGTGCTG GTGACATT TTGTTTCTTT TTACGTGGTG GCACAAACAGT AGGAAAAACG AAAATTCGA
 7491 AATTTTTTAC AATTTGTCTT AAAAAAAACA GGGGTGTTG GTGCCACTAT GGACAACAAA GTTGAAC
 7561 CCTACCGCGC CACACACACACA CACACACATA GAGAGAGAGA GAGAGAGAGA GAGAGAGAGA AAGAAAGAAA
 7631 GAGAGAGAGA GTTGGGATG TGATACTCT TTTAGGAAAA TGGAGTTATA TCTTTGATAT TGTATTTTT
 7701 TAATGTAATT TAATGTTAATC ATCATTTAG TTATTAAGTT NTATTTTATIN GGNTATGAAA AAAAAGTCT
 7771 TTATTAACATT GGATTTAACAA TAAATCTC ACAATTAAAC TCAAAGAC CAAACATGTC GACAATTATG
 7841 TATATAATTAA ATTCACAAATA GTCTTGTAGA ATAGTATTAT ATATATAATT AATTCTCAAT GGTCTTGT
 7911 ATAGTAAGTT CTTATATTTC AAACCTTTGC CACAATTCTT TGCCTTACTTT GACACTTTTC CTTCTTAAC
 7981 TTACATATAT ATATATATTAA AAGCGCAAAG GTCATAGGAA TATAATATT TCTTATTATTC TACGTTTGTG
 8051 CACAAAAGTT TGAACACTTT GCCACTTTT GTCCCTCCTT AACCTTTCA ATGTTTGGC ACACAAAGTTC
 8121 CAAAACCTTG CCACTTTGAT CATTCTCAA CTTTCACCG CATTAGTTG TGGAGTTGGC AGTTTGGTC
 8191 CCTCTAACTT CGATATTCTC TACTGCTAGC CAAAAGGGT TCCAGAGTTT CACACTTTG GTCCCTGACA

RLG 2B cont.

8261 GTAACC>AAAT GTGAGATGTC AAATTTTGC CACATTAGTT TGTGGAGTTG TCCCTTTGG TCCCCCCCACA
 8331 TTCGATATTTC TACTATACGA TCTTATTTT CTCAAATAAC AACACGTATA TTTCATC:CT AATGGAAAAA
 8401 AGAGTTTAA AA:AAATAAC GACTAGG::: G:GC:GAGTT TTTTTT:ACA AGTTTGTATC AAATCATATC
 8471 AAAATTAAAG GTGGAACGGT GACCACATTA ACCAGAAATG TAATTTATTC TTTGATTITG ATAATTTITA
 8541 ATATTTGTT GTGATCTATG TATTTAAAAG TAAACAAACAA AGAACATAAT CAAAACCCCT AAATIGCAAG
 8611 TCTCGCCCAA TTTCTCTATC ACTAGTCCTC ACTTACGATG GCGTTACGTC GCTCTCTCAC TGCTTACAAC
 8681 CCTTGTGTC TACTCATTAC AATAACGAAA AGTGAATAT CCATATTTT ATTGGATGT GGAATTGAAC
 8751 GAATCTCGTC AAAATTITGA TTTTGTGAT GGATTGAGT AGAAGTTGGC GCGAACCGG AATGATGGTC
 8821 TGCAAGTGGT TATAAACTTG ATTCTGAGTT ATTACTATAT ATGAGCCTC TTTACAACGA CCAAGGTTTC
 8891 TICCAGGTAC CATTGATCT TTTTGAACCT TAGTTTCTG AAACACCCCTG ATTGGATCA AATATCACCA
 8961 ACAACTCTTA AAAACTTGAT TAATCAATG TTTCTTCAT CTGATAACA AGTGGAAATGA TTTTCTACTT
 9031 AGATTAACCTT GAAAAAAAG GTCCATGTGC GTCTGGTGGA TCTGGTAAT GAAGATGGAA GGGAGAGCTG
 9101 ACTTTAAAGA CACAAACACG TCACCATATC TCTTATTTTA TTTTAAATTG GCTTTGGTG TATTTCCTT
 9171 TTTCCATTCTT CTTCTTTCT TGATCTCCAG ATGGTATGTG GTGIGGATAA TTTACACCTA GAGATTGGGA
 9241 ACGATGGGAA GGGGTCTGTG ATTTATGGCT GGCGGAGTTT TACTTTATTAAC CTCAATTCA ACCTAAATTG
 9311 TGATTCTGTG TTGAAAATAA GTTGCATCTT TTTTGTGTA TAATCTGTG GCATAGGATC CTTAGCATTCT
 9381 TTAAATAATT TATTGAGG TGAAAGATCCC AACTATTITG TAGCTGTGTT CATTTCAT CATTGCAAC
 9451 TGTTCTTGA AAAAAAAATA CCTAAAATAA AAATAACCAT TTCAATTCC AAAATTATAA GAGAGAATTG
 9521 TAAATGGACA TGGAAATCATA AATCATTAAAC ACAGTCAGT AAACAGTTG CTAATTACAT TTCTTGCTGT
 9591 GCAGATTGAA ATTCTATCG AGAAAGAGAC ATTACAAGAA GCCACTGGCA GTATTTCAAA TCTTGTATTG
 9661 CCATCCTGTC TCATGCACTC TTTTCATAAC CTCCGTGTGC TTACATTGGG TAATTATGAA GGAGTGGAGG
 9731 TGGTATTGGA GATAGAGAGT GAGAGTCCAA CATGTAGAGA ATGGTAACA ACTCGAATA ACCAACAAACA
 9801 GCCTATTATA CTTCCCTACC TCCAGGATTT GTATCTAAGG AATATGGACA ACACGAGTC TGTGTGGAAG
 9871 TGCAGCAACT GGAATAAAATT CTTCACTCTT CCAAACAAAC AATCAGAAC CCCATTCCAC AACCTCACAA
 9941 CCATAAAATAT TCTAAATGCA AAAAGCATT AGTACTTGTG TTGCGCTCTC ATGGCAGAAC TTCTTCCAA
 10011 CCTAAAGGAT ATCCGGATAA GTGAGTGTGA TGGTATTTAA GAAGTGTGTT CAAACAGAGA TGATGAGGAT
 10081 GAAGAAATGA CTACATTTCAC ATCTACCCAC ACAACCCACA CTTGTGTTCCC TAGCTTGTAT CTCCTCACTC
 10151 TAAGTTCTT GGAGAATCTG AAGTGTATTG GTGGAAGTGG TGCCAAGGGAT GAGGGGAGCA ATGAAATATC
 10221 TTCAATTAAAT ACCACTGCAA CTACTGCTGT TCTTGTATCAA TTGAAAGTAT GCTTGTACA TATTCCATTA
 10291 TTATTTAAT TTCTTTTTT ATTTGCAATA TTCTATAAAAT AATACATTIT ATACCCACTA TACTAAGATA
 10361 ATAATT>CCT AGAGGGATGG ATGCTATGAC ACAGCTGCTA CACTTCAGAA ACTCTARTAA GGGCAGTTAT
 10431 GGAAGTCAA TAAAATGATA ATGGCATCTT TTGATGGGTA ATATAGGCAA TTTAAGTTTT ATTCTGTTA
 10501 AAGCACTT TAGCAAGTAC TGGCCAGTAG GAGAGGAGAA TATCACCTTT TGTAAGGAAATC TGGTCATIGT
 10571 ACCCAGAATT TAGTTAAATG TAACATTITA GATATTAGGG GTTATCAGGT GACAGATATT GTAGAATAGA
 10641 ACAATATGTA ATATTACCA AAACATTIT TTCTAAGGTT GCTCTGTAA ATAATGIGCTT TCTTGATTTC
 10711 ATTGAATTG CATTCTATA TTTTGTGTT TAAAGTGTGTT GTCTCTTC TAAATCCCGA AATTTTTAA
 10781 TTAACAAAAA AAAAAACAAA AGTAAATTG TGATATGGAG AGCAGTGGTA TCAATTAGTA TATAAAAAC
 10851 AGATTTGAA TTAAGTTCTT TATATAAAAG CTGTGTATAT AGTTTAATTG GTTTTACATC ATTTCCTAC
 10921 GTGGTGTGTC AGTGTCTGA AGCAGGTGGT GTTCTTGGG GCTTATGCCA ATACGCTAGA GAGAAAAAA
 10991 TAGGC>ACTG CCATGCATTG TCAAGTGTGA TTCCATGTTA TGCAGCAGTA CAAATGCAGA AAGCTT

SEQ ID No: 23

RLG 2 B a.u.

MSDPTGIAGAIINPIAQTA LPVPTDHVGYMICRKYVRVMQMKMTELNTSRISVEEHISRNRNHLQIP
SQTKEWLDQVEGIRANVENFPIDVITCCSLRIRHKGQKAFKITEQIESLTRQLSISWTDDPV?LGRVG
SMNASTSASLSDDFPSREKTFTQALIALEPNQKFHMVALCGMGGVGKTRMMQRLKKA?EEKKLFNYIV
GAVI?EKTDPFAIQEAIADYLGQLNEKTKPARADKLREWFKNSDGGKTKFLVLDVWQLVDLEDIGL
SPFPNQGVDFKVLLTSRDSQVCTMMGVEANSIINVGLLTEAEAQSLFQQFVETSEPELQKIGEDIVRC
CGLPIAIKTMAC?LRNKRKDAWKDALSRIEHYDIHVAPKVFETSYHNLQEEETKSTFLMCGLFPEDFDI
PTEELMRYGWGLKLFDRVYTIREARTRLNTCIERLVQTNLLIESDDVGCVKMHDLVRAFLGMFSEVEH
ASIVNHGNMPGWPDENDMIVHSCKRISLTCKGMIEIPVDLKFPKLTILKLMHGDKSLRFQDFYEGMEKL
HVISYDKMKYPLLPLAPRCSTNIRVLHLTECSLKMFDCCSIGNLSNLEVLSFANSHIEWLPSTVRNLKKL
RLLDLRFDGGLRIEQGVLSFVKLEEFYIGDASGFIDDNCNEMAERSYNLSALEFAFFNNKAEVKNMSFE
NLERFKISVGCSFDENINMSSHSYENMLQLVTNKGDVLDLSKLNGLFLKTEVLFLSVHGMNDLEDVEVKS
THPTQSSFCNLKVLJISKCVELRYLFKLNLANTLSRLEHLEVCECENMEELIHTGIGGCGEETITFPKLKF
LSLSQLPKLSSLCHNVNIIGLPHLVDLILKGIPGFTVIYPQNKLRTSSLLKEGVVIPKLETLQIDDMENLEE
IWPCELSGGEKVKLRAIKVSSCDKLVNLFPNPMSSLHHLEELTVENCGSIESLFNIDLDCVGAIGEEDN
KSLLRSINVENLGKLREVWRIKGADNSDLINGFOAVESIKIEKCKRFRNIIFTPTANFYLEALLEIQIEGCG
GNHESEEQVTLSISLS

SEQ ID NO: 24

SEARCHED NO:

→ 25

-----GGAGAC-ACATGATCCA-----	-ACGTCGAGCTGCTGAGA-----	TTATATCTGCGGTTATAGCGGAAAGACGCC	-----						
10	20	30	40	50	60	70	80	90	100
-GGCGAAGCCACATATCGCC-----	TTCTATCCCTTAAAGAAAGCT-----	TTATATCTGCGGTTATAGCGGAAAGACGCC	99 → 27						
-----TGGCGAAGCTGAGCTGAGA-----	AAATCTTAAAGAAAGCT-----	TTATATCTGCGGTTATAGCGGAAAGACGCC	100 → 28						
-----AAAC-----	AAATCTTAAAGAAAGCT-----	TTATATCTGCGGTTATAGCGGAAAGACGCC	92 → 29						
-----ACGTCGAGCTGCTGAGA-----	AAATCTTAAAGAAAGCT-----	TTATATCTGCGGTTATAGCGGAAAGACGCC	70 → 30						
-----AAAG-----	AAATCTTAAAGAAAGCT-----	TTATATCTGCGGTTATAGCGGAAAGACGCC	95 → 31						
-----CGAGAC-ACATGATCCA-----	AAATCTTAAAGAAAGCT-----	TTATATCTGCGGTTATAGCGGAAAGACGCC	100 → 32.						
-----CTTGAGAGACACATGATCCA-----	AAATCTTAAAGAAAGCT-----	TTATATCTGCGGTTATAGCGGAAAGACGCC	95 → 33						
-----CGAGAC-ACGATGATGAGA-----	AAATCTTAAAGAAAGCT-----	TTATATCTGCGGTTATAGCGGAAAGACGCC	73 → 34						
-----TG-AAGAGCTGAGAGCTGAGA-----	AAATCTTAAAGAAAGCT-----	TTATATCTGCGGTTATAGCGGAAAGACGCC	87 → 35						
-----GCTCGTC-ACAGTATGATGAGA-----	AAATCTTAAAGAAAGCT-----	TTATATCTGCGGTTATAGCGGAAAGACGCC	71 → 26						
-----GAAAGA-----	AAATCTTAAAGAAAGCT-----	TTATATCTGCGGTTATAGCGGAAAGACGCC	99 → 37						
-----TTTGAGAC-ACGATGATGAGA-----	AAATCTTAAAGAAAGCT-----	TTATATCTGCGGTTATAGCGGAAAGACGCC	45 → 38						
-----G-----	AAATCTTAAAGAAAGCT-----	TTATATCTGCGGTTATAGCGGAAAGACGCC	74 → 39						

RLG2A RLG2B RLG2C RLG2D RLG2E RLG2F RLG2G RLG2H RLG2I RLG2J RLG2K RLG2L RLG2M

AGCAGAAGCAGCAAGTTGTTGTTCCACCAATTGTGAAACTC-----	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2A	410	420	430	440	450	460	470	480	490	500
AGCAGAAGCAGCAAGTTGTTGTTCCACCAATTGTGAAACTC-----	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2B	497									
AGCAGAAGCAGCAAGTTGTTGTTCCACCAATTGTGAAACTC-----	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2C	485									
AGCAGAAGCAGCAAGTTGTTGTTCCACCAATTGTGAAACTC-----	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2D	477									
AGCAGAAGCAGCAAGTTGTTGTTCCACCAATTGTGAAACTC-----	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2E	455									
AGCAGAAGCAGCAAGTTGTTGTTCCACCAATTGTGAAACTC-----	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2F	480									
AGCAGAAGCAGCAAGTTGTTGTTCCACCAATTGTGTTCACTC-----	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2G	485									
TGTAGAAGCAGCAAGTTGTTGTTGTTGTTGTTGTTGTTGTTGAACTC-----	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2H	489									
TGTAGAAGCAGCAAGTTGTTGTTGTTGTTGTTGTTGTTGTTGAACTC-----	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2I	467									
TGTAGAAGCAGCAAGTTGTTGTTGTTGTTGTTGTTGTTGAACTC-----	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2J	481									
AGRAAGAAGCAGCAAGTTGTTGTTGTTGTTGTTGTTGAACTC-----	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2K	64									
AGRAAGAAGCAGCAAGTTGTTGTTGTTGTTGTTGTTGAACTC-----	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2L	484									
AGCAGAAGCAGCAAGTTGTTGTTGTTGTTGTTGAACTC-----	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2M	459									
 TGTG - CGGTCTACCCATTGCCCCTACTCTAGAATAAGAAGCTGACTTCTGTTAGACCTAT	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2A	510	520	530	540	550	560	570	580	590	600
TGTG - CGGTCTACCCATTGCCCCTACTCTAGAATAAGAAGCTGACTTCTGTTAGACCTAT	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2B	586									
TGTG - CGGTCTACCCATTGCCCCTACTCTAGAATAAGAAGCTGACTTCTGTTAGACCTAT	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2C	584									
TGTG - CGGTCTACCCATTGCCCCTACTCTAGAATAAGAAGCTGACTTCTGTTAGACCTAT	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2D	576									
TGTG - CGGTCTACCCATTGCCCCTACTCTAGAATAAGAAGCTGACTTCTGTTAGACCTAT	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2E	554									
TGTG - CGGTCTACCCATTGCCCCTACTCTAGAATAAGAAGCTGACTTCTGTTAGACCTAT	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2F	579									
TGTG - CGGTCTACCCATTGCCCCTACTCTAGAATAAGAAGCTGACTTCTGTTAGACCTAT	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2G	584									
TGTG - CGGTCTACCCATTGCCCCTACTCTAGAATAAGAAGCTGACTTCTGTTAGACCTAT	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2H	588									
TGTG - CGGTCTACCCATTGCCCCTACTCTAGAATAAGAAGCTGACTTCTGTTAGACCTAT	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2I	566									
TGTG - CGGTCTACCCATTGCCCCTACTCTAGAATAAGAAGCTGACTTCTGTTAGACCTAT	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2J	560									
TGTG - CGGTCTACCCATTGCCCCTACTCTAGAATAAGAAGCTGACTTCTGTTAGACCTAT	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2K	564									
TGTG - CGGTCTACCCATTGCCCCTACTCTAGAATAAGAAGCTGACTTCTGTTAGACCTAT	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2L	581									
TGTG - CGGTCTACCCATTGCCCCTACTCTAGAATAAGAAGCTGACTTCTGTTAGACCTAT	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									
RLG2M	529									
 TGTG - CGGTCTACCCATTGCCCCTACTCTAGAATAAGAAGCTGACTTCTGTTAGACCTAT	-----TGAGCCCAGCTCA-TAACATAGGAGAAGATATTGTGAAAG									

SEQ ID NO:

GETT-----LKEVWEEKKMFVYI		IQAVALDYLQI		ELAESTKTPA		RADKLRM		FKAEDGK		FPLSPFNGC		-40					
RIG2A	protein	GRTRPAMHILKVKVKEKKLFLNFI	EAUGVIEKTTTIA	IQAVALDYLQI	NEKTKTPA	RADKLRM	FKAEDGK	FPLSPFNGC	IQAVALDYLQI	ELAESTKTPA	RADKLRM	FKAEDGK	FPLSPFNGC				
RIG2B	protein	GRTRPAMHILKVKVKEKKLFLNFI	EAUGVIEKTTTIA	IQAVALDYLQI	NEKTKTPA	RADKLRM	FKAEDGK	FPLSPFNGC	IQAVALDYLQI	ELAESTKTPA	RADKLRM	FKAEDGK	FPLSPFNGC				
RIG2C	protein	MTRK--	AKAEFVAKKEKEEF	YI	EAUGVIEKTTTIA	IQAVALDYLQI	NEKTKTPA	RADKLRM	FKAEDGK	FPLSPFNGC	IQAVALDYLQI	ELAESTKTPA	RADKLRM	FKAEDGK	FPLSPFNGC		
RIG2D	protein	EVAK--	XX--	--RK-	EVAK--	IQAVALDYLQI	NEKTKTPA	RADKLRM	FKAEDGK	FPLSPFNGC	IQAVALDYLQI	ELAESTKTPA	RADKLRM	FKAEDGK	FPLSPFNGC		
RIG2E	protein	GRHND-	AKVEEVK	ENRHM	YI	EAUGVIEKTTTIA	IQAVALDYLQI	NEKTKTPA	RADKLRM	FKAEDGK	FPLSPFNGC	IQAVALDYLQI	ELAESTKTPA	RADKLRM	FKAEDGK	FPLSPFNGC	
RIG2F	protein	LEDTH-MLRACKRKF	--ELK	EVKUQKSEN	I	EAUGVIEKTTTIA	IQAVALDYLQI	NEKTKTPA	RADKLRM	FKAEDGK	FPLSPFNGC	IQAVALDYLQI	ELAESTKTPA	RADKLRM	FKAEDGK	FPLSPFNGC	
RIG2G	protein	GRHDD-	KEVDRKMF	SI	EVKUQKSEN	I	EAUGVIEKTTTIA	IQAVALDYLQI	NEKTKTPA	RADKLRM	FKAEDGK	FPLSPFNGC	IQAVALDYLQI	ELAESTKTPA	RADKLRM	FKAEDGK	FPLSPFNGC
RIG2H	protein	--	--	--	--	--	--	--	--	--	--	--	--	--	--		
RIG2I	protein	CKKS--	--	--	--	--	--	--	--	--	--	--	--	--	--		
RIG2J	protein	ERGR--	--	--	--	--	--	--	--	--	--	--	--	--	--		
RIG2L	protein	LEDTH-MLRACKRKF	--ELK	EVKUQKSEN	I	EAUGVIEKTTTIA	IQAVALDYLQI	NEKTKTPA	RADKLRM	FKAEDGK	FPLSPFNGC	IQAVALDYLQI	ELAESTKTPA	RADKLRM	FKAEDGK	FPLSPFNGC	
RIG2M	protein	AEE-----	--	--	--	--	--	--	--	--	--	--	--	--	--		
VDFKVLJLTSRDHSVCTVGV														-5/			
VDFKVLJLTSRDHSVCTVGV														-5/			
RIG2A	protein	VDFKVLJLTSRDHSVCTVGV	ENSTENVKL	IEA	QSLFOF	VETS	-E--	--	PELKJIGEDIV	KCCGLP	IAIKTM	ACTL	LRNKRKDADSLRLEHHD	-5/			
RIG2B	protein	VDFKVLJLTSRDHSVCTVGV	ENSTENVKL	IEA	QSLFOF	VETS	-E--	--	PELKJIGEDIV	KCCGLP	IAIKTM	ACTL	LRNKRKDADSLRLEHHD	-5/			
RIG2C	protein	VDFKVLJLTSRDHSVCTVGV	ENSTENVKL	IEA	QSLFOF	VETS	-E--	--	PELKJIGEDIV	KCCGLP	IAIKTM	ACTL	LRNKRKDADSLRLEHHD	-5/			
RIG2D	protein	VDFKVLJLTSRDHSVCTVGV	ENSTENVKL	IEA	QSLFOF	VETS	-E--	--	PELKJIGEDIV	KCCGLP	IAIKTM	ACTL	LRNKRKDADSLRLEHHD	-5/			
RIG2E	protein	VDFKVLJLTSRDHSVCTVGV	ENSTENVKL	IEA	QSLFOF	VETS	-E--	--	PELKJIGEDIV	KCCGLP	IAIKTM	ACTL	LRNKRKDADSLRLEHHD	-5/			
RIG2F	protein	VDFKVLJLTSRDHSVCTVGV	ENSTENVKL	IEA	QSLFOF	VETS	-E--	--	PELKJIGEDIV	KCCGLP	IAIKTM	ACTL	LRNKRKDADSLRLEHHD	-5/			
RIG2G	protein	VDFKVLJLTSRDHSVCTVGV	ENSTENVKL	IEA	QSLFOF	VETS	-E--	--	PELKJIGEDIV	KCCGLP	IAIKTM	ACTL	LRNKRKDADSLRLEHHD	-5/			
RIG2H	protein	VDFKVLJLTSRDHSVCTVGV	ENSTENVKL	IEA	QSLFOF	VETS	-E--	--	PELKJIGEDIV	KCCGLP	IAIKTM	ACTL	LRNKRKDADSLRLEHHD	-5/			
RIG2I	protein	VDFKVLJLTSRDHSVCTVGV	ENSTENVKL	IEA	QSLFOF	VETS	-E--	--	PELKJIGEDIV	KCCGLP	IAIKTM	ACTL	LRNKRKDADSLRLEHHD	-5/			
RIG2J	protein	VDFKVLJLTSRDHSVCTVGV	ENSTENVKL	IEA	QSLFOF	VETS	-E--	--	PELKJIGEDIV	KCCGLP	IAIKTM	ACTL	LRNKRKDADSLRLEHHD	-5/			
RIG2L	protein	VDFKVLJLTSRDHSVCTVGV	ENSTENVKL	IEA	QSLFOF	VETS	-E--	--	PELKJIGEDIV	KCCGLP	IAIKTM	ACTL	LRNKRKDADSLRLEHHD	-5/			
RIG2M	protein	VDFKVLJLTSRDHSVCTVGV	ENSTENVKL	IEA	QSLFOF	VETS	-E--	--	PELKJIGEDIV	KCCGLP	IAIKTM	ACTL	LRNKRKDADSLRLEHHD	-5/			

SECTIONS:

SEQ ID NO:

810

820

AC15-2A
AC15-2B
AC15-2C
AC15-2D
AC15-2E
AC15-2F
AC15-2G
AC15-2H
AC15-2I
AC15-2J
AC15-2L
AC15-2N
AC15-2O

TAGTACTGTTTCACTCTCGG - 56
TAGTACTGTTTCACTCTCGG - 57
TAGTACTGTTTCACTCTCGG - 58
TAGTACTGTTTCACTCTCGG - 59
TAGTACTGTTTCACTCTCGG - 60
TAGTACTGTTTCACTCTCGA - 61
TAGTACTGTTTCACTCTCGA - 62
TAGTACTGTTTCACTCTCAC - 63
TAGTACTGTTTCACTCTCAC - 64
TAGTACTGTTTCACTCTCAC - 65
TAGTACTGTTTCACTCTCAC - 66
TAGTACTGTTTCACTCTCAC - 67

779
777
777
788
721
781
738
722
784
699
779
763

1 1 1

SEQ ID NO:68

RLG3 (real RLG3)

[Strand]

1 AATGGCAAAA GAAGTCGGAG CAAGAGCTAA GTTAGAGCAT CTATTTGACG TCATTATCAT GGTAGATGTC
71 ACTCAAGCAC CCAACAAAGAA CACAAATCAA AGTAGTATTTC CAGAACAGTT GGGATTTAAAAA CTGCAAGAAG
141 AGAGCTTGTGTT GGTAAAGAGCA GCTAGGGTAA GTGCGAGGGTT AAAAATGCTT ACAAGGGTGC TGGTGATATT
211 AGACGATATA TGGTCAAGGC TTGACATGGA GGAACCTTGGG ATTCCCTTTG GATCAGATAG ACAACACCCAC
281 GGCTGCAAAA TCTTGTGAC TTCAAGAAGT ATTAGTGCTT GTAACCAGAT GAGAGCTGAT AGAATCTTTA
351 AAATACGAGA AATGCCACTG AATGAAGCAT GGCTTCTTTT CGAAAGAACCA GCTAAAAAAG CTCCGAATCT
421 GCATCAAGTA GCAAGAGATA TCGTGGAGGA GTGTGGTGGG C

RLG 4
SEQ ID NO: 69

1 GAATTCCGTG TTGGTAAGAC AACTCTTGC C TCTCTGTTT ATGATGAAAT CTCTAGCAAG TTTGATGGTT
71 GCTGCTTTCT AAAAATATCT GGGAGGAATC AAGTAATAAA GACGGTATAG AAAGATTGCA AGAAAAAAATC
141 ATTTGTGATG TTTTGAACCA AGAGCAAGTG GGCCTAGGGA GAGTGTGAGA AGGAAGGCAG ATGATAAAGG
211 ATAGGTTACA ACATAGAAAG GTATTTGTTG TGCTTGTGA TGTGACAC AC TTGAGCACC TAGCTAGAAC
281 AGTTGGCTGG ATCACATGAT TGGTTGGTG AAGGTAGCCG CATAATAATC ACAACTAGAG ATGAACATGT
351 ATTAATTGCA CACAAAGTAG ATGTGATACA CAATATAAGC TTGTTAAACA ACGATGAAGC TATGCATCTC
421 TTCTGCAAGC AAGCACCACG GGGTCACAAA CGTATACAAG ATTATGAGCA ACTTTTAAAAA CATGTGGTTT
491 CTTATGCTGG TGGGCTTCCA CTAGCACTGT CGAC

SEQ.ID NO: 70

RLG1-E169

[Strand]

1 ATCGTAACCG TTCTGACGAG ANCGCTGTCC CTCCCTTCATC TTTTGTCTATA TGTCTATTC TCATNNATTN
 71 TGCCACATTTT AATTTTGTGG TTATTTTAAA TTAATTTTTA TTCCACATGT CATTTTATGA GTTTTCTAT
 141 TTATTTGAGT TTACATAAT ATTTAAATGT AATAACAATA AATGCTATTT TATTTTCTT TAATATAAAGC
 211 CATATAATAT ATAGATTTAA ATCATATAAT ACATAGGTAA AACTCATATA ATACATATGT TCATCCCCAG
 281 TTATTTATAA TGTCCTCATCC TTAATTATT TATTATTTAT TTATTAGAGT AGATGATCTT TGATATTAA
 351 AAAATTTAAT TTGTTCAAAA TTAAATTTA TTAAATAATCC CACCAATTGAA ATAAAATTAA AAAAAATGGN
 421 CCCACCAATTG GTCTCATCACT TTTCAGCTC ATCAATATCG TGAGTATTCT CTTCTGTTTC CACCCATAATC
 491 AATATTTCCA GCGAATGACA GACTCTTACG CGCTTCTGAA ATTTCGTTTC CGACACTGTT CATGAAAGG
 561 GATAATAAAT CAAATGGAGC TGCTCCAATG TTCTTGTG ATGAAAGGTG ATTTGTTGTTG GAAAGANAATG
 631 TCAGGCGATCN ATCTCCATCC GGAACCCACCA ACATATCAG TGCTACCCCA ACCACTCAA AACGGYGGAA
 701 GTAGRRAKAC WRKAAAGTC TGAAGAATAG ATTATTTTG TGCTCATGGG CTGACTGAGG AGCCGGTTTA
 771 GTTCATCAT TTCTCTTGA CAAAGAATTG TGCTCTTGC GAAATTTCAC ATGACAAAG AAGTTTCACT
 841 TCGCAATGTT TGTAAACATC ATTTTAATC TTTTATCTT TTCTGTGAAA CTCCTCAATT GCAACTTGC
 911 ACTTGCACAT TTCTGGGCCA CAAATTTGIG GTGGGCGTTA ATTTAATCC CATTTCATC GTAAACANT
 981 ATTCACATCG ATCTCTGTT ATCCCATTC TCAACATCTC TTGATAATTG AAATCATTCA CGCTTCATCC
 1051 ATTTCATCCA CATTCTATAC ATATTCTCTG CTCCTATCAT ATTAACAGAT GGCTGAAATC GTCTCTCTG
 1121 CCTCTCTGAC AGTGGTGTGTT GAAAAGCTGG CATYTGAGC CTGAGAAGAG ATTTGTTGCT CCAAAAGAAT
 1191 TGAATCTGAG CTTAAGAAAT TGAAGGAGAC ATTAGACCAA ATCCAGATC TGCTTAACGA TGCTTCCAG
 1261 AAGGAAGTAA CTATGAGC CGTTAAAGA TGGCTGAATG ATCTCCAAACA TTGGCTTAT GACATAGACG
 1331 ACCTACTTGA TGATTTGCA ACTGAAGCTG TTCAWGTTA TTGACCCAG GAGGGTGGAG CCTCTCTCAG
 1401 TATGGTAAGA AAACAAATCC CAAGTTGTTG CACAAGTTC TCACAAAGTA ATAGGATGCA TGCCAAGTTA
 1471 GATGATATTG CCACCCAGTT ACAAGAACTG GTAGAGGCAA AAAATAATCT TGGTTTAAGT GTGATAACAT
 1541 ATGAAAAGCC AAAATTGAA AGGTATGAGG CGTCTTTGGT AGATGAAAGC GTTACTGTCG GACGTGAAGA
 1611 TGATAAGAALA AAAATTGCTGG AGAACGTTT GGGGGATAAA GATGAATCAC GGAGTCAAAATTTCTCAG
 1681 GTCCCCATAG TTGGTATGGG TGGAGTTGGT AAAACAACCTC TAGCTAGACT TTGTTATGAT GAAAAGAAAG
 1751 TGAAGGATTC CTTCTGAACTC AGGGCTTGGG TTGGTGTTC TGATGAGTT AGTGTCTCCA ATATAAGCAG
 1821 AGTTATTTAT CANTCTGTA CTGGGAAAGA GAAGGAGTTT GAAGACTTAA ATCTGCCTCA AGAAGCTCTT
 1891 AAAGAGAACAC TTAGGAAACCA GCTATTCTTA ATAGTTTGTG ATGATGTTGTCG TCTGAAAGC TATGGTGA
 1961 GGGAGAAATT AGTGGGCCA TTCTCTGGG CGTCTCTGGG AAGTGAATAA ATCATGACAA CTCCGAAGGA
 2031 GCAATTGCTC AGAAAGCTGG CTTTTCTCA TCAAGACCCCT CTGGAGGGTC TATCACAGA TGATGCTTIG
 2101 TCTTTGTTG CTCACACCC ATTTGGTGTAA CCAAACTTTG ATTACACATCC AACACTAAGG CCACATGGAG
 2171 AACATGTTGTT GAAGAAATGT GATGGCTTAC CTCTGGCTT AAGAACACTC GGAAAGGTTTAT TAAGGACAAA
 2241 AACAGACGGG GAACAATGGA AGGAGCTGTT GGATAGTGG ATATGGAGGT TAGGAAAGAG CGATGAGATT
 2311 GTTCCGGCTC TTGACTTAAG CTACAATGAT CTTCTGCCW CTTGTAGCT TTGTTTGTCA TAYTGTCTT
 2381 TGTTTCCCA GGACTATGAG TTGACCAAGG AGCGATTTGTT CTGTTTGTGG ATGGCAGAAG GGTTTTGCA
 2451 CCAACCAACTC AYAAACAAAGT CAAAGAACG KTTGGGTCTT GAATATTTRR AAGAGTTTGT GTCAAGRTR
 2521 TTTTTCAAC ATGCTCTTCA TRRCAATC TSCTTGTGAA TGCTGACCTT ATGAAATGAT TTGCTCAT
 2591 TTGTTGCTGAGAATTTTT TCAAGGTTAG ACATAGAGAT GAAGAAGGAA TTGAGGATGS AATCTTTGGA
 2661 RAAGCACCCT CATATGTCAT TTGTATGTGA GRATACATA GGTACAAAAA RGTGGAGGCC ATTTAGAGGA
 2731 GCTAAAAATT TGAGAACATTTGAGCATG TCTGTTGGG TGTTAGAAGA TTGGGAAGATG TTTTACTTAT
 2801 CAAACAACCT CTGAAATGAC WTACTTCARG ATTTACCATG GTTAAGGGTC CTRAKTTTGA TTTRCTTAY
 2871 AATAASYRAG GTACCARAAK TCGTSGGTAG TATGAAASCAC TTGCGGTATC TTAATCTATC WGRAACTTWA
 2941 ATCACMCATT TACCGGAAWA TKTCTGCAAT CTTTATAATT TACARACCCCT GATTTGTRCT GGCCTGTGAM
 3011 ATTTAGTTTCA KTTGCCCCAA ACCTTCTCAA ASCTTAAATT TTGTCASCAT TTGACATGA GGGTACTCC
 3081 KAAKTTRAAR AACATGCCCT TARGGATGG TGTTGAAARTCTACATTAA CTCTCTTGYG TAACATTGCC
 3151 ATGAGCAATT CCGAGCTAA GAACCTGCA AAYCTCCATG GGGAAATTG TATTGGGGGG CTGGGAAAAAA
 3221 TGAAAATTC NGTGGGATGAC ACGTAAAGCG AACTTGTCTC A: AAAAAGGT TWAATGARTT ANAAACTGGR
 3291 WTKGGGGGTG ATRAATTAA TTGTTTCCGA AATGGGAACAA CTGAAAAAAA NAAGGTCTC AATGAATTGA
 3361 ATGCCCTCAAC ATGCTTAYTC AAMWAARR YYWTARWWAT TWGKAWRRK GKGTYYATRR TKTTMYRAAW
 3431 WAGRGTXTTR KARGTAGTT TCATCCATC ACCCAAGTGG GAAAATAGAT GATTTTCTCA CGGCYTA
 3501 ATGAGATGTT GAGAGCTATG ATAGGGTNTC TTGGGGCGGT AGAAAGAAATA AGCATCCATT CTGTTAATGA
 3571 AATAAGATTTT TTGTTGGGAT CAGAACCGAGA GCGAAGTAAAG GTCTCTTATGA ATTTAAAGAA GTGTTGATTA
 3641 CGTGAATGCG AAAATTGGT GAGTTAGGG GAGAAAAGG AGGATAATCA TAATATTAAT AGTGGGAGCA
 3711 GCCTAACATC TTGTTAGGGG TTGAAATGTT GGAGATGTA CAGCTGGAG CATTGCGAGGT GTCCAGATAG
 3781 CATGGAGAAAT TTGTTATGCA ACATGTTGAA TTCAATNACA TCCCTCTCTT TCCCAACAGG AGGAGGACAG
 3851 AGAGTAACTC CACTTACCAT CACTGATTGC AAGAAGCTTT CGAAGAGGAA GTGGGAGGA CGAGAGAGGA
 3921 CAAGAGTGGT TATAAATCTA AAAATGAGA TGCTTGAATC AGTAGATATA CGTAATTGCC CAAATCTGAA
 3991 ATCTATCATC GAATGAGTT GCTTCAATTCA CCTGAACAGA TTATATAT CAAACTGTCG GAGTRTGAG
 4061 TCATTCTCTC ACCATGAGTT GCGAAATCTC ACCTCTTAA CAGATCGAAG GAGGGACAG CGATTTCTG

RLG1-E169
[Strand]

4131 ACGAACGGTT ACGATTGGAC TGGCCGTCGT TTT

SEQ ID NO: 70

Further Characterization of RG2 Family Members:

Further sequencing of cloned RG2 polynucleotide sequences, as discussed above, identified additional RG2 species, listed below. Additionally, further sequencing of the 5' sections of RG2 sequences listed above resulted in modified and/or new sequence information, also listed below. The AC15 sequences found in the 3' sections of RG2 family have not changed.

Listed below are: four full length species, RG2A, RG2B, RG2C and RG2S; two near complete, but with a gap in the largest intron, RG2D and RG2J; three nearly complete RG2 gene sequences, RG2K, RG2N, and RG2O. The deduced translation products (polypeptides) encoded by these RG2 species are listed below. The polynucleotide sequences do not contain any gaps (as with some of the polynucleotide sequences), because all of the gaps in the sequences are in introns, *i.e.*, there are no gaps in exon, or coding, sequences.

They include: an RG2A polynucleotide sequence (SEQ ID NO:87) and its deduced polypeptide sequence (SEQ ID NO:88); an RG2B polynucleotide sequence (SEQ ID NO:89) and its deduced polypeptide sequence (SEQ ID NO:90); an RG2C polynucleotide sequence (SEQ ID NO:91) and its deduced polypeptide sequence (SEQ ID NO:92); an RG2D polynucleotide sequence (SEQ ID NO:93) and (SEQ ID NO:94), and its deduced polypeptide sequence (SEQ ID NO:95); an RG2E polynucleotide sequence (SEQ ID NO:96) and its deduced polypeptide sequence (SEQ ID NO:97); an RG2F polynucleotide sequence (SEQ ID NO:98) and its deduced polypeptide sequence (SEQ ID NO:99); an RG2G polynucleotide sequence (SEQ ID NO:100) and its deduced polypeptide sequence (SEQ ID NO:101); an RG2H polynucleotide sequence (SEQ ID NO:102) and its deduced polypeptide sequence (SEQ ID NO:103); an RG2I polynucleotide sequence (SEQ ID NO:104) and its deduced polypeptide sequence (SEQ ID NO:105); an RG2J polynucleotide sequence (SEQ ID NO:106) and (SEQ ID NO:107), and its deduced polypeptide sequence (SEQ ID NO:108); an RG2K polynucleotide sequence (SEQ ID NO:109) and (SEQ ID NO:110), and its deduced polypeptide sequence (SEQ ID NO:111); an RG2L polynucleotide sequence (SEQ ID NO:112) and its deduced polypeptide sequence (SEQ ID NO:113); an RG2M polynucleotide sequence (SEQ ID NO:114) and its deduced polypeptide sequence (SEQ ID NO:115); an RG2N polynucleotide sequence (SEQ ID NO:116) and its deduced polypeptide sequence (SEQ ID NO:117); an RG2O

polynucleotide sequence (SEQ ID NO:118) and its deduced polypeptide sequence (SEQ ID NO:119); an RG2P polynucleotide sequence (SEQ ID NO:120) and its deduced polypeptide sequence (SEQ ID NO:121); an RG2Q polynucleotide sequence (SEQ ID NO:122) and its deduced polypeptide sequence (SEQ ID NO:123); RG2S polynucleotide sequence (SEQ ID NO:124) and its deduced polypeptide sequence (SEQ ID NO:125); an RG2T polynucleotide sequence (SEQ ID NO:126) and its deduced polypeptide sequence (SEQ ID NO:127); an RG2U polynucleotide sequence (SEQ ID NO:128) and its deduced polypeptide sequence (SEQ ID NO:129); and RG2V polynucleotide sequence (SEQ ID NO:130) and its deduced polypeptide sequence (SEQ ID NO:131); and, an RG2W polynucleotide sequence (SEQ ID NO:132) and its deduced polypeptide sequence (SEQ ID NO:133).

Characterization of New RG Family Groups and RG Species:

Further BAC insert characterization and sequencing, as discussed above, identified new RG polynucleotide sequences. The new sequences were characterized as belonging to new RG families; designated RG5 and RG7. These RG polynucleotides sequences, and their predicted translation products (the polypeptides which are encoded by these sequences) are summarized and listed below.

Identified and listed below is an RG5 family member, designated as the RG5 polynucleotide sequence set forth in SEQ ID NO:134, and its deduced polypeptide sequence (SEQ ID NO:135). This sequence contains an NBS region sequence.

Also identified and listed below is an RG7 family member, designated as the RG7 polynucleotide sequence set forth in SEQ ID NO:136. No deduced polypeptide sequence is given for the new RG7 family member as this sequence appears to be a pseudogene.

RG2A polynucleotide sequence (SEQ ID NO:87)

AAAGTTCATATCCAAGCTTGCCTCCAACCTCTAGCTCCTCAATGGCACC
30 TCCTTCTCTTCAAAAGCACACAAGAACACTTCAAGCTCAACCACACTCA
CACAAAGCTCTAGAACGAGGGTTAGGGCACATTAGGGTTTGCTCTGG
AAATGGTGTCTAAAGTGAGGCCATAATGTTCTTATATAAGGCTCACTC
CCACAATTAGGCTTCAATCTGAACGTANTACGCCAGTGTACACTATGG
TACGCCAACGTACTCGGTAGTCTCCCGGTCAANAATACACTCATGAGTA

CGCGAACGTACTTCCCTTACGCCAGCGTACTCAAAAGCCAAACATTCTTTCAAGGACTAATTTGACAACTTGAGGAAAGAAAAGGATCAAAGANA
TATACTTGAATTCCGGGATGTTACAATGAAGTTGANACCTTGGCTAAAAA
ATTAAATTGGTGTGGAAGCCGTTGAGCAAGCAACAAAGGGTAAAAT
5 TCGTAATCTACAAATGGTGTATTTCTATTCTTCTTATTATTTACTTGATTTACGGGTAGTTTTCTTACAAAAAATATTAAGTTGATAAAG
TATAGCCACTAAAATTGACTTTCCAAAACATAATGTCAAATGGTGCCT
ATATGTATCATGTTGTATTANATAATGAATATGATGATNCTGTTCTATT
AANCCGAAAAAAATTATCTAATGATTATATTGGAAAACAAAGTTGTGAT
10 TTTNGCATAATATAATCAAATCCNCTTTGTNTGGAGGTGGATAAATG
TGGTAAATTANAACAAGTGTNTNACNTTGAAGGGNTGGAAAGGTTGA
AAAAAGTTAAAATGATAAAATGTTACACAAATGTTGATCCGACTGAAT
ATNATGTTAAGGATNATTGATTAAATTGTTGATATAGTAAGCATAA
ATATTAGAATTGTGACTTAAATTATAAGTTATNCNACTGGATTGAAA
15 CATTGATATANATTAGGAATGAAAATGAGCAACCCCTAACATACTTAT
CTTGTTAGTTGGTTATTATTTATTANAATATAGAANCATCCCTT
TATTAAACCCATATTGGACGGACTTGAATAAATGGGAAAATGTAC
CTTGTCTATTAGCACAAAAAAATTATAAAATGTACATTGCTATTAGCA
CAAACAAAAAAACTTATCCTTTGCATTAGGTACAAAGAAAATA
20 TAAAATGGGAAATGTGTTGCTATTAAATGCACTAAAAGAAACTATTTGC
CTTATTAAACCGGGTAAACCAATAGAAAAATGGAAGTACATTGTCTT
AGCATGAAAAAAATAACTTCCATTGGCATCCGGTCACAATAATAG
AAAAATGAAAGTACGTTGCTATTAGCGAAACTAACCTCCTTTCTTT
TTGGCATCGTATCATAAAATATAGACTAAAATACGTTAGTTACATT
25 TAATACATTGAAATGTCTAATCCACATGTTATTCTATAAAAGGGAAATG
TAATTACTTATTCTTGATTCTTGGCTTCTTTAGTACCCAAAACAT
CCCTCTATCCATCTATTCCAACATAAAATAATGAAAACATATTCCCTCCA
TTGTAGGGATGTTATAAATTGTAATTGTTTATGCAAAAAAGTGT
30 TTTGTTAACTAGATTAACGAGATTCACTTCAAGCATTAGGAGAAGTT
CATCCATCTTGGATATGAAGTGCAAGCCAAGTTCTTAACATGGAATA
TGAGGTCCCTATATGCTAAAAAATGCAAATGAGAAATTGTTAAATTG
GATCCCCATAAAAGAAAATTGTTAATGGTGTGTTAATATTGGTCAATG
TGTCCACCGGATGAGCATAACTAGTTATAAGGGTAAAGGTGGGTT
GGTGGGCCCTTTATCTTATTATCTAAAGTCAGAATTAAAGTAAAAA
35 AAATTATAAGATAAATACCAAGGATAAAAAATCATTATTGGACCA
AAGACCAAAGTTGTTAAGGGCTGTTGTTTTGTGAAGAGCTGTGC
AACCACTTTGTCTGCGCCGCACAGACAACGTGCAGACATATGCCCTCGC
AGAGTGTGTTGTTGAAAGTGCAGACACAAAAACGTCTGCGCGAG
GTCATCCTGGCGCATATATGTGTCAGTCTCAAAGGTCTCAGACCTC
40 ATTGTTAACCAAAAAAAGACCACCGGTTTTTTTTNTTC
TTTCTCTGTTAGCTGAAATGCATTAAATCTTATGACATGAAATTAA
GTTTGGAAAAATTAAATTATTCAACAGCTGTAGACGTTAAAACAAACAG
TCTTCTTGTGCAGACTGTGGACATTGGTCCACCTCTACCGCAGAG

ACTTGCAGATGTGGTCCGCAGACTGCAGACATTTGGCTCAAATAAAC
AACATCACCTAATTGACTACACCACACGGACCTCAAATGTAACAAAAAA
AAGGTTGAAACAAAGTTGCCTATTCTCCATATCCAGGGGCCATTTATGT
AAGAGTTATCTAAATTAGTTAGTCGGTAGATCAGTTCTCACATTTAACCG
5 GGTAAAGTGTATGTGTACCGCGCACCTGAAAGGTTGAANGTAACCT
CCAAACTGAANCAANAATCGATATGAAGTATCAAGTTAGAGGTTCAATTG
GTGAAGGAATCAGCTGGAGGTTGGGAATCGAGCTTCCACTATTAAGGTA
AAATCCATAACCCTAAATGTTGGTACGCTCATATATCAAATTGCGTGT
10 TGTTGAATGAAAAAGCATGCTAAAAACCAGTGTAAAGGCACGGTATAT
GACATATTATAGTTACTGATAACAAATTATGATAATTGGGTTACGT
AAGTTAGGATTCGTACTTCACCCAAATGTAATAGTTTGAGTCTATC
TATGTATTGGGAAATCACATTAGCAACGGGATTGTAAGTAAATTGAA
AAAGTCTTAAATAATTCTGTTATAATTATGAATAGTTAGCG
15 ACATCTAATATTAAATAGAATGTATCTGATATTGAATTATGTCCTTAAT
GTGAAACATAGACCTTCCATTACTAATGCCTAATTATTAGTTCTAAT
CAATAAATTAAATTCTGTTATGCTCTAAGACAATAAAATCCATG
ATTACCTTAAATATTAACAAAATGACCATAAATAAATAAAATTAG
GATACCAACCCCCCGCCATGCCAATGTCTAAATTCTGATGCTTT
TGCTTTCCCTTTCCCTGTTAGTCTATTATTCTGGAGAGTTGAGAG
20 AGTTTCATACAAGAAAATTCAAGAAGAAAGCAAAGGTCCAGGTATTCTC
TTTCTTAATTATGTATTAACCTACAAGCATTTCACGATCCATGGT
TTTTGTGTATGTTTCAAATTGAAACTAGATTGGACTTTGCCCTG
ATGATTCTAAGATATTGCATGGAGTTGAGATTGTGAAGAAAAGTGGTG
AATAGAAAGAGCAAGTGAATCCAGATATAGTATTGTAATATATGATGAT
25 GAGATAGAGATATGTTAAACTGGCTAGAAAATTGTTAATTGAAATT
TAGGTTGTTGAATTGAAAGATAACCAAGCTAATAACTAATTAGTTATGCT
AAAATAGTTATAAGAACAAACAAACTCGTAGTTTTTCATGATTTC
ACCTCTCGTACCAAACCTAAATTATAACAAAATTGAATATCATTCTGC
AATCAATTAACTTTGTTATTATCATCATGTCTAAATTGCCACAAGT
30 TTATTTCATAGTCATATTGGATTATGAAAGGACTATTTCACCAATTAC
ATCTTACTTATGCCAAAGCTAATACAATCCGACTAAACTAAAGGATT
CTAGGATGCATAGTTGCTCCCCGATTATAGATTCTATCTAATTGT
CTATTGTTACTAATTAGGTGCCACCACAAGTAAATTCTGAAATGGATGT
CGTTAATGCCATTCTAAACCAAGTTGTCGAGACTCTCATGGTACCCGTTA
35 AGAAACACATAGGGTACCTCATTCTGCAGGCAATATATGAGGGAAATG
GGTATCAAAATGAGGGGATTGAATGCTACAAGACTTGGTGTGAGAGCA
CGTGAACCGAACATAAGCAACCAGCTGAGGTTCCAGCCCAAGTCAGGG
GTTGGTTGAAGAAGTAGGAAAGATCAATGCAAAAGTGGAAAATTCCCT
AGCGATGTTGGCAGTTGTTCAATCTTAAGGTTAGACACGGGGTCGAA
40 GAGAGCCTCCAAGATAATTGAGGACATCGACAGTGTATGAGAGAACACT
CTATCATCATTGGAATGATCATTCCATTCTTGTAGGAAGAATTGATTCC
ACGAAAGCATCCACCTCAATACCATCAACCGATCATGATGAGTTCCA
GTC.AAGAGAGCAAACCTTACAGAACGACTAAACGCACTCGATCCTAAC

ACAAATCCCACATGATGCCTATGGGAATGGCGGAGTGGGAAGACG
ACAATGATGCATCGGCTAAAAAGTTGTAAAGAAAAGAAAATGTTAA
TTTATAATTGAGGCGGTTGTAGGGAAAAACAGACCCCATTGCTATT
AATCAGCTGTAGCAGATTACCTAGGTATAGAGCTCAATGAAAAACTAAA
5 CCAGCAAGAACTGAGAAGCTCGAAATGGTTGTGGACAATTCTGGTGG
TAAGAAGATCCTAGTCATACTCGACGATGTATGGCAGTTGTGGATCTGA
ATGATATTGGTTAACGCTTACCAAATCAAGGTGTCGACTTCAGGTG
TTGTTGACATCACGAGACAAAGATGTTGCACTGAGATGGGAGCTGAAGT
TAATTCAACTTTAATGTGAAAATGTTAATAGAAACAGAACAAAGTT
10 TATTCCACCAATTATAGAAATTCTGGATGATGTTGATCCTGAGCTCCAT
AATATAGGAGTGAATATTGTAAGGAAGTGTGGGGCTACCCATTGCCAT
AAAAACCATGGCGTGTACTCTAGAGGAAAAAGCAAGGATGCATGGAAGA
ATGCACTCTCGTTAGAGCACTATGACATTGAAAATATTGTTAATGGA
GTTTTAAAATGAGTTACGACAATCTCAAGATGAGGAGACTAAATCCAC
15 CTTTTGCTTGTGGAATGTATCCGAAGACTTGTATTCTACCGAGG
AGTTGGTGAGGTATGGATGGGGTTGAAATTATTAAAAAGTGTATACT
ATAGGAGAACGAAAGAACCAAGGCTAACACATGCATTGAGCGGCTATTCA
TACAAATTGTTGATGGAAGTTGATGATGTTAGGTGCATCAAGATGCATG
ATCTTGTTCGTGCTTGGATATGTATTCTAAAGTCGAGCATGCT
20 TCCATTGTCAACCATACTAGAACACTAGAGTGGCATGCAGATAATGCA
CGACTCTGAAAAGACTTCATTAAACATGCAAGGGTATGCTAAGTTTC
CTACAGACCTGAAGTTCCAAACCTCTCCATTGAAACTATGCATGAA
GATATATCATTGAGGTTCCAAAAACTTTATGAAGAAATGGAGAAGCT
TGAGGTTATATCCTATGATAAAATGAAATATCCATTGCTCCCTCATCAC
25 CTCATTGTCGTCAACCTCGCGTGTTCATCTACATAAATGCTCGTTA
GTGATGTTGACTGCTCTGTATTGAAATCTGCGAATCTAGAAGTGCT
TAGCTTGCTGATTCTGCCATTGACCGGTTGCCTCCACAATCGGAAAGT
TGAAGAACGCTAAGGCTACTGGATTGACGAATTGTTATGGTGTTCGATA
GATAATGGTGTCTAAAAAAATTGGTCAAACCTGGAGGAGCTATATGAC
30 AGTGGTTATCGAGGTCGAAAGGCATTAGCCTCACAGATGATAACTGCA
AGGAGATGGCAGAGCGTTAAAAGATATTATGCATTAGAACCTGAGTT
TTGAAAACGATGCTCAACAAAGAATATGTCATTGAGAAGCTACAACG
ATTCCAGATCTCAGTGGGGCGTATTATATGGAGATTCCATAAGAGTA
GGCAGTCGTATGAAAACACATTGAAGTTGGTCTTGGAAAAAGGTGAATT
35 TTGGAAGCTCGAATGAACGAGTTGTTAAGAAAACAGAGGTGTTATGTT
AAGTGTGGAGATATGAATGATCTTGAAGATATTGAGGTTAAGTCATCCT
CACAACTTCTCAATCTCTCGTCAACAATTAAAGAGTCCTGTGCGTT
TCAAAGTGTGCGAGAGTTGAAACACTCTTACACACCTGGTGTGCAAACAC
TTTAAAAAAAGCTTGAGCATCTTGAAGTTACAAATGTGATAATATGGAAG
40 AACTCATACGTAGCAGGGTAGTGAAGAAGAGACGATTACATTCCCCAAG
CTGAAGTTTATCTTGTGGCTACCAAAGCTATCGGGTTGTGCGA
TAATGTCAAAATAATTGAGCTACCACAACTCATGGAGTTGGAACCTGACG
ACATTCCAGGTTCACAGCATATCCCATGAAAAAGTTGAAACATT

AGTTTGTGAAGGAAGAGGTAAATATAAATTAAATGCTAATACATTAC
AAAGGATCTTCAGTTAAATCTTCAAAATATATTGTAATTGATTGTA
TGGGGTATTATTGTTGGATGGGACTATTAATAATGATTATCTGCAGGT
TCTGATTCCCTAAGTTAGAGAACTGCATGTTAGTAGTATGTGGAATCTGA
5 AGGAGATATGCCCTGCGAATTAAATATGAGTGAGGAAGTTAAGTCAGA
GAGATTAAGTGAGTAACTGTGATAAGCTGTGAATTGTTCCGCACAA
GCCCATATCTCTGCTGCATCATCTGAAGAGCTTAAAGTCAAGAATTGTG
GTTCCATTGAATCGTTATTCAACATCCATTGGATTGTGTTGGTGCACACT
GGAGATGAATACAACAACAGTGGTGTAGAATTAAAGTGTACAGTTG
10 TGATAAGCTTGTGAATCTCTTCCACACAATCCCAGTCTATAGTCATC
ATCTTGAAGAGCTTGAAGTCGAGAATTGTGGTCCATTGAATCGTTATT
AACATTGACTGGATTGTGCTGGTGCATTGGCAAGAAGACAAACAGCAT
CAGCTTAAGAACATCAAAGTGGAGAATTAGGAGCTAAGAGAGGTGT
GGAGGATAAAAGGTGGAGATAACTCTCGTCCCTGTTCATGGCTTCAA
15 TCTGTTGAAAGCATAAGGGTTACAAAATGTAAGAAGTTAGAAATGTATT
CACACCTACCACCAAAATTAAATCTGGGGCACTTTGGAGATTCAA
TAGATGACTGCGGAGAAAACAGGGAAATGACGAATCGGAAGAGAGTAGC
CATGAGCAAGAGCAGGTAGGATTCAATTCACTGTCTTAATTAAATGAT
TAAGCTCCTGCTTTGAATAAAAAGGGACAAACCATTGACTTAA
20 TGTAGCAATACAAGTCATGTATAAGAGTGACCAACTCTTTTATTATA
AAATGACTACAAAATATTTTTTCAATTAGAGATCATGTATAATGTGAC
TAATTTTCACTCACCTAACTTAGTTGATAATCTTATAATGTCACTA
GTTACTTTCAAGTAAAATAACAAATTAAATTATCAACAAAAAGCAT
CAACTAAAAAAATCCCACAACCGTAATAATTAAAATAAAAGGATTAA
25 CATCTAACAGAACAAATTCTAAACATGATTGGACCAAATATCA
CCAGCAACTCAAGTTGGATCGATTGCTAAACTGACAGCATAA
TTAGATAGATGAGAGTTGAAGCTAAAGTGCCTATATAAGTCGTTCATC
TTTTTCTTGTATCTGATAGCAAGTTGAATGATTCTTCTTCAAATTG
ATAAAAATCTACATTATAAGAGACTAGCTGAAAAAAATGGCTAGGT
30 GGGTCTTGGGTTCTGGTAGATGAAGATGGAAGGGAGAGTAGATTCAA
GACACAACACATCCTCATTATTATTATTATTATTATTATTG
ATATCTTGTCTCATATTGTTACAGATATGTGAGGTCTATTAAATCTTTA
AATATATAAAAAATAAAATAACATAATGAGAAAATTAAATAAGAATAA
ATTATAAGGGCACAAATAGTCTTTAGGTAAAGACAAGGACCAACACGC
35 AACAAAAATAAACAGTAGGGACCATCCGATTAAAAAAATAATTAGGGA
CCAAAAACATAAATTCCCCAAACCATAGGGACCATTCATGTAATTACT
CTTACTTTGTTGTCATATTGGTAACTATTTTTGTACACAT
CTAGGTAAACGAACCTGTTGAAGTGTCCCATTAGGATGTGACCTACTAC
AACCGATCATAATAGTCATATGTGAACACTCCAACAATTACTTA
40 GGTGTGTACAAAAAAACAATAGTTACCATGATGTGAACATACTGAAAAAT
TAATTACCTTAGCAAGTTATTCCCATTAGGTTGTATGGAAACAGTTC
CGTGAGACCGTGACTTGGATGGTAGATAAAATTAGTAAACTTAACCCCTC
AATTAACCTACCTTTCTTATTAACTCAATTCAACCTAAATTCTGATT

CTTGTGAAAGTAAGTGCATCTTATTTGTATTATCTTGTGCATA
GGATCCTAGCATCTTAATAATTATTTGAAGGTGAAAGATCCAAC
TTTTAATCTGTTGGCATTTCATCATTGCAACTGTTCTGAAAAAA
AAATACCTAAAATCAAAATAACCATTTCAAATCCAAAATTATAAGAGAG
5 AATTGAAATGGACATGGAATCATAAATCATTACACAGTCAGTAAACA
AGTTGCTAATTACATTCTGCTGTGCAGATTGAAATTCTATCAGAGAAA
GAGACATTACAAGAAGCCACTGACAGTATTCTAATGTTATTCCCATC
CTGTCTCATGCACCTTTCTATAACCTCCAGAAACTTATATTGAACAGAG
10 TTAAAGGAGTGGAGGTGGTGGAGATAGAGAGTGGAGAGTCCAACAAGT
AGAGAATTGGTAACAACCTACCAACCAACAAACCTATTATACTTCC
CAACCTCCAGGAATTGATTCTATGGAATATGGACAACATGAGTCATGTGT
GGAAGTGCAGCAACTGGAATAAATTCTTCACTCTTCCAAAACAATCA
GAATCCCCATTCCACAACCTCACAAACATAAAAATTATGTATTGCAAAAG
CATTAAGTACTTGTTCGCCTCTATGGCAGAACTCTTCCAACCTAA
15 AGC.ATATCAAGATAAGAGAGTGTGATGGTATTGGAGAAGTGTGTTCAAAC
AGAGATGATGAGGATGAAGAAATGACTACATTACATCTACCCACACAAC
CACCACTTGTCCCTAGTCTGATTCTCACTCTAAGTTCTGGAGA
ATCTGAAGTGTATTGGTGGAGGTGGGCCAGGATGAGGGGAGCAATGAA
ATATCTTCAATAATACCACTGCAACTACTGCTGTTCTGATCAATTGA
20 GGTATGCTTGTACATATTCAATTATTATTAAATTCTTTTATTG
CAATATTCTATAATAATACATTACACAGCTCTCACTCTAAGATAATAAT
TACCTAGAGGGATGGATGCTATGACACAGCTGCTACACTCAGAAACTCT
AGTAAAGGGCAGTTATGGAAGTTCAATAAAATGATAATGGCATCTTGAT
GGGTAATATAAGGCAATTAAAGTTTATTCTGTTAAAGCAGTATTAGCA
25 AGTACTGGCCAGTAGGAGAGGAGAATATCACCTTGTGAAAATCTGGTC
ATTGTACCCAGAATTAGTTAAATGTAACATTAGATATCAGGGTCAT
CAGGTGACAGATATTGTTAGAATAGAACATATAATATCACCCAAA
ATTTTTCTAAGGTTATTCTGTTAAATATGTGCTTCTGTTCTGATNGA
ATTNGCATTCTGATATTAGGTGTTAAAGTGTGATTTNTCTCAATAAAAT
30 CCCGAAATTAAATTAAAAAAAAACAAAAGTACATTGATGTGGAG
AGC. ACTGGTATCACTTAGTATATAAAAGCTGATTGAAATTAACTTTC
TTATACAAAAGTTGTATATAGTTAATTAGTTACATCATTCTCA
TGTGGTGTGCAGTTGTCTGAAGCAGGTGGTGTCTGGAGCTATGCC
AATACGCTAGAGAGATGAGAATAGAATTCTGCAATGCATTGCAAGTGT
35 ATTCCATGTTATGCAGCAGGACAAATGCAAAAGCTCAAGTGCTGACAGT
AAGTGATTGCAAAGGGATGAAGGAGGTATTGAAACTCAATTAGGAGGA
GCAGCAACAAAACAACAAAGAGTGGTCAGGTGAGGAAGGAATTCCAAGA
GTAAATAACAATGTTATTATGCTTCTGGTCTGAAGATATTGAAATCAG
CTTTGTGGGGTTGGAACATATATTACACATTCTCTGCACTTGAAAGCC
40 TGAGACAGCTCCAAGAGTTAAAGATAACATTGCTACGGAATGAAAGTG
ATTGTGAAGAAGGAAGAAGATGAATATGGAGAGCAGTAAACAACAAC
AAC. AACAAATAACGAAGGGGCATCATCATCATCTTCTCATCTTCTA
AGGAGGTTGTGGTCTTCCTCGTCTCAAATCCATTGAACTAAATGATGTA

CCAGAGCTGGTAGGATTCTTCTGGGAAAGAATGAGTTCCGGTTGCCTC
ATTGGAAGAAGTTACCATCAAGTATTGCTAAAAATGATGGTGTTCAG
CTGGTGGGTCCACAGCTCCCCACTCAAGTATATACACACAGAATTAGGC
AGACATGCTCTGATCAAGAATCTGGCCTTAACCTTCATCAGGTATATAT
5 ATTTCTTAATTGGCATCATCTAATTAAGAAAGATATCATTCCCTGCCAAG
TAAATTTACTTCAAACACATTACACACTGGTTCACTCTAAGTTATGTTG
TTCTAGGAAGGCCAAATGGGAAAGCAAGATAGGGAAAAATAGTGTATTT
CAGTGGAAAGGGTATTTAGGTATTTCTGTCAAAAGTTGTATTGCAGG
10 CTTTTAGTACCTGGAATCGTGTGGGAGGAGCATTATTATTCTGATTT
GCTTGTTCCTTATCATTCTTAGCCTCTGGAACAGCTAGAAACCT
TTTAAATCTTTGATTTCAATGACAAAATTTCTGTTACTACATTGA
TTGTTGTTCTCATGGTTCAAGTGAGTTATTGGCTCATCTGTTACTTCT
TTTGATTGTTATTTCATATCATGTTAGTCACCTGAATCAAGCTTTCTA
15 TTTCAACCAGGGCAAAAGGTCAAAAGTAACCTACTTATGAGATCAAAA
ACAGCAACCCATCGGATAACTTTAGTTGGAGTTAATAGTTACAATTAC
ATTGTGATTAATAATTATAATATCTTGTATTAATTCTATTTGTTAC
AGCACATATATGACATTCAAAGGTTTGTTGACATATATATGCCTCT
GGCGTTTCTTATTGGACATGCAGACCTCATTCAAAGTTATACGGTG
ACACCTTGGGCCCTGTAACCTCAGAAGGGACAACCTGTTCTTCTATAAC
20 TTGATCGAATTATATATGGAATTAAATGATGCTGTTAAAAGATTATTCC
ATCCAGTGAGTTGCTGCAACTGCAAAAGCTGGAAAAGATTCTATGTGACTT
ATTGTAATTGGTAGAGGGAGGTATTGAAACTGCATTGGAAGCAGCAGGG
AGAAATGGAATAGTGGATTGGTTGATGAATCGTCACAAACAAACTAC
CACTACTCTTGTCAATCTTCAAACCTCAGAGAAATGAAGTTATGGTATC
25 TAAATTGTCTGAGGTATATGGAAGAGCAATCAGTGGACAGCATTGAG
TTTCCAAACCTAACAAAGAGTCGATATATGGGGATGTGATAGGTTAGAAC
TGTATTTACTAGTCCATGGTTGGTAGTCTATTGCAACTCCAAGAGCTAC
GCATATGGAACTGCAGTCAGATAGAGGTCGTGATTGTTAGGATGCAGAT
GTTTGTGAGAAGAAGACAAAGAGAAAGAATCTGATGGCAAGACGAATAA
30 GGAGATACTTGTGTTACCTCGTCTAAAGTCCTGATATTAAAACACCTTC
CAWGTCTTAAGGGTTAGCTTGGGAAGGAGGATTTCTATTCCCATTA
TTGGATACYTGGAAATCTACRAATGCCAGCAATAACCACCTTCACCAA
GGGAAATTCCRCTACTCCACAGCTAAAAGAAATTGAAACAMATTGGCT
TCTTTATGCTGCAGGGAAAAAGACATCAACTCCTCTATTATAAGATC
35 AAACAACAGGTAAACCAGATCTTGTGCTTNNATAATTCTAAACNACA
TNTGAAAAGCTTCATGCAAGTTTTNGTTATATNGTCAAAAACCGCAA
CCTACATTTCAGCTTANATTATGTACTTTATGCAGGATTCAAACAA
GAECTGATTAATGTGAAGTGAATATTAAAGGTAAATTATATTTCATGT
TCCTAGTNGCCTATTAATTAAAGGCCTTGTAGTCGNGATTGGATGT
40 ATTCTTCATGATGATGTCAATCTTCTAATACCCCATCATTGTTGGTTG
AATGTTGACTCTATGTCAGGATGAATATTCAAGGGAAAGAATTGTTCATCA
TATGAAGGACATTAAAGAACATGGATGCTGAAGATGTTGGAACACA

RG2A deduced polypeptide sequence (SEQ ID NO:88)

MDVVNAILKPVVETLMVPVKHIGYLISCRQYMREMGIKMRGLNATRLGVEEHVN
 RNISNQLEVPAQVRGWFEVGKINAKVENFPSDVGSCFNLKVRHGVGKRASKIIEDI
 DSVMREHSIIWNDHSIPLGRIDSTKASTSIPSTDHDEFQSREQTFTTEALNALDPNHK
 5 SHMIALWGMGGVGKTTMMHRLKKVVKEKKMFNFIIAEVGEEKTDPIAIQSAVADY
 LGIELNEKTKPARTEKLRKWFVDNSGGKKILVILDDVVWQFVDLNDIGLSPLPNQGV
 DFKVLLTSRDKDVCTEMGAEVNSTFNVKMLIETEAQSLFHQFIEISDDVDPELHNIG
 VNIVRKCGGLPIAKTMACTLRGKSKDAWNALLRLEHYDIENIVNGVFKMSYDNL
 QDEETKSTFLLCGMYPEDFDILTEELVRYGWGLKLFKKVYTIGEARTRLNTCIERLI
 10 HTNLLMEVDDVRCIKMHDLVRAFVLDMSKVEHASIVNHSNTLEWHADNMHDSC
 KRLSLTCKGMSKFPTDLKFPNLSILKLMHEDISLRFPKNFYEEEMEKLEVISYDKMKY
 PLLPSSPQCSVNLRVFHLHKCSLVMFDCSCIGNLSNLEVLSFADSAIDRLPSTIGKLK
 KLRLLDLTNCYGVRIDNGVLKKLVKLEELYMTVVDRGRKAISLTDDNCKEMAERS
 15 KDIYALELEFFENDAQPKNMSFEKLQRFQISVGRYLYGDSIKSRHSYENTLKLVLEK
 GELLEARMNELFKKTEVLCLSVGDMNDLEDIEVKSSSQLQSSSFNNLRVLVVSKC
 AELKHFFTPGVANTLKKLEHLEVYKCDNMEELIRSRGSEEETITFPKLKFLSLCGLP
 KLSGLCDNVKIIELPQLMELELDDIPGFTSIYPMKKFETFSLLKEEVLIPKLEKLHVSS
 MWNLKEIWPCEFNMSEEVKFREIKVSNCDKLVNLFPHKPISLLHHLEELKVKNCGSI
 ESLFNIHLDGVGATGDEYNNSGVRIIKVISCDKLVNLFPHPMSILHHLEELEVENC
 20 GSIESLFNIDLDCAGAIGQEDNSISLRNIKVENLGKLREVWRIKGGDNRPLVHGFQS
 VESIRVTKCKKFRNVFTPTTNFNLGALLEISIDDCGENRGNDESEESSHEQEIQIEILS
 EKETLQEATDSISNVVFPSCLMHSFHNLQKLILNRVKGVVEVVFEIESESPTSRELVTT
 HHNQQQPIILPNLQELILWNMDNMSHVWKCSWNKFFTLPKQQSESPFHNLTTIKI
 25 MYCKSIKYLFSPLMAELLSNLKHICRECDGIGEVVSNRDEDEEMTTFTSTHTTT
 LFPSLDSLTLFLENLKCIGGGAKDEGSNEISFNNTTATTAVLDQFELSEAGGVSW
 SLCQYAREMRIEFCNALSSVIPCYAAGQMQLQVLTVDCKGMKEVFETQLRRSSN
 KNNKSGAGEEGIPRVNNNVIMLSGLKILEISFCGGLEHIFTFSALESLRQLQELKITFC
 YGMKVIVKKEEDEYGEQ.TTTTTTITKGASSSSSSSSKEVVVFPRLKSIELNDVPELV
 GFFLGKNEFRLPSLEEVTIKYCSKMMVFAAGGSTAPQLKYIHTELGRHALDQESGL
 30 NFHQTSFQSLYGDTLGPVTSEGTTCSFHNLIELYMEFNDAVKKIIPSSELLQLQKLEK
 IHVTYCNWVEEVFETALEAAGRNGNSIGFDESSQTTLVNLPNLREMKLWYL
 NCLRYIWKSNQWTAFEFPNLTRVDIWGCDRLEHVFTSSMVGSSLQLQELRIWNCSQ
 IEVVTVQDADVCVEEDKEKESEDGKTNKEILVLPRLKSLLKHLPLKGFSLGKEDFSF
 PLLDTLEIYKCPAITFTKGNSTPQLKEIETHFGFFYAAAGEKDINSSIIKIKQQDFKQ
 35 DSD.CEVNIK

RG2B polynucleotide sequence (SEQ ID NO:89)

TTTTTTAAGATCAGGGATTCAAATTAGGCCCTAGTGATTACAATTGTGTC
 TAAACTTCCCATAACCTTCACATTATTGTAAGTATACTTCTCAGTTCT
 40 CTCTTGGAAAGCTTCCCTGGTATTAACTCGTGTCTAATATTAACCT
 GATAGTTATTTGGCCAATCTACTATCTGCATGTCCGGTTATTGAATCCG
 AAGGCACTGGAATCTTGGATTCCATTCCGTTGTGTTGGTTGCCAAAT

GAACGGAATTGAATTATGTAAGATTCCCTCAAAATCCATGTTAGGTATA
TCGTTGTTCTGGGATGGATGGTAAAGAACCGAACCTCTCCTGTTCAATT
TTTAATGAAAGACCAAATTGACCTTATAAACCTGTTAAAAAAATTACAT
TCCAGTTTCTAACAAACTGAAAATGGTAAAGGAGTGTGATTGAATTCC
5 AATCTGTTCTGTCCAAAACACGTGACGGAATTACAATTCCCTCAAA
TTTCATTTCTAAATTGTTATTCCCTTCTACAAAAACAAGGTAAACG
AAACACCCGCTTACTTAATCATACTCCTACATGATGTAATGAAAAGGGT
ATAAAATGGTATTTATTACAGGGATGAGTCACCATGGTCATGAAAGAAT
CATTAACCGCCCTAACCAATTCATGTTGCCCTAAAATATGATTAAA
10 GTAATATTGGCTTATGGGATTCAAGTTGACTTTTGTGGCGAAGAAATA
ATGAAAATCTCATTCTAAAGTGTCTTCTACCACTGACATTCTAAGA
AAGAACTTGCTAGAAGAAGGTGGGTTGTTAGTCTTTACTCTTAAAT
GTGAAGACTGTTGAGTTATTATTATTATTTGCCAATATGCCATTATGCGATTATTCTGA
15 AATAATTATCAAAACGCAGGAAACAATGTAGAATAATACTGGTATAAT
TAATTATATAAAGTTATTAGGCTGAAATCTGAGGCTACTATAATTAAAT
TATCATAATTGAAAATCATCAAATTGTATTCCATGTATATTATGTTAT
CAGATAATTAAATAATATGTGAGCCACACAAATCCACATCATCAGACACCC
CACCTTATTGTCGGCTACCTCACCACTGATGATCCGACATCTTCCA
20 ACCCCACCGACGACTGGGGTCTCTTAATATATCAATTATTCTGTAA
GTATTATTGTGAAATGTGTAATGTCATTACCTTTCTAATATA
TACAGAAACATAAATTAAATGAAATTCAACTGCGTTCATCTGCAT
TAAAAAAAAGACTGTAAGTGTCAATTATTACTTATAACCTGATTAA
TTAATTAAAGCGTAATTGATAATTGCATTAGGTTGTAATTGTGTTT
25 TATAGGGAGGGTGAGGGTCACCGGGAAATCAAAGCACTTATGAAAAGCAG
GGAAATACAAAAAATTACTCGAAACAAATTATTCAATTAAAGTGAGA
TAATAATGTTCTGATTAGATTATGAGAACTAGGAGATTAAAGTGATATAT
CCCATTAAAAGAAATTGCATTATTAATTGGATCTCTGATGATGACA
AAATTAACTCGTACAGGTATATATCATATACAAATGAGTGGCTATGC
30 TTTCGCTTCCAAAAGCAATTATAGTTATACTACACCTACAAATTAA
AAGGGGTTAACATATCAAATACTGATAAGTAATTATATAAATATGCA
TTTAAACCTCTAAAGAAAATGCTACTAAGCTGGACCATCTCAGAATTAC
AATCATAACCCTTCCCTCAAAAAGATTGCTATATATCATGTCATTGGC
ATTCAATTCTTTCAAAATTCACTAGTTCTATTCTCAAAAATTGAGTT
35 CTCGTATTGTAAGGAAGATCAGAAGAGACTGTTCACACAGGTACTCT
TTTATTATTGATTCACATTCAATATGTTATTGTTCTGCTTAATGG
TTTCGTCAGTCTAACTGCGCTGCTGATTAAATTCTTCACTTCTTCC
ACGGATTTTAAATATTAGTTGTAATGAAACAATTGGTAAGGAAAG
AAACATGGGAGTCTTCTAAAGTAAACCTAGATACTTAGGTTATAAGGG
40 TATATGCTAAAATGAACTATGCCATTACCTTGCCTTTCTTACTT
TTTATGTTTAGAATCCAAGTTCATATGTTATCTCGATGTGAGAAGA
ATAGGCATTAGAAAGGTAAAGGACGTACATAAAATTGATTAAATTAGTGA
TGTTCTTGTATCATTATTCTCATAAAAAGCATATAGATCAA

5 CACAAATTGCTACTTGTAGTGTAAACAACCTCGACTTAATAATGTTAATA
ATCAAGATTCTCTGATTCAACTATTTCTAACCGAACAGCTCACTAA
AAACTCATATTGCTTGAGTCTGAGTGGTTATATTGGGGTTTACATT
TAATTGGTGCATGAATGTGAAAATAGACTGCTTATTGATTCTTGTG
TTTCATTGAGTTGATTTCATTATTACTACCTAACAAATTGCTCAGTGAT
AGATTCCATTAATTGCTAATTGGTCTAACATGTAGGAGCTA
CTAAAGCAAAATATCGAGCAATGTCGGACCCAACGGGGATTGCTGGTG
CCATTATTAAACCAATTGCTCAGACGGCCTGGTCCCGTTACGGACCAT
GTAGGCTACATGATTCCCTGCAGAAAATATGTGAGGGTCATGCAGATGAA
10 AATGACAGAGTTGAATACTCAAGAACATCAGTGTAGAGGAACACATTAGCC
GGAACACAAGAAATCATCTTCAGATTCCATCTCAAACATAAGGAATGGTTG
GACCAAGTAGAAGGGATCAGAGCAAATGTGGAAAACCTTCCGATTGATGT
CATCACTTGTGTAGTCTCAGGATCAGGCACAAGCTGGACAGAAAGCCT
TCAAGATAACTGAGCAGATTGAAAGTCTAACGAGACAACTCTCCCTGATC
15 AGTTGGACTGATGATCCAGTTCTCTAGGAAGAGTTGGTCCATGAATGC
ATCCACCTCTGCATCATTAAGTGTGATTCCCATCAAGAGAGAAAACCT
TTACACAAGCACTAAAGCACTCGAACCCACCAAAAATTCCACATGGTA
GCCTTGTGTGGATGGTGGAGTGGGAAGACTAGAATGATGCAAAGGCT
GAAGAAGGCTGCTGAAGAAAAGAAATTGTTAATTATATTGTTGGGCAG
20 TTATAGGGAAAAGACGGACCCCTTGCATTCAAGAACGCTATAGCAGAT
TACCTCGGTACAACACTCAATGAAAAAAACTAACGCCAGCAAGAGCTGATAA
GCTTCGTGAATGGTTCAAAAAGAATTCAAGATGGAGGTAAGACTAACGTTCC
TCATAGTACTTGACGATGTTGGCAATTAGTTGATCTGAAAGATATTGGG
TTAAGTCCTTCCAAATCAAGGTGTCGACTTCAGGTCTTGTGACATC
25 ACGAGACTCACAAGTTGCACTATGATGGGGGTGAAGCTAACATTCAATT
TTAACGTGGCCTCTAACTGAAGCAGAACGCTCAAAGTCTGTTCCAACAA
TTTGTAGAAACCTCTGAGCCCAGCTCCAGAACGATAGGAGAGGATATCGT
AAGGAAGTGTGCGGTCTACCTATTGCCATAAAACCATGGCATGTACTC
TTAGAAATAAAAGAAAGGATGCATGGAAGGATGCACCTTCGCGCATAGAG
30 CACTATGACATTACAATGTTGCGCCAAAGTCTTGAACACGAGCTACCA
CAATCTCCAAGAACGAGGAGACTAAATCCACTTTTAATGTTGGTTGT
TTCCCGAAGACTTCGATATTCTACTGAGGAGTTGATGAGGTATGGATGG
GGCTTGAAGCTATTGATAGAGTTATACGATTAGAGAACGAAACCAG
GCTCAACACCTGCATTGAGCGACTGGTGCAGACAAATTGTTAACATTGAAA
35 GTGATGATGTTGGGTGTCAAGATGCATGATCTGGTCCGTGCTTTGTT
TTGGGTATGTTCTGAAGTCGAGCATGCTCTATTGTCACCATGGTAA
TATGCCTGGGTGGCCTGATGAAAATGATATGATCGTGCACCTTGCAAAA
GAATTTCATTAACATGCAAGGGTATGATTGAGATTCCAGTAGACCTCAAG
TTTCTAAACTAACGATTGAAACTTATGCATGGAGATAAGTCGCTAACG
40 GTTCCCTCAAGACTTTATGAAGGAATGGAAAAGCTCCATGTTATATCAT
ACGATAAAATGAAGTACCCATTGCTCCTTGGCACCTCGATGCTCCACC
AACATTGGGTGCTTCATCTCACTGAATGTTCAATTAAAGATGTTGATTG
CTCTCTATCGGAAATCTATCGAATCTGGAAGTGAGCTTGCACATT

CTCACATTGAATGGTTACCTCCACAGTCAGAAATTAAAGAAGCTAAGG
TTACTTGTATCTGAGATTTGTGATGGTCTCCGTATAGAACAGGGTGTCTT
GAAAAGTTTGTCAAACCTGAAGAATTATATTGGAGATGCATCTGGGT
TTATAGATGATAACTGCAATGAGATGGCAGAGCGTTCTAACACCTTCT
5 GCATTAGAATTCGCGTCTTAATAACAAGGCTGAAGTGAAGGAAATATGTC
ATTTGAGAATCTTGAACGATTCAAGATCTCAGTGGATGCTCTTGATG
AAAATATCAATATGAGTAGCCACTCATACGAAAACATGTTGCAATTGGTG
ACCAACAAAGGTGATGTATTAGACTCTAAACTTAATGGGTATTTGAA
AACAGAGGTGCTTTTAAGTGTGCATGGCATGAATGATCTGAAAGATG
10 TTGAGGTGAAGTCGACACATCCTACTCAGTCCTCTCATTCTGCAATTAA
AAAGTTCTTATTATTCAAAGTGTGTAGAGTTGAGATACCTTTCAAACCT
CAATCTTGCAAACACTTGTCAAGACTGAGCATCTAGAAGTTGTGAAT
GTGAGAATATGGAAGAACTCATACATACTGGAATTGGGGTTGTGGAGAA
GAGACAATTACTTCCCTAACGCTGAAGTTTATCTTGAGTCAACTACC
15 GAAGTTATCAAGTTGTGCCATAATGTCAACATAATTGGGCTACCACATC
TCGTAGACTTGATACTTAAGGGCATTCCAGGTTCACAGTCATTATCCG
CAGAACAAAGTTGCGAACATCTAGTTGTAAGGAAGGGTAGATATATG
TTCTTATGTTAACAAATTAAATAATTTCACCAAAATTTCATAA
TATATCTGTAATTGATTGTATGATGTGTTATGTTATATGTGGCTATT
20 AAGGGATGATTATTTCAGGTTGTGATTCTAACGTTGGAGACACTCAA
ATTGATGACATGGAGAACTTAGAAGAAATATGGCCTGTGAACCTAGTGG
AGGTGAGAAAGTTAAGTTGAGAGCGATTAAAGTGAGTAGCTGTGATAAGC
TTGTGAATCTATTCCCGCGCAATCCATGTCTCTGTTGCATCATCTGAA
GAGCTTACAGTCGAGAATTGCGGTTCCATTGAGTCGTTATTCAACATTGA
25 CTTGGATTGTGCGGTGCAATTGGAGAAGAACACAAGAGCCTCTAA
GAAGCATCAACGTGGAGAATTAGGGAGCTAACAGAGAGGTGTGGAGGATA
AAAGGTGCAGATAACTCTCATCTCATCAACGGTTCAAGCTGTTGAAAG
CATAAAGATTGAAAAATGTAAGAGGTTAGAAATATATTACACACCTATCA
CCGCCAATTATCTGGTGGCACTTTGGAGATTAGATAGAAGGTTGC
30 GGAGGAAATCACGAATCAGAACAGAGCAGGTAACGCTTCAATTCACTTTC
TTAATTAAATTAAAGGACTAACGCTCTGTTTGAATAATAAGAGGTGGG
ATGACTAAACTGGGCATCACAATTGCAACAAAATGTTACAAACCATGAA
ACGTTCAAACCATTCTGAATTAGGTTCAATACAAGTCATTAAAAAA
TATGGCTAAATTTTTATATTATGTATCAACATGATTTCATTAG
35 AGATCATTATTATAATAGTAAGTTAAAGCAATTAAATCAGAACTAATT
CTAACTTTAGCTAATAAAATCGTTATAAATGTAATAATTACTTTAGTG
AAATAAGCAACGGATTAATAAGTTAACAACTTAAATGTCATTCTAAC
AAAAAAAACATTGGTTCAAGAAAACCGTAATTCAAGATAACTAAAATA
AAAATATTGACATTCACTAACAGAGCATTCTAAATATGATTGCA
40 AATGAATAAAACTTAAATTATACAGAAAATTCTTTATATGTTATAC
AAAATTACAAATTGAAATTGGATATGTTAATTACGGTTATAATTCTG
GTATCACAAAGGGATATATAATAAAATATTATTTCTGTAGTCATTGTA
ATTGTACTAGTTATAACCCGTGGGAACCATGAGTTCTAAAATTAGTTAA

ACTTTCATAATAAAATTATAATTATTATTATTAAATAATTATTAA
5 ATTAAGAGATATATCAAAAATTAAAGTTATTATAACTTCAAATTAAACA
TATAATTAGAAAATATGATCATAACTTCTGCAACTCTCTTTGTAT
TAAAATGACCAGAGAAGCTCTTAGTATATTCTAATCAAAGTCTCAAAMC
TAATGAAGCATATAATTGTGAAAATCAATTAGCATTAGGTTAAAGAGT
CACCAAATTCAAAGAATAATCCAATGCTTCATTACCACTATGGAGAAAA
10 TATTTCTTAGTTAAATGAAATGAAAACAAACATTCAAACAAATTGTTG
CTTATTAAACCAAAGACCCATTACTTAGCCAAGAGTTAACAAAAAAA
TTACATTCATGTATCATTATCATGACTAGATATATGAACATGAAGGG
AGTTTTATAGAAAATATAATCATAGATATTCAACATAACTCAGGGAAT
15 TCCTCAAAATAACCAAGTTATTCAAGAAATTACATCCAAGTCAACCAAAG
AGAAGTTAGCCTAGCATGGCTAAACTCAAGAAACTAAAATAAGGATTAG
AAGTACCAAACATGTAGTAAGAATCACAGTAAAAGATGATGTTGTTCTG
ATGTTCTCTAAGTTCTCAAGTCTCCAGTTGCTCTAATAATGCAAAGG
AGAGCCATTAAATTCTGTATGTATTGATCCCTCAAAAGCTGCACCAACCT
20 CCCTTAAATAACACTCAAAGCAAAATGACAAAATTGCCCTGAAGGACC
CTATGTGGGTGCCTTGCACGGGTGGAGCTGCATACGAAAGGTCTTGGTC
TTTGTGAGGGTGTGTTGCGGGATAGCTTGTGCATGGTGTGCGTTCTGAGTTT
TTCACGCACATGTGCACAGGTGATGCATGGTGTGCGTTCTGAGTTT
GAGCCTCCGATGCTTAGTCCACTTGGCCAATTGAGTCCAATCAGCTTA
25 TAACCCATTTCCTCAAGTTATCTCAAGTTAAGCCAATTGCCTCT
CCAAATCATCCATAACTTCACAGAACGCCCCGTTCATCTTAATCCCGAT
GCACAATTATTCTCCGTCTCATTTAAGCAAGATACCACCTTCTCAT
GCTTCATCCATCAATAGTACACTCATGTATCATCTACTAGTTATT
GTCCACAATCCTGTTGCTCCAATTAAATTATCTCATTTAGTTCCCG
30 TTCCGCTAGTTCTTAAAATTGCAATTAGCTCAGAGAAATATTAAAGT
ACCCGAAATGGTCATAAAATAACAAAAAGGAAATATGCATGAAGATTAA
CTAAATGATGAACGAAATATGCTAAAATAGACTATAAAATGAAGTAAATA
AAATGAAATTATCGCACTCCGACCACCCCTATAGGCTGTAGTCCACCCA
CCCTCATTCTGTACCAATATGGGATGGAAACATCATTAATTAAAGCCA
35 AAAAGCTAACATATAAGGGTTAGTGACAAAGGTAAGTACTAAAGATGAA
AATAATCCATTTCCTGTATATACACACACACACATAGGGCAGACGT
AGGATTCAAAGTACAGATTGTTGGCACATAAGTGTGCTGGTGACA
TTTTTTTTTTTACGTAGTGGCACACAGTAGGAAAAACGAAAAAT
TCGAAATTTCACAATTGTCTAAAAAAACAGTGGTTGTTGGTGCCAC
40 TATGGACACCAAAGTTGAAC TGCCCCACGCGCGCACACACACACACACA
CATAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAAAGAAAGAGAGAGA
GAGAGTTGGGATGTGATACCTCTTTAGGAAAATGGAGTTATATCTTG
ATATTGTATTTCATAATGTAATTATATATTAAATCATTTAGTTATA
AGTTTATTATTGATATGAAAAAAAAGTCTTTATACATTGGATT
AACATAAAATCCAACAATATTAATCAAAAAGACCACACATGTGGACAMW
TATGTATATAAWTAATTCAACATAGTCTTAGGAATAGNATTATATAT
AATTAATTCTCAATGGTCTTAGGAATAGTAAGTTATATTCAAACCTT

TNGCCACAATTCTTGKTTACTTWGACACTTYCCTCTCTAATTATATA
TATATATATATATATATATACACACACACACACACTAG
ATGTGTGCCCGCGAAAGCAGTGACGTNNNGAGAANACTTCTTAAGCA
5 TAAATAATTATTATTTTATTGGGTATTATATAATAAAAAATTACAA
CTTTAAATAAAATTTATGTTATACTTATATTATATTGCTTGTAT
ACTATTAATATAATAAAATTATTTATGTCTAATTATGAAATGTAAAT
TAATTAAATACATGAATTAAATTTAAATTTCAAGTTGCTTCAA
10 ATTGAGTTCTTAATTATTTTAATTCAAGTTGCTTCAA
AGTATTAAAGAATTATTTATGCATAATTGATTATAACAAAAACTTGTA
ACTTATACATCTAAATTCAAGATATAACTAACATGTTTACAATATAT
AT
TAAAGCGCAAAGGTCAAGGAATAGAATATTCTATTATCTACGTTT
15 GCCACAAAAGTTGAACACTTGCCTTTGTCCCTCCTAACCTTT
CAATGTTTGCACAAAAGTCCAAAACTTGCCACTTGATCATTCTC
AACTTTCACCGCAATTAGTTGTGGAGTTGGCAGTTGATCCCCCTAA
CTTCGATATTCTCTACTGCTAGCCTAAAGGGTCCAGAGTTCACACTT
TTGGTCCCTGACAGTAACCAAATGTGAGATGTCAAATTGACATTAA
20 GTTTGTGGAGTTGTCCCTTTGGTCCCCCACATTGATATTCTANTATA
CGACCTTATTNTCAAATAACAACACGTATATTAAATTACCAATTATA
GAAATAGATATCAAATAAGTATTGTAACACTGTGTAAGAACGGTGCTA
25 CTATAGGTAAAAATAAACATTCAAAGTACGATATTCTAATTGGAAAAAG
AGTTTAAAAATAACGACTAGGGCGAGTTTTACAAGTTGATCTAT
CAAATCATATCAAATTAAAGGTGGAACGGTGACCACATTACCAAGAAAT
GTAATTATTCTTGATTTGATAATTAAATATTGTTGATCTAT
GTATTAAAAGTAAACAACAAAGAACATAATTCCAAAACCTAAATTGCAA
30 GTCTGCCAATTCTCTACTAGTCCTACTACGATGGCGTTACGT
CGCTCTCACTGCTACAAACCTTGTGACTCATTACAATAACGAA
AAGTTGAATATCCATATATTGATGTGGAATTGAACGAATCTCGT
CAAATTGATTTGTTGATGGATTGAGTAGAAGTTGGCAGAACGG
GAATGATGGCTGCAAGTGGTATAAAACTGATTCTGAGTTATTACTATA
TATGTAGCCTCTTACAACGACCAAGGTTCTCCAGGTACCTTGATC
35 TTTTAGAACTTAGTTCTGAAACACCCCTGATTGATCAAATATCACC
AACAACTCTAAAAACTGATTAATCAATTGTTCTCATTTGATAAC
AAGTGGAAATGATTTCTACTTAGATTAACCTGAAAAAGGTCCATGTG
CGTCTGGTGGATCTGGTAAATGAAGATGGAAGGGAGAGCTGACTTAAAG
ACACAAACACGTCACCATATCTCTTATTAAATTGCTTGGT
40 GTATTCTTCTTCTTCTTCTTCTTCTTCTGATCTCCAGATGGTATGT
GGTGTGGATAATTACACCTAGAGATTGGAAACGATGGAAAGGGTCTGT
GATTATGGCTGGCCGAGTTTACTTATTAAACTCAATTCAACCTAAATT
CTGATTCTGTTGAAAATAAGTGCATCTTATTGTTGATCTGT
TGCATAGGATCCTAGCATCTTAAATAATTGAGGTGAAAGATC
CAACTATTAGCTGTTGGCATTTCATCATTGCAACTGTTCTG
AAAAAAAAATACCTAAAATAACCAATTGCAAATCCAAAATTATA

AGAGAGAATTGTAATGGACATGGAATCATAAATCATTAACACAGTCAG
TAAACAAGTGCTAATTACATTCCTGCTGTGCAGATTGAAATTCTATCA
GAGAAAGAGACATTACAAGAAGCCACTGGCAGTATTCAAATCTTGTATT
CCCATCCTGTCTCATGCACTCTTCATAACCTCCGTGCTTACATTGG
5 ATAATTATGAAGGAGTGGAGGTGGTATTGAGATAGAGAGTGAGAGTCCA
ACATGTAGAGAATTGGTAACAACACTCGCAATAACCAACAACAGCCTATTAT
ACTTCCCTACCTCCAGGATTGTATCTAAGGAATATGGACAACACGGAGTC
ATGTGTGGAAGTGCAGCAACTGGAATAAATTCTCACTCTCCAAAACAA
CAATCAGAATCCCCATTCCACAAACCTCACACCATAAAATTCTTAAATG
10 CAAAAGCATTAAAGTACTTGTTCGCCTCTCATGGCAGAACTTCTTCCA
ACCTAAAGGATATCCGGATAAGTGAGTGTGATGGTATTAAAGAAGTTGTT
TCAAACAGAGATGATGAGGATGAAGAAATGACTACATTACATCTACCCA
CACAAACCACCACTTGTCCCTAGTCTGATTCTCACTCTAAGTTCC
TGGAGAATCTGAAGTGTATTGGTGGAGGTGGTGCAGGATGAGGGGAGC
15 AATGAAATATCTTCAATAATACCACTGCAACTACTGCTGTTCTGATCA
ATTTGAGGTATGCTTGTACATATTCAATTATTATTAAATTCCCTTTT
TATTGCAATATTCTATAAATAACATTATACCCACTATAACTAAGAT
AAATAATTACCTAGAGGGATGGATGCTATGACACAGCTGCTACACTCAGA
AACTCTAGTAAGGGCAGTTATGGAAGTTCAATAAAATGATAATGGCATCT
20 TTTGATGGGTAATATAGGCAATTAAAGTTTATTCTGTTAAAGCAGTAT
TTAGCAAGTACTGGCCAGTAGGAGAGGAGAATATCACCTTGTGAAAAT
CTGGTCATTGTACCCAGAATTAGTTAAATGTAACATTAGATATTAGG
GGACATCAGGTGACAGATATTGTAGAATAGAACAAATATAATTACCC
AAAACATTTCCTAAGGTATTCTGTTAAATATGTGCTTCTGATT
25 CATTGAATTGCAATTCTATATTAGGTGGTAAAGTGATTGTCTCTCA
ATAAAATCCGAAATTAAATTAAAAAGAAAAAAACAAAGTAAATTGAA
TATGGAGAGCACTGGTATCATTAGTATATAAAAAAACTAGATTGAAAT
TAAGTTCTTATATAAAAGCTGTATATAGTTAATTAGTTACATCA
TTTTCCATGTTGCAGTTGTCTGAAGCAGGTGGTGTGAGGAG
30 TTTATGCCAATACGCTAGAGAGATARAATAGKTGGATGCTATGCATTGT
CAAGTGTGATTCCATGTTATGCAGCAGGACAAATGCAAAAGCTCAAGTG
CTGAGAATAGAGTCTGTGATGGCATGAAGGAGGTATTGAAACTCAATT
AGGGACGAGCAGCAACAAAAACACGAGAAGAGTGGTGGCAGGAAAGGAA
TTCCAAGAGTAAATAACAATGTTATTATGCTTCCAACTCAAAGATATTA
35 AGTATTGGAAATTGTTGGGGTTGGAACATATATTCAACATTCTCTGCACT
TGAAAGCCTGAGACAGCTCAAGAGTTAAAGATAAAATTGCTACGGAA
TGAAAGTGATTGTGAAGAAGGAAGAAGATGAATATGGAGAGCAGCAAACA
ACAACAAACAACGAAGGGGCACTTCTTCTTCTTCTTCT
TTCTTCTTCTAAGAAGGTGGTGTGCTTCTTCTTGTCTAAAGTCCATTGTAT
40 TGGTCAATCTACCAGAGCTGGTAGGATTCTTCTTGGGATGAATGAGTTC
CGGTTGCCTTCATTAGATAAAACTTAAGATCAAGAAATGCCAAAAATGAT
GGTGTGTTACAGCTGGTGGTCCACAGCTCCCCAACTCAAGTATATACACA
CAAGATTAGGCAAACATACTCTGATCAAGAATCTGGCCTTAACCTTCAT

CAGGTATATATATTTCTTAATTGGCATCATCTAATTAAGAAAGATAT
CATTCCGCCAAGTAAATTACTTCAAACACATTCACACTGGTTCAGTC
TAAGTTATGTTCTAAGAAGGCCAAATGGGAAAGCAAGATAGGGAA
AAATAGTGTATTCAGTGGAAAGGGTATTTAGGCATTTCTGTCAAAAG
5 TTGTTATTGCAGGCTTTAGTACCTGGAATCGTGTGGAGGAGCATT
ATT.ATTCTGATTGCTTCTTATCATTTCCTAGCCTCTCGAAC
AGCTAGAAACCCTTTAATCTTTGATTTCAATGACGAAATTTCCCT
GTTACTCCATTGATTGTTCTCATGGTCTAAGTGAGTTATTGGCT
CATCTGTTACTCTTTGATTGTTATTCATATCATGTTGTCCTTGAA
10 TCAAGCTTTCCATTTCACCAGGGCAAAAGGTCAAAAGTAACCTACTT
TATGAGATCAAAAACAGCAACCCATCGGATAACTTTAGTGGAGTTAAT
AGTTACAATTACCATGTGATTAATAATTATAATCTTGTATTAATTCA
TAAAAAATTGGTACAGCACATATATGACATTCAAAGGTTTGTTGACA
TAT.ATATGCCTCTGGCTTCTTATTGGACTTGCAAGACCTCATTCAA
15 AGTTATACGGTACACCTGGGCCCTGCTACTTCAGAAGGGACAACCTG
GTCTTTCATAACTTATCGAATTAGATGTGGAAGGTAATCATGATGTTA
AAAAGATTATTCCATCCAGTGAGTTGCTGCAACTGCAAAAGCTGGAAAAG
ATT.AATGTAAGGTGGTAAAAGGGTAGAGGGAGGTATTGAAACTGCATT
GGAAGCAGCAGGGAGAAATGAAATAGTGGAATTGGTTTGATGAATCGT
20 CACAAACAACCAACTACTCTTGTCAATCTCAAACCTAGAGAAATG
AACTTATGGGTCTAGATTGCTGAGGTATATATGGAAGAGCAATCAGTG
GACAGCATTGAGTTCCAAACCTAACAGAGTTGATATCTATAATGTA
AAAGGTTAGAACATGTATTACTAGTCCATGGTTGGTAGTCTATCGCAA
CTCCAAGAGCTACATATATCCAACACTGCAGTGAGATGGAGGAGGTGATTGT
25 TAAGGATGCAGATGATTCTGTAGAAGAAGACAAAGAGAAAGAATCTGATG
GGGAGACGAATAAGGAGATACTGTGTTACCTCGTCTAAACTCCTTGATA
TTAAGAGAACTTCCATGTCTAAGGGTTAGCTGGGAAGGAGGATT
TTC.ATTCCCATTATTGGATACTTAAAGAATTGAGGAATGCCAGCAATAA
CCACCTTCACCAAGGGAAATTCCGCTACTCCACAGCTAAAGAAATTGAA
30 ACACATTGGCTCGTTGTGCTGCAGGGAAAAAGACATCAACTCTCT
TATAAAGATCAAACACAGGTAAATCAGATCTTGTGCTTAAATAATTCT
TTAAACTACATTGAAAAGCTTCATGCAAGTTTTTGTATATTGTCA
AAAACCGCAACCTACATTTCAGCTTATATTATGTACTTTATGCAGGA
GTTCAAACAAAGACTCTGATTAATGTGAAGTAAATACTAAAGGTAAATTAT
35 ATTTCATGTTCTAGTTGCCTATTAAATTAAATTGCCTTTAGTCATGAT
TTTGGATGCATTCTCATGATGTCAATCTCTAATACCCATTCA
TGTTGGTTGAATGTTGACTCTATGTCTGATGAATATTCAAGGGAAAGAA
TTGTTCATCATGAAGGACATTAAAGAAGAACATGGATGCTATGAAGAT
GTGGGAAAACAA

RG2B deduced polypeptide sequence (SEQ ID NO:90)

5 MSDPTGIAGAINPIAQTA LPVPTDHGVY MISC RKYVR VMQM KMT E LNTS RIS VEE
 HISRNTRNHLQIPSQTKEWLDQVEGIRANVENFPIDVITCCSLIRHKL GQKAFKITE
 QIESL TRQLS LISWTDDPVPLGRVGS MNASTS ASLS DDFPSREKTFTQALKALEPNQK
 FHMVALCGMGGVGKTRMMQRLK KAAE EKKLFNYIVGA VIGEKTDPFA IQEAIADY
 LGIQLNEKTKPARADKLREWFKKNSDGGTKFLIVLDDVWQLVDLEDIGLSPFPNQ
 GVDFKVLLTSRDSQVCTMMGVEANSIINVGLTEAEAQSLFQQFVETSEPELQKIGE
 DIVRKCCGLPIAKTMACTRNRKDAWKDAL SRIEHYDIHNAPKVFETSYHNLQ
 EEETKSTFLMCGLFPEDFDIPT EELMRYGWGLKLFD RVY TIREARTRLNT CIERLVQ
 10 TNLLIESDDVGCVKMHD L VRAFVLGMFSEVEHASIVNHGNMPGP DENDMIVHSC
 KRISLTCKGMIEIPVDLKFPKL TILKLMHGDKSLRFPQDFYEGMEKLHV ISYDKMKY
 PLLPLAPRCSTNIRVLHLTECSLKMFD C S S I G N L S N L E V L S F A N S H I E W L P S T V R N L K
 KLRL L D L R F C D G L R I E Q G V L K S F V K L E E F Y I G D A S G F I D D N C N E M A E R S Y N L S A L E F
 15 AFFNNKAEVKNMSFENLERFKISVGCSFDENINMSSHSYENMLQLVTNKG D V L D S K
 LNGLFLKTEVLF L S V H G M N D L E D V E V K S T H P T Q S S S F C N L K V L I I S K C V E L R Y L F K L
 NLANTLSRLEHLEVCECENMEELIHTGIGGC GEETITFPKLKFLSLSQLPKLSSLC H N
 VNIIGLPHLVDLILKGIPGFTVIYPQNKLRTSSLKEGVVIPKLETLQIDDMENLEI W
 PCELSSGGEVKLRAIKVSSCDKL VNL FPRNPM SLLHHLEELT VENCGSIE S L F N I D L D
 20 CVGAIGEEDNKSLLRSINVENLGKLREVWRIKGADNSH LINGFQAVESIKIEKCKRFR
 NIFTPITANFYLVALLEI QIEGCGGNHESEEQIEILSEKETLQEA TGSISNLVFPSCLMH
 SFHNLRVLTLDNYEGVEVVF EIESESPTCRELV TTRNNQQQPIILPYLQDLYLRNMD
 NTSHVWKCSWNKFFTLPKQQSESPFHNLTTINILKCKSIKYLFSPLMAELLSNLKDI
 RISECDGIKEVVSNRDDEDEEMTTFTSTHTTTLFPSLDSLTL SFL ENLK CIGGGGAK
 25 DEGSNEISFNNTTATTAVLDQFELSEAGGVWSLCQYAREIEIVGCYALSSVIPCYAA
 GQM QKL

RG2C polynucleotide sequence (SEQ ID NO:91)

30 ATAATATTACACAAAGGT AACGT CATT AATT AATTACGATACGAGACAGA
 CTTTTCACTCGGACATNAACGGTCTATT CCTAACTNNANNTAATTNAAT
 GAATTAGGATGTGCTAATATGCATGTAANATT CGTACCCGTATCTTC
 AAATGACCATA TTTTATGTATTATAATGAATCAATGAAAAACCGGATT
 TCTATTAAAATTCTAAAACCTCATCTTTAAGCCAGGGTGAATACAAT
 TGCTAGATCCACTGTTAATTCCATCGAATTATGCCTGATCAATTGTTGG
 CTGCCTACGATGCAGGTGCTACCACAAGAATATGCCATGGAAACTGCTA
 35 ATGAAATTATAAAACAAGTTGTTCCAGTTCTCATGGT CCTATT AACGAT
 TACCTACGCTACCTCGTT CCTGCAGAAAGTACATCAGTGACATGGATT
 GAAAATGAAGGAATTAAAAGAAGCAAAAGACAATGTTGAAGAGCACAAGA
 ATCATAACATTAGTAATCGTCTTGAGGTTCCAGCAGCTCAAGTCCAGAGC
 TGGTTGGAAGATGTAGAAAAGATCAATGCAAAAGTGGAAACTGTT CCTAA
 40 AGATGTCGGCTGTTGCTCAATCTAAAGATTAGGTACAGGGCCGG AAGGG
 ATGCCTTCAATATAATTGAGGAGATCGACAGTGT CATGAGACGACACTCT
 CTGATCACTGGACCGATCATCCCATT CTTGGGAAGAGTTGATTCCGT

GATGGCATCCACCTCTACGCTTCACTGAACACAAATGACTCCAGTCAA
GAGAGGTAAGGTTAGTGAAGCACTCAAAGCACTTGAGGCCAACCATG
ATAGCCTTATGTGGAATGGGGGGAGTGGGAAGACCCACATGATGCAAAG
GCTGAAGAAGGTTGCCAAAGAAAAGAGGAAGTTGGTTATATCATCGAGG
5 CGGTTATAGGGAAATATCGGACCCATTGCTATTCAAGCAAGTTGTAGCA
GATTACCTATGCATAGAACTGAAAGAAAGCGATAAGAAAACAAGAGCTGA
GAAGCTTCGTCAAGGGTTCAAGGCCAAATCAGATGGAGGTAACACTAAGT
TCCTCATAATATTGGATGATGTCAGTCCGTTGATCTAGAAGATATT
GGTTAAGCCTTCTCCAATCAAGGTGTCAGTCAAGGTCTTGTGAC
10 TTCACGAGACGAACATGTTGCTCACTGATGGGGTTGAAGCTAATTCAA
TTATTAAACGTGGGACTTCTAATTGAAGCAGAAGCACAAGATTGTTCCAG
CAATTGTAGAAACTTCTGAGCCCAGCTCCACAAGATAGGAGAAGATAT
TGTAGGAGGTGTTGCGGTCTACCCATTGCCATAAAACCATGGCGTGT
CTCTAAGAAATAAAAGAAAGGATGCATGGAAGGATGCACTTCTCGTTA
15 CAACACCATTGACATTGTAATGTTGCTACTGCAGTTTTAGAACCAAGCTA
TGAGAATCTCCGGACAAGGAGACAAAATCTGTTTTGATGTGTGGTT
TGTTCCCGAAGACTTCAATATTCCCTACCGAGGAGTTGATGAGGTATGGA
TGGGGCTTAAAGTTATTGATAGAGTTATACAATTATAGAAGCAAGAAA
CAGGCTCAACACCTGCATTGACCGACTGGTCAGACAAATTACTAATTG
20 GAAGTGATAATGGTGTACATGTCAAGATGCATGATCTGGTCCGTGTTT
GTTTGGGTATGTATTCTGAAGTCGAGCAAGCTTCAATTGTCAACCATTGG
TAATATGCCTGGGTGGCCTGATGAAAATGATATGATCGTGCACCTTGCA
AAAGAATTTCATTAACATGCAAGGGTATGATTGAGTTCCAGTAGACCTC
AAGTTCTAAACTAACGATTGAAACTTATGCATGGAGATAAACGCT
25 AAAGTTCTCAAGAATTATGAAGGAATGGAAAAGCTCCGGTTATAT
CATACCATAAAATGAAGTACCCATTGCTTCTTGGCACCTCAATGCTCC
ACCAACATTGGGTGCTTCATCTCACGGAATGTTCAATTAAAGATGTTGA
TTGCTCGTGTATTGAAATCTATCGAATCTGGAAAGTGCTGAGCTTGCTA
ATTCTGCATTGAGTGGTACCTCCACGGTCAGAAATTAAAAAGCTA
30 AGGTTACTTGATTGAGATTGTGTTATGGTCTCCGTATAGAACAGGGTGT
CTTGAAAAGTTGGTCAAACCTGAAGAATTATATTGAAATGCATATG
GGTTTATAGATGATAACTGCAAGGAGATGGCAGAGCGTTCTACACCTT
TCTGCATTAGAATTGCGTTCTTAATAACAAGGCTGAAGTGAAAATAT
GTCATTGAGAATCTGAACGATTAAAGATCTCAGTGGATGCTTTG
35 ATGGAAATATCAATATGAGTAGCCACTCATACGAAAACATGTTGCGATTG
GTGACCAACAAAGGTGATGTATTAGACTCTAAACTTAATGGGTATTTT
GAAAACAGAGGTGCTTTTTAAGTGTGCATGGCATGAATGATCTGAAG
ATGTTGAGGTGAAGTCGACACATCCTACTCAGTCCTCTCATTCTGCAAT
TTAAAAGTCCTTATTATTCAAAGTGTAGAGTTGAGATAACCTTTCAA
40 ACTCAATGTTGCAAACACTTGTCAAGACTTGAGCATCTAGAAGTTGTA
AATGCAAGAATATGGAAGAACTCATACATACTGGGATTGGGGTTGTGGA
GAAGAGACAATTACTTCCCCAAGCTGAAGTTTATCTTGAGTCAACT
ACCGAAGTTATCAGGTTGTGCCATAATGTCAACATAATTGGGCTACCAC

ATCTCGTAGACTTGAAACTTAAGGGCATTCCAGGTTCACAGTCATTAT
CCGCAGAACAAAGTTCGAACATCTAGTTGTTGAAGGAAGAGGTAGATAT
ATGTTCTTATGTTAACATAACATTAAACAATATTTCAACCAAATTTCA
TAATATATCTGTAATTGATTGATGTGTTATTGTTATATGTGGCT
5 ATTAAGGGATGATAATTTCAGGTTGTGATTCTTAAGTGGAGACACTT
CAAATTGATGACATGGAGAACTTAGAAGAAATATGGCCTGTGAACCTAG
TGGAGGTGAGAAAGTTAACAGTTGAGAGAGATTAAAGTGAGTAGCTGTGATA
AGCTTGTGAATCTATTCCCGCGCAATCCCATGTCTGTGCATCATCTT
10 GAAGAGCTTACAGTCGAGAATTGCAGGTTCCATTGAGTCGTTATTCAACAT
TGACTTGGATTGTGCGTGCATTGGAGAAGAACACAAGAGCCTCT
TAAGAACATCAACGTGGAGAATTAGGGAAAGCTAACAGAGAGGTGAGGAGG
ATAAAAGGTGCAGATAACTCTCATCAATGGTTTCAAGCTGTTGA
AAGCATAAAAGATTGAAAAATGTAAGAGGTTAGAAATATATTACACACCTA
TCACCGCCAATTTCATCTGGTGGCACTTTGGAGATTAGATAGAAGGT
15 TCGGGAGGAAATCAGAACATCAGAACAGAGCAGGTAACGCTTCAATTCACT
TTCTTAATTAAATTANGGACTAAGCTCCTGTTTTGAATAATAAGAGGT
GGGATGACTAAACTTGGGCATCACAATTGCAACAAAATGTTACAAACCAT
GAAACGCTAAACCAATTCTGAATTAGGTTCAATACAAGTCATTAA
AAATATGGCTTAAATTTCATATTATGTATCAACATGATTTCATT
20 AGAGATCATTATTATAATAGTAAGTTAAAGCAATTAAATTAGAACTAA
TTCTAACTTAGCTAATAAACCGTTAAATGTAAGAAATTACTTTAG
TGAAATAAGCAACGGATTAAATAAGTTAACAACTTAAATGTCATTCTA
ACAAAAAAACTATTGGTCAGAAAAACTGTAATTCAAGATAACTAAAA
TAAAAATATTGACATTCACTAACAGAGCATTTCATAATGATTGCA
25 AATGAATAAAACTTAAATTACAGAAAAGATTTCATATGTTATAC
AAAATTACAAATTGAAATTGGATATGTTAAATTACGGTTATAATTCTG
GTATCACAAAGGGATATATAATAAAATTATTTCATGTAGTCATTAT
AATTGTACTAGTTATAACCCGTGGAACCATGAGTTCTAAAATTAGTTA
AACTTCATAATAAAATTATAATTATTATTATTAAATAATTATT
30 AATTAAAGAGATATCAAAATTAAAGTTATTATAACTTCAAATTAAAC
ATATAATTAAAAATTATGATCATAACTTCCGCAACTCTTCTTTGTA
TTAAAATGACCAGAGAAGCTCTAGTATATTCTAAATCAAAGTCACAA
AACTAATGAAGCATATAATTGTGAAAATCAATTAGCATTAGGTTTAA
GAGTCACCAAAATTCAAAGAGTAATCCAATGCTTCATTACCACTATGGAG
35 AAAATTTCCTAGTTAAATGAAATGAAAACAAACATTCAAACAAATT
GTTGCTTATTAAACCAAGACCCATTACTTAGCCAAGAGTTAACCAAAA
AAAATTACATTGATCATATTAAATGACTAGATATATGAAATATGA
AGGGAGTTTATAGAAAATATAATCATAGATATTCAACATAACTTCATG
GAATTCCCTAAAATAACCAAGTTATTCAAGAAATTACATCCAAGTCACCC
40 AAAGAGAAGTTAGCCTAGCATGGCTAAACTCAAGAAAATAAAATAAGGA
TTAGAAGTACCAACATGTAGTAAGAATCACAGTAAAGATGATGTTGTT
CTTGATGTTCTTAAGTTCAAGTCTCCAGTTGCTCCTAATAATGCA
AAGGAGAGGCCATTAAATTGATGTATTGATCCCTCAAAAGCTGCACCA

ACCTCCCTAAATAACACTCAAAGCAAAATGACAAAATTGCCCTGAAG
GACCCTATGCAGGGTGCCTGCGCGGGTGGAGCTGAATATGAAAGGTCTT
GGTCTTGTGAGGGTGTAGTTGCGGGTAGCTGTCGATGCTCCGC
GCGGTTCGCGCACATGTGCACAGGTGATGCATGGTGTACGTTCTGAC
5 TTTGAGCCTCCGATGCTTAGTCCACTTGGCCAATTGAGTCCAATCAA
CTTATGACCCATTTCCTCAAGTTATCTCAAGTTAAGGCCAATTGCC
TTCTCAAATCATCCATAACTCACAGAACATGCCGTTCATCTTAATCCC
GAATGAACAATTATTCTCCCGTCTCATTTAAGCAAGATACCACCTCT
10 TCATGCTTCATCCATCAATAGTACACTTCATGTATCATCTACTAGTTA
TTTAGTCCACAGTCCTGTTGCTCCAAATTAAATTATCTCATTAGTT
CCC GTTCCGCTAGTTCTTAAAATTGCAATTAGCTCACAGAAATT
AAGTACCCGAAATGGTCATAAAATAACAGAAAGGAAATATGCATGAAGA
TTAACTAAATGATGAACGAAATATGCTAAAATAGACTATAAAATGAAGTA
AATAAAATGAAATTATCGCACTCCGACCACCCCTATAGGCTTGTAGTCCA
15 CCCACCCCTTCATTCTGTACCAATATGGGATGGAAACATCATTAAATTAA
GCCAAAAAAACTAACATATAAGGGGTGAGTGACAAAGGTAAAGTACTAAAGA
TGAAAAAAATCCATTTCCTGTATATACACAACACACATAGGGCAG
ACGTAGGATTTCATAGTACAGATTGTTGGCACATAAGTGTGCTAGT
GACATTTTTTTCTTACGTAGTGGCACAAACAGTARAAAAAACRAAA
20 AATTGAAATTTCACAATGTGCCTAAAAAAACAGTGGTTGTTGGTGC
CACTATGGACACCAAAGTTGAAC TGCCCCTGCGCGCACACACACAC
ACATAAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGTTG
GGATGTGATACTCTTTGGAAAATGGAGTTATATCTTGATATTGTAT
TTTTTAATGTAATTATATTTAATCATTAGTTATAAGTTTATT
25 TATTTKGATATGAAAAAAAGTCTTATACATTGGATTAAACATAAAA
ATCCAACAATATTAATCAAAAAGACCAAACATGTGGACAATTATGTATAT
AATTAATTACAATAGTCTTAGGAATAGNATTATATATAATTAAATT
TCAATGGTCTTAGGAATAGTAAGTTCTTATATTCAAACNTTGCCACAN
TTCTTGNTTACTNGACACTTYCTCTMWNNANWMWWTWATATATATAT
30 ATATATATATATAHAHAHAHAVACACACACACTAGATGTGTGCCMCGCA
AAGCAGTGACGTNNNGAGAANACTTCTTAAGCATAAATAATTATTATA
TTTTTATTGGGTATTATATAATAAAAAATTACAACCTTTAAATAAAAATA
TTTATGTTATACTTTATATTATATTGCTTGTATACTATTAAATAATA
AATTAATATTATGTCTAATTATGAAATGTAATTAAATTAAATAACATG
35 AATTAAATTTAAAATTTCAGTTGCTCAAATTGAGTTCTTAAT
TATTGACCAAACATGTGGACAATTATGTATATAATTAAATTCAACATAGTC
TTTAGGAATAGTATTATATAATTAAATTCTCAATGGTCTTAGGAATA
GTAAGTTCTTATATTCAAACCTTGCACAAATTCTTGCTTACTTGAC
ACTTTCTCCTAACTTACATATATATATATTAAAGCGCAAAGGTC
40 ATAGGAATATAATTTCTATTATTCTACGTTGCCACAAAAGTTGA
ACACTTGCCACTTTGTCCCTCCTAACCTTTCAATGTTGCGACA
AAAGTTCCAAAACTTGCCACTTGATCATCCTCAACTTTCACCGCAT
TAGTTGTGGAGTTGGCAGTTGGCCCTCTAACCTCGATATTCTCTAC

TGCTAGCCAAAAAGGGTCCAGAGTTCACACTTTGGTCCCTGACAGTA
ACCAAATGTGAGATGTCAAATTTGCCACATTAGTTGTGGAGTTGTCC
CTTTGGTCCCCCACATTGATATTCTACTATACGATCTTATTTCTC
AAATAACAAACACGTATATTAATTACTAATGATAGAAATAGATATCAAAT
5 AAAGTATTGTAACACTGTGTAGAGTTTTACAAGTTGTATCAAAT
TCATATCAAATTAAGGTGGAACGGTGACCACATTAACCAGAAATGTAA
TTTATTCTTGATTTGATAATTTAATATTTGTTGTGATCTATGTAT
TTAAAAGTAAACAACAAAGAACATAATCCAAAACCCTAAATTGCAAGTCT
CGCCCAATTCTCTATCACTAGTCCTCACTTACGATGGCGTTACGTCGCT
10 CTCTCACTGCTTACAACCCTTGTTGCTACTCATTACAATAACGAAAAGT
TGAATATCCATATATTATTGGATGTGGAATTGAACGAATCTCGTCAAAT
TTTTGATTTAGTTGATGGATTGAGTAGAAGTTGGCAGAACGGGAAT
GATGGTCTGCAAGTGGTATAAACTGATTCTGAGTTACTATATG
TAGCCTCTTACAACGACCAAGGTTCTCCAGGTACCATTTGATCTTT
15 TAGAACTTAGTTCTGAAACACCCCTGATTGGATCAAATATCACCAACA
ACTCTAAAAACTTGATTAATCAATTGTTACTTCATCTTGATAACAAGT
GGAATGATTTCTACTTGAAAAAAAAGGTCCATGTGCGTCTGGTGGATCT
GGTAAATGAAGATGGAAGGGAGAGCTGACTTTAAAGACACAAACACGTCA
CCATATCTTTATTTATTAAATTCTTTCTTCTTCTTCTTCTTCTTCTT
20 CTTGATCTCCAGATGGTATGGGTGGATAATTACACATAGAGATTGG
GAACGACTGTGATTTAGAGAGGACGTGGCTGGGTTGAGGATGGTTAT
GGCTGGCCGAGTTCATTTATATAACAAACAAATATATAAAACAAGGGG
TAAAATGGCCATCTTATATGTATTAAACCGTCCCTTTTTTTTTTT
TTTTTTTTTTTTTTGTAAATTAAAGAAGGGTATACCAGTGTCA
25 CTCTTATTCCCAACCAGTCAAATAGGGACTTAGGTTGGAAACAGTT
CCGTGAGACCGTGACTGGATGGTAGATAAAATTAGTAAACTTAAACCC
CAATTAAACCTACCTTTCTTATTAACTCAATTCAACCTAAATTCTGAT
TCTTGTGAAAATAAGTGCATCTTATTGTTGATTATCTGTTGCAT
AGGATCCTTAGCATCTTAAATAATTATTGAAGGTGAAAGATCCA
30 ACTTTAAATCTGTTGACGTTCCATCATTGCAACTGTTCTGAAAAAA
AAAATACCTAAAATCAAACAAACCAATTCAAAATCCAAAATTATAAGAGA
GAATTGTAATGGACATGGAATCATAATCATTAAACACAGTTCA
AAGTTGCTAATTACATTCTGCTGTGCAGATTGAAATTCTATCAGAGAA
AGAGACATTACAAGAAGCCACTGGCAGTATTCAAATCTGTT
35 CCTGTCTCATGCACTCTTCAAAACCTCCGTGTGCTTACATTGGATAAT
TATGAAGGAGTGGAGGTGGTTGAGATAGAGAGTGGAGAGTCCA
TAGAGAATTGGTAACAACACTACAATAACCAACAAACAGCCTATTATA
CCTACCTCCAGGAATTGTATCTAAGGAATATGGACAACACGAGTC
TGGAAAGTGCAGCAACTGGAATAATTCTTCACTCTCCAAAACA
40 AGAATCACCATTCCACAACCTCACAACCATAGAAATGAGATGGTGT
GCTTAGGTACTTGTGTTCGCCTCTCATGGCAGAACTTCTTCAACCTA
AAGAAAGTCAAGATACTGGGTGTGATGGTATTAAAGAAGTGT
CAGAGATGATGAGGATGAAGAAATGACTACATTACATCTACCC
ACAAAAA

CCACCAACTTGTCCCTCATCTTGATTCTCACTCTAAACCAACTGAAG
AATCTGAAGTGTATTGGTGGAGGTGGTGCAGGATGAGGGGAGCAATGA
AATATCTTCAATAATACCACTGCAACGACTGCTGTTCTGATCAATTG
AGGTATGTTGTACATATTCAATTATTATTAATTCTTTTATTT
5 GCAATATTCTATAAATAATACATTATACCCACTATACTAAGATAATAA
TTACCTAGAGGGATGGATGCTATGACACAGCTGCTACACTCAGAAACTC
TAGTAAGGGCAGTTATGGAAGTTCAATAAAATGATAATGGCATTTGA
TGGGTAATATAGGCAATTAAAGTTTATTCTGTTAAAGCAGTATTAGC
AAGTACTGGCCAGTAGGAGAGGAATATCACCTTTGTGAAAATCTGGT
10 CATTGTACCCAGAATTAGTAAATGTAACATTAGATATTAGGGGTTA
TCAGGTGACAGATATTGTAGAATAGAACAAATATGTAATATTACCCAAAAC
TATTTTTCTAAGGTTGCTCTGTTAAATATGTGCTTCTGATTTCATTG
AATTTCGATTCCATATTAGGTGGTAAAGTGATTGTCTCTCAATAAAA
15 TCCCAGAAATTAAATTAAAAAAAAAAACAAAAGTAAATTGGATATGGA
GAGCACTGGTATCATTAGTATATAAAAAACTAGATTGAAATTAAAGTT
TCTTATATAAAAGCTGTGTATATAGTTAATTAGTTTACATCATTTC
CATGTGGTGTGCAGTTGCTGAAGCAGGTGGTGTCTGGAGCTTATG
CCAATACGCTAGAGAGATAAAAATAGGCAACTGCCATGCATTGTCAAGTG
TGATTCCATGTTATGCAGCAGGACAAATGCAAAAGCTCAAGTGCTGAGA
20 GTAATGGCTTGCAATGGGATGAAGGAGGTATTGAAACTCAATTAGGGAC
GAGCAGCAACAAAAACAACGAGAAGAGTGGTGTGAGGAAGGAATTCCAA
GAGTAAATAACAATGTTATTATGCTCCCAATCTAAAGATATTAAGTATT
GGAAATTGTGGGGGTTGGAACATATATTCACATTCTCTGCACTTGAAAG
CCTGAGACAGCTCCAAGAGTTAACGATTAAGGTTGCTACAGAATGAAAG
25 TGATTGTGAAGAAGGAAGAAGATGAATATGGAGAGCAGCAAACAACAACA
ACAACAACGAAGGGGGCATCTTCTTCTTCTTCTAAGAAGGTGGT
GGTCTTCTTGTCTAAAGTCCATTGTATTGGTCAATCTACCAAGAGCTGG
TAGGATTCTCTGGGGATGAATGAGTTCCGGTTGCCCTCATTAGATAAA
CTTATCATCGAGAAATGCCAAAAATGATGGTGTACAGCTGGTGGTC
30 CACAGCTCCCCACTCAAGTATATACACACAAGATTAGGCAAACATACTC
TTGATCAAGAATCTGGCCTTAACCTTCATCAGGTACATATATATTCTTT
AATTGGCATCATCTAATTAAAGAAAGATATCATTCTGCCAAGTAAATTAA
CTTCAAAACACATTACACTAGTTCAAGTTATGTTCTAGGA
AGGCCAAAATGGGAAAGCAAGATAGGGAAAAATAGAGTATTTCAGTGGAA
35 AGGGTATTCTAGGTATTCTGTCAAAATTGTTATTGCAGGCTTTAG
TACCTGGAAAGAGCATGATTATTCTCGATTGCTGTTCTTATCATT
TCTTAGCCTAGCATATTCAATGAAATCTTCCCTGTTACTCCATTG
ATTGTTGTTCTCATGGTTCTAAGTGAGTTAGTGGCTCATCTGTTACTTC
TTTGATTGTTATTTCATAGCATGTTGTCACCTGAATCAAGCTTTCCA
40 TTTCAACAAAGGACAAAAGGTCAAAACTAACCTACTTATGAGATCAAAA
ATAGCAACCCATCGGATAACTTTAGTTGGAGTTAAACTTACAATTACC
ATTGTGATTAATAATTATAATCTGTATTAATTCTACAAAAATTGGTAC
AGCACATATATGACATTCAAAGGTTTGACATATATGCCTCT

5 GGCGTTTCTTATTGGACATGCAGACTCATTCAAAGTTATACGGTG
 ACACCTTGGGCCCTGCTACTCAGAAGGGACAACCTGGTCTTCATAAC
 TTTATCGAATTAGATGTGAAATCTAATCATGATGTTAAAAAGATTATTCC
 ATCCAGTGAGTTGCTGCACTGCAAAAGCTGGTAAAGATTAATGTAATGT
 GGTGTAAGGGTAGAGGAGGTATTGAAACTGCATTGGAAGCAGCAGGG
 AGAAATGGAAATAGTGGATTGGTTGATGAATCGTCACAAACAACACTAC
 CACTACTCTGTCAATCTTCAAACCTGGAGAAATGAAGTTACGGGTC
 TCGATTGTCTGAGGTATATATGGAAGAGCAATCAGTGGACAGCATTGAG
 TTTCCAAACCTAACAGAGTTGAAATTATGAATGTAATTCAATTAGAAC
 10 TGTATTTACTAGTCCATGGTGGTAGTCTATTGCAACTCCAAGAGCTAG
 AGATTGGTTGTGCAACCATAATGGAGGTGCGATGTTCAAGGATGCAGAT
 GTTTCTGTAGAAGAACAAAGAGAAAGAACATCTGATGGCAAGATGAATAA
 GGAGATACTTGTGTTACCTCATCTAAAGTCATTGAAATTACTACTCTTC
 15 AAAGTCTTAAGGGTTAGCTGGGAAGGAGGATTTCAATTCCCATT
 TTGGATACTTGGAAATCTACGAATGCCAGCAATAACCACCTCACCAA
 GGGAAATTCCGCTACTCCACAGCTAAAGAAATGAAACAAATTGGCT
 TCTTTATGCTGCAGGGAAAAAGACATCAACTCCTCTATTATAAGATC
 AAACAAACAGGTAAACCAGATCTTGTGCTTAATAATTCTAAACTACA
 20 TTTGGAAAAGCTTCATGCAAGTTTTTGTATATTGTCAAAACCGCAA
 CCTACATTTCAGCTTATATTATGTACTTATGCAGGATTCAAACAA
 GACTCTGATTAATGTGAAGTGAATATTAAAGGTAAATTATTTCATGT
 TCCTAGTTGCCTATTAAATTAAAGGCCTTGTAGTCGTGATTTGGATGT
 ATTCTTCATGATGATGTCAATCTTCTAATACCCATTGTTGGTTG
 AATGTTGACTCTATGTCAGGATGAATATTCAAGGGAAGAATTGTTCATCA
 25 TATGAAGGACATTAAAGAACATGGTGCTAT

RG2C deduced polypeptide sequence (SEQ ID NO:92)

30 MAMETANEIIKQVVPVLMVPINDYLRYLVSCRKYISDMDLKMKELKEAKDNVEEH
 KNHNISNRLEVPAAQVQSWLEDVEKINAKVETVPKDVGCCFNLKIRYAGRDAFNI
 IEEIDSVMRRHSLITWTDHPIPLGRVDSVMASTSTLSTEHNDQSREVRFSEALKALE
 ANHMIALCGMGGVGKTHMMQRLKKVAKEKRKFGYIIEAVIGEISDPIAIQQVVADY
 LCIELKESDKKTRAEKLQRQGFKAKSDGGNTKFLIILDDVWQSVDLEDIGLSPSPNQG
 VDFKVLLTSRDEHVCVSMGVEANSIINVGLLIEAEAQLFQQFVETSEPELHKIGEDI
 VRRCCGLPIAIKTMACTLRNKRKDAWKDALSRQLQHHDIGNVATAVFRTSYENLPD
 35 KETKSVFLMCGLFPEDFNIPITEELMRYGWGLKLFDRTYTIIEARNRLNTCIDRLVQT
 NLLIGSDNGVHVKMHDLVRAFVLGMYSEVEQASIVNHGNMPGPDENMDIVHSC
 KRISLTCKGMIEFPVDLKFPKLTIKLKLMHGDKSLKFPQEYEGMEKLRVISYHKMKY
 PLLPLAPQCSTNIRVLHLTECSLKMFDCCSCIGNLSNLEVLSFANSCIEWLPSTVRNLK
 KLRLLDLRLCYGLRIEQGVLSVKLEEFYIGNAYGFIDDNCKEMAERSYNLSALEF
 40 AFFNNKAEVKNMSFENLERFKISVGCSFDGNINMSSHSYENMLRLVTNKGDVLDK
 LNGLFLKTEVLFLSVHGMNDLEDVEVKSTHPTQSSFCNLKVLISKCVELRYLFKL
 NVANTLSRLEHLEVCKCKNMEELIHTGIGGCGEETITFPKLKFLSQLPKLSQLGLCH

NVNIIGLPHLVDLKLKGIPGFTVIYPQNKLRSSLLKEEVVIPKLETLQIDDMENLEI.
 WPCELSGGEVKLREIKVSSCDKLVNLFPRNPMSSLHHLEELTVENCGSIESLFNID
 LDCVGAIGEEDNKSLRSINVENLGKLREVWRIKGADNSHLINGFQAVESIKIEKCK
 5 RFRNIFTPITANFYLVALLEIQIEGCGGNHESEEQIEILSEKETLQEATGSISNLVFPSC
 LMHSFHNLRVLTLDNYEGVEVVFEIESPSTSRELVTTHNNQQQPIILPYLQELYLR
 NMDNTSHVWKCSWNKFFTLPKQQSESPFHNLTTIEMRWCHGFRYLFSPPLMAELL
 SNLKKVKILGCDGIKEVVSNRDEDEEMTTFTSTHKTTNLFPHLDSTLNQLKNLK
 CIGGGGAKDEGSNEISFNNTTATTAVLDQFELSEAGGVWSLCQYAREIKIGNCHAL
 10 SSVIPCYAAGQMQLQVLRVMACNGMKEVFETQLGTSSNKNNEKSGCEEGIPRVN
 NNVIMLPNLKILSIGNCGGLEHIFTFSALESLRQLQELTIKGCYRMKVIVKKEEDEYG
 EQQTTTTTKGASSSSSSKKVVVFPCPLKSIVLVNLPELVGFFLGMNEFRPLPSLDKLI
 EKCPKMMVFTAGGSTAPQLKYIHTRLGKHTLDQESGLNFHQTSFQSLYGDTLGPAT
 SEGTTSFHNFIELDVKSNDVKKIIPSELLQLQKLVKINVMWCKRVEEVFETALE
 15 AAGRNGNSGIGFDESSQTTTTLVNLPNLGEMLRGLDCLRYIWKSQNQWTAFEFPN
 LTRVEIYECNSLEHVFTSSMVGSLQLQLEIIGLCNHMEVVHVQDADVSVEEDKEK
 ESDGKMNKEILVPLHLKSLKLLLLQLKGFSLGKEDFSFPLLDTLEIYECPAITTFTK
 GNS.ATPQLKEMETNFGFFYAAAGEKDINSSIIKIKQQDFKQDSD.

RG2D polynucleotide sequence (SEQ ID NO:93) and (SEQ ID NO:94)

20 ACGACCACTATAGGGCGAATTGGGCCGACGTCGCATGCTCCGGCCGCC
 ATGGCCGCGGGATGTAACACGACGCCAGTCGAATCGAACCGTTCGTAC
 GAGAACATCGCTGCCTCTCCTCAACCATTAAATGTATATGAGCTAAATTG
 AAACATCTACTATCATGTTAAATTATAAACTTTCTCTTAGATTAC
 TTGTCTGGATGTGTTAATAAAACCAATTCCCACATGCGTAGAGATCA
 25 TAGATGTAACTATTGTTAATCAATTTCGCTGCCAAGTTTAATAATTAT
 ACTTGGATATTAACAAAACCTTATCTAACGACCAAGGTAATTAAAAAT
 AGGTTATTATTCTTCATGCTAATTAAAAGATGGGTTGCAAAGTGAGACC
 ATGAAAACATTAACACGTTGATATTTCACCTTTATTCTTCATATTCA
 CCATATTTCACCTTCGTATTGATTAATCATCTTCAATCACAGGCTCC
 30 TTGGCAAAAGTCAGATCTATTAACAAATACTCCATGTGGTTGCAAATT
 ACAAGGATTCAACATAATTACCAAAACATAGCATTATCATAAGATCGAA
 TAATAATCAAATTCTCTATAATATTACACAAAGGTAACTGTCATTAATT
 ATTACGATACGAGACAGACTTTCACTCGTGACATCAACGGTCTATTCT
 AACTTTACTTAATTAAATGAATCTAGGATGTGCTCATATGCATGTAATAT
 35 TTGCTACCGTCATCTTCAAATGACCATATTTCATTTATGTTATTATAATGAA
 TCAATGAAAAACCGGATTCTATTAAATCTTAAACTTCATCTTCA
 AGCCAGGGTGAATACAATTGTAGATCCACTGTTAATTCCATCGATTATG
 CGTGATCAATTGTTGGCTGCATACGATGCAGGTGCTACCACAAGAATATG
 GCCATGGAAACTGCTAATGAAATTATAAAACAAGTTGTTCCAGTTCTCAT
 40 GGTTCCATTAAACGATTACCTACGCTACGTCGTTCTGCAGAAAGTACA
 TCAGTGACATGGATTGAAAATGAAGGAATTAAAAGAAGCAAAAGACAAT
 GTTGAAGAGCACAAGAATCATAACATTAGTAATCGTCTGAGGTTCCAGC

AGCTCAAGTCCAGAGCTGGTTGGAAGATGTAGAAAAGATCAATGCAAAAG
TGGAAACTGTCCTAAAGATGTCGGCTGTTCAATCTAAAGATTAGG
TACAGGGCCGGAAGGGATGCCTCAATATAATTGAGGAGATCGACAGTGT
CATGAGACGACACTCTGATCACTGGACCGATCATCCCATTCTTGG
5 GAAGAGTTGATTCCGTGATGGCATCCACCTACGCTTCAACTGAACAC
AATGACTTCCAGTCAAGAGAGGTAAGGTTAGTGAAGCACTCAAAGCACT
TGAGGCCAACACATGATAGCATTATGTGGAATGGGAGAGTGGGAAGA
CCCACATGATGCAAAGGCTGAAGAAGGTTGCCAAGAAAAGAGGAAGTT
GGTTATATCATCGAGGCAGTTAGGGAAATATCGGACCCCATTGCTAT
10 TCAGCAAGTTGAGCAGATTACCTATGCATAGAGCTGAAAGAAAGCGATA
AGAAAACAAGAGCTGAGAAGCTTCGTCAAGGGTTCAAGGCCAAATCAGAT
GGAGGTAACACTAAGTTCCTCATAATATTGGATGATGTCTGGCAGTCCGT
TGATCTAGAAGATATTGGTTAAGCCTCTCCAATCAAGGTGTGACT
TCAAGGTCTTGTGACTTCACGAGACGAACATGTTGCTAGTGTATGGGG
15 GTTGAAGCTAATTCAATTATTACGTGGACTTCTAATTGAAGCAGAAC
ACAAGAATTGTCAGCAATTGTAGAAAACCTCTGAGCCGAGCTCCACA
AGATAGGAGAAGATATTGTTAGGAGGTGTTGCGGTCTACCCATTGCCATC
AAAACCATGGCGTGTACTCTAAGAAATAAAAGAAAGGATGCATGGAAGGA
TGCACCTTCTCGTTACAACACCATGACATTGTAATGTTGCTACTGCAG
20 TTTTGTAGAACAGCTATGAGAATCTCCGGACAAGGAGACAAAATCTGTT
TTTTGATGTGGTTGTTCCGAAGACTCAATATTCTACCGAGGA
GTTGATGAGGTATGGATGGGCTTAAAGTTATTGATAGAGTTATACAA
TTATAGAAGCAAGAACAGGCTAACACACTGCATTGAGCGACTGGTGCAG
GCAAATTACTAATTGGAAGTGATAATGGTGTACACGTCAAGATGCATGA
25 TCTGGTCCGTGCTTGTGGTATGTATTCTGAAGTCGAGCAAGCTT
CAATTGTCAACCAGGTAAATATGCCTGGGTGGCCTGATGAAAATGATATG
ATCGTGCACCTTGCAAAAGAATTTCATTAACATGCAAGGGTATGATTGA
GATTCCAGTAGACCTCAAGTTCTAAACTAACGATTGAAACTTATGC
ATGGAGATAAGTCTCTAAAGTTCTCAAGAATTATGAAGGAATGGAA
30 AAGCTCCAGGTTATATCATACTGATAAAATGAAGTACCCATTGCTTCTT
GGCACCTCAATGCTCCACCAACATTGGGTGCTCATCTCACTGAATGTT
CATTAAAGATGTTGATTGCTCTATCGGAAATCTATGAATCTGGAA
GTGCTGAGCTTGCTAATTCTCGCATTGAATGGTACCTCCACAGTCAG
AAATTAAAGAAGCTAAGGTTACTTGATCTGAGATTGATGGTCTCC
35 GTATAGAACAGGGTGTCTGAAAAGTTGGTCAAACATTGAAGAATTTAT
ATTGGAAATGCATATGGGTTATAGATGATAACTGCAAGGACATGGCAGA
GCGTTCTAACCTTCTGCATTAGAATTGGCTCTTAAATAACAAGG
CTGAAGTAAAAATATGTCATTGAGAATCTGAACGATTCAAGATCTCA
GTGGGGTGTCTTGATGGAAATATCAGTATGAGTAGCCACTCATACGA
40 AAACATGTTGCAATTGGTGACCAACAAAGGTGATGTATTAGACTCTAAC
TTAATGGGTTATTTGAAAACAGAGGTGCTTTTAAGTGTGCATGGC
ATGAATGATCTGAAAGATGTTGAGGTGAAGTCGACACATCCTACTCAGTC
CTCTCATTCTGCAATTAAAAGTCCGTATTATTCAAAGTGTGTAGAGT

TGAGATACCTTTCAAACCTCCATGTTGCAAACACTTTGTCAAGCCTTGAG
CATCTAGAAGTTGTGGATGCGAAAATATGGAAGAACTCATACATACTGG
GATTGGGGTTGTGGAGAAGAGACAATTACTTCCCCAAGCTGAAGTCTT
TATCTTGAGTCAACTACCGAAGTTATCAGGTTGTGCCATAATGTCAAC
5 ATAATTGGGCTACCACATCTCGTAGACTGAAACTTAAGGGCATTCCAGG
TTTCACAGTCATTATCCGCAGAACAAAGTTGCGAACATCTAGTTGTTGA
AGGAAGAGGTAGATATATGTTCTTATGTTAACACAATTAAATAATT
TTCAACCAAAATTCTATAATATATCTGTAATTGATTGTATGATGTTA
10 TTGTTATATGTGGCTATTAAAGGGATGATTATTTGCAGGTTGTGATTCC
TAAGTTGGAGACACTCAAATTGATGGCATGGAGAACTTAGAAGAAATAT
GGCCTTGTGAGCTTAGTGGAGGTGAGAAAGTTAAGTTGAGAGAGATTAAA
GTGAGTAGCTGTGATAAGCTTGTGAATCTATTCCGCACAATCCCATGTC
15 TCTGTTGCATCATCTGAAGAGCTAAAGTCAAAATTGTCGTTCCATTG
AGTCGTTATTCAACATCGACTTGGATTGTGTCAGTGCATTGGAGAAGAA
GACAACAAGAGCATCTTAAGAAGAACAAAGTGAAGAATTAGGGAAGCT
AAGAGAGGTGTGGAGGATAAAAGGTGCAGATAACTCTGTCCTCATCC
20 ATGGCTTCCAGCTGTTGAAAGCATAAGTATCTGGGGATGTAAGCGGTTT
AGAAATATATTACACACCTATCACCGCCAATTGATCTGGTGGCACTTTT
GGAGATTCACATAGGAAATTACAGAGAAAATCATGAATCGGAAGAGCAGG
TAACGCTTCAATTCACTTCTTAATTAAAGGACTAAGCTCTGTT
25 TTTGAATAATAAGAGGTGGGATGACTAAACTTGGGCATCACAATTGTA
ACAAAATGTTACAAACCATGAACGTACAAACCATTCTTGAATTAGGTT
TCAATACAAAGTCATTACAAATATGGCTTAAGTTTTTATATTATGTA
TCAACATTATTTCATTAGAGGTATTATTATAATAGTAAGTTAAAGC
AATTAAATTAGCACTAATTTCATCATCTAACTTTAGCTAATAAACATG
30 TTATAAAATGTCATAGCTAAAATAAAATATTGACATTCACTGAGAGCA
ATTTTTCTAAACATGATTGCAAATGATTAAAACCTAAATTAAACTAAA
AAGATTTTATATATGTTACAAAATTACAAATTGAAATTGGATATGT
TAATTAAACAGTTATAATTATTGATTACAAAGCGATATATAATAAAATA
TTATTTCCTGAGTCATGTATAATTGATATGAAATGATTTTAAGA
35 TGGTAGAAGTGGAAACTAGTCATCTCACTTAACACTCATTGTCACACCAGT
TTTATATCCGTTCTCTCTCTCTCTCTGCTCCATTTTTCAAC
TCATAACACATAAAACATATTTCACACATTTAACATTTAACACTACCA
CATCATTATTTAATTAAATTAAATTAGAAAATATAAAATTAAATAAAA
CATAACATTTTATTAAAAGGCACTAATACAAATAAAAGATAACACGG
40 TAAATAAAAAACGATAATTAGAAAAAAACATAATAAAAAAGACAACA
TTAAAAATAWAAAGCGACAACCTAAACTAATGATCAAGAAAATTCT
AAAACCTCCACCATATTTCCTGCAATTGTCATTATGTTCAAACACCA
TTCGCAGAATCCCTCCTATCAAGTGTGATCATGTTGATTGAGAAAAACTGT
ATGTCCTCTCATGTATCTCCAAGTCCAACAAGTTAGCTTCATTCTC
ATTTCCTCATGTAAGACGCAAATTTCATCCCGATATTGTTCTATCTT
CCACCTCTACTTATTACAGTGTGGATGAAGGAGAGGACAGCGATTCTC
GTACGAACGGTTACGATTGACTGGCCGTCGTTACAATCCCGCGGCCA

TGGCGGCCGGGAGCATGCGACGTCGGGCCATTGCCCTATAGTGGTCGT
AATACA (SEQ ID NO:93)

Sequence gap

TGAGCCTCCGATGCTTAGTCCACTTGGCACAGTTCAAGTCCAATCAACTT
5 ATAACCCATTTCTCAAGTTGTCTCAAGTTAAGCCCAATTGCCCTC
TCCAAATCATCCATAACTTCATGGAATGCCCTTCATCTTAATCCGAA
TGCACAATTATTCTCCATCTCATTITAAGCAAGAGGCCACCTTCTCA
TGCTTCATCCATCAATAGTCTGTTGAATAGTGTCTAAGGCTGCAACTAT
ATTAGACAAGTATTGACCCGGTTGTGCATGGCCTTTGGGTTGCCCTC
10 ACCATAGCAACTTGATAGGATGATTATAAGAGAGAGTAAATATTATA
ATATATTATGAGAATAATATAATGAATAATATATTGTTATTGATTAAT
ATAAGTCATAGAATTAATTAGAATTAATTGGTGACTIONAAGAGATTAAT
TAAATAAAGGGTATAAAGTCAATTGTTGATAGTTAAGCTTAGACT
GTAAATCCATTGGATATGGTATGGACGAATCCTAAGGGATTAGGATAG
15 CTAAAATCGTCATATGAGTTATCTAAGAAGGATTGGATAGCCTTAAGA
GAAGATTATCTGATAGGGACTTATCTGTAACTCTTAAGGAGTCTACAAGT
ATAAAATAGACCTATGGCTGATGGAATTGACACATCTCCTAAAGTAAGA
GAGCCTTGGCGAATTCTCCCTCACCTCTCCTAAATCATTCTTCTT
GCTATTGGTGTGTAAGCCATTAGAGGAGTGACATTGTGACTCTAGAA
20 TCTCCAAGACCTCAAGATCAACAAGGAATTCAAAGGTATGATTCTAGATC
TGTTCAATGTTGTTATTGCTCTAATTAGTCATTAGAAGACTTGGATT
AAAGCATGTTATTAGAAAGCCTAGATCYGAGCAATAGGGTTTGCATGC
GCACATAGGAAAGTCTTATGGCTAAACCCATCATAGTCCACTTCATGT
ATCATCTCTACTAGTTATTAGTCATAATCCTTGTGCTCTCCAAGTT
25 AATTACCTCCCTAGTCCTGTTCTGCTAGTTCTTAAATTGCTATT
AAGATCACAGAACTAGAGAGTACCCAAAATGGTTATAAAATAACAAAAAG
GAAAATATGCATGAAGATTAACTAAATTATAATGTAATATGCTAAAATA
AACTATAAAAAAAAGTAAATAAAATGAAACTATCACACTCCGACCACCC
TTATAGGCTTGTACTGCACCCACCTCATTCTGTACCAATATGGGAT
30 GGAAACATTATTCATTAAGCCAAAAACTAACATTAAAGGGTGAGTGAC
AAAGGTAAGTACTAAAGACAACAATAATCCATTTCCTGTACATACACA
ACACACACATAGGGCGGACGTAGGATTGAGTATGTGTTGGGTGAC
ACATTTCCTTACGTAGTACACAATAGTAGAGAAAACGAGAAATT
CAATTTCCTACATTGTGTTGAAAAATATAACAGGGTTGCTGGTGTAC
35 TCTGGGCACCAAAAGTGGAACCGCCCTGCACACACACACATAGAGGGA
GAGAGAGAGGAGAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGATT
TGGGATGTGATACTCTTGGAAAATGGAGCAATATCTTAATATTGT
ATTTCCTTAATGTAATTATATAATTAAATCATTTAGTTATAACTTTA
GTTTTTTTATTAAATCTGTATATTAAATCATTTAGTTATAAGTTT
40 ATTATTTGGTATACCAAGAAAAAAAGTCTTTATGTGTTGGATTAAAC
ATAAAAATCTAACATATTAAATCAAAAAGACCAACATGTGGACAATTAT
GTATATAATTAAATTCTCAATGGTCTAGTGTAAACGATATAAAATTCAAAA
CAATTTCACATTAAAAACACTTCAGTCATAATTGTTATAAAATTA

TCATTGTATCACAAAATCAGTTCATAACATCACATCCCAAGATCAATAAA
GTGTAAATACTCCTCATGTGTGTACTAATCAAGCCGACGCCCTCCCGCGA
TTCTCACTGGTACCTGAAACACGTAACATAACAACTGTAAGCATAATGC
TTAGTGAGTTCCCCAAAATACCACATACCACATATGCCTTCCAGGCC
5 ATAACCTGTAGGATCTTCCGACCCAAGTGTCTCAGGGGACTTCCGTCCC
GAATCCCGGTAGACCTTCCGGTCTACCCGTATTGACCTTCCGGTCCGTA
TCATACATAACATACATAACACACATAACATACATAACATAACACATAGCAC
ATACATCTCATAACATAAAAGACCTCCGGTCACATAAAGGTACCCCTCC
10 AGGTACAGTATAGTGAGAANACTCACCTCGTATGATGTCTAATACCTCAC
GTGCTCGATATCCCTGAATCTGAAACAAATGACCTAGCCCCGCCTACTCA
CATAAAAGTAATTATTCAAATCATTAACGGCTCTCAAGGCTAGACTACAT
CCCTTCTATAAAATCCACAGAAGGGTAAAAGACCATTACCCCTCCTG
ACCCAAAAGTCCAAATGTTGATCAAACCCCCAAAAGTCAACGAAAGACAA
TGGTCAACTTGACCCCTACTCGTGGAGTGACAAAGGTGACTCGGCAAGT
15 ACATGCGGGTCCTCTGAATCCTTCAGTCTCTTGGCTCGTCGAGTCTT
TCTTCCACCCGACGAGTTACACCTGTATGAATCGCGGGCAACCCCGAC
TCGACTTGTGAGTCCGCTCATGGACTCAACGAGTTCAATTCCATGCTCAC
ACTCAAATGACCTCCTGAGGTAGATCTGTTCTTAATCCATAGATCTG
ACCTCCCAAGCTCAATAAACACGTAAGGTTGAACTTGATACTCATGC
20 AACGTCCAAATGATTCTACTTGATGATTAGCCCCAAATACAACATCCTA
AGTCACATACGACCTTATTTCTCAAATAACAACACATATATTAATTAC
CAA TGACAGTAATAGATATCATATAAAGTATTGTAACACTTGTAAGAA
CCTTGCTACTATAGGTAAAAAGAACATTCAAAGTACATGCCCTAATT
GAAAAAAAGTTATAAAAAAATAATGACTAGGGCGTGTTTTTACTAG
25 TTTGTATCAAATTATATCAAATTTAAGGTGGAAAAGAATGACGACCACA
TTA-ACCAGAAATGTAATTATTTTATTGTAATTAAATATTGTT
GTGATCTATGTATTTAAAAGTAAATATCAAACAAGAACATAATCCAAACC
CTAAATTGCAAGTCTCGCCCAATTCTCTATCACTAGTCCTCACTTACGA
TGGCGTTACGTCGCTCTCACTTACAACCCATTGTTGCTACTAATT
30 AACTAACGAAAAGTTGAATATCCATATATTATTGGATGTGAAATTGA
ACGAATCTCGTCAAATTTTATTGTTGATGGATTGAGTGGAAAGTT
AGGCAGAACGGGAATGATGGTCTGCAAGTGGTATAAACATGGGTGAAGA
TAAAATGGAGTTGTCGCCGTTGTATTAGATCTCTTAGGGGTTGATTG
TGAGTTATTACTGTATACGTAGCCTCTTACAACGACCATTCTCCAAGT
35 ACCATTGATCTTTAGAATCCAGTTGTCTGAAACACCCCTGATTGGAT
CAAATATCACCAACAACACTCTAACGAAACTGGACTAATTAAATTGTTCTG
ATCTTGATAACAAGAGGAAACACGTCACCATATCTTATTAAATTG
CTTTGGTGTATTCTCTTCCATTCTTGTATCTGTTCCAGAT
GGTATTGGTGTGGATAATTACACCTGGAGATTGTGAACGATGGGAAGG
40 GGTATGTGATTACAGAGGATGTGGCTTGTGGTTGAGGATGGTTATGGC
TGGCCGAGTCTAATTATATTATAACAAATAAAATATAAAACAAG
GGTAAAATATGTATTAAAGCGTCCTTTAATGGTGACAATTTCACAG
TTTACTCTCTTGTGTTTAATTGTGATGCCACGATCGAACTCATTCA

CCCCCCCCCTTTTTTAAAATAAAAAATTAAAGAAGGGTACCAACCAT
ATACCCGTGTCAGCTCTTATTCCCAAGCAGTCAAATAGGGACTTAGGTT
GTATGGAAACAGTCCGTGACTGGATGGCAGATAAATTAGTAAACTTA
ACCCTCAATTAAACCTACCTTTCTTATTAACTCAATTCAAGCTAAAT
5 TCTGATTCTGTTGAAAATAAGTGCATCTTATTTCATATTATCT
TGTTGCATAGGATCCTAGCATCTTTAATAGTTATTGAAGCTGAAAG
ATCCAACTAGTTGATCTGGCATTTCATCATTGCAACTGTTTC
TTGAAAAAAAATACCTAAAATCAAATAACCATTCAAATCCAAAATTA
TAAGAGAGAATTGTTAATGGACGTGGAATCATAAATCATTAAACACAGTTC
10 AGTACACAAGTTGCTAATTACATTCTGCTGTGCAGATTGAAATTCTAT
CAGAGAAAGAGACATTACAAGAAGTCACTGATACTAATATTCTAATGAT
GTTGTATTATTCCCATCCTGTCTCATGCACTCTTCATAACCTCCATAA
ACTTAAATTGAAAATTATGAAGGGAGTGGAGGTGGTGTGAGATAGAGA
15 GTGAGAGTCCAACATGTAGAGAATTGTAACAACTCACAATAACCAACAA
CAGCCTATTATACTCCAACCTCCAGGAATTGTATCTAAGGAATATGGA
CAACACGAGTCATGTGTGGAAGTGCAGCACTGGAATAAATTCTCACTC
TTCCAAAACAACAATCAGAACCTCCACAAACCTCACAACCATAGAA
ATGAGATGGTGTATGGCTTAGGTACTTGTGTTCGCCTCTCATGGCAGA
ACTTCTTCCAACCTAAAGAAAGTCAAGATACTTGGGTGTGATGGTATTG
20 AAGAAGTTGTTCAAACAGAGATGATGAGGATGAAGAAATGACTACATT
ACATCTACCCACACAACCACCAACTGTTCCCTCATCTGATTCTCTCAC
TCTAAAATACATGCACTGTCTGAAGTGTATTGGTGGAGGTGGTGCCAAGG
ATGAGGGGAGCAATGAAATATCTTCAATAATACCACTACAACCTACCGAT
CAATTAAAGGTATGTTGTACATATTAAATTATATTTAATTTCCTTGT
25 TAATTCCCTTCTTGCAATATTCTATGCGAACTCAAGAATGGGATTG
GAGGCATATAAAGTTACATTCAATTGAACAAAGTATTACCTTTATTGTT
ATTTATCATTTCATATCAAGTACCTATAACATTCTTTTATTCT
AATTAGAAGAGGTCCACATGTCTAATTAGGTTCCATTCTATGTGTAAC
CTCTATTCTCTGTAACTCAAGCATCTAGATTATTATCCATTTCATA
30 ATTGTGTTATTTCACAGTTTTTTATTAAATTAAATAATTAA
TTTAATTATTATTATTATTGTTGGTAATTGCAACCTGTCAATT
TCAAGTCTTAATGTAACATAATAACATTATACCTTACCCACTATAACTAAGA
TAATAATTACCTAAAGGGATGGATGCCATGACACTGCTACACTCAGNAA
CTCTAGTAAGGGCAGTTATGGAAGTCAATAAAATGATAATGGCATCTT
35 TGATGGTAATATAGGCAATTAAAGTTATTCTGTAAAGCAGTATT
AGCTAGTAGTGGCCAGTAGGAGAGGAGAATATCACCTTGTCAAAATCT
GGTCATTGTACCCAGAATTAGTTAAATGTAACATTAGATATTAGGGG
TCATCAGGTGACAGATATTGAGAATAGAACAAATATGTAATATTACCCAA
AACTATTCTAAGGTTGCTCTGTTAAATATGTGCTTCTGATTCA
40 TTGAATTGCAATTGCTATTAGGTGGTAAACTGATTGCTCTTCAAT
AAATCCTGAAATTAAATTAAAAAAAAACAAAAGTACATTGATT
GGAGAGCACTGGTATCATTAGTATAGAAAAAAACTAGATTGATTAY
CTTCTTATATAAAAGTTGTATAGTTAATTAGTTACATCATT

TTCTATGTGTTGCAGTTGCTGAAGCAGGTGGTGGAGCTT
 ATGCCAATACTCTAGAGAGATAGAGATATAGGTGTGATGCACTGTCAA
 GTGTAATTCCATGTTACGCAGCAGGACAAATGCAAAAGCTGCAAGTGCTG
 ACAGTCAGTTCTGTAATGGTCTGAAGGAGGTATTGAAACTCAATTAGG
 5 GACGAGCAGCAACAAAAACACGAGAAGAGTGGTGTGAGGAAGGAATTG
 CAAGAGTAAATAACAATGTTATTATGCTCCCAATCTAAAGATATTGGAA
 ATCTACGGTTGTGGGGTTGGAACATATATTCACATTCTGCACTTGA
 AAGCCTGAGACAGCTCCAAGAGTTACGATTAAGGGTTACTACTCTGTC
 AATCTTCCAAACCTCAAAGAAATGAGGTTGGAGTGGCTAAGTAATCTGAG
 10 GTATATATGGAAGAGCAATCAGTGGACAGCATTGAGTTCCAAACCTAA
 CAAGAGTTGAAATTGTGAATGTAATTCACTAGAACATGTATTTACTAGT
 TCCATGGTTGGTAGTCTATTGCAACTCCAAGAGCTACATATATTAACTG
 CAGTCTGATGGAGGAGGTAAATTGTTAAGGATGCAGATGTTCTGTAGAAG
 15 AAGACAAAGAGAAAGAACATCTGATGGCAAGACGAATAAGGAGATACTTGTG
 TTACCTCATCTAAAGCCTTGAATTACAACCTCTCGAAGTCTTAAGGG
 GTTAGCTGGGAAGGAGGATTTCACTCCATTATTGGATACTTTAG
 AAATCAAAAGATGCCAACAAATAACCACCTCACCAAAGGAAATTCCGCT
 ACTCCACAACTAAAAGAAATACAAACAAATTGGCTCTTTATGCTGC
 20 AGGGGAAAAAGACATCAACTCTTATAAAAGATCAAACAAACAGGTAAATC
 CAAGTTTTGTTATATTGCAAAACCGCACCTACATTCACTGTTAT
 ATTATGTACTTTATGCAGGATTCAAACAAAGACTCAGATTAATGTGAAG
 TGAATATTAAAGGTAAATTATTTCATGTTCTAGTTGCCTATTAAATT
 AATGGCCTTTAGTCATGATTTGGATGTATTCTCATGATGATGTGA
 25 ATCTTCTAATACCCATTCAATTGTTGGTGAATGTTGACTCTATGTCAG
 GATGAATATTCAAGGGAAGAATTGTCATCAWATGAAGGACATTAAAGAA
 CATGGATGCTATGAAGATGTTGGAAAACATATGTATCAAGTGGCAARCT
 GCTTAATGATCTAAGTTGTTGGTGANATGTTGATTAAATATTCAA
 ATTCAATTGGTTATATGGGCTTATCAATAGTGTAAATGGGATAATGAGTGA
 30 CTTAACCTAAATTATGTTGGTAAATGTTGGACAAGTATGGAAAATTA
 GGAATGACTTGTGAAAAAAAATAAAAAAAA (SEQ ID NO:94)

RG2D deduced polypeptide sequence (SEQ ID NO:95)

MAMETANEIIKQVVPVLMVPINDYLRYVVSCRKYISMDLKMELKEAKDNVEE
 35 HKNHNISNRLEVPAAQVQSWLEDVEKINAKVETVPKDVGCCFNLKIRYRAGRDAF
 NIIEIDSVMRHSLSITWTDHPIPLGRVDSVMASTSTLSTEHNDQSREVRFSEALKA
 LEANHMIALCGMGRVGKTHMMQRLKKVAKEKRKFGYIIIEAVIGEISDPIAIQVVA
 DYLCIELKESDKKTRAEKLQRQFKAKSDGGNTKFLIILDDVVWQSVDLEDIGLSPSPN
 QGVDFKVLLTSRDEHVCVSMGVEANSIINVGLLIEAEAQRLFQQFVETSEPELHKIG
 40 EDIVRRCCGLPIAIKTMACTLRNKRKDAWKDALSRLQHHDIGNVATAVFRTSYENL
 PDKETKSVFLMCGLFPEDFNIPITEELMRYGWGLKLFDRVYTIIEARNRLNTCIERLV
 QANLLIGSDNGVHVKMHDLVRAFVLGMYSEVEQASIVNHGNMPGWPDENDMIVH

SCKRISLTCKGMIEIPVDLKFPKLTILKLMHGDKSLKFPQE FYEGMEKLQVISYDKM
 KYPLLPLAPQCSTNIRVLHLTECSLKMFDCCSIGNLSNLEVLSFANSRIEWLPSTVRN
 LKKLRLLDLRFCDGLRIEQGVLSLVKLEEFYIGNAYGFIDDNCKDMAERSYNLSA
 LEFAFFNNKAEVKNMSFENLERFKISVGCSFDGNISMSSHSYENMLQLVTNKGDVL
 5 DSKLNGLFLKTEVLFSLVHGMNDLEDVEVKSTHPTQSSFCNLKVRIISKCVELRYL
 FKLHVANTLSSLEHLEVCGCENMEELIHTGIGGCGEETITFPKLKSLSQLPKLSGL
 CHNVNIIGLPHLVDLKLKGIPGFTVIYPQNKLRTSSLKEEVVIPKLETLQIDGMENL
 EEIWPCELSGGEKVKLREIKVSSCDKLVNLFPHNPMSSLHHLEELKVKNCRSIESLF
 10 NIDLDCVSAIGEEDNKSILRRIKVKNLGKLREVWRIKGADNSRPLIHGFPAVESISIW
 GCKRFRNIFTPTANFDLVALLEIHIGNYRENHESEEQIEILSEKETLQEVTDTNISND
 VVLFPSCLMHSFHNLLHKLKLENYEGVEVVFEIESESPTCRELVTTTHNNQQQPILPN
 LQELYLRNMDNTSHVWKCSNWNKFFTLPKQQSESPFHNLTTIEMRWCHGFRYLF
 PLMAELLSNLKKVKILGCDGIEEVVSNRDDDEEMTTFTSTHTTNLFPHLDSTLK
 YMHCLKCIGGGGAKDEGSNEISFNNTTTDQFKLSEAGGVCWSLCQYSREIEIYRC
 15 DALSSVIPCYAAGQMQLQVLTVSSCNGLKEVFETQLGTSSNKNNEKSGCEEGIPR
 VNNNVIMLPNLKILEIYGCGLHEIFTFSALESLRQLQELTIKGYYTLVNLPNLKEM
 RLEWLSNLRYIWKSQNQWTAFEFPNLTRVEICECNSLEHVFTSSMVGSLQLQELHIF
 NCSLMEEVIVKDADVSVEEDKEKESDGKTNKEILVPLHLKSLKLQLLRSLKGFSLGK
 EDFSFPLLDTLEIKRCPTITTFTKGNSATPQLKEIQTNGFFYAAAGEKDINSLIKIKQQ
 20 DFKQDSD.CEVNIK

RG2E polynucleotide sequence (SEQ ID NO:96)

TGGGAAGACACAATGATGCAAAGGTTGAAGAAGGTTGCTAAAGAAAATAGAAT
 GTTCAATTATATGGTTGAGGCAGTTAGGGAAAAGACAGACCCACTTGCTAT
 25 TCAACAAGCTGTAGCGGATTACCTTGTATAGAGTTAAAAGAAAGCACTAAACC
 AGCAAGAGCTGATAAGCTTCGTGAATGGTTAAGGCCACTCTGGAGAAGGTA
 AGAATAAGTCCTTGTAAATATTGATGATGTTGGCAGTCGTTGATCTGGAAG
 ACATTGGTTAAGTCATTTCCAATCAAGGTGTCGACTTCAGGTTGATCTGGAAG
 CTTCACGAGACGAACATGTTGCACAGTAATGGGGTTGAAGCTAATTCAATT
 30 TTAATGTGGACTTCTAGTAGAACAGCAGAACAAAGTTGTTCCAGCAATTG
 TAGAAACTTTGAGCCGAGCTCCATAAGATAGGAGAACATCGTAAGGAAG
 TGTTGTGGTTACCTATTGCCATTAAAACCATGGCATGTACTCTAAGAAATAAA
 AGAAAGGATGCATGGAAGGATGCACCTTGCAATTAGAGTACCATGACATTAGC
 AGTGTGCGCCCAAAGTCTTGAACAGAGCTACCATATCTCCACAACAAGGAG
 35 ACTAAATCTGTGTTTGATGTGTGGTTTTCCTGAAGACTTCATATTCAA
 TCGAGGAGTTGATGAGGTATGGATGGGCTAAAGATATTGATAGAGTTATA
 CTATTAGACAAGCAAGAACATCAGGCTCAACACCTGCATTGAGCGACTGGTGCAG
 ACAAAATTGTTAATAGAAAGTGTGATGGTGTGCACGTCAAGATGCATGATCTG
 GTCCGTGCTTCGTTGGTTATGTTCTGAAGTTGAACATGCTTCATTATCA
 40 ACCATGGTAATATGCTTGGATGGCCTGAAAATTATATGACCAACTCTTGCAAAA
 CAATTTCATTAACATGCAAGAGTATGTCTGAATTCCGGGAGATCTCAAGTTTC
 CAAACCTAACGATTGAAACTCATGCATGGAGATAAGTTGCTAAGATATCCTC

5 AAGACTTTATGAAGGAATGGAAAAGCTCTGGGTATATCATATGATGAAATGA.
 AGTATCCATTGCTCCCTCGTTACCTCAATGCTCCATCAACCTCGAGTGCTTCA
 CCTCCATCGATGCTCATTAATGATGTTGATTGCTCTGTATTGGAAATATGTTG
 AATCTGGAAGTGCTTAGCTTGTAAATCTGGCATTGAATGGTTACCTCCACA
 ATAGGAAATTAAAGAAGCTAAGGTTACTTGATCTGAGAGATTGTTATGGTCTT
 CGTATAGAAAAAGGTGTCTGAAAAATTGGTGAAGGAAATTGGAGGAATTATATT
 GGTAGAGCAGATATTATAGAT

RG2E deduced polypeptide sequence (SEQ ID NO:97)

10 WEDTMMQRLKKVAKENRMFNYMVEAVIGEKTDPLAIQQAVADYLIELKESTKP
 ARADKLREWFKANSGECKNFKLVIFDDVWQSVLEDIGLSHFPNQGVDFKVLLLTS
 RDEHVCTVMGVEANSILNVGLLVEAEAQSLFQQFVETFEPELHKIGEDIVRKCCGL
 PIAIKTMACTLRNKRKDAWKDALLHLEYHDISSVAPKVFETSYHNLHNKETKSVFL
 MCGFFPEDFNIPIEELMRYGWGLKIFDRVYTIRQARIRLNTCIERLVQTNLLIESDDG
 15 VHVKMHDLVRAFVLVMFSEVEHASINHGNMLGWPNEMTNSCKTISLTCKSMSE
 FPGDLKFPNLTILKLMHGDKLLRYPQDFYEGMEKLWVISYDEMKYPLLPSLPQCSI
 NLRVLHLHRCSSLMMFDCSCIGNMLNLEVLSFVKSGIEWLPSTIGNLKKLRLLDLRD
 CYGLRIEKGVLKVLVKIGGIYIGRADIL.

20 RG2F polynucleotide sequence (SEQ ID NO:98)

CTGTGGAAGACACAATGATGCAAAGGCTAAAAAGGTTGTGCATGAAAAGAAA
 ATGTTAACCTTATTGTTGAAGCAGTTATAGGGAAAAGACAGACCCCCGTTGCC
 ATTCAAGGATGCTATAGCAGATTACCTAGGTGTTAGAGCTCAATGAAAAATCTAAG
 CAAGCAAGAGCTGATAAGCTCCGTCAAGGATTCAAGGACAAATCAGATGGAGG

25 CAAAAATAAGTTCTTGTAAATTGACGATGTTGGCAGTCTGTTGATCTGGA
 AGATATTGGTTAACGCCTTCCAAATCAAGGCGTCGACTTCAAGGTCTGTT
 GACATCACGAGACAGACATGTTGCACAGTGTAGGGGTTGAAGCCAATTAA
 TTCTAACGTGGACTTCTAATTGAAGCTGAAGCACAAAGTTGTTCCACCAAT
 TTGTTGTCACTCTGAGCCGAGCTCCATAAGATAGGAGAAGATATTGAAAGA

30 AGTGTTCGGTCTGCCAATTGCCATCAAAACCATGGCATGTACTCTACGACATA
 AAAGAAAGGATGCATGGAAGGATGCACTTCACGTTAGAGCACCACATGACATT
 CAAAGTGTGCTAAAGTATTGAAACGAGCTACAACAACTCAAAGACAA
 GGAGACTAAATCCGTATTTGATGTGGTTGTTCTGAAGACTGGATAT
 ACCTATCGAGGAGTTGATGAGGTATGGATGGGGCTTAAGATTATTGATAGAGT

35 TAATACTATTACACAAGCAAGAAACAGGCTCAACACCTGCATTGAGCGACTGG
 TGCACACAAATTGTTAATTGAAAGTGTGATGGTGTGCATGTCAAGATGCATG
 ATCTGGTTCGTGTCTTGTGGAAATGTTCTGAAGTGGAGCATGCTTCAAT
 TGTCAACCAGGTAAATATGCCCGAGTGGACTGAAAATGATATGACTGACTCTG
 CAAACAAATTCTTACATGCAAGAGTATGTTGGAGTTCTGGAGACCTCAA

40 GTTCCAAACCTAAAGATTGAAACTTATGCATGGAGGTAAGTCACTAAGGTA
 TCCTCAAGACTTTATCAAGGAATGGAAAAGCTGGAGGTTATATCATACGATGA
 AATGAAGTATCCATTGCTTCCCTCGTTGCCTCAATGTTCCACCATCCTCGAGTG

CTTCATCTCCATGAATGTTCATTAAGGATGTTGATTGCTCTCAATCGGTAATC.
 TTTCAACATGGAAGTGCTCAGCTTGCTAATTCTAGCATTGAATTGTTACCTTC
 CGTAATTGAAATTGAAGAAGTTGCGGCTGCTAGATTGACAAACTGTTATGG
 5 TGTTCGTATAGAAAAGGATGTCTGAAAAATTGGTGAAGACTTGAAGAGCTTA
 TATTAGGAATGGTCTACCAGTTACAGAGGAT

RG2F deduced polypeptide sequence (SEQ ID NO:99)

VEDTMMQRLKKVVHEKKMFNFIVEAVIGEKTD PVAIQDAIADYLGV ENEKSKQA
 RADKLRQGF KDKSDGGKNKFFVILDDVWQSV DLEDIGLSPFPNQGVDFKVLLTSRD
 10 RHVCTVMGVEAKLILNVGLLIEAEAQSLFHQFVVTSEPELHKIGEDIVKKCFGLPIAI
 KTM ACTLRHKRKD AWKDALSRL EHHD IQS VVPKV FETSYNNLKD KETKS VFLMCG
 LFPEDLDIPIEELMRYGWGLRLFDRVNTITQARNRLNT CIERLVHTNLLIESVDGVH
 VKMHD LVRAFVLGMFSEVEHASIVNHGNMPEWTENDMTDCKQISLTCKSMLEFP
 15 GDLKFPNLKILKLMHGGKSLRYPQDFYQGM EKLEVISYDEM KYPLLPSLPQCSTILR
 VLHLHECSLRMFDCSSIGNLFNMEVLSFANSSIELLPSVIGNLKKLRLLDLTCYGV
 RIEKDVLKNLVKLEELYIRNGLPVYRG

RG2G polynucleotide sequence (SEQ ID NO:100)

GAAGACACGATGATGAAGAACTGAAGGAGGTCGTGGGACAAAAGAAATCATTG
 20 AATATTATTATTCAAGTGGTCATAGGAGAGAAGACAAACCTATTGCAATTCAAG
 CAAGCTGTAGCAGATTACCTCTCTATAGAGCTGAAAGAAAACACTAAAGAAC
 AAGAGCTGATAAGCTCGTAAACGGTTGAAGCCGATGGAGGAAAGAATAAGT
 TCCTTGTAACTTGTACGATGTATGGCAGTTGTCGATCTGAAGATATTGGTT
 AAGTCCTCTGCCAAATAAAGGTGTCAACTCAAGGTCTTGTGACGTCAAGAGA
 25 TTCACATGTTGCACTCTGATGGGAGCTGAAGCAAATTCAATTCTTAATATAAA
 AGTTTAAAAGATGTAGAAGGACAAAGTTGTCGCCAGTTGCTAAAATGC
 GGGTGATGATGACCTGGATCCTGCTTCAATGGGATAGCAGATAGTATTGCAAG
 TAGATGTCAAGGTTGCCATTGCCATCAAAACATTGCCCTAAGTCTAAAGG
 TAGAAGCAAGTCTGCATGGGACGTTGCACTTCTCGTCTGGAGAATCATAAGAT
 30 TGGTAGTGAAGAAGTTGCGTGAAAGTTTAAAATTAGCTACGACAATCTCCA
 AGATGAGGTTACTAAATCTATTTTTACTTTGTGCTTATTCCCTGAAGATT
 GATATT CCTACTGAGGAGTTGGT GAGGTATGGTGGGGCTTGAAATTATTATA
 GAAGCAAAACTATAAGAGAAGCAAGAACAGGCTCAACACCTGCACTGAGCG
 GCTTAGGGAGACAAATTGTTATTGGAAGTGTGATGACATTGGATGTCAAGAT
 35 GCACGATGTGGTGC GTGATT TGTGTTGCATATATTCTCAGAAGTCCAACACGC
 TTCAATTGTCAACC ATGGTAACGTGTCAGAGTGGCTAGAGGAAAATCATAGCAT
 CTACTCTGTAAAAGAATTCAATTACATGCAAGGGTATGTCTCAGTTCCCAA
 AGACCTCAAATTCCAACCTTCAATTGAAACTTATGCATGGAGATAAGTC
 ACTGAGCTTCCCTGAAAACTTTATGGAAAGATGGAAAAGGTTCAAGGTAATATC
 40 ATATGATAAATTGATGTATCCATTGCTCCCTCATCACTGAATGCTCCACCAA
 CGTTGAGTGCTTCATCTCATTACTGTCATTAAGGATGTTGATTGCTCTCA
 ATTGGTAATCTCTCAACATGGAAGTGCTCAGTTGCTAATTCTAACATTGAA

TGGTTACCATCTACAATTGGAAATTGAAGAAGCTAAGGCTACTAGATTGACA .
 AATTGTAAAGGTCTCGTATAGATAATGGTGTCTAAAAAATTGGTCAAACCT
 GAAGAGCTTATATGGGTGTTAACGTCCGTATGGACAGGCCGTTAGCTGACA
 GATGAAAA

5

RG2G deduced polypeptide sequence (SEQ ID NO:101)

RHDDEELKEVVGQKKSFNIIIQVVIGEKTNPIAIQQAVADYLSIELKENTKEARADKL
 RKRFEADGGKKNKFLVILDDVWQFVDLEDIGLSPLPNKGVNFKVL LTSRDSHVCTL
 MGAEANSILNIKVLKDVEGQSLFRQFAKNAGDDDLDPAFNGIADSIASRCQGLPIAI
 10 KTIALSLKGRSKSAWDVALSRLENHKIGSEEVVREVFKISYDNLQDEVTKSIFLLCAL
 FPEDFDIPIEELVRYGWGLKLFIEAKTIREARNRLNTCTERLRETNLLFGSDDIGCVK
 MHDVVRDFVLHIFSEVQHASIVNHGVSEWLEENHSIYSCKRISLTCKGMSQFPKDL
 KFPNLSILKLMHGDKSLFPENFYGKMEKVQVISYDKL MYPLLPSSLECSTNVRVLH
 15 LHYCSLRMFDCSSIGNLLNMEVLSFANSNIEWLPSTIGNLKKLRLLDLTNCKGLRID
 NGVLKNLVKLEELYMGVNRPYQAVSLTDE

RG2H polynucleotide sequence (SEQ ID NO:102)

TGAAGGAGGTTGTGGAACGAAAGAAAATGTTAGTATTATTGTTCAAGTG
 GTCATAGGAGAGAACGAAACCCATTGCTATTCAAGCAAGCTGTAGCAGA
 20 TTACCTCTCTATAGAGCTGAAAGAAAACACTAAAGAACGAAAGAGCTGATA
 AGCTTCGTAATGGTCGAGGCCGATGGAGGAAAGAACGAAAGATATTGTTCAAG
 ATACTTGACGATGTATGGCAGTTGTCGATCTGAAGATATTGTTCAAG
 TCCTCTGCCAAATAAAGGTGTCAACTCAAGGTCTGTTGACGTCAAGAG
 ATTACACATGTTGCACTCTGATGGAGGCCAACGCAATTCAATTCTCAAT
 25 ATAAAAGTTAACAGCTGTAGAACGGACAAAGTTGTTCCGCCAGTTGC
 TAAAATGCGGGTGATGATGACCTGGATCCTGCTTCAATAGGATAGCAG
 ATAGTATTGCAAGTAGATGTCAAGGTTGCCATTGCCATCAAAACCATT
 GCCTTAAGTCTAAAGGTAGAACGAAAGCCTGCGTGGACCATGCGCTTC
 TCGTTGGAGAACATAAGATTGGTAGTGAAGAACGTTGCGTGAAGTT
 30 TTAAAATTAGCTATGACAATCTCAAGATGAGATTACTAAATCTATT
 TTACTTTGTGCTTATTCTGAAGATTGATATTCTACTGAGGAGTT
 GATGAGGTATGGATGGGCTTGAAATTATTAGAACGAAAAACTATAA
 GAGAACGAAACAGGCTAACACCTGCACTGAGCGGCTAGGGAGACA
 AATTGTTATTGGAAGCGATGACATTGGATGCGTCAAGATGCACGATGT
 35 GGTGCGTGATTGTTGCATATTCTCAGAACGTCAGCACGCTTCAA
 TTGTCACCATGGAACGTGTCAGAGTGGCTAGAGGAAAATCATAGCATC
 TACTCTGTAAAAGAATTCTTACATGCAAGGGTATGTCTGAGTTCC
 CAAAGACCTCAAATTCCAACCTTCAATTGAAACTATGCATGGAG
 ATAAGTCGCTGAGCTTCTGAAAACCTTATGGAAAGATGGAAAAGGTT
 40 CAGGTAATATCATATGATAAAATTGATGTATCCATTGCTCCCTCATCACT
 TGAATGCTCCACTAACGTTGAGTGTCTCATCTCATTATTGTTCAATTAA
 GGATGTTGATTGCTCTCAATTGGAATCTCTAACATGGAAGTGCTC

AGCTTGCTAATTCTAACATTGAATGGTTACCATCTACAATTGGAAATT
 GAAGAAGCTAAGGCTACTAGATTGACAAATTGTAAGGTCTCGTATAG
 ATAATGGTGTCTAAAAAATTGGTCAAACCTGAAGAGCTTATATGGGT
 GTTAATCATCCGTATGGAC

5

RG2H deduced polypeptide sequence (SEQ ID NO:103)

KEVVERKKMFSIVQVVIGEKTNPIAIQQAVADYLSIELKENTKEARADKLKWFEA
 DGGKNKFLVILDDVWQFVLDIGLSPLPNKGVNFVLLTSRDSHVCTLGAEAN
 SILNIKVLTAVEGQSLFRQFAKNAGDDDLDPAFNRIADSIASRCQGLPIAIKTIALSLK
 10 GRSKPAWDHALSRLENHKIGSEEVREVFKISYDNLQDEITKSIFLLCALFPEDFDIP
 TEELMRYGWGLKLFIEAKTIREARNRLNTCTERLRETNLLFGSDDIGCVKMHDVVR
 DFVLHIFSEVQHASIVNHGVSEWLEENHSIYSCKRISLTCKGMSEFPKDLKFPNLSI
 LKLMHGDKSLSFPENFYGKMEKVQVISYDKLMPPLPSSLECSTNVRVLHLHYCSL
 15 RMFDCCSIGNLLNMEVLSFANSNIEWLPSTIGNLKKRLLDLTNCKGLRIDNGVLKN
 LVKLEELYMGVNHPYG

RG2I polynucleotide sequence (SEQ ID NO:104)

AAGAAGAGCTGAAGGAGGTTGTGGAACAAAAGAAAACGTTCAATATTATT
 GTTCAAGTGGTCATAGGAGAGAAGACAAACCCATTGCTATTAGCAAGC
 20 TGTAGCAGATTCCCTCTCTATAGAGCTGAAAGAAAACACTAAAGAAGCAA
 GAGCTGATAAGCTTCGTAAATGGTCGAGGCTGATGGAGGAAAGAATAAG
 TTCCCTCGTNACTTGACGATGTATGGCNGTTGTTGATCTGAAGATAT
 TGGTTTAAGTCCTCATCCAATAAAGGTGTCANCTCAAGGTCTTGTGA
 CGTCAAGAGATTACATGTTGCACTCTGATGGGAGCTGAAGCCAATTCA
 25 ATTCTCAATATAAAAGTTTAAAAGATGTAGAAGGAAAAGTTGTTCCG
 CCAGTTGCTAAAATGCGGGTGTGATGATGACCTGGATCCTGCTTCATTG
 GGATAGCAGATAGTATTGCAAGTAGATGTCAAGGTTGCCATTGCCATC
 AAAACCATTGCCTTAAGTCTAAAGGTAGAAGCAAGTCTGCATGGACGT
 TGCACTTCTCGTCTGGAGAATCATAAGATTGGTAGTGAAGAAGTTGTGC
 30 GTGAAGTTTAAAATTAGCTATGACAATCTCAAGATGAGGTTACTAAA
 TCTATTTTTACTTGTGCTTATTCTCTGAAGATTGATATTCTAC
 TGAGGAGTTGGTGAGGTATGGGTGGGCTTGAATTATTAGAAGCAA
 AACTATAAGAGAAGCAAGAAACAGGCTCAACACCTGCACTGAGCGGCTT
 AGGGAGACAAATTGTTATTGGAAGTGTGACATTGGATGCGTCAAGAT
 35 GCACGATGTGGTGCCTGATTTGTCATATATTCTCAGAAGTCCAGC
 ACGCTTCATTGTCACCAGGTAATGTGTCAGAGTGGCTAGAGGAAAAT
 CATAGCATCTACTCTGTAAAAGAATTCTTAACATGCAAGGGTATGTC
 TGAGTTCCCAAAGACCTCAAATTCCAACCTTCATTTGAAACTTA
 TGCATGGAGATAAGTCGCTGAGCTTCCTGAAAACCTTGAATTGAAAGATG
 40 GAAAAGGTTCAAGGTAATATCATATGATAAATTGATGTATCCATTGCTTCC
 CTCATCACTGAATGCTCCACCAACCTCGAGTGCTCATCTCCATGAAT
 GTTCATTAAGGATGTTGATTGCTCTCAATTGTAATCTTCTAACATG

GAAGTGCTCAGCTTGCTAATTCTGGCATTGAATGGTTACCATCTACAAT
 TGGAAATTGAAGAAGCTAAGGCTACTGGATCTGACAGATTGTGGAGGTC
 TTCATATAGATAATGGCGTCTTAAAAAATTGGTCAAACCTGAAGAGCTT
 TATATGGGTGCTAATCGTCTGTTGGAAAGTGCCAT

5

RG2I deduced polypeptide sequence (SEQ ID NO:105)

EELKEVVEQKKTFNIVQVVGKTNPIAQVAADSLIELKENTKEARADKLRKWF
 EADGGKNKFLVILDDVV?FVDLEDIGLSPHPNKGV?FKVLLTSRDHVCTLMGAEA
 NSILNIKVLKDVEGKSLFRQFAKNAGDDDDLPAFIGIADSIASRCQGLPIAKTIALSL
 10 KGRSKSAWDVALSRLENHKIGSEEVVREVFKISYDNLQDEVTKSIFLLCALFPEDFDI
 PTEELVRYGWGLKLFIEAKTIREARNRLNTCTERLRETNLLFGSDDIGCVKMHDVV
 RDFVLHIFSEVQHASIVNHGNVSEWLEENHSIYSCKRISLTCKGMSEFPKDLKFPNLS
 ILKLMHGDKSLSPENFYGKMEKVQVISYDKLMLYPLPSSLECSTNLRVLHLHECSL
 RMFDCCSIGNLLNMEVLSFANSGIEWLPSTIGNLKKLRLLDLTDGGHLIDNGVLKN
 15 LVKLEELYMGANRLFGKCH

RG2J polynucleotide sequence (SEQ ID NO:106) and (SEQ ID NO:107)

ATGTCCGACCCAACAGGGATTGTTGGTGCATTATTAAACCAATTGCTCA
 AACGGCCTTGGTTCCCTTACAGACCATGTAGGCTACATGATTCTGCA
 20 GAAAATATGTGAGGGACATGCAAATGAAAATGACAGAGTTAAATACCTCA
 AGAACATCAGTGCAGAGGAACACATTAGCCGGAACACAAGAAATCATCTTCA
 GATTCCATCTCAAATTAGGATTGGTTGGACCAAGTAGAGAAGGGATCAGAG
 CGAATGTTGCAAACCTTCCAATTGATGTCATCAGTTGTTAGTCTCAGG
 ATCAGGCACAAGCTTGGACAGAAAGCCTCAAGATAACTGAGCAGATCGA
 25 AAGTCTAACGAGACAAAATCGCTGATTATCTGGACTGATGAACCTGTT
 CCCTGGGAAGAGTTGGTCCATGATTGCATCCACCTCTGCAGCATCAAGT
 GATCATCATGATGTCTTCCCTCAAGAGAGCAAATTTAGGAAAGCACT
 AGAACGCACTGAACCCGTCAAAATCCCACATAATAGCCTATGGGGGA
 TGGCGGAGTGGGAAGACACGATGATGAAGAAGCTGAAAGAGGTCGTG
 30 GAACAAAAGAAAACGTGCAATATTATTGTTCAAGTGGTCATAGGAGAGAA
 GACAAACCTATTGCTATCCAGCAAGCTGTAGCAGATTACCTCTATAG
 AGCTGAAAGAAAACACTAAAGAAGCAAGAGCTGATAAGCTTCGTAACCGG
 TTCGAAGCCGATGGAGGAAAGAATAAGTTCTTGTAAATACCTGACGATGT
 ATGGCAGTTTCGATCTTGAAGATATTGGTTAAGTCCTCTGCCAAATA
 35 AAGGTGTCAACTCAAGGTCTTGTGACGTCAAGAGAGATTCACATGTTGC
 ACTCTGATGGGAGCTGAAGCCAATTCTATTCTCAATATAAAAGTTTAAA
 AGATGTAGAAGGAAAAAGTTGTTCCGCCAGTTGCTAAAAATGCGGGTG
 ATGATGACCTGGATCCTGCTTCAATTGGATAGCAGATAGTATTGCAAGT
 AGATGTCAAGGTTGCCATTGCCATCAAAACCATTGCCTTAAGTCTTAA
 40 AGGTAGAAGCAAGTCTGCATGGACGTCGCACTTCTCGTCTGGAGAATC
 ATAAGATTGGTAGTGAAGAAGTTGCGTGAAGTTTTAAAATTAGCTAT
 GACAATCTCCAAGATGAGGTTACTAAATCTATTTTACTCTGTGCTT

ATTCCTGAAGATTTGATATTCTATTGAGGAGTTGGTGAGGTATGGGT
GGGGCTTGAATTATTATAGAAGCAAAAACATAAGAGAAGCAAGAAAC
AGGCTCAACAACACTGCACTGAGCGGCTTAGGGAGACAAATTGTTATTGG
AAGTCATGACTTGGGTGCGTCAAGATGCACGATGTGGTGCGTGTGTTG
5 TTTGCATATGTTTCAAGAAGTCAGCATGCTCAATTGTCAACCATGGT
AACATGTCAGAGTGGCCAGAGAAAAATGATACCAGCAACTCTGTAAAAG
AATTCATTAACATGCAAGGGTATGCTAAGTTCTAAAGACATCAACT
ATCCAAACCTTTGATTTGAAACTTATGCATGGAGATAAGTCGCTGTGC
10 TTTCTGAAAACCTTTATGGAAAGATGGAAAAGGTTAGGTAAATATCATA
TGATAAAATTGATGTATCCATTGCTCCCTCATCACTGAATGCTCCACTA
ACGTTCGAGTGCTTCATCTCCATTATTGTCATTAAGGATGTTGATTGC
TCTTCATGGTAATCTTCTCAACATGGAAGTGCTCAGCTTGCTAATT
TAACATTGAATGGTACCATCTACAATTGAAATTGAAAGCTAAGGC
15 TACTAGATTGACAAATTGTAAGGCTTCGTATAGATAATGGTGTCTTA
AAAAATTGGTCAAACCTGAAGAGCTTATATGGTGTAAATCGTCCGTA
TGGACAGGCCGTTAGCTGACAGATGAAAATGCAATGAAATGGTAGAAG
GTTCCAAAAAAACTTCTTGCACTAGAAATATGAGTTGTTAAATACAATGCT
CAAGTGAAGAATATACTCCTCGAGAATCTTAAACGATTCAAGATCTCAGT
20 GGGATGTTCTTACATGGATCTTCAGTAAAAGCAGGCACTCATACGAAA
ACACGTTGAAGTTGGCCATTGACAAAGGCGAATATTGGAATCCCGAATG
AACGGTTGTTGAGAAAACGGAGGTCTTGTTAAGTGTGGGGATAT
GTATCATCTTCAGATGTTAAGGTGAAGTCCTCTCGTTCTACAATTAA
GAGTCCTGTCGTTCAGAGTGTGCAGAGTTGAAACACCTCTTCACACTT
25 GGTGTTGCAAATACTTGTCAAAGCTTGAGCATCTTAAAGTCTACAAATG
CGATAATATGGAAGAACTCATACATACCGGGGGTAGTGAAGGAGATAACAA
TTACATTCCCCAAGCTGAAGCTTTATATTGATGGCTGCCAACCTA
TTGGGTTGTCTTAATGTCAACGCAATTGAGCTACCAAAACTTGTGCA
AATGAAGCTTACAGCATTCCGGTTCAACAGCATTATCCGCGGAACA
AGTTGGAAGCATCTAGTTGAAAGAAGAGGTACATATACATATAGTT
30 TATGTTAATACATTTAAACAATCTTCAACTAAAAGTTCTAGAATATA
TCTGTATTGATTGTATGATGTGTTAGTGTGGATGTGGCTATTAAAG
GATATTGAGCTTGAGGTTGATTGAGCTTCAAGTTGGATATACTGAAATT
ATGACATGGAGAATTAAAGGAAATATGGCCTAGTGAGCTAGTAGAGGT
GAGAAAGTTAAGTTGAGAAAGATTAAAGTGTGAGAAATTGTGATAAAACTTGT
35 GAATCTATTCCACACAATCCATGCTCTGCTGCATCATCTGAAGAGC
TTATAGTCAGAAATGTGGTCCATTGAAGAGTTGTTCAACATCGACTTG
GATTGTGCCAGTGTAAATTGGAGAAGAAGACAACACAGCAGCTTAAGAAA
CATCAATGTGGAGAATTCAATGAAGCTAAGAGAGGTGTGGAGGATAAAAG
GTGCAGATAACTCTCGTCCCTCTTCGTGGCTTCAAGTTGTTGAAAAG
40 ATAATCATTACGAGATGTAAGAGGTTACAAATGTATTCACACCTATCAC
CACAAATTGATCTGGGGCACTTTGGAGATTCAGTTGATTGTAGAG
GAAATGATGAATCAGACCAAAAGTAACCAAGAGCAAGAGCAGGTATGGATT
TCAATTACTCTTTACTTAATTAAATGATTAAGCCCCGTCTTTAATA

AAAAGGGGACAAACCATTCTGACTTAATGTTGCAATACAAGTCATGTA
TAAGAGTGATTAACCTTTTTATTATAAAATACTACAAAACATGTT
TTTCATTATAGATCATGTATAAATGTGACTAATTTTCATGCCAAC
TTTGTTGATAAAATCATTAGAAATGTCACTAATTACTTTAGTATTAT
5 AAAATAACTACAAAACATGTTTTCATTATAGATCATGTATATATCAC
AAAAAATATTATTCCCTTACACAAAAAAAAGGTTCAAGAAAAGCCTGTA
TTTCGAAATAACTAAAAAGAAAATATTGATATTCACTAAGAGAAAATT
TTTCTAAACATGATCGCAAATGATTAACCTAAATTAAAACAAAAAGA
TTTTATATATGTTATNCAAAATTAAAATTGAAATTAAAGTTATAATT
10 TNGTNTCACAAAGGGATATATAGTAAAATATTATTTTCAGTCAT
GCATAGTTGTATTTAAATGATTATTAACGTGGTAGGAGTGGAAACCA
CTCAATCTAGTAGACCCACTATCACATGTACATCAGCTTACATCTATT
TTTCTTCTCCTTTTCATCTTTAAACTCATAACACNTAAAANTANC
15 ATATTTCACACACTNAACTCATTGTCACATTATTATTTTAATTAA
TTAAATTNGAAAATTAAAATTAAANTAAANCNTAACATTTTAATTAAAA
AATATTAATCCAAATAAAAANTNCACGATAAATTAAAAANGTTANTTG
GAA-AAAAANCC (SEQ ID NO:106)
Sequence gap
ATAACCCCTTCAAGGGTCAACTCAAGTCCAAGTAAAGTCAGGTCAAAA
20 CCTTGGTTAAAGTCAACTTGGTCAAAGTCAACATCTACTGACTCACCT
CACCGAGTTGGTCCACCAACTTGTGAGTCCCTTAATCCACAAACTTCAA
GAACCTCGATCCTACTCGTCGAGTCTTCAAGAACTCTCGAGTTCCAT
TACACAGAATCGGGACCTTGCTCATGACTCGCCAGTTCATCCTGAA
CTTGTGAGTCTAGCTTACAGAGTTGAGTGTTCAGTCTGACTCGT
25 CGAGTTCTCCTTGAACTCGTCGAGTCCATCTCGTATAGTTGGGACATT
GCCTTGAACTCACCAGTTCATCATTGAACTCATCGAGTCCTCGATCTT
CAAGTCCATAATCCTGTCCATCTTGTGAGTCCTCTTAGACTCAACCA
GATTCTCAGAAACAGAAAAGGTTAGGGAACCTACCTGACTCGCCGAG
TCCCAAGAACGAATCCCCGAGTCCCCAATGTCCATGACCATAATCGA
30 TTTTCGTTGGGCTATTGCATCCAAAGCATAGATCTAACCTCTAGGGTC
CATATTACACGTAAAGCTACGAACCTGACGTCCATGCATGGGGATTGG
CTCAAATGGCATTAAAATGGGTTATCTGATGCATGGACTCCATGGC
CATAAAGTTAACACCTTATGCCATGGAAATCCTCAATGGTCCATATCT
GAAGTTAACACTCTACAATATGTTCTAAACCCGAAGGTGGCTAGAAATG
35 CCCCAAAATGGCAAGATTCAAGCCTAAAGGAGATCTAACAAATGATAAG
TCAAGGTTCAAGCTTTACCTTGAATAAGCTGGAAATGAAGCAAAATCT
CTGGATCCACTTGCCTTCAAGAACCCCCAAGCTCCACTTCTCCTTC
AAGTTCAAACAACTTTAAACACTCAAAATGGCTCAAGAACACTCAAAA
AGCTTAGGGTTCGAGTTAGGGCTTTGGAAGCGAGAGGGACGATGGG
40 GGCTGAAATGAGGCTAGAAAAAGTGTAAATAGGGGGCAAACCTAAAT
ATTAGGGTTCATCCAGGCAGCCCTACTCGTCGAGTCGGGCTCCGACTC
GTCGAGTAGGTCACTTAAACCCCGTCCATAATCCAGTCACTCGACGA
GTTGGGCCTCCAACTCGTCATTCCGAGTGCACAAACGTTCAATTACTTAA

ATTTAAATATGTACCAGGAACCGGGTGTACAGTTGAGACTTATACCTC
CATAAAGATAGATCTAGGTGCACATAGCCTGGATCCACAAGCTCCATGTCA
ACAAGCGACTCTTCAAGAAGTTCATTCTCCTCTTAAGCACCAAAAAAC
ACACAAAATCACCATGAAGCTCAAGAAATACTCAAATAGAGGATAGGGTT
5 TCGTTCGTAGGGTTAGAGAGGGATGGAGGCTAGAGGAAATGAGGGATAGAG
GCGAGTTAAGGTCTTAAATAGGGTCCAAGACCCTAAATTAGGGTTTAA
TCTGCCAGACGAACGCAGGGTGTCCCAAATGCATATGTGTCCAAATTC
TCGTGTGCGCCATGCGTACCTCCCTGTACGCCATGTGTACCGGGTTGG
TCCAAACCCTCTAACTCAAATGATCATAACTTGACCCCTATCTGTT
10 TTCGATGTTCTTATATCCACGGAAAGGTAACAAGAACGCCCTATACTTCT
ATAAAACCTTATTAACTGAAAACCAACCGAAATTAAATCCAAAATTCA
AAAAGTCCCAGACCAACACATTACCGATAACCCTGGGCTCCAAAACACA
AATTGAAAACCCGGATCATCCAAACTACATCATCCACCTCCAAATGAGCC
CAAACCTCAATTATTCAAGGGTTCTAAGCCTGTTAATGCCCACTCCTCGAT
15 TACCACCCCGCAATGGGAAACGATTCAAACAGGGCGTTACATAATTGT
TGTGGTTTGTATTTTATTCCGGTGAAGGTGAAAGATCCAACATT
TTAATCTGTTGGCATTTCCATCATTGCAACTGTTCTGAAAAAAA
TACCTAAAATCAAACCAACATTTCAAATCCAAAATTATAAGAGAGAAT
TGTAAATGGACATGGAATCTAAATCATTAAACACAGTTCACTACACAAGT
20 TGCTAATTACATTCTGCTGTGCAGATTGAAATTCTATCAGAGAAAGAG
ACATTACAAGAAGCCACTGACAGTATTCTAATGTTGTATTCCCATCCTG
TCTCATGCACTCTTCATAACCTCCAGAAACTTATATTGAACAGAGTTA
AAGGAGTGGAGGTGGTGTGAGATAGAGAGTGAGAGTCCAACAAGTAGA
GAATTGGTAACAACTCACCATAACCAACAAACAGCCTGTTATATTCCCAA
25 CCTCCAGCATTGGATCTAAGGGTATGGACAACATGATTGCGTGTGGA
AGTGCAGCAACTGGAATAAATTCTCACTCTTCCAAAACAACAATCAGAA
TCCCCATTCCACAACCTCACAACCATAAAATTGATTTGCAGAACAT
TAAGTACTTGTTCACCTCTCATGGCAGAACTCTTCCAACCTAAAGA
AAGTCAATATAAAATGGTGTATGGTATTGAAGAAGTTGTTCAAACAGA
30 GATGATGAGGATGAAGAAATGACTACATTACATCTACCCACACAACCAC
CATCTTGTCCCTCATCTGATTCTCACTCTAAGTTCTGGAGAATC
TGAAGTGTATTGGTGGAGGTGGTGCAGGGATGAGGGGAGCAATGAAATA
TCTTCAATAATACCACTGCAACTACTGCTGTTCTGATCAATTGAGGT
ATGCTTGTTCATATTCAATTATTATAATTCTTTTATTGCAA
35 TATTCTATAAATAATACATTATACCCACTATAACTAAGATAATAATTAC
CTAGAGGGATGGATGCTATGACACAGCTGCTACACTCAGAAACTCTAGT
AAGGGCAGTTATGGAAGTTCAATAAAATGATAATGGCATCTTGATGGG
TAATATAGGCAATTAAAGTTTATTCTGTTAAAGCAGTATTAGCAAGT
ACTGGCCAGTAGGAGAGGAATATCACCTTGTGAAAATCTGGTCATT
40 GTACCCAGAATTAGTTAAATGTAACATTAGATATCAGGGGACATCAG
GTGACAGATATTGTTAGAATAGAACAAATATAATTACCCAAAACATT
TTTCTAAGGTTTCTGTTAAATATGTGCTTCTGATTCATTGAATT
TGCATTCTATATTAGGTGGTAAAGTGATTGTCTTCAATAAAATCCC

GAAATTAATTAAAAAAAAAAAAACAAAAGTAAATTTGATATGGAGA
5 GCACTGGTATCATTAGTATATAAAAAACTAGATTTGAATTAAGTTCT
TTATATAAAAGCTGTGTATAGTTAATTAGTTACATCATTTC
TGTGGTGTGCAAGTGTCTGAAGCAGGTGGTCTTGGAGCTATGCC
AATACGCTAGAGAGATAAGTATAGAATTCTGCAATGCATTGTCAGTGTG
ATTCCATGTTATGCAGCAGGACAAATGCAAAAGCTCAAGTGCTGACAGT
CAGTTCTGTAAATGGTCTGAAGGAGGTATTGAAACTCAATTAAGGAGGA
GCAGCAACAAAACAACGAGAAGAGTGGTGTGATGAAGGAAATGGTGGA
ATTCCAAGAGTAAATAACAATGTTATTATGCTTCTGGTCTGAAGATATT
10 GGAAATCAGCTTTGTGGGGTTGGAACATATATTACACATTCTGCAC
TTGAAAGCCTGAGACAGCTCGAAGAGTTAACGATAATGAATTGCTGGTCA
ATGAAAGTGATTGTGAAGAAGGAAGAAGATGAATATGGAGAGCAGCAAAC
AACAAACAACAACGAAGGGACTTCTCTCTCTCTCTCTCTCTCTCT
CTTCT
15 TTTCTTGTCTAAAGTCCATTGTATTGGTCAATCTACCAAGAGCTGGTAGG
ATTCTCTGGGGATGAATGAGTCCGGTTGCCTTCATTAGATGAACCTTA
TCATCGAGAAATGCCAAAAATGATGGTGTACAGCTGGGGTCCACA
GCTCCCCAACTCAAGTATATACACACAAGATTAGGCAAACATACTATTGA
TCAAGAATCTGGCCTTAACCTTCATCAGGTATATATGTTCTTAATTGG
20 CATCATCTAATTAAGAAAGATATCATTCTGCCAAGTAAATTACTCAA
ACACATTCACACTGGTTCACTCTAAGTTATGTTCTAGGAAGGCCA
AAATGGGAAAGCAAGATAGGGAAAAATAGTGTATTCACTGGAAAGGGTA
TTTAGGTATTTCTGTCAAAAGTTGTTATTGCAGGCTTTAGTACCTG
GAATCGTGTGGGAGGAGCATTATTATTCTGATTGCTTGTCTTCTTAT
25 CATTCTTAGCCTCTCGAACAGCTAGAAACCCCTTTAATCTTTGAT
TTAAATGACAAAATTCTCCCTGTTACTCTATTGATTGTTGTTCTTCA
TGGTTCTAAGTGAGTTATTGGCTCATCTGTTACTCTTTGATTGTTATT
TTCATAGCATGTTAGTCACCTGAATCAAGCTTTCTTCAACCAGGG
30 CAAAAGGTCAAAAGTAACCTACTTTATGAGATCAAAACAGCAACCCATC
GGATAACTTTAGTGGAGTTAATAGTTACAATTACCATTGTGATTAATA
ATTATAATATCCTGTATTAATTCAAAAAATTGGTACAGCACATATATGA
CATTCAAAGGTTTGTGACATATATATGCCTCTGGCTTTCTTAA
TTGGACTTGCAGACCTCATTCAAAGTTATACGGTGACACCTGGGCC
TGCTACTTCAGAAGGGACAACCTGGTCTTCTATAACTGATTGAATTAG
35 ATGTGAAATTAAATAAGGATGTTAAAAGATTATTCCATCCAGTGAGTTG
CTGCAACTGCAAAAGCTGGAAAAGATAAAATAAACAGTTGTGTTGGGGT
AGAGGAGGTATTGAAACTGCATTGGAAGCAGCAGGGAGAAATGGAAATA
GTGGAATTGGTTTGATGAATCGTCACAAACAACTACCAACTACTCTGTC
AATCTTCAAACCTTAGAGAAATGAACCTATGGGTCTAGATTGTCTGAG
40 GTATATATGGAAGAGCAATCAGTGGACAGCATTGAGTTCCAAAACAA
CAAGAGTTGAAATTAGTAATTGCAACAGTTAGAACATGTATTACTAGT
TCCATGGTTGGTAGTCTATCGCAACTCCAAGAGCTACATATAAGTCAGTG
CAAACCTATGGAGGAGGTATTGTTAAGGATGCAGATGTTCTGTAGAAG

5 AAGACAAAGAGAAAGAATCTGATGGCAAGATGAATAAGGAGATACTTGCG
 TTACCTAGTCTAAAGTCCCTGAAATTAGAAAGCTTACCATCTCTTGAGGG
 GTTAGCTGGGAAGGAGGATTTCATTCCCATTATTGGATACTTTAA
 GAATTGAGGAATGCCAGCAATAACCACCTCACCAAGGGAAATCCGCT
 ACTCCACAACTAAGAGAAATAGAAACAAGATTGGCTCGGTTATGCAGG
 GGAAGACATCAAATCCTCTATTATAAAGATCAAACAACAGGTAAATCAGA
 TCATTGTTGGTTAATAATTCTAAACTACATTGAAAAGTTCATGTAA
 GTTTTATTATTGTCAAAAGCCGCAACCTATATTCAACTTATATT
 ATGTACTTTATGCAGGATTCAAAAAAGCCCAGGACTCTATTAATGTGA
 10 AGTAAATACTAGAAGAGGTAAATTCTATTACATGTCTCCTGATTGCCTA
 TTAATTAAATGGCCTTCAGTCATGGTTTGGATGTATTCTCATGATG
 ACGTGAATGTTAAATACCCCCTAGTTAATTGTTAGGTTGAATGTTGAT
 GACCAAAGGACTATATGTCGGGAAGAATATTCAAGGAAAGAATTGTCAT
 CATATGAAGGGCATTAAATTAAAGAAGAACATGGATGCTATGAAGATGTTG
 15 GGAAAATATATGAATCAAATAACAAGCTACTCACTTATCTAAGTTGTTG
 GTTGAGGATGTTGATTAAATATTCAAATTCAATTGGTATCATTATATGG
 GTTTATCAGTAGTGTAAATGGATAATGAGCAACTAACCTAAATTATG
 CTGTTGGTAAATGTTGGACTCAAGTATGGAAAATTAGGAATAACTGTGA
 AAAATATATGCAAAAGTAGGATTGAGATTCAATGAAAAAAATTATGAA
 20 ACTATACTACTATAGTATATAAATAAAATTCAACTTACTGTTGGGTATATT
 GGAAGCACATATCATGAAAGTAACTAGAAGCAGAATTGTTCCCATCTC
 ATCTACTTATAGTTCCATTCTTACTGTAAAAACTGATTAAACTTTA
 GAGTTATTCTATTACCAACAAAATTTCATATAAAGGCCACAAG
 T (SEQ ID NO:107)

25 RG2J deduced polypeptide sequence (SEQ ID NO:108)
 MSDPTGIVGAIINPIAQTAALVPLTDHVGYMICRKYVRDMQMCKMTELNTSRISAEHH
 ISRNTRNHLQIPSQIKDWLDQVEGIRANVANFPIDVISCCSLRIRHKLQKAFKITEQI
 ESLTRQNSLIWTDEPVPLGRVGSMAIESTSAASSDHDFVFPREQIFRKALEALEPVQ
 30 KSHIIALWGMGGVGKTTMMKKLKEVVEQKKTCNIIIVQVVIKEKTNPIAIQQAVADY
 LSIELKENTKEARADKLKRFEADGGKNKFLVILDDVWQFFLEDIGLSPLPNKGV
 NFKVLLTSRDSHVCTLMGAEANSILNIKVLKDVEGKSLFRQFAKNAGDDDDPAFI
 GIADSIASRCQGLPIAIKTIALSLKGRSKSAWDVALSRLENHIGSEEVVREVFKISYD
 NLQDEVTKSIFLLCALFPEDFDIPIEELVRYGWGLKLFIEAKTIAREARNRLNNCTERL
 35 RETNLLFGSHDFGCVKMHDVVRDFVLHMFSEVKHASIVNHGNMSEWPEKNDTSN
 SCKRISLTCKGMSKFPKDINYPNLLILKLMHGDKSLCPENFYGKMEKVQVISYDKL
 MYPLLPSSLECSTNVRLHLHYCSLRMFDCSSIGNLLNMEVLSFANSNIEWLPSTIG
 NLKKLRLLDLTNCKGLRIDNGVLKNLVKLEELYMGVNRPYGQAVSLTDENCNEM
 VEGSKKLLALEYELFKYNAQVKNISFENLKRKISVGCSLHGSFSKSRHSYENTLKL
 40 AIDKGELLESRMNGLFEKTEVLCLSVGDMYHLSDVVKSSSFYNLRVLVVSECAEL
 KHLFTLGVANTLSKLEHLKVKCDNMEELIHTGGSEGDTITFPKLKLLYLHGLPNL
 LGLCLNVNAELPKLVQMKLYSIPGFTSIYPRNKEASSLLKEEVVIPEELIVEKCGSI
 EELFNIDLDCASVIGEEDNNSSLRNINVENSMLREVWRIKGADNSRPLFRGFQVVE

KIIITRCKRFTNVFTPITTNFDLGALLEISVDCRGNDESDQSNQEQQIEILSEKETLQE
 ATDSISNVVFPSCLMHSHNLQKLILNRVKGVEVVFEIESESPTSRELVTTHHNQQP
 VIFPNLQHLDLRGMDNMIRWKCSWNKFFTLPKQQSESPFHNLTTINIDFCRSIKY
 LFSPLMAELLSNLKKVNIKWCYGIIEVVSNRDEDEEMTTFTSTHTTILFPHLDL
 5 TLSFLENLKCIAGGGAKDEGSNEISFNNTTATTAVLDQFELSEAGGVWSLCQYAR
 EISIEFCNALSSVIPCYAAGQMQLQVLTVSSCNGLKEVFETQLRRSSNKNNEKSGC
 DEGNGGIPRVNNNVIMLSGLKILEISFCGGLEHIFTFSALESLRQLEELTIMNCWSMK
 VIVKKEEDEYGEQQTTTKGTSSSSSSSSSSSSPPSSKKVVFPCLKSIVLVNLP
 10 ELVGFFLGMNEFRLPSLDELIIEKCPKMMVFTAGGSTAPQLKYIHTRLGKHTIDQES
 GLNFHQDIYMPЛАFSLLDLQTSFQSLYGDTLGPATSEGTTWSFHNLIEDVKFNKD
 VKKIIPSELLQLQKLEKININSCVGVEEVFETALEAAGRNGNSIGFDESSQTTTTL
 VNLPNLREMNLWGLDCLRYIWKSQNQWTAFEFPKLTRVEISNCNSLEHVFTSSMVGS
 15 LSQQLQELHISQCKLMEEVIVKDADVSVEEDKEKESDGKMNKEILALPSLKSLSKLES
 PSLEGFSLGKEDFSFPLLDTLRIECPAITTFTKGNSATPQLREIETRFGSVYAGEDIKS
 SIIKIKQQDFKKAQDSI.CEVNTR

RG2K polynucleotide sequence (SEQ ID NO:109) and (SEQ ID NO:110)

TGGGATTCCATATATAAAAACATATATTTTATAAAGTGGGATTCCATTG
 TTTATATAGATTTTATTCACCAATAGACAATAGATTAAGATATA
 20 AAAACATGTCGGCTTTGACTAAAAATATAGATTTTATGAATAGAATAT
 TCAATTGCTTAACTCGTTAAAAAAATGAAAAAGATGTCGATATAAAA
 TCTCATATGGGCCTTCTTACCATCAAATAGTAAAATAGTAAAAGATAC
 TTGTTTGGGCATGAACGTGACCATAGTCAAACCCATACAAAATCAAACGA
 ATCCCACATGGATGATGACGATGGGGTCGCAGTAAATGTGTTTGGCCT
 25 TTTTTTCGAGAGAACAGAACAGAGCTCTGCTCTCATCTTCTTAGATTTG
 GGGATTTCAGGGTTGTGAGTGGAAACTAAATTGAAGCAAA
 AAAGTATGGTATAATTGGTGCTAGTGAAATTGATGCTTCTATTACTAT
 CATCTTAAAATTGTCAAACATTATGTATTAATTATGAGATCGAAAGT
 GGTCTATGGGCCAAAGGTAAATACAAGCTTACTCAATGAAATGAATCTAGG
 30 ATGCATCATGCATGTATTGGTTAGATTAAGATTTCATCAAATTCCCT
 TATCAAATTGTTGATACCATGTTATGTAGGTGCTACCACAAGCCATAAC
 ATCGAGCAATGGAGTGTATTACTGGCATCTTAGCAACCCGTTGCTCAG
 TGTCTCATCGCTCCTGTGAAAGAACACCTTGCCTCTGATTTCTATAC
 ACAATATGTAGGGGATATGCTTACTGCAATGACGGAGTTGAATGCTGCAA
 35 AAGACATTGTTGAAGAGCGGAAGAATCAAACGTAGAAAATGTTGAG
 GTTCCAAACCATGTCAACCGTTGGTGGAAAGATGTTCAAACAAATCAACAG
 AAAAGTGGAACGTGTTCTAACGATAATTGCAATTGGTTCAATCTATGTA
 ATAGGTACATGCTCGAGTGAAAGCCTGGAGATAACTCAGGAGATCGAT
 CATGCCATGAAACAACTCTCGGATAGAATGGACTGATGATTCAAGTCC
 40 TTTGGGAAGAAATGATTCCACAAAGGCATCCACCTCTACACCATCAAGTG
 ATTACAATGACTTCGAGTCAAGAGAACACACTTTAGGAAAGCACTTGAA
 GCACCTGGATCCAACCACACATCCCACATGGTAGCCTATGGGGATGGG

TGGAGTTGGGAAGACCACGATGATGAAGAGGGCTAAAAATATTATAAG
AAAAGAGGACGTTCATTATATTGTTGGTGGTATAAAGGAAAATATG
GATCTCATTCCATCCAGGATGCTGTAGCAGATTATCTGGATATGAAGCT
AACAGAAAGCAATGAATCAGAAAGAGCCGATAAACTCGTGAAGGGTTTC
AGGCCAAATCAGATGGAGGTAAAGAATAGGTCCTCATAATACTGGATGAT
GTATGGCAATCTGTTAATATGGAAGATATTGGTTAAGTCCTTCGAA
TCAAGGTGTCGACTTCAAGGTCTTGTGACCTCGGAAAACAAAGATGTT
GTGCAAAAATGGGAGTTGAAGCTAATTAAATTTCGACGTGAAATTCTTA
ACAGAAGAAGAAGCACAAAGTTGTTATCAATTGTAAAAGTTCTGA
10 TACCCACCTTGATAAGATTGGAAAAGCTATTGTAAGAAACTGTGGTGGTC
TACCCATTGCCATCAAAACCATAAGCCAATACTCTTAAAATAGAAACAAG
GATGTATGGAAGGATGCACTTCTCGTATAGAGCATCATGACATTGAGAC
AATTGCACATGTTGTTTCAAATGAGCTACGACAATCTCCAAAACGAAG
AAGCTCAATCCATTGGCTTGTGGATTGTTCTGAAGACTTGAT
15 ATTCCACTGAGGAATTGGTGAGGTATGGATGGGATTGAGAGTATTAA
TGGAGTGTATACTATAGGAGAACAGAACACAGGGTGAACGCCTACATCG
AGCTGCTCAAGGATTCTAATTATTGATTGAAAGTGATGATGTTCACTGC
ATCAAGATGCATGATTAGTCGTGCTTGTGGATGTTCTGAAGACTTGAT
ATTCAAGCATTCTTGATTGTTAACCATGGTAATGGTGGTATGTTAGGGT
20 GGCCTGAAAATGATATGAGTGCCTCATCTGCAAAAGAATTCTATTAAATA
TGCAAGGGCATGTCGATTTCCTAGAGACGTAAAGTTCCAAATCTCTT
GATTTGAAACTTATGCATGCAGATAAGTCTTGAAGTTCTCAAGACT
TTTATGGAGAAATGAAGAACGCTTCAGGTATATCATAACGATCACATGAAG
TATCCCTGCTTCAACATCACCTCAATGCTCCACCAACCTCGTGTGCT
25 TCATCTTCATCAATGCTCATTGATGTTGATTGCTCTTCTATTGGAAATC
TGTTGAATCTGGAAGTGCTCAGCTTGCTAATTCTGGTATTGAGTGGTTG
CCTTCCACAATCGGAAATTGAAGGAGCTAAGGGTACTAGATTGACAAA
TTGTGATGGTCTCGTATAGATAATGGTGTCTAAAGAAATTGGTGAAAC
TTGAAGAGCTTATATGAGAGTTGGTGGTCGATATCAAAAGGCCATTAGC
30 TTCACTGATGAAAATGCAATGAAATGGCAGAGCGTTCAAAAAATCTTC
TGCATTAGAATTGAGTTCTCAAAAACAATGCTCAACCAAAGAATATGT
CATTGAGAATCTGAACGATTCAAGATCTCAGTGGGATGTTATTAAAG
GGAGATTCTGGTAAGATCTTCACTCTTGAAAACACGTTGCGGTTGGT
CACCAACAGAACTGAAGTTCTGAATCTAGGCTTAATGAGTTGTTGAGA
35 AAACAGATGTTCTTATTAAAGTGTGGGAGATATGAATGATCTTGAAGAT
GTTGAGGTAAAGTTGGCACATCTTCTAAATCCTCTTCCACAATT
AAGAGTCCTTATCATTCTGAGTGTAGAGTTGAGATACCTTTCACAC
TTGATGTTGCAAACACTTGTCAAAGCTTGTGAGCATTCAAGTTACGAA
TGCATAATATGGAAGAAATCATACATACAGAGGGTAGAGGGAGAAGTGAC
40 AATTACATTCCAAAGCTGAAGTTTATCATTGTGTGGGCTACCAAATC
TGTTGGGTTGTGGTAATGTGCACATAATTAAATCTACCACAACTCACA
GAGTTGAAACTTAATGGCATTCCAGGTTTACAAGCATATATCCTGAAAA
AGATGTTGAAACATCTAGTTGTTGAATAAGAGGTAAATGTGTTATG

TTAATACAATACAATCTTTCAATTAAACCGTTCAAAATATATTGTATGA
5 TTTATTTGTTGGATGGGGTTATTAAATGGGTGATTATTCTCAGGGTG
TAATTCTAATTGGAGAAACTGATATTAGTTATATGAAGGATTGAAA
GAGATATGGCCTGTGAATTAGGGATGAGTCAGGAAGTTGATGTTCTAC
GTTGAGAGTGATTAAAGTAAGCAGTTGTGATAATCTTGTGAATCTATTCC
CGTGCAATCCTATGCCATTGATACATCACCTGAAGAGCTCAAGTGATA
10 TTTGTGGTCCATTGAAGTGTATTCAACATTGAGTTGGATTCTATTGG
TCAAATTGGAGAAGGCATCAACAATAGCAGCTGAGAATCATCCAATTGC
AGAACTTAGGAAAGCTAAGTGAGGTGTGGAGGATAAAAGGTGCGGATAAC
TCTAGTCTTCATCAGTGGTTCAAGGTGTGAAAGCATTATCGTTAA
CAAATGCAAGATGTTAGAAATGTATTACACCTACCAACCAATTG
ATCTGGGGGCACTTATGGAGATTGGATACAAGATTGTGGAGAAAAGAGG
AGAAACAAACGAATTGGTAGAGAGTAGCCAAGAGCAAGAGCAGGTATGGCT
TTCAATTTCACTTCTTACTTAATGAAGGATTAAGCTCCTGCTTTTGAA
15 TAAAAAGTGGATGAATGACTAAATTGGGAATGCCACCCGGAAAGTTATC
AACCATTTAGCTACACCATTGGAACTAATGTTGCAATAAATGCATAA
TATAATTAAAAATGGTCATTGATAAAATGTAACCAACCTTTTATTAA
TTAAAATGTCTACAATAAATGATTTCTTATTATATATCATTTATAAC
AATAAGCTTAAAGATGTTAAATGCCAATGTCAGTTAGATCGTAAC
20 AATTGTTATTAACTAGTTTAGTTAAGATATCACTCATTATTATTTTA
TAGAAAAAGACAAGATTGGCTAACCTCATAAGAATTGGAAGATTAA
GCAAAATATAGAGCTTCCAAACATAGCCAATAGTTCTTGCAGGTC
CCATCTACGAAATTATCAATAGATTGCGATTTTGGCACCCGGGA
AATTCCATTAATTAAAAAAAGTTCAAGCCATTGTTAGTTGGCACCTG
25 CAAAATGGTAGTTGCACCTGCGGAAATCACCTTCACCATTGCGATCT
ATGACTTGTGAAAATGTTAATTGAAATGGTCATGTGCACCTCATGAG
AAATACGAAATGGTCAGTAATATGACTTTTATATAAATATGATGGTGG
CATATATTATAGGAAAATATAGCTGCACGATATTAAATTAGTGAAT
TAGTTAACTGTATACGATAAGTATACAAAATTATGATGAAGTATAC
30 TCAATTAGGACGACTCGGGCAATGAAATCATCATTAAATAGGAGCAATG
AAATCATTTCGAAAAATGTTACAAATGAATAAAATATTAAATTAAACT
TAAAACATTGTTAGTAGTTGAAATTACAAACTGAAATTGTTGTAT
TTATTAACATTATAAATGTTGACTATGATTTCCTGTTGCAAAT
ATTCCCTAAAATCCACCTAAAATCAAATAATTAAATCTTTCAAGTTG
35 AAAATGAAAATCGTATGATATAACCGTGTGGATGTGGAATTATATAT
CAGTTACTAATTACATTGTTGGATATATGTGCGCAGATTGATATT
GCAATCCCATTCACTCTCACACACTCTTCAAAACCTCCGTAAACTG
TTGGAAAAGTATGAAGGAGTGGAGGTGGTTGAGATAGAGAGTCCAA
CAAGTAGAGAATTGATAACAATTACCCATAATCAACAACCAACTACTCCC
40 AACCTTGAGTTATTGGATATAAGTTATGGACAGCATGAGTCATGTATG
GAAGTGCAACTGGAATAAAATTCTCATTCTCAAAAACAACAGTCAGAAT
CCCCATTCTGTAATCTCACAAACCATACATATTCAATATTGCCAAAGCATT
AAGTACTTGTGTTCAACTCTCATGGCAAAACTCTTCCAACCTAAAGAA

GGTCGAGGTAAGAGAGTGTATGGTATTGAAGAAGTTGTTCGAACAGAG
ATGATGAAGATGAGGAAAAGACTACATTCATCTACATCTTCTGAAAAAA
AGCACTAATTGTTCCCTCGTCTGAATCTCTCGCTTTATCAACTTCC
AAATCTCAAGTGTATTGGTGGTGGTCTGCCAACAGTGGAACAAATG
5 AAATATCTCTTGATAATTCCACTACTACTACTTCTTTGTTGATCAATCT
AAGGTATGTTTTTTNTNCCCTT (SEQ ID NO:109)

Sequence gap

CCTCCCTAATAATACATGTTATGCACACTATACTAACATATTAGACACGT
AAAGGATAAAATGCTATGCCTCATATAATACGTTATATTATAATCTTAA

10 ACAATCAAATTATTAAACAAATAACTAAGTGTGAGCAAAGGCAGGTACC
CGACTAAATTGCCAAAACCAGTCTGGTGGTCTGGGAATGTTGGGCCAG
GTCGTAAAACGTCTACACACCGGTTCTTAAATCACAGATCCGCTCTC
ATACTGTGAACCCGGTTAATTAAAAGAAAATTTCATTATAAAGTAA
ATGACTTAAACCAATTACAAACAACAAAATTACCAATTACAATGTTGGAC

15 TATCATTATTGCAACATAAAACTGAAAATACACATATTCCCTCTGATA
TCAGCATGAGTGGCTGGTGGCTAACCCAAAAATCCATGCATTGTAGATG
TGTGTTACAACACATAGTATCAATGAAAGGCATATTAGGCTAGAATT
TAACAATCTGTAATAATATTCCCTAAAACAAATAATCATCATCAACCAACT
AATATAAAACCATTGGGTTCGTCAATTAGGTACAAAACATAGATTTC

20 TAAGCTTGTGTATTAAACATATGCTTCTAAACTTAATTGATTTGCA
TTCCAAAATTAGGTGAAAGTGGTATGTCATTGTTGCTTTCAAC
ATTAAATTGTACAAAACCAAAACTACATAATTGATGTAGATATCATAACA
ATTGTGTTATTAGTATATAAAAACAAATTGAAATTGAATTCTTATA
CAAAGTTGTCTATGTATACATGTTATGTAGGTAATAGACAATTAGT

25 CTCTGTTAAGTATATGGAGTTAATTAGACTAATTTCATGTGTTG
CAGTTTATCAGGCAGGTGGCGTTTTGGACGTTATGCCAATACTCCAG
AGAGATAAAATATAAGGGAGTGTATGCATTGTCAAGTGTAAATTCCATGTT
ATGCAGCAGGACAGATGCAAAATGTTCAAGTGTGAATATACAGGTGC
AACTCAATGAAGGAGTTATTGAAACTCAAGGGATGAACAACAACAATGG

30 TGACAGTGGTTGTATGAAGGAAATGGTTGATACAGCAATTCCAAGAC
TAAATAACGTTATTATGCTACCCAACTAAAGATATTGAAGATTGAAGAT
TGTGGTCATCTGGAACATGTATTCACATTCTCTGCACTTGGAAAGCCTGAG
ACAGCTCGAAGAGTTAACGATAGAGAAATGCAAGGCAATGAAAGTGTAG
TGAAGGAAGAAGATGAATATGGAGAGCAAACAACAACAATGG

35 GAGGTTGTGGCTTCTCGTCTCAAGTCCATTGAACGGAAAATCTACA
AGAGCTCATGGGTTCTACTTAGGGAAGAATGAGATTAGCTGGCCTTCAT
TGGATAAGGTATGATCAAGAATTGCCAGAAATGATGGTGTGTTGCACCT
GGTGGAGTCCACAGTCCCAAGCGCAAGTATATAAATACAAGCTTGGCAT
ATAATGGGATGGAGGAGGTACTTGAAACTCAAGGGATGAACAACAATAATG

40 ATGACAATTGTTGTATGATGGAAATGGTGGAAATTCCAAGACTAAATAAC
GTTATTATGTTCCAAATATAAAGATATTGCAAATCAGCAATTGTGGCAG
TTTGGAACATATATTACACATTCTGCACTTGAAAGCCTGATGCAGCTCA
AAGAGTTAACATAGCGGATTGCAAGGCAATGAAAGTGTGAAGGAG

GAATATGATGTAGAGCAAACAAGGGTATTGAAGGCTGTGGTATTTCTTG
 TCTAAAGTCCATTACACTATGCCATCTACCAGAGTTGGTGGGTTCTCT
 TGGGGAAAGAACATGAGTTCTGGTGGCCTCATTGGATAAGGTTACCATCATT
 GATTGCCACAAATGATGGGGTCACACCTGGTGGGTCACAAACTCCCA
 5 CCTCAAGTACATACACTCAAGCTTAGGCAAACACATACTCTGAATGTGGCC
 TTAATTCAAGTCACAACACTGCATATCATCAGGTATAATTATTATTCT
 TTNACACCATCTAATTATGGAATCATGACGCTAATTACAGTATTAAACAC
 (SEQ ID NO:110)

10 RG2K deduced polypeptide sequence (SEQ ID NO:111)

MECITGIFSNPFAQCLIAPVKEHLCLLIFYTQYVGDMLTAMTELNAAKDIVEERK
 NQNVEKCFEVPHVNRWLEDVQTINRKVERVLNDNCNWFNLNCNRYMLAVKAL
 EITQEIDHAMKQLSRIEWTDSPVPLGRNDSTKASTSTPSSDYNDFESREHTFRKAL
 EALGSNHTSHMVALWGMGGVGKTTMMKRLKNIKEKRTFHYIVLVVIKENMDL
 15 ISIQDAVADYLDMKLTESNESERADKLREGFQAKSDGGKNRFLIILDDVVWQSVN
 MEDIGLSPFPNQGVDFKVLLTSENKDVCAMGVEANLIFDVKFLTEEEAQSLFY
 QFVKVSDTHLDKIGKAIVRNCGGLPIAKTIANTLKNRNDVWKDALSRIEHHD
 IETLAHVVFQMSYDNLQNEEAQSFLLCGLFPEDFDIPTTEELVRYGWGLRVFNGV
 YTIGEARHRLNAIYELLKDSNLLIESDDVHCIKMHDLVRAFVLDTFNRFKHSLIV
 20 NHGNGGMLGWPENDMSASSCKRISLICKGMSDFPRDVKFPNLLILKLMHADKS
 LKFPQDFYGEMKKLQVISYDHMKYPLLPTSPQCSTNRLVHLHQCSLMFDCSSI
 GNLLNLEVLSFANSGIEWLPSTIGNLKELRVLDLTNCGLRIDNGVLKKLVKLEELY
 MRVGGRYQKAISFTDENCNEMAERSKNLSALEFEFFKNNAQPKNMSFENLERFKIS
 VGCYFKGDFGKIFHSFENTRLVTNRTEVLESRLNELFEKTDVLYLSVGDMNDLED
 25 VEVKLAHLPKSSSFHNLRLVLIISECIELRYLFTLDVANTLSKLEHLQVYECDNMEEII
 HTEGRGEVTITFPKLKFLSLCGLPNLLGLCGNVHIINLPQLTELKLNGIPGFTSIYPEK
 DVETSSLLNKEVVIPNLEKLDISYMKDLKEIWPCELGMSQEVDVSTLRVIKVSSCDN
 LVNLFPNPMPMLIHHLEELQVIFCGSIEVLFNIELDSIGQIGEGINNSSLRIIQLQNLGK
 LSEVWRIKGADNSSLLISGFQGVESIIVNKCKMFRNVFTTTNFDLGALMEIRIQDC
 30 GEKRRNNELVESSQESEQ

RG2L polynucleotide sequence (SEQ ID NO:112)

35 GGAAGACACAATGATGCAAAGACTGAAGAAGGTTGCCAAAGAAAATAGAA
 TGTTCAGTTACATGGTCGAGGCAGTTATAGGGAAAAGACAGACCCAATT
 GCTATTCAACAAGCTGTAGCCGATTACCTTCGTATACAGTTCAAAGAAAG
 CACTAAACCAGCAAGAGCTGATAAGCTTCGTGAATGGTCAAGGCCACT
 CTGNAGACGGAAGATAAGTCCTCGTAATATTGATGACGTCTGGCAG
 TCCGTTGATCTGGAAAGATATTGGNTTAAGTCCTTCAAATCAAGGTGT
 CGACTTCAAGGTCTTGTGACTTCACGAGACGAACACGTTGCACAATGA
 40 TGGGGTTGAAGCTAATTCAAGTTATTAAATGTGGACTTCTAACTGAAGTA
 GAAGCACAAAGTCTGTTCCAGCAATTGTAGAAACTTTGAGCCGAGCT
 CTGTAAGATAGGAGAAGTTATCGTAAGAAAGTGTGCGGTCTACCTATTG

CCATCAAAACCATGGCGTGTACTCTAAGAAATAAAAGAAAGGATGCATGG
 AAGGATGCACTTCACGTATAGAGCACTATGACATTGCTAGTGGTGC
 TAAAGTCTTGAACAAAGCTATCACAACTCCAAGACAGGGAGACTAAAT
 CCGTGTGTTGATGTGGTTGTTCTGAAGACTCAATATTCTACC
 5 GAGGAGTTGATGAGGTATGGATGGGCTTAAAGCTATTGACAGAGTTA
 TACAATTAGAGAAGCAAGAACCAAGGCTCAACACCTGCATTGAGCGACTTG
 TGCAAGACAAATTGTTAATTGAAAGTGATGATGTTGGGTGTCAAGATG
 CATGATCTGGTGCCTGCTTGTGGTATGTATTCTGAAGTCGAGCA
 TGCTTCAATTGTCACCATGGTAATATGCATGGTGGACTAAAAATGATA
 10 TGAACGACTCTGCAAAACAGTTCTTAACATGCGAGAGTGTGAG
 TTTCCAGGAGACCTCAAGTTCAAACCTAAAGCTTTGAAACCTATGCA
 TGGAGATAAGATGCTAAGGTTCTCAAGACTTTATGAAGGAATGGAAA
 AGCTCCAGGTAAATATCATAACCATAAAATGAAGTATCATTGCTCCCTCG
 TCACCTCAATGCTCCACCAACCTCGAGTGCTCATCTCATCGGTGTT
 15 ATTACGGATGCTGATTGCTCTGTATCGGAAATTGACGAATCTGGAAG
 TGTTGAGCTCGCTAATTCTGGCATTGAACGGATACCTCAGCAATCGGA
 AATTGAGAAAGCTTAGGCAACTTGATCTGAGAGGTCGTTATGGTCTTG
 TATAGAACAGGGTGTCTGAAAAATTGGTCGAACTGAAGAACTTTATA
 TTGGAAATGCATCTGCGTTAGAGATTATAACTGCAATGAGATGGCAG
 20

RG2L deduced polypeptide sequence (SEQ ID NO:113)

EDTMMQRLKKVAKENRMFSYMVEAVIGEKTDPIAIQQAVADYLRIQFKESTKPAR
 ADKLREWFKAHSDGKNKFLVIFDDVVQSVLEDIGLSPFPNQGVDFKVL
 25 HVCTMMGVEANSVINVGLTEVEAQSLFQQFVETFEPELCKIGEVIVRKCCGLPIAI
 KTMACTLRNKRKDAWKDALSRIEHDIRSVA
 LFPEDFNIPT
 EELMRYGWGLKLFDRVYTIREARTRLNT
 CIERLVQTNLLIESDDVGC
 VKMHDLVRAFVLGMYSEVEHASIVNHGN
 MHGWT
 KNDMNDSC
 KTVSLT
 CESVSEF
 PGDLKF
 PNLKLLKLMHGDKMLRFSQDFYEG
 MEKLQV
 ISYH
 KMKYPL
 PSSPQC
 30 NLRV
 LHLHRC
 SLRMLDC
 CSCIGN
 LTN
 LEVLS
 FANS
 GIER
 IPSA
 IGN
 NLKK
 LRQL
 DLRGR
 YGLCIEQGV
 LKNL
 VELE
 ELYIGN
 ASA
 FRD
 DYNC
 NEMA

RG2M polynucleotide sequence (SEQ ID NO:114)

GGGGAAGACACAATAGATGCAAAGGCTGAAGAAGTTGCCAAAGAAAAGAG
 AATGTTCA
 GTTATATCATTGAGGC
 GGTATAGGGAAAAGACAGAC
 35 CCCA
 TTTCCATTCA
 GGAAGCTATATCATATTAC
 CCTGGTGTAGAGCTCA
 AGGGTTCAAGGCCAA
 ATCTGATGTAGGT
 AAGGATAAAATTCT
 TAATAACTCGAC
 GATGTATGGC
 AGTCTGTTGATT
 GGAAAGATATTG
 GATTAAAGTCCATT
 CCAATCAAGGT
 GTTAACTTCA
 AGGT
 CCTGTTAACAT
 CACGAGAC
 CGACATATTG
 CACTGT
 40 GATGGGGGTTGA
 AGGT
 CATTG
 GATT
 TTAATGT
 GGGACTTCT
 CACAGAAG
 CAGAAT
 CAAAAGAT
 GTTCTGG
 CAGTTGT
 AGAAGGTTCT
 GATCCTGAG
 CTCCATA
 AGATAGG
 GAGAAGATATT
 GTAAGTA
 AGTGT
 GGTCTACCC
 CAT

5 TGCCATTAAAACCATGGCATGTACACTTAGAGATAAAAGTACGGATGCAT
 GGAAGGGATGCACTGTCTCGTTAGAGCATCATGACATTGAAAATGTTGCC
 TCTAAAGTTTAGAGCGAGCTATGACCATCTCCAAGACGAGGAGACTAA
 ATCCACTTTTCTATGTGGATTGTTCCAGAAGATTCCAATATTCTA
 TGGAGGAGTTGGTAGAGGTATGGTGGGATTGAAATTATTAAAAAGTG
 TATACCATAAGAGAAGCAAGAACTAGGCTAACACTTGCAATTGAGCGGCT
 10 CATCTATACCAATTGTTGATAAAAGTTGATGATGTTAGTCAGTCATCAAGA
 TGCACTGATCTCATCCGTTCTTGTTGGATATGTTCTAAAGTTGAG
 CATGCTTCGATTGTCAACCAGGTAAACGCTAGAGTGGCCTGCAGATNA
 TNTGCACGACTCTGTAAAGGGCTTCATTAACATGCAAGGGTANATGTG
 AGTTTGTGGAGACCTNAANTTCCAACCCTAATGATTTAAAACCTATG
 CATGGAGATAATCGCTAAGGTTT

RG2M deduced polypeptide sequence (SEQ ID NO:115)

15 GEDTIDAKAEEVAKEKRMFSYIIIAVIGEKTDPISQEAISYYLGVELNANTKSVRAD
 MLRQGFKAQSDVGDKFLIILDDVWQSVLEDIGLSPFPNQGVNFVLLTSRDRHI
 CTVMGVEGHSIFNVGLLTEAESKRLFWQFVEGSDPELHKIGEDIVSKCCGLPIAIKT
 MACTLRDKSTDWKDALSRLEHHDIENVASKVFRASYDHLQDEETKSTFFLCGLFP
 20 EDSNIPMEELVRYGWGLKLFKKVYTIREARTRLNTCIERLIYTNLLIKVDDVQCIKM
 HDLIRSFVLDMSKVEHASIVNHGNTLEWPAD??HDSCKGLSLTCKG?CEFCGDL?F
 PTLMILKLMHGDKSLRF

RG2N polynucleotide sequence (SEQ ID NO:116)

25 AGGTAAAATCCATAACCCTAAATGTTGGTACGCTCATATATCAAATTGCG
 TGTTTGTGAATGAAAAAAGCATGCTAAAAACCAAGTGTAAAGGCACGG
 TATATGACATATTATAGTTACTGATAACAAATTATGATAATTTGGGTT
 TACRTAAGTTAGGATTCGTACTTCAACCAAATGTAATAGTTTGAGT
 CTATCTATGTATTGGGAATCACATTAGCAACGGGATTGTACTAGTAAT
 TCGAAAAAGCTTTAAATAATTCTGTTATAATTATGAATAGTT
 30 TAGCGACATCTAATATTAAATAGAATGTATCTGATATTGAATTATGTCC
 TTAATGTGAACATAGACCTTCCATTACTAATGCCTAATTATTAGTT
 CTAATCAATAAAATTAAATTCTGTTATGCTTCTAAGACAATAAAAT
 CCATGATTACCTTAAATATTAACAAAAATGACCATAAATAAAATAAAAA
 ATTAGGATACCAACCCCCCGCCATGCCAATGTCTAAATATTCTGAT
 35 GCTTTGCTTCCCTTTCTGTTAGTCTATTATTCTGGAGAGTTT
 GAGAGAGTTCATACAAGAAAATTCAAGAAGAAAGCAAGGTCCAGGTA
 TTCTCTTCTTAATTATGTATTAACCTACAAGCATTACGATCC
 ATGGTTTTGTATGTTCAAATTGAAACTAGATTGGGACTTTGC
 CCTTGATGATTCTAAGATATTGCATGGAGTTGAGATTGTGTAAGAAAAG
 40 TGGTGAATAGAAAGAGCAAGTGAATCCAGATATAGTATTGTTAATATG
 ATGATGAGATAGAGATATGTTAAAAGCTGGCTAGAAAATTGTTAATTG
 AAATTAGGTGTTGAATTGAAAGATACCAAGCTAATAACTAATTAGTT

ATGCTAAWTAGTTATAAAGAACAAACAACTCTTAGTTTTTTTTCATGA
TTTCAACCTCTTGTACCAAACAAATTATAGCAAAATTGAATATCATT
CTCTGCAATCAATCTTAACCTTTGTTATTATCATCATGTCTAAAATTGCC
ACAAGTTATTTCAAAGTCATATTGGATTATGAAAGGACTATTTTAC
5 AATTACATCTTACTTTATGGGCCAAAGCTAATAACAATCCGACTAAACTA
AAGGAATATGGGATGCATATAGTTGCTCCGATTATAGATTCTATCT
AATTGTCTATTGTACTAATTAGGTGCCACACAAGTAAATTGTAAA
TGGATATCGTTAATGCCATTCTAAACCAGTTGTCGAGACTCTCATGGTA
10 CCCGTTAAGAACACATAGGGTACCTCATTCTGCAGGCAATATATGAG
GGAAATGGGTATCAAAATGAGGGGATTGAATGCTACTAGACTTGGTGTG
AAGAGCATGTGAACCGGAACATAAGCAACCAGCTTGAGGTTCCAGCCAA
GGCAGGGGTTGGTATGAAGAAGTAGGAAAGATCAATGCAAAAGTGGAAAAA
TTTCCTAGCGATGTTGGCAGTTCAATCTTAAGGTTAGACACGGGG
TCGGAAAGAGAGGCCTCCAAGATAATTGAGGACATCGACAGTGTATGAGA
15 GAACACTCTATCATCATCTGGAATGATCATTCCATTCTTAGGAAGAAT
TGATTCCACGAAAGCATCCACCTCAATACCATCAACCGATCATCATGATG
AGTTCCAGTCAAGAGAGCAAACCTTCACAGAAGCACTAAACGCACTCGAT
CCTAACCAACAAATCCCACATGATAGCCTATGGGGAAATGGCGGAGTGGG
GAAGACGACAATGATGCATCGGCTGAAAAAGGTTGTGAAAGAAAAGAAAA
20 TGTTTAATTATTGTTGAGGCGGTTGTAGGGGAAAAAACAGACCCCCATT
GCTATTCAATCAGCTGTGGCAGATTACCTAGGTATAGAGCTCAATGAAAAA
AACTAAACCAGCAAGAACTGAGAAGCTCGTAAATGGTTGTGGACAATT
CTGCTGGTAAGAAGATCCTAGTCATACTCGACGATGTATGGCAGTTGTA
GATCTGAATGATATTGGTTAACGTCTTACCAAATCAAGGTGTCGACTT
25 CAAGGTGTTGTTGACATCACGAGACAAAGATGTTGCACTGAGATGGGAG
CTGAAGTTAACACTTTAACATGTGAAAATGTTAATAGAACAGAACAGCA
CAAAGTTATTCCACCAATTGTAGAAATTCTGGATGATGTTGATCGTGA
GCTCCATAATATAGGAGTGAATATTGTAAGGAAGTGTGGCGGTCTACCCA
TTGTCATCAAAACCATGGCGTGTACTCTTAGAGGAAAAAGCAAGGATGCA
30 TGGAAGAACATGCACTCTCGTTAGTGAACACAAACATTGAAAATATAGT
GAATGGAGTTTTAAAATGAGTTACGACAATCTCCAAGATGAGGAGACTA
AATCCACCTTTGCTTGTGAATGTTCCGAAGACTTAAATATTCC
ACCGAGGAGTTGGTGAGGTATGGATGGGGGTTGAAATTATTTAAAAAGT
GTATACTATAGGAGAACAGAACATCAGGCTCAACACATGCATTGAGCGGC
35 TCATTACACAAATTGTTGATTGAAGTTGATGATGTTAGGTGCATCAAG
ATGCATGATCTGTCCGTGCTTTGTTGGATATGTATTCTAAAGTCGA
GCATGCTCCATTGTCAACCATGGTAATAACACTAGAGTGGCATGTGGATA
ATATGCACAACTCTGTAAAAGACTTCATTAACATGCAAGGGTATGTCT
AAGTTCTACAGACCTCAAGTTCAAACCTCTCGATTGAAACTTAT
40 GCATGAAGATATATCATTGAGGTTCCAAAAACTTTATGAAGAAATGG
AGAAGCTTGAGGTTATATCCTATGATAAAATGAAATATCCATTGCTTCCC
TCATCACCGCAATGCTCCGTCAACCTTGTGCGTGTTCATCTCCATAAAATG
CTCGTTAGTGTGTTGACTGCTCTGTATTGAAATCTGTCGAATCTAG

AAGTGCTTAGCTTGCTGATTCTGCCATTGACCTGTCCTCCACAATC
GGAATTGAAAGAAGCTAAGGCTACTGGATTGACAAATTGTTATGGTCT
TTGTATAGCTAATGGTGTCTTAAAAAATTGGTCAAACCTGAAGAGCTCT
ATATGACAGTGGTTAATGGAGGAGTCGAAAGGCATCAGCCTCACTGAG
5 GATAACTGCAATGAGATGGCAGAACGTTCAAAAGACCTTCTGCATTAGA
ACTTGAGTTCTTGAAAACAATGCTCAGCCAAAGAATATGTCATTGAGA
AGCTACAACGATTCCAGATCTCAGTGGGTGCTATTATATGGAGCTTCC
ATAAAGAGCAGGCACTCGTATGAAAACACATTGAAGTTGGTATTGACAA
AGGTGAATTATTGAATCTTGAATGAACGGCCTGTTAAGAAAACAGAGG
10 TGTTATGTTAAGTGTGGGAGATATGAATGATCTTGAAGATRTTGAGGTT
AAGTCATCCTCACAAACYTCTCAATCTTCTCGTTCAACAATTAAAGAGT
CCTTGTGCGTTCAAAGTGTGCAGAGTTGAAACACTTCTCACACCTGGTG
TTGCAAACACTTAAAAAAGCTTGAGCATCTTGAAGTTACAAATGTGAT
AATATGGAAGAACTCATACGTAGCAGGGTAGTGAAGAAGAGACGATTAC
15 ATTCCCCAAGCTGAAGTTTATCTTGTGTGGCTACCAAAGCTATCGG
GTTTGTGCGATAATGCAAAATAATTGAGCTACCACAACTCATGGAGTTG
GAACTTGACGACATTCCAGGTTACAAGCATATATCCCATGAAAAAGTT
TGAAACATTAGTTGTTGAAGGAAGAGGTAATATAAATTAAATGCT
AATACATTACAAAGGATCTTCAGTTAAATCTTCAAAATATATTGAA
20 TTTGATTGTATGGGTATTATTGTTGGATGGACTATTAATAATGATTA
TCTTGCAGGTCTGATTCTTAAGTTAGAGAAACTGCATGTTAGTAGTATG
TGGAAATCTGAAGGAGATATGCCCTGCGAATTAAATATGAGTGAGGAAGT
TAAGTTCAGAGAGATTAAAGTGAAGTAACTGTGATAAGCTTGTGAATTGT
TTCCGCACAAGCCCATACTCTGCTCGTCATCTTGAAGAGCTAAAGTC
25 AAGAATTGTGGTCCATTGAATCGTTATTCAACATCCATTGGATTGTGC
TGGTGCAACTGGAGATGAATACAACAACAGTGGTGTAAAGAATTATAAAG
TGATCAGTTGTGATAAGCTTGTGAATCTCTTCCACACAATCCCATGTCT
ATACTGCATCATCTTGAAGAGCTTGAAGTCGAGAATTGTGGTCCATTGA
ATCGTTATTCAACATTGACTTGGATTGTGCTGGTGCATTGGCAAGAAG
30 ACAACAGAACGAGCTTAAGAAACATCAAAGTGGAGAATTAGGAAAGCTA
AGAGAGGTGTGGAGGATAAAAGGTGGAGATAACTCTCGTCCCCTGTTCA
TGGCTTCAATCTGTGAAAGCATAAGGGTACAAAATGTAAGAGGTTA
GAAATGTATTCACACCTACCACCAAAATTAAATCTGGGGCACTTTG
GAGATTCAATAGATGACTGCGGAGAAAACAGGGAAAATGACGAATCGGA
35 AGAGAGTAGCCATGAGCAAGAGCAGGTAGGATTCAATTCACTTCACTTCKT
ACTTAATTAAATGATTAAGCTCCTGCTTTTRAATAAAAAAGGGACAAACC
ATTTCATGACTTAATGTAGCAATACAAGTCATGTATAAGAGTGACCAACT
CTTTTTATTATAAAATGACTACAAAATTTTTTCATTAGAGATCA
TGTATAAAATGTGACTAATTTCATCACCTAACCTAGTTGATAAAATCTT
40 TATAAAATGTCACTAGTTACTTTCACTAAAATAACAAATTAAATAAAATT
TCAACAAAAAGCATCAACTAAAAAAATCCCACAACCCGTAATAATTAAA
ATAAAAGGATTAAACATCTAATACGAACAATTTTCTAAACATGATT
TGGACCAAATATCACCAGCAACTCAAGTTGGAATCGATTCTGAGCTAAAA

5 CTTGACCACATAATTAGATAGATGAGAGTTGAAGCTAAAGTGCCTATAT
AAGTCGTTCATCTTTCTTGATCTGATAGCAAGTTGAATSATT
CTTCTCAAAATTGATAAAAATCTACATTATAAAGAGACTAGCTGAAAA
AAAATGGTCTAGGTGGGTCTGGGTCTGGTAGATGAAGATGGAAGGGAGA
GTAGATTCAAAGACACAAACACATCTCATTATTATTATTATT
TTATTATTGATATCTGCTCATATTGTTACAGATATGTGAGGTCT
ATTAAATCTTTAAATATATAAAAATAACATAAAATGAGAAAATTAA
ATAAAGAATAAATTAAATAAGGGACAATAGCTTTGGTAAGACAAGG
ACCAAAAGCGCAACAAAAGTAAACAGTAGGGACCATCCGATTAAAAAAT
TAATTAGGGACCAAAAACATAAAATTCCCCAAACCATAGGGACCATTG
GTAATTACTCTGCTTTCGTTGTCATATTGGTAACTATT
TTGTACATATCTAGGTAACGAACCTGTTGAAAGTGTACATCTACGATG
TGACCTACTACAACCGATCATAATGGTCATATATGAACACTCCAACAAG
TTTGTATCTAGGTGTGTACAAAAAAACGATAGTTACCATGATGTGAACA
TACCAAAAATTAAATTACCTAGCAAGTTATTCCCATTAGTTGTAT
GGAAACAGTTCCGTGAGACCGTGACTTGGATGGTAGATAAATTAGTAAA
CTTAACCCTCAATTAAACCTACCTTTCTTATTAACTCAATTCAAGCT
AAATTCTGATTCTGTTGAAAGTAAGTTGCATCTTATGTTGTATT
CTTGTGCATAGGATCCTAGCATCTTAAATAATTATTGAAGGTGAA
AGATCCAACATTAACTCTGTTGGCATTTCATCATTGCAACTGTT
TCTTGAAAAAAA:::TACCTAAAATCAAACCAACATTCAATCCAAA
TTATAAGAGAGAATTGTAACGGACATGGAATCATAAAATCATTAACACAG
TTCAGTACACAGGTTGCTAATTACATTCTGCTGTGCAGATTGAAATT
TATCAGAGAAAGAGACATTACAAGAAGCCACTGGCAGTATTCAAATATT
GTATTCCCATCCTGTCTCATGCACTCTTCAAACTCCATAAACTTAA
CTTGAACAGAGTTGAAGGAGTGGAGGTGGTTGAGATAGAGAGTGAGA
GTCCAACAAGTAGAGAATTGGTAACAACCTCACCATAACCAACAACCT
ATTATACTTCCAAACCTCCAGGAATTGATTCTATGGAATATGGACAACAT
GAGTCATGTGGAAGTGCAGCACTGGAAATAATTCTCACTCTTCAA
30 AAGAACAAATCAGAATCCCCATTCCACAAACCTCAGTAACATACATATT
GAATGCAAAAGCATTAAAGTACTTGTGTTCACCTCTCATGGCAGAACTTCT
TTCCAACCTAAAGCATATCGAGATAAGAGAGTGTGATGGTATTGAAGAAG
TTGTTCAAAAAGAGATGGTGAGGATGAAGACATGACTACATCTAC:::
:::GCACACAACCAACCACTTTCCCTCATCTGATTCTCTCACTCTAAA
35 GCAACTGAAGAATCTGAAGTGTATTGGTGGAGGTGGTGCACAGGATGAGG
GGAGCAATGAAATATCTTCAATAATACCAACTGCAACTACTGCTGTTCT
GATCAATTGAGGTATGTTGTACATATTCAATTATTATTAAATT
TTGTTAATTCTTCTTGTCAATTCTATGAAAAAAATCACCAAA
TCACAAATAAGAGATTAAACTTTATTCAACACCCATGCGGACTCAAGA
40 ATGGGATTGGAGGCATATAAGTTACATTCAATTGAACAGTATTACCA
TTTATTGTTATTATCATTTCATATCATTACTGATAACATTCTT
TTACTTTCTAATTAGAAAAGGTCCACATGTCTAATTAGGTTTCCATT
TATGTGAATCCTCTATTCTGTCTGTAATTCAAGCATCTTAGATTATTATC

CATTTCTATAATTGTGTTATATTGACAGTTTTCTTTATAGTTGT
 AATTGCAACCTGTCATATWTTMWWKKCWWWATKYWMWWARTAATAACATT
 TATAACCCWCTATACTAAGATA

5 **RG2N deduced polypeptide sequence (SEQ ID NO:117)**

LGKTTMMHRLKKVVKEKKMFNFIVEAVVGEKTDPIAIQSAVADYLGIELNEKTKPA
 RTEKLRKWFVDSAGKKILVILDDVWQFVDLNDIGLSPLPNQGVDFKVLLTSRDKD
 VCTEMGAEVNSTFNVKMLIETEAQSLFHQFVEISDDVDRELHNIGVNIVRKCGGLPI
 VIKTMACTLRGKSKDAWKNALLRLVNYNIENIVNGVFKMSYDNLQDEETKSTFLL
 10 CGMFPEDFNIPTTEELVRYGWGLKLFKKVYTIGEARIRLNTCIERLIHTNLLIEVDDVR
 CIKMHDLVRAFVLDMSKVEHASIVNHGNTLEWHVDNMHNSCKRLSLTCKGMSK
 FPTDLKFPNLSILKLMHEDISLRFPKNFYEEEMEKLEVISYDKMKYPLLPSQCQCSVNL
 CVFHLHKCSLVMFDCSCIGNLSNLEVLSFADSAIDL PSTIGILKKLRLLDLTCYGL
 CIANGVFKKLVKLEELYMTVVNGGVRKAISL

15

RG2O polynucleotide sequence (SEQ ID NO:118)

TTGTAAAACGACGGCCAGTCGAATCGAACCGTTCTACGAGAACATCGCTG
 TCCTCTCCTTCATTGAATCATGATATTGAATATCGATACTTTGACTG
 TAGCTTTGGGTCGATTTTAGCAAGATAACATAACTGGCCAAACCCATT
 20 GGCTATTTAGCCAAAATATGAAATGGACTGGATTGTTTTCTTCCTTC
 TAACACGCACACATCTGGCGATCAGTATCACTCCATTATGAAGACCTAGT
 CAAATTCACTAACGTTCACTCGTTCTCAAAGTTCAAAGTTCCAACCT
 CCAACTTCCCTTTTTCTTCCTCGATTCTGATTGAATCCGAT
 TCTGCGACGAAGGAGAGCTTGGTCAGAGGGCTGTGATTCTGAGTCTGA
 25 CCTCCGAATCTAGCTGGATTATTCGACACACCAGACCACGTATCAGGT
 TGCTCATCCCGAAATACTGCTTGCAAACTGTTGTATCATCGCCTAGGAA
 ATTAAGTTCTTTGGCTCTGTTACTGAATCAGTAGCTTGCAACTTG
 CTCATTATAAGCTGATCCATATTTACATATCTTGAAGAATAATAGGT
 ACTGACTTTACCTTCTGATGAGAGCGATTAAGAGATAACCTCTGTAAAA
 30 TCCATTGGTGAAGGGATCTGGTTAGTTAAAGGATTGCTACAAC
 AGTATCCCACAAACGATCTATTCCCATTNACTCATCCGCTCAAGATCT
 ATCCACCTTATATATGTTAATTGGGAGTCTCCATGGTCAATGAATCT
 AGGATGCATTAGAAGCCAAATCCATTACAAGTTCATCCAATTCTATG
 TGACAAGTTGGTTACTATGTAGGTACTTCCACAATTAGAATTCCA
 35 GCAATGGATGTTGTTAATGCCATTCTAAACCAGTTGCCAGACACTTAT
 GGAACCTGTTAAGAAACATCTAGGCTACATCATTCCAGCACAAACATG
 TGAGGGATATGAGTAACAAATGAGGGAGTTGAACGCTGCAAGACATGCT
 GAAGAAGACCACTGGACAGGAACATAAGAAACTCGTCTGAGATTCAA
 TCAAGTTAGGAGTTGGTTAGAAGAAGTAGAAAAGATCGATGCAAAAGTAA
 40 AAGCCCTTCAGTGTACCGCTTGTGAGTCTCAAGATCAAACAT
 GAAGTCGGAAGGGAAGCCTGAGCTAATTGTGGAGATTGAAAGTGCCAC
 AAGACAACACTCTTGATCACCTGGACTGATCATCCCATTCTCTGGAA

AAGTTGATTCCATGAAGGCATCGATGTCCACAGCATCAACCGATTACAAT
GACTTTCAGTCAGAGAAAAAACTTTACTCAAGCATTGAAAGCACTTGA
ACCAAAACAACGCTTCCCACATGATAGCGTTATGTGGGATGGGTGGAGTGG
GGAAGACCACAATGATGCAAAGACTAAAAAAAGTTGCTAAACAAAATAGA
5 ATGTTCAGTTATGGTTGAGGCAGTTATAGGGAAAAGACGGACCCAAT
TGCTATTCAACAAAGCTGTAGCGGATTACCTCGTATAGAGTTAAAGAAA
GCACTAAACCAGCAAGAGCTGATAAGCTTGTGAATGGTTCAAGGCCAAC
TCTGGAGAAGGTAAGAATAAAATTCTTGTAAACTTGATGACGTCTGGCA
10 GTCTGTTGATCTAGAAGATATTGGTTAAGTCCTTCAAATCAAGGTG
TCGACTTCAAGGTCTTATTGACTTCACGAGACGAACATGTTGCACAGTA
ATGGGAGTTGGATCTAATTCAATTCTTAATGTGGGACTTCTAATAGAAC
AGAACGACAAAGTTGTTCCAACAATTGTAGAAACTTCTGAGCCCGAGC
TCCATAAGATAGGAGAAGATATTGTAAGGAAGTGTGCGGTCTACCTATT
GCCATCAAAACCATGGCATGTACTCTTAGAAATAAAAGAAAGGATGCTTG
15 GAAGGATGCACTTCGCGTATAGAGCACTATGACCTTCGCAATGTTGCGC
CTAAAGTCTTGAACGAGCTACCACAATCTCCATGACAAAGAGACTAAA
TCAGTGTGTTGATGTGGTTGTTCCCGGAAGACTTCAATATTCTAC
TGAGGAGTTGATGAGGTATGGATGGGGATTAAAGATATTGATAGAGTCT
ATACATTATAGAAGCAAGAACAGGGATCAACACCTGCATTGAGCGACTG
20 GTGCAGACAAATTGTTAATTGAAAGTGTGATGTTGGGTGTCAAGAT
GCATGATCTGGTCCGTGCTTGTGTTAGGTATGTATTCTGAAGTAGAGC
ATGCTTCAGTTGTCAACCATGGTAATATACCTGGATGGACTGAAAATGAT
CCGACTGACTCTTGTAAAGCAATTCTACCATGCGAGAGTATGTCTGG
AACACATTCCAGGAGACTTCAAGTTCCAAACCTAACGATTGAAACTTA
25 TGCATGGAGATAAGTCGCTAACGATTCCACAAGACTTTATGAAGGAATG
GAAAAGCTCCAGGTTATATCATAACGATAAAATGAAGTATCCAATGCTTCC
CTTGTCTCCTCAATGCTCCACCAACCTTCGAGTGCTTCATCTCCATGAAT
GTTCATTAAGATGTTGATTGCTCTGTATTGGAAATATGGCAATGTG
GAAGTGTGAGCTTGCTAACCTGCATTGAAATGTTACCTTCCACTAT
30 CGGAAATTAAAGAACGTAAGGTTACTGATTTAACAGATTGTCATGGTC
TTCATATAACACACGGTGTCTTAACAATTGGTCAAACATTGAAGAGTTG
TATATGGGATTTCTGATCGACCTGATCAAACCTCGTGGTAATATTAGCAT
GACAGATGTCAGCTACAATGAATTAGCAGAACGTTCAAAAGGCCTTCTG
CATTAGAGTTCCAGTTGAAAACAATGCCAACCAAATAATATGTCG
35 TTTGGGAAACTTAAACGATTCAAGATCTCAATGGGATGCACTTATATGG
AGGATCAGATTACTTAAGAAAACGTATGCTGTCCAAAACACATTGAAGT
TGGTTACTAACAAAGGTGAACATTGGACTCTAGAATGAACGAGTTGTT
GTTGAAACAGAAATGCTTGTAAAGTGTGATGATATGAATGATCTTGG
TGA TGTGTTGTGAAAGTCCTCACGTTCTCCTCAACCTTCTGTGTTCAAAA
40 TTCTAAGAGTCTTGTGCTTCCAAGTGTGTTGAGTTGAGATACCTTTC
ACAATTGGTAGCCAAGGATTGTCAAATCTTGAGCATCTTGAAGTTGA
TTCATGTAATAATATGGAACAACACTCATATGATTGAGAATGCTGGAAAAG
AGACAATTACATTCTAAAGCTGAAGATTATCTTGAGTGGCTACCA

AAGCTTCGGGTTGTGCCAAAATGTCAACAAACTGAGCTACCACA
 CATAGAGTTGAAACTTAAGGGCATTCCAGGGTTCACATGCATTATCCGC
 AAAACAAGTTGAAACATCTAGTTGTTGAAGGAAGAGGTAGATATATGT
 TTTATGTTAATACAAGTTAAAAAAATCTTTTAACAAAAGTTCACTATA
 5 TATATCTATATGTCTATAATTGATTATATGATGTATTAGTGTGGATG
 TGGCTATTAAGGGATGATTATTTGCAGGTTGTGATTCTAACAGTTGGAGA
 CACTTCAAATTGATGAGATGGAGAATTAAAGGAAATATGGCATTATAAA
 GTTAGTAATGGTGAGAGAGTTAAGTGAGAAAGATTGAAGTGAGTA
 10 TGATAAGCTTGTGAATCTATTCCACACAACCCATGTCTGCTGCATC
 ATCTTGAAGAGCTGAAGTCAAGAAATGTGGTCCATTGAATCGTTATTC
 AACATCGACTGGATTGTGATGCCATAGGAGAAGAACATGAG
 GAGCTTAAGAAACATTAAGTGAAGAATTCACTGGAAAGTTAAGAGAAGTGT
 GGTGTATAAAAGGTGAAATAACTCTGCCCTGTTCTGGCTTCAA
 GCTGTTGAAAGCATAAGCATTGAAAGTTGAAGAGGTTAGAAATGTATT
 15 CACACCTACCACCAATTAAATATGGGGGACTTTGGAGATATCAA
 TAGATGACTGTGGAGAATACATGGAAAATGAAAAATCGGAAAAGAGTAGC
 CAAGAGCAAGAGCAGGTATGGATTCAATTCACTTCTTACTTAA
 GGATTAAGCTTGTGTTTTGAATAAAAAAGGGACATCTCTAATAATG
 CACATCTAAATTAAAAAGTATTAAATTGTTGCATAGCAGCGTATAACAT
 20 CTTCTAATAATTATCTGAAGGTGAAAGATCCAACACTTCTAATTGTT
 AACAAATTCAATCATTGCAAATGTTCTAAAAAATTAAATTACCTGAAA
 TCAAAACAATCTTCTCAAATCCAAAATTATGAGACAGAATTGAGAAGGG
 ATGTGAAATTATAACCATTAAACACAATTCCATGCTCACGTTACTAATT
 CATTCTTGTGGATATATATGTACAGACTGATATTGTCAGAGGAAG
 25 TGAATTACAAGAAGTCACTGATACTATTCTAATGTTGATTACATCG
 TGTCTCATACACTCTTTATAACAAACCTCCGTAAACTCAACTGGAGAA
 GTATGGAGGAGTTGAGGTTGTGTTGAGATAGAGAGTTCAACAAGTAGAG
 AATTGGTAACAACATACCATAAACACAACAACAACAACAACCTATATT
 CCCAACCTTGAGGAATTATATCTATATTATGGACAACATGAGTCATGT
 30 ATGGAAGTGCAACAACTGGAATAAATTAAACAAACATCAGAATCCCCAT
 TCCACAAACCTCACAACCATAACACATGTCCGATTGCAAAAGCATTAAGTAC
 TTGTTTCACCTCTCATGGCAGAACTTCTTCCAACCTAAAGAGAAATCAA
 TATTGACGAGTGTGATGGTATTGAAGAAATTGTTCAAAAAGAGATGATG
 TGGATGAAGAA

35

RG2O deduced polypeptide sequence (SEQ ID NO:119)

MDVVNAILKPVAETLMEPVKKHLGYIISSTKHVRDMSNKMRELNAARHAEEDHLD
 RNIRTRLEISNQVRSWLEEVEKIDAKVKALPSDVTACCSLKIKHEVGREALKLIVEIE
 SATRQHSLITWTDHPIPLGKVDSMKASMSTASTDYNDFQSREKTFTQALKALEPNN
 40 ASHMIALCGMGGVGKTTMMQRLKKVAKQNRMFSYMVEAVIGEKTDPIAIQQAVA
 DYLRIELKESTKPARADKLREWFKANSGEGKNKFLVILDDVVQSVLEDIGLSPFP
 NQGVDFKVLLTSRDEHVCTVMGVGSNSILNVGLLIEAEAQSLFQQFVETSEPELHKI

GEDIVRKCCGLPIAIKTMACTLRNKRKDAWKDALSRIEHYDLRNVAPKFETSYHN
 LHDKETKSVFLMCGLFPEDFNPTEELMRYGWGLKIFDRVYTFIARNRINTCIEL
 VQTNLIESDDVGCVKMHDLVRAFVLGMYSEVEHASVNVHGNIPGWTENDPTDSC
 KAISLTCEMSGNIPGDFKFPNLTILKLMHGDKSLRFPQDFYEGMEKLQVISYDKMK
 5 YPMLPLSPQCSTNLRVHLHESLKMFDSCIGNMANVEVLSFANSGIEMLPSTIGN
 LKKLRLLDLTDCHGLHITHGVFNNLVKLEELYMGFSDRPDQTRGNISMVDVSYNE
 LAERSKGLSALEFQFFENNAQPNNMSFGKLKRFKISMGCTLYGGSDYFKKTYAVQ
 NTLKLVTNKGEELDSRMNELFVETEMLCLSVDDMNDLGDVCVKSSRSPQPSVFKIL
 10 RVFVVSKCVELRYLFTIGAKDLSNLEHLEVDCNNMEQLICIENAGKETITFLKLKI
 LSLSGLPKLSGLCQNVNKLELPQLIELKLKGIPGFTCIYPQNKLETSSLLKEEVVIPKL
 ETLQIDEMENLKEIWHYKVSNGERVKLRKIEVSNCDKLVNLFPHNPMSSLHHLEEL
 EVKKCGSIESLFNIDLDCVDAIGEEDNMRSLRNIKVNSWKLREVWCIGENNCP
 VSGFQA VESIESCKRFRNVFTPTTTFNMGALLEISIDDCGEYMEMEKSEKSSSEQ
 15 EQTDILSEEVKLQEVTDTISNVVFTSCLIHSFYNNLRKLNLEYGGVEVVFEIESSTS
 RELVTTYHKQQQQQQPIFPNLEELLYYYMDNMMSHVWKCNNWNKFLQQSESPFH
 LTTIHMSDCKSIKYLFSPLMAELLSNLKRINIDECDGI

RG2P polynucleotide sequence (SEQ ID NO:120)

CCCATTGCTATTAGGAAGCAGTAGCAGATTACCTCNGTATAGAGCTCAA
 20 AGAAAAAAACTAAATCNGCAAGAGCTGATATGCTTCGTAAAATGTTAGTTG
 CCAAGTCCGATGGTGGTAAAAATAAGTCCCTAGTAATACTTGACGATGTA
 TGGCAGTTGTTGATTAGAAGATATCGGTTAACGTCCCTTGCCAAATCA
 AGGTGTTAACCTCAAGGTCTGCTAACATCACGGGATGTAGATGTTGCA
 CTATGATGGGAGTCGAAGCCAATTCAATTCTAACATGAAAATCTTACTA
 25 GATGAAGAAGCACAAAGTTGTTACGGAGTTGACAAATTTCGAGTGA
 TGTTGATCCCAAGCTTCATAAGATAGGAGAAGATTGTAAGAAAGTGT
 GTGGTTGCCTATTGCCATAAAACCATGGCCCTTACTCTTAGAAATAAA
 AGCAAGGATGCATGGAGTGATGCACTTCTCGTTAGAGCATCATGACCT
 TCACAATTGTGAATGAAGTTTGGATTAGCTACGACTATCTTCAAG
 30 ACCAGGAGACTAAATATCTTTGCTTGTGGATTGTTCCCGAAGAC
 TACAATATTCCCTCGAGGAGTTAATGAGGTATGGATGGGGCTTAAATT
 ATTTAAAAAAAGTGTACTATAAGAGAAGCAAGAGCCAGACTAACACCT
 GCATTGAGCGGCTTATCCATACCAATTGTTGATGGAAGGAGATGTTGTT
 GGGTGTGTAAAGATGCATGATCTAGCACTGCTTTGTTATGGATATGTT
 35 TTCTAAAGTGCAGGATGCTCAATTGTCACCCATGGTAGCATGTCAGGGT
 GGCCTGAAAATGATGTGAGTGGCTTGCCTAAAGAATTCAATTACATGC
 AAGGGTATGTCGGGTTCCATAGACCTCAACTTCCAAACCTCACAAT
 TTTAAAACCTATGCATGGAGATAAGTTCTCAAGTTCCCTCAGACTTT
 ATGAACAAATGGAAAAGCTCAAGTTGATCGTTCATGAAATGAAATAT
 40 CCGTTCTCCCTCGTCCTCAATTGCTCCACCAACCTCGAGTTCT
 TCATCTCCATCAATGCTCATTGATGTTGATTGCTCTGTATTGGAAATC
 TGTTAATCTGGAAGTGTGAGCTTGCTAATTCTGGCATTGAATGGTTA

CCTTCCAGAATTGAAATTGAAGAAGCTAAGGCTACTAGATTGACAGA
 TTGTTTGGTCTCGTATAGATAAGGGTGTCTAAAAAATTGGTCAAAC
 TTGAAGAGGTTATATGAGAGTTGCTGTCGAAGAAAAAGCCGGAAAT
 AGAAAAGCCATTAGCTCACAGATGATAACTGCAATGAGATGGCAGAGCG

5 TTC

RG2P deduced polypeptide sequence (SEQ ID NO:121)

PIAIQEAVADYL?IELKEKTKSARADMLRMLVAKSDGGKNKFLVILDDVWQFVDL
 EDIGLSPLPNQGVNFKVLLTSRDVDVCTMMGVEANSILNMKILLDEEAQSLFMEFV
 10 QISSDVDPKLHKIGEDIVRKCCGLPIAKTMALTLRNKSKDAWSDALSRLEHHDLHN
 FVNEVFGISYDYLQDQETKYIFLLCGLFPEDYNIPPEELMRYGWGLNLFKKVYTIRE
 ARARLNTCIERLIHTNLLMEGDVVGCVKMHDLALAFVMDMFSKVQDASIVNHS
 MSGWPENDVSGSCQRISLTCKGMSGFPIDLNPNLTILKLMHGDKFLKFPPDFYEQ
 15 MEKLQVVSFHEMKYPFLPSSPQYCSTNRLVLHLHQCSLMFDCCSICGNLFNLEVLSF
 ANSGIEWLPSRIGNLKKLRLLDLTCFGLRIDKGVLKNLVKLEEVYMRVAVRSKKA
 GNRKAISFTDDNCNEMAERS

RG2Q polynucleotide sequence (SEQ ID NO:122)

TGGGGAAGACACAGTGATAGAAAARAAAAAGAATGTTGTGGAAAAGAGGA
 20 AAATGTTGATTATGCTGTTGGCGGTTATAGGGAAAAGACGGACCC
 ATTGCTCTCAGAAAACGTGTCGGATTACTTGCATATTGAGCTAAATGA
 AAGCACTAAACTAGCAAGAGCAGATAAAACTTGCATGGTTCAAGGACA
 ACTCGGATGGAGGTAAGAAAAAGTTCCCTCGTAATACTCGACGATGTTGG
 CAATCTGTTGATTGGAAGATATTGTTAAGTACTCCTTCCAATCA
 25 AGGTGTCAACTCAAGGTTGACATCACGAAAGAGAGAAATTGCA
 CAATGATGGGAGTTGAAGCTGATTAATTCTCAATGTCAAAGTCTTAGAA
 GAAGAAGAACACAAAAGTTGTCCTCCAGTTGTAGAAATTGGTACCA
 ATACCACGAGCTTCATCAGATAGGGTACATATAGAAAGAAGTGTATG
 GTTACCCATTGCCATTAAAACCATGGCTCTTACTTTAAGAAATAAAGA
 30 AAGGATTCATGGAAGGACGCACCTCTCGTTAGAGGACCATGACACTGA
 AAATGTTGCAAATGCAGTTTCGAGATGAACTACCGCAATCTACAAGATG
 AGGAGACCAAGCCATTGGCTTGCAGTTGTCCCGAAGACTTT
 GATATCCTACTGAGGAGTTGGTGAGGTATGGATGGGGCTAAATCTATT
 TAAAAAAAGTGTATACCATAAGAAAGGCAAGAACGAGATCGCATAACATGTA
 35 TTGAGCGACTCTTGGATTCAAATTGTTGATTGAAAGTAACGATATTGG
 TCGTCAAGATAACCGATCTGGTGCAGCTTGTGTTGGATATGTATTG
 TAAAGTTGAGCATGCTCAATTGTCAACCATTGTAATATGCGGACCGAAT
 ATAATATGGCTGACTCTGAAAACAATTCTTACATAACATAAGAGTATG
 TCTGGGTTGAGTTCCAGGAGACCTCAAGTTCCAAACCTAACAGTTT
 40 GAAACTTATGCANGGAGATAAGTCTCAAGGTTCCTCAAGACTTTATC
 AATCAATGGAAAAACTTCGGGTTATATCATATGATAAAATGAAGTATCCA
 TTGCTTCCCTCATCACCTCAATGCTCCACTAACATCCGAGTGCTCGTCT

5 CCATGAATGTTCATTAAGGATGTTGATTGCTCTTGTATTGGAAAGCTAT
 TGAATTGGAAGTCCTCAGCTTTTAATTCTAACATTGAATGGTTACCT
 TCCACAATCAGAAATTAAAAAGCTAAGGCTACTAGATTGAGATATTG
 TGATCGTCTCGTATAGAACAAAGGTGTCTGAAAAATTGGTCAAACTTG
 AAGAACTTATACTGGATATACATCAGCGTTACAGA

RG2Q deduced polypeptide sequence (SEQ ID NO:123)

10 GEDTVIEKKKNVVEKRKMFDYAVVAVIGEKTDPIALQKTVADYLHIELNESTKLAR
 ADKLCKWFKDNSDGGKKKFLVILDDVWQSVLEDIGLSTPFNPQGVNFKVLLTSR
 KREICTMMGVEADLILNVKVLEEEEAQKLFQFVEIGDQYHELHQIGVHIVKKCYG
 LPIAIKTMALTLRNKRKDSWKDALSRLLEDHDTENVANAVFEMNYRNLQDEETKAI
 FLLCGLFPEDFDIPEELVRYGWGLNLFKKVYTIRKARTRSHTCIERLLDSNLLIESN
 15 DIRCVKIHDLVRAFVLDMYCKVEHASIVNHGNMRTEYNMADSKTISLTYKSMMSG
 FEFPGDLKFPNLTVLKLMTDKSLRFPQDFYQSMEKLRVISYDKMKYPLPSSPQCS
 TNIRVRLHECSLRMFDCCSCIGKLLNLEVLSFFNSNIEWLPSTIRNLKKLRLLDLRYC
 DRLRIEQGVLKNLVKLEELYTGYTSAFTE

RG2S polynucleotide sequence (SEQ ID NO:124)

20 ATTTGGGTTTACATTAAATTGGTGCATGAATGTAAAAATAGACTG
 CTTATTGATTCTTGTTGATTGAGTTGATTTCATTATTACTACCTT
 ACAAAATTGCTCAGTGATAGATTCCATTAAATTGCTAATTGGTTGCTTC
 TAAATATGTTAGGAGCTACTAAAAGCAAAATATCGAGCAATGTCGGACCC
 AACGGGGATTGCTGGTGCATTATTAAACCCATTGCTCAGAGGGCCTTGG
 25 TTCCCGTTACAGACCATGTAGGCTACATGATTCTGCAGAAAATATGTG
 AGGGTCATGCAGACGAAAATGACAGAGTTGAATACCTCAAGAACATAGTGT
 AGAGGAACACATTAGCCGGAACACAAGAAATCATCTTCAGATTCCATCTC
 AAATTAAAGGATTGGTGGACCAAGTAGAAGGGATCAGAGCAAATGTGGAA
 AACTTTCCGATTGATGTCATCACTTGTAGTCTCAGGATCAGGCACAA
 30 GCTTGGACAGAAAGCCTTCAAGATAACTGAGCAGATTGAAAGTCTAACAA
 GACAGCTCTCCCTGATCAGTTGGACTGATGATCCAGTTCTCTAGGAAGA
 GTTGGTTCCATGAATGCATCCACCTCTGCATCATCAAGTGATGATTCCC
 ATC.AAGAGAGAAAACCTTTACACAAGCACTAAAAGCACTCGAACCCAAACC
 AACAAATTCCACATGGTAGCCTTGTGGATGGGTGGAGTAGGGAAGACT
 35 AGAATGATGCAAAGGCTGAAGAAGGCCGCTGAAGAAAAGAAATTGTTAA
 TTATATTGTTAGGGCAGTTAGGGAAAAGACGGACCCCTTGCACATT
 AAGAAGCTATAGCAGATTACCTCGGTATACAACCTCAATGAAAAAAACTAAG
 CCAGCAAGAGCTGATAAGCTTCGTGAATGGTTAAAAAGAATTCAAGATGG
 AGGTAAGACTAAGTTCTCATAGTACTTGACGATGTTGGCAATTAGTTG
 40 ATCTTGAAAGATATTGGGTTAAGTCCTTTCCAATCAAGGTGTCGACTTC
 AAGGTCTTGTGACATCACGAGACTCACAAAGTTGCACTATGATGGGGGT
 TGAAGCTAATTCAATTAAACGTGGGCCTCTAACTGAAGCAGAAGCTC
 AAAGTCTGTTCCAGCAATTGTAGAAACTTCTGAGCCGAGCTCCAGAAG

ATAGGAGAGGATATCGTAAGGAAGTGTGCGGTCTACCTATTGCCATAAA
AACCATGGCATGTACTCTTAGAAATAAAAGAAAGGATGCATGGAAGGATG
CACTTCGCGCATAGAGCACTATGACATTACAATGTTGCCCAAAAGTC
TTTGAACGAGCTACCACAATCTCCAAGAAGAGGAGACTAAATCCACTT
5 TTAATGTGTGGTTGTTCCGAAGACTTCGATATTCTACTGAGGAGT
TGATGAGGTATGGATGGGGCTTGAAGCTATTGATAGAGTTATACGATT
AGAGAAGCAAGAACCAAGGCTCAACACCTGCATTGAGCGACTGGTGCAGAC
AAATTGTTAATTGAAAGTGTGATGTTGGGTGTCAAGATGCATGATC
10 TGGTCCGTGCTTGTGTTGGGTATGTTCTGAAGTCAGGATGCTTCT
ATTGTCAACCAGGTAAATATGCCGAGTGGACTGAAAATGATATAACTGA
CTCTGCAAAAGAATTCACTAACATGCAAGAGTATGTCTAAGTTCCAG
GAGATTCAAGTTCAAACCTAATGATTTGAAACTATGCATGGAGAT
AAGTCGCTAAGGTTCTCAAGACTTTATGAAGGAATGGAAAAGCTCCA
15 TGTTATATCATACTACGATAAAATGAAGTACCCATTGCTCCTTGGCACCTC
GATGCTCCACCAACATTGGGTGCTTCATCTCACTAAATGTTCACTAAAG
ATGTTGATTGCTCTGTATTGGAAATCTATCGAATCTGGAAAGTGTGAG
CTTGCTAATTCTCGCATTGAATGGTACCTCCACAGTCAGAAATTAA
AGAAGCTAAGGTTACTGATCTGAGATTGATGGTCTCCGTATAGAA
CAGGGTGTCTGAAAAGTTAGTCAAACCTGAAGAATTATATTGGAAA
20 TGCATCTGGGTTATAGATGATAACTGCAATGAGATGGCAGAGCGTTCTG
ACAACCTTCTGCATTAGAATTGCGTTCTTAATAACAAGGCTGAAGTG
AAAAATATGTCATTGAGAATCTGAACGATTCAAGATCTCAGTGGGACG
CTCTTGTGATGGAAATATCAATATGAGTAGCCACTCATACGAAAACATGT
TGCATTGGTACCAACAAAGGTGATGTATTAGACTCTAAACTTAATGGG
25 TTATTTGAAAACAAAGGTGCTTTTAAGTGTGCATGGCATGAATGA
TCTTGAAGATGTTGAGGTGAAGTCGACACATCCTACTCAGCCTCTTCAT
TCTGCAATTAAAAGTTCTTATTATTCAAAGTGTGTAGAGTTGAGATAC
CTTTCAAACACTCAATTGCAAACACTTGTCAAGACTTGAGCATCTAGA
AGTTGTGAATGCGAGAATATGGAAGAACTCATACTGGAATTGTTG
30 GAGAAGAGACAATTACTTCCCTAACGCTGAAGTTTATCTTGAGTC
CTACCGAAGTTATCAAGTTGTGCCATAATGTCAACATAATTGGGCTACC
ACATCTCGTAGACTTGATACTTAAGGGCATTCCAGGTTCACAGTCATT
ATCCGCAGAACAAAGTTGCGAACATCTAGTTGTGAAGGAAGAGGTAGAT
ATATGTTCTTATGTTAACAAATTAAATAATTCAACCAAATT
35 CATAAATATCTGTAATTGATTGTATGATGTGTTATTGTTATATGTGG
CTATTAAGGGATGATTATTGCAAGGTTGTGATTCTAACATTGGAGACAC
TTCAAATTGATGACATGGAGAACTTAGAAGAAATATGGCCTTGTGAACCT
AGTGGAGGTGAGAAAGTTAACGTTGAGAGAGATTAAAGTGAGTAGCTGTGA
TAAGCTTGTGAATCTATTCCCGCGCAATCCCATGTCTCTGTGCATCATC
40 TTGAAGAGCTAAAGTCAAGAACATTGCGGTTCCATTGAATCGTTATTCAAC
ATTGACTTGGATTGTGCGGTGCAATTGGAGAACAGACAACAGAGCCT
CTTAAAGAACATCAACATGGAGAACATTAGGGAGCTAACAGAGAGGTGGA
GGATAAAAGGTGCAGATAACTCTCATCAACGGTTCAAGCTGTT

GAAAGCATAAAGATTGAAAAATGTAAGAGGTTAGCAATATATTACACC
TATCACCGCCAATTTTATCTGGTGGCACTTTGGAGATTAGATAGAAG
GTTGCGGAGGAAATCACGAATCAGAAGAGCAGGTAACGCTTCAATTAA
CTTTCTTAAGTAATTAAGGACTAACCTCCTGTTTTGAATAATAAAGAG
5 GTGGGATGACTAAACTGGGCATCACAAATTGCAACAAAATGTTACAAACC
ATGAAACGTTCAAACCATTCTGAATTAAGGTTCAATACAAGTCATT
AAAAATATGGCTTAAATTTTTATTTATGTATCAACATGATTTCA
TTAGAGATCATTATTATAATAGTAAGTTAAAGCAATTAAATTAGAACT
AATTCTAACTTAGCTAATAAATCGTTAAATGTAATAATTACTTT
10 AGTGAATAAGCAACGGATTAAATAAGTTAACAACTTAAATGTCATTCC
TAACAAAAAAACTATTGGTCAGAAGAACCGTAATTCAAGATAACTAA
AATAAAAATATTGACATTCACTAAGAGCATTCTTCTAAATATGAT
TGCAAATGAATAAAACTTAAATTACAGAAAAGATTTTATATGTT
ATACAAAATTACAATTGAAACTGGATATGTTAAACGGTTATAAT
15 TCTGGTATCACAAAGGGATATATAATAAAATTATTATTCTGTAGTCATT
TATAATTGTACTAGTTATAACCGTGGAACCATGAGTTCTAAAATTAG
TTAAACTTCATAATAAAAATTATAATTATTATTAAATAATT
ATTAAATTAAAGAGATGTATCAAAAATTAAAGTTATTATAACTTCAAATT
AACATATAATTAGAAAATATGATCATAACTTCCGCAACTCTTCTTT
20 GTATTAAAATGCCAGAGAAGCTCTAGTAYATTCTAAATCAAAGTC
CAAAACTAATGAAGCATATAATTGTGAAAATCAATTAGCATTAGGTT
TAAGAGTCACCAAATTCAAAGAGTAATCCAATGCTTCATTACCACTATG
GAGAAAATATTCTTAGTTAAATGAAATGAAAACAAACATTCAAACAA
ATTGTTGCTTACTAAACCAAGACCCATTACTTAGCCAAGAGTTAACCA
25 AAAAATTACATTACATGTATCATTATTCACTAGATAGATATATGAACA
TGAAGGGAGTTTATAGAAAATATAATCATAGATATTCAACATAACTC
ATGGAATTCTCAAATAACCAAGTTATTCAAGAAATTACATCCAAGTCA
ACC.AAAGAGAAGTTAGCCTAGCATGGCTAAACTCAAGAAAATAAA
GGATTAGAAGTACCAAACATGTAGTAAGAATCACAGTAAAAGATGATGTT
30 GTTCTTGATGTTCTCTAAGTTCTCAAGTCTCCAGTTGCTCTAATAAT
GCAAAGGAGAGCCATTAAATTCTGTATGTATTGATCCCTCAAAAGCTGCA
CCAACCTCCCTAAATAACACTCAAAGCAAAAATGACAAAATTGCCCTG
AAGGACCTATGCGGGTGCCTGCGGGTGGAGCTGAATACGAAAGGTC
TTTGGTCTTGTGAGGGTGTGCTGTGCGGGTAGCTTGTGCGCATGTTCTC
35 CGCGCGGTCGCGCACATGTGCACAAGTGTGATGCTGGTGTACGTTCTT
GAGTTTGAGCCTCCGATGCTTAGTCCATTGGCCAATTGAGTCAAAT
CAGCTTATGACCCATTCTCAAGTTATCTCAAGTTATCTCAAGTT
AAGCCAAATTGCCTCTCAAATCATCCATAACTTCACAAAATGCCCG
TTCATCTTAATCCCAGATGCACAATTATTCTCCTGCTTCTTAAAGCA
40 AGATACCACCTCTCATGCTCATCCATCAATAGTACACTCATGTATC
ATCTCTACTAGTTATTAGTCCACAATCCTTATTGTCCTCCAAATTAAAT
TATCTCATTAGTCCACTAGTTCTTAAATGCAATTAAAG
CTCACACAAATTAAAGTACCTGAAATGGTCATAAAATAACAAAAAGGAA

AATATGCATGAAGATTAACATAATGATGAACGAAATATGCTAAAATAGAC
TATAAAATGAAGTAAATAAAATGAAATTATCGCACTCCGACCACCCCTAT
AGGCTTGTAGTCCATCCACCCCTCATTCTGTACCAATATGGGATGGAA
ACATCATTAATTAAGCCAAAAAACTAACATATAAAGGGTGAGTGACAAAG
5 GTAAGTACTAAAGATGAAAATAATCCATTTCYTGTATATACACAACAC
ACACATAGGGCAGACGTAGGATTCTAGTACAGATTGTTGGCACA
TAAGTGTGCTGGTGACACTTTTTCTTACGTAGTGGCACAACAG
TAGAAAAAACGARAAATTGAAATTTCATAATGTGTSTAAAAAAAYA
GTGGTTGTTGGTGCACATGGACACCAAGTGAACTGCCCCTGCGCGC
10 RCACACACACACACATAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG
ARAGWAWGRRRGAKAKARMCSMSYTTGGATGTGATACTCTTTAGGAA
AATGGAGTTATATCTTGATATTGTATTTCATAATGTAATTATATATT
TAATCATTAGTTATAAGTTTATTGATATGAAAGAAAAAAAGT
CTTTTACATTGGATTAAACATAAAATCCAACAATTAAATCAAAAG
15 ACCAMACATGTGGACAMWTATGTATATAAWTAATTACAATAGTCCTTAG
GAATAGNATTATATATAATTAAATTCTCAATGGTCTTAGGAATAGTAAG
TTCTTATATTCAAACCTTNGCCACAATTCTTGKTTACTWGACACTY
CCTCTCTCAATTATATATATATATATATATATATATACACA
CACACACACACACTAGATGTGTGCCCGCGCAAAGCAGTGACGTNNNGG
20 AGAANACTTCTTAAGCATAAATAATTATTATATTATTTATTGGGTATTA
TATAATAAAAAATTACAACCTTTAAATAAAATTATGTTATACCTTA
TATTATATTGCTGTACTATTAAATATAATAATTATGTTATGTCT
AATTATGAAATGTAATTAAATTAAACATGAATTAAATATTAA
ATTTCAGTTGCTCAAATTGAGTTCTTAATTATTTCATTACAN
25 GTATTCAAACCTTGTAAAGTATTAAAGAATTATTATGCACAATTGATT
TATACAAAAAAACTTGTAACTTACATACATCTAAAATTCAAGATATAACTA
ACATGTTTACAATATATATATATANATATATATATATATATATAT
ATATATATATATAGTAAAGCGCANAGGTACAGGNANAGANTATT
TCTATTATTCTACGTTGCCACAAAGTTGAACACTTGCCTTT
30 GTCCCTCCTAACCTTCAATGTTGCGACAAAAGTTCCAAAACCTTG
CCACTTGTACCTCCTCAACTTTCACCGCATTAGTTGTGGAGTTGGC
AGTTTGGTCCCCCTAACCTCGATATTCTCCTGCTAGCCAAAAGGGT
TCCAGAGTTCACANTTTGGTCCCTGACAATAACCAATGTGAGATGTC
AAATTGGCACATTAGTTGTGGAGTTGCCCTTGGTCCCCCACA
35 TTCGATATTCTACTATACGACCTTATTCTCAAATAACAACACGTATA
TTTAAATTACCAATGATAGAAATAGATATCAAATAAAAGTATTGTAACACC
GTGTAAGAACGGTGTACTATAGTAAAAAAACATTCAAAGTACGAT
GTCCTAATTGGAAAAAGAGTTAAAAAAATAACAACAGGGCGAGTT
TTTTACAAGTTGTATCAAATCATACAAATTAAAGGTGGAACGGTGA
40 CCACATTAACCAGAAATGTAATTATTCTTGATTTGATAATTAAAT
ATTTCAGTTGTGATCTATGTATTAAAGTAAACAAACAAAGAACATAATCC
AAAACCCCTAAATTGCAAGTCTCGCCAAATTCTCTACACTAGTCGTAC
TTACGATGGCGTTACGTCGCTCTCACTTACAACCCCTTGTGCTA

CTCATTACAATAACGAAAAGTTGAATATCCATATATTATTGGATGTGG
AATTGAACAAATCTCGTCAAATTTGATTTGATGGATTGAGTAG
AAGTTGGGCAGAACCGGAATGATGGTCTGCAAGTGGTTATAAACTTGAT
TCTGAGTTATTACTATATGTAGCCTCTTACAACGACCAAGGTTCTT
5 CCAGGTACCATTGATCTTTAGAACCCAGTTGTCGAAACACCCCTGAT
TTGGATCAAATATACCAACAACACTCTAAAAACTGATTAATCAATTGTT
TTCTTCATCTTGATAACAAGTGGATGATTTCTACTTAGATTAACCTGA
AAAAAAAGGTCCATGTGCGTCTGGTGGATCTGGTAAATGAAGATGGAAGG
GAGAGCTGACTTTAAAGACACAAACACGTCACCATATCTTTATTTATT
10 TTAAATTGCTTTTCCTATTCTTCTTGATCTCCAGATGGTAT
GTGGTGTGGATAATTACACATAGAGATTGGAACGACTGTGTTTAGAG
AGGACGTGGCTGGGGTTGAGGATGGTTATGGCTGGCCGAGTTCATTT
ATATAAACAAACAAATATATAAAACAAGGGGTAATGCCATCTTATAT
GTATTAAACCGTCCTTTTATTTTTATTTAAATTAAAGAAGG
15 GGTATACCACTAGTGTCAACCTCTTATTCCAACCAGGCAACCAGTC
GGACTTAGGTTGGAAACAGTTCCGTGAGACCGTGACTGGATGGTA
GATAAAATTAGTAAACCTAACCCCTCAATTACCTACCTTTCTTATT
ACTCAATTCAACCTAAATTCTGATTCTGTTGAAATAAGTTGCATCT
TTATGTTGTATTATCCTGTTGCAAGGATCCTAGCATCTTTAATAAT
20 TTATTGAAGGTGAAAGATCCAACATTAGCTGTTGGCATTTC
TCATTGCAACTGTTCTGAAAAAAACACCTAAACAAATAACCA
TTTCAAATCCAAAATTATAAGAGAGAATTGTTAATGGACGTGGAATCGT
AAATCATTAAACACAGTTCAAGTACACAAGTTGCTAATTACATTCTGCTG
TGCAGATTGAAATTCTATCAGAGAAAGAGACATTACAAGAAGTC
25 ACTAAATATTCTAATGATGTTGATTATTCCCATCCTGTCATGC
TTTCATAACCTCCATAAAACTAAATTGGAGAGAGTTAAAGGAGTGGAGG
TGGTGTGAGATAGAGAGTGGAGAGTCCAACAAAGTAGAGAATTGGTAACA
ACTCACCATAACCAACACATCCTATTATACTTCCAACCTCCAGGAATT
GGATCTAAGTTTATGGACAACATGAGTCATGTGTTGAAGTGCAGCAACT
30 GGAATAAATTCTCACTCTTCCAAAACAACAAATCAGAATCCCCATTCCAC
AACCTCACAACCATACACATGTTCAAGCTGCAGAAGCATTAAAGTACTGTT
TTCGCCTCTCATGGCAGAACTCTTCAACCTAAAGGATATCTGGATAA
GTGGGTGTAATGGTATTAAAGAAGTTGTTCAAAGAGAGATGATGAGGAT
GAAGAAATGACTACATTACATCTACCCACACAACCACCATCTGTTCCC
35 TCATCTGATTCTCACTCTAAGACTACTGGAGAATCTGAAGTGTATTG
GTGGAGGTGGTGCAGGATGAGGGAGCAATGAAATATCTTCAATAAT
ACCACAGCAACTACTGCTGTTGATCAATTGAGGTATGCTTGTACA
TATTCAATTATTATTAAATTCTTTCTTGCAATATTCTATAAAAT
AATACATTTATACCCACTATAACTAAGATAATAATTACCTAGAGGGATGG
40 ATGCTATGACACAGCTGCTACACTCAGAAACTCTAGTAAGGGCAGTTAT
GGAAGTTCAATAAAATGATAATGGCATCTTGATGGTAATATAGGCAA
TTTAAAGTTTATTCTGTTAAAGCAGTATTAGCAAGTACTGGCCAGTAG
GAGAGGAGAATATCACCTTGTGAAATCTGGTATTGTACCCAAGAAT

TTAGTTAACATGAAACATTAGATATCAGGGGACATCAGGTGACAGATAT
TGTAGAACATGAAACATATATAATATTACCCAAAACATTCTTCTAAGGT
TATTCTGTTAAATATGTGCTTCTGATTCAATTGAAATTGCATTCTAT
ATTTAGGTGGTAAAGTGATTGTCTCTCAATAAATCCCAGAAATTAATTA
5 AAAAAGACAAAGTAAATTGATATGGAGAGCACTGGTATCA
TTTAGTATATAAAAAACTAGATTGAATTAGTTCTTATATAAAAAGC
TGTGTATATAGTTAATTAGTTACATCATTTCATGTGGTGTGCA
GTTGTCTGAAGCAGGTGGTGTCTGGAGTTATGCCAATACGCTAGAG
AGATAGAGATATCTAAGTGTAAATGTATTGTCAAGTGTGATTCCATGTTAT
10 GCAGCAGGACAAATGCAAAAGCTCAAGTGCTGAGAGTAACGGGTGTGA
TGGCATGAAGGAGGTATTGAAACTCAATTAGGGACGAGCAGCAACAAAA
ACAGAAAGGGTGGTGGTGTGAAGGAAATGGTGGATTCCAAGAGTAAAT
AACAAATGTTATTATGCTCCCAATCTAAAGACATTGAAAATCTACATGTG
CGGGGGTTTGGAACATATATTACATTCTGCACCTGAAAGCCTGACAC
15 AGCTCCAAGAGTAAAGATAGTGGGTTGCTACGGAATGAAAGTGTGATTGTG
AAGAAGGAAGAAGATGAATATGGAGAGCAGCAAACAACAACAACAAC
AACGAAGGGGGCATCTCTTCTTCTTCTTCTAAGAAGGTTG
TGGTCTTCCCCGTCTAAAGTCCATTGAACTATTCAATCTACAGAGCTG
GTAGGATTCTCTGGGGATGAATGAGTTCCGGTGCCTTCATTGGAAGA
20 AGTTACCATCAAGTATTGCTAAAAATGATGGTGTGTCAGCTGGTGGGT
CCACAGCTCCCCACTCAAGTATATACACACAAGATTAGGCAAACATACT
CTTGATCAAGAATCTGGCCTTAACTTCATCAGGTATATATATTCTT
TAATTGGCATGATCTAATTAGAAAGATATCATTCTGCCAAGTAAATT
ACTTCAAACACATTACACACTGGTTCACTCTAAGTTATGTTGTTCTAGG
25 AAGGCCAAAATGGGAAAGCAAGATAGGGAAAATAGTGTATTCACTGGGA
AAGGGTATTAGTATTCTGTCAAAAGTTGTTATTGCAGGCTTTA
GTACCTGGAATCGTGTGGGAGGAGCGTTATTCTGATTGCTTGTGTT
TCTTATCATTCTTAGCCTCTCGAACAGCTAGAAACCCCTTTAATC
TTTGATTAAATGACAAAATTCTCTGTTACTCTATTGATTGTTG
30 TTCTCATGGTCTAAGTGAGTTATTGGCTCATCTGTTACTCTTTGAT
TGTTATTCTATCATGTTGCTTGAATCAAGCTTCCATTCTCAA
CCAGGGCAAAGGTCAAAGTAACCTACTTATGAGATCAAAACAGCAA
CCCATCGGATAACTTAGTGGAGTTAATAGTACAATTACCAATTGTGA
TTAATAATTATAATCTTGTATTAAATTCAATTAAAATTGGTACAGCACAT
35 ATATGACATTAAAGGTTGTTTGTTWGACATATATATGCCTCTGGC
GTTTCTTATTGGACATGCAGACCTCATTCAAAGTTATACGGTGACA
CCTCGGGCCCTGCTACTCAGAAGGGACAACCTGGTCTTCATAACTTG
ATCGAATTAGATATGGAATTAAATTATGATGTTAAAAGATTATTCCATC
CAGTGAGTTGCTGCAACTGCAAAAGCTGGAAAAGATTGAGTAGTT
40 GTTATTGGTAGAGGGAGGTATTGAAACTGCATTGGAAGCAGCAGGGAGA
AATGGAAATAGTGGATTGGTTGATGAATCGTCACAAACTACTACTAC
TACTACTCTTCAATCTCGAAACCTCAGAGAAATGAAGTTGCATTTC
TACGTGGTCTGAGGTATATGGAAGAGCAATCAGTGGACAGCATTGAG

TTTCCAAACCTAACAAAGAGTCATATAAGTAGGTGAGAAGGTTAGAAC
 TGTATTACTAGTCCATGGTGGTAGTCTATTGCAACTCCAAGAGCTAG
 ATATTAGTGGTGCAACCATATGGAGGAGGTGATTGTTAAGGATGCAGAT
 GTTCTGTTGAAGAACAAAGAGAGAGAATCTGATGGCAAGACGAATAA
 5 GGAGATACTTGTACCTCGTCTAAAATCCTGAAATTAAAATGCCTC
 CATGTCTTAAGGGGTTAGCTGGGAAGGAGGATTTCATTCCCATT
 TTGGATACTTAGAAATCTACAAATGCCAGCAATAACGACCTTCACCAA
 GGGAAATTCTGCTACTCCACAGCTAAAAGAAATAGAAACAAAGATTGGCT
 CGTTTATGCAGGGAAAGACATCAACTCCTCTATTATAAAAAGATCAAAC
 10 AACAGGTAAATCAGATCTTGTGCTTAATAATTCTAAACTACATTG
 AAAAGCTTCATGCAAGTTTTTGTATATTGTCAAAAACCGAACCTA
 CATTTCAGCTTATATTATGTACTTATGCAGGAGTTCAAACAAACT
 CTGATTAATGTGAAGTGAATATTAAAGGTAAATTATTTCATGTTCC
 AGTTGCCTATTAATTAATGGCCTTTAGTCRTGATTTGGATGTAGTY
 15 WTCATGATGATGTGAATCTCTAATACCCATTCAATTGTTGGTGAATG
 TTGACTCTATGTCAGGATGAATATTCAAGGGAAGAATTGTTCATCATATG
 AAGGACATTAAAGAACATGGATGCTATGAAGATGTTGGAARAC

RG2S deduced polypeptide sequence (SEQ ID NO:125)

20 MSDPTGIAGAIINPIAQRALVPVTDHVGYMISCRKYVRVMQTKMTELNTSRISVEEH
 ISRNTRNHLQIPSQIKDWLDQVEGIRANVENFPIDVITCCSLIRHKLQKAFKITEQI
 ESLTRQLSLISWTDDPVPLGRVGSMNASTSASSDDFPSREKTFQALKALEPNQQF
 HMVALCGMGGVGKTRMMQLKKAAEEKKLFNYIVRAVIGEKTDPFAIQEAIADYL
 GIQLNEKTKPARADKLREWFKNSDGGKTKFLIVLDDVWQLVDLEDIGLSPFPNQG
 25 VDFKVLLTSRDSQVCTMMGVEANSIINVGLLTEAEAQSLFQQFVETSEPELQKIGED
 IVRKCCGLPIAIKTMACTLRNKRKDAWKDALSRIEHYDIHNVAPKFETSYHNLQE
 EETKSTFLMCGLFPEDFDIPIEELMRYGWGLKLFDRTVYTIREARTRLNTCIERLVQT
 NLLIESDDVGCVKMHDLVRAFVLGMFSEVEHASIVNHGNMPEWTENDITDSCKRIS
 LTCKSMSKFPGDFKFPNLMILKLMHGDKSLRFPQDFYEGMEKLHVISYDKMKYPLL
 30 PLAPRCSTNIRVLHLTKCSLKMFDSCSCIGNLSNLEVLSFANSRIEWLPSTVRNLKKLR
 LLDLRFCDGLRIEQGVLSVKLEEFYIGNASGFIDDNCNEMAERSDNLSALEFAFF
 NNKAEVKNMSFENLERFKISVGRSFBDGNINMSSHSYENMLQLVTNKGDVLDKLN
 GLFLKTKVLFLSVHGMNDLEDVEVKSTHPTQSSFCNLKVLIIASKCVELRYLFKLN
 ANTLSRLEHLEVCECENMEELIHTGICGEETITFPKLKFLSQLPKLSSLCHNVNIIG
 35 LPHLVDLILKGIPGFTVIYPQNKLRTSSLKEEVVIPKLETLQIDDMENLEEIWPCELS
 GGEKVKLREIKVSSCDKLVNLPRNPMSSLHHLEELKVKNCGSIESLFNIDLDCVGA
 IGEEDNKSLLRSINMENLGKLREVWRIKGADNSHLINGFQAIVESIKIEKCKRFSNIFT
 PITANFYLVALLEIQIECGGNHESEEQIEILSEKETLQEVTDTNISNDVVLFPSCLMH
 SFHNLHKLKLERVKGVVVFEIESESPTSRELVTTHHNQQHPIILPNLQELDLSFMD
 40 NMSHVWKCSWNKFFTPKQQSESPFHNLTTIHMFSRSIKYLFSPMAELLSNLK
 DIWISGCNGIKEVVSKRDEDEEMTTFTSTHTTILFPHLDSSLRLLENLKCIGGGG
 AKDEGSNEISFNNTTATTAVLDQFELSEAGGVWSLCQYAREIEISKCNVLSSVIPCY

AAGQMQLQVLRVTGCDGMKEVFETQLGTSSNKNRKGGDEGGNGIPRVNNNVI
 MLPNLKTLKYMCGGLEHIFTFSALESLTQLQELKIVGCYGMKVIVKKEEDEYGEQ
 QTTTTTTKGASSSSSSSSKKVVVFPRLKSIELFNLPELVGFFLGMNEFRLPSLEEVT
 IKYCSKMMVFAAGGSTAPQLKYIHTRLGKHTLDQESGLNFHQTSFQSLYGDTS GPA
 5 TSEGTTWSFHNLIEDMELNYDVKKIIPSSELLQLQLEKIHVSSCYWVEEVFETAL
 EAAGRNGNSGIGFDESSQTTTTLFNLRLNREMKLHFLRGLRYIWKSQNQWTAFEF
 PNLTRVHISRCRRLEHVFTSSMVGSLLQLQELDISWCNHMEEVIVKDADVSVEEDK
 ERESDGKTNKEILVLPRLKSLLKCLPCLKGFSLGKEDFSFPLLDTLEIYKCPAITTFT
 KGNSATPQLKEIETRFGSFYAGEDINSSIIKRSNNRSSNKTLINVK.JLK

10

RG2T polynucleotide sequence (SEQ ID NO:126)

GGAAGACGACAATGGTGCAACGGTTGAAGAAGGTTGTGAAAGATAAGAAG
 ATGTTCCATTATATTGTCGAGGTGGTTGTAGGGGCAAACACTGACCCCAT
 TGCTATCCAGGATACTGTTGCAGATTACCTCAGCATAGAACTGAAAGGAA
 15 ATACGAGAGATGCAAGGGCTTATAAGCTTCGTGAATGCTTAAGGCCCTC
 TCTGGTGGAGGTAAAGATGAAGTTCTAGTAATTCTTGACGATGTATGGAG
 CCCTGTTGATCTGGATGATACGGTTAACGTTCTTGCCAAATCAAGGTG
 TTGACTTCAAGGTCTTGCTGACATCACGCAACAGTGATATCTGCATGATG
 ATGGGAGCTAGTTAACCTCAATATGTTAACAGACGAGGAAGC
 20 ACATAATTTCGTCGATACGCAGAAATTCTTATGATGCTGATCCCG
 AGCTTATTAAGATAGGAGAAGCTATTGTAGAGAAATGTGGTGGTTACCC
 ATTGCCATCAAAACTATGCCGTTACTCTTAGAAATAACGCAAAGATGC
 ATGGAAAAGATGCACTTCTCGTTAGAGCACCGTGACACTCATAATGTTG
 TGGCTGATGTTCTAAATTGAGCTACAGCAATATCCAAGACGAGGAGACT
 25 CGGTCGATTTCGATGTGGTTGTTCTGAAGACTTTGATATTCC
 TACCGAAGACTTAGTGAGGTATGGATGGGATTGAAAATATTACAGAG
 TGTATACTATGAGACATGCAAGAAAAAGGTTGGACACGTGCATTGAGCGG
 CTTATGCATGCCAACATGTTGATAAAAAGTGATAATGTTGGATTGTCAA
 GATGCATGATCTGGTCGTGCTTGTGGCATGTTATCTGAAGTCG
 30 AGCATGCATCAATTGTCACCATGGGGATATGCCAGGGTGGTTGAAACT
 GCAAATGATAAGAACAGCTTGTGCAAAAGAATTCTTAAACATGCAAAGG
 TATGTCGCGATTCTGAAGACCTCACGTTCAAACCTCTCGATCCTGA
 AATTAAATGGATGGAGACGAGTCAGTGAGGTTCTGAAGGCTTTATGGA
 GAAATGGAAAACCTCAGGTTATATCATATGATAACATGAAGCAGCCATT
 35 TCTTCCACAATCACTCAATGCTCCAATGTCGAGTGCTTCATCTCCATC
 ACTGCTCATTAATGTTGATTGCTCTTCTATTGGAAATCTTGTAACTCTC
 GAGGTGCTCAGCATTGCTAATTGCCATTAAATTGTTACCCCTCCACTAT
 TGGAGATCTGAAGAAGCTAAGGCTCCTGGATTGACAAATTGTGTTGGTC
 TCTGTATAGCTAATGGCGTCTTAGAAATTGGTCAAACCTGAAGAGCTT
 40 TATATGAGAGTTGATGATCGAGATTGTTTGAAAGCTGATGACAG
 CAAGACCATTACCT

RG2T deduced polypeptide sequence (SEQ ID NO:127)

KTTMVQRLKKVVKDKKMFHYIVEVVVGANTDPIAIQDTVADYLSIELKGNTNDAR
 AYKLRECFKALSGGGKMKFLVILDDVVSPVLDLDIGLSSLPNQGVDFKVLLTSRNS
 5 DICMMMGASLIFNLNMLTDEEAHNFFRRYAEISYDADPELIKIGEAIIVEKCGGLPIAI
 KTMAVTLRNKRKDAWKDALSRLLEHRDTHNVVADVLKLSYSNIQDEETRSIFLLCG
 LFPEDFDIPTEDLVRYGWGLKIFTRVYTMRHARKRLDTCIERLMHANMLIKSDNVG
 FVKMHDLVRAFVLGMLSEVEHASIVNHGDMPGWETANDKNSLCKRISLTCKGMS
 AIPEDLTFPNLSILKLMDGDESLRFPEGFYGEMENLQVISYDNMKQPFLPQSLQCSN
 10 VRVLHLHHCSLMFDCCSIGNLLNLEVLSIANSAIKLLPSTIGDLKKRLLDLTCVGL
 CIANGVFRNLVKLEELYMRVDDRDSFFVKADDSKTIT

RG2U polynucleotide sequence (SEQ ID NO:128)

GCCTTGTGTGGATGGGTGGAGTGGGAAAGACCACTGTGATGAAGAAGCT
 GAAGGAGGTTGTGGTAGGAAAGAAACTGTTAACATTATGTTGAGGCAG
 15 TTATAGGGAAAAGACAGACCCCCATTGCTATTCAACAAGCTGTTGCCGAG
 TACCTTGGTATAAGTCTAACCGAAACCACTAAACCAGCAAGAACTGATAA
 GCTCCGTACATGGTTGCAAACAACCTCAAATGGAGGAAAGAAGAAGTTCC
 TGGTAATAACTAGACGATGTATGGCAACCAGTTGATTGGAAGATATTGGT
 20 TTAAGTCGTTTCCAAATCAAGATGTTGACTTCAAGGTCTTGATTACATC
 ACGGGACCAATCAGTTGCACTGAGATGGGAGTTAAAGCTGATTTAGTTC
 TCAAGGTGAGTGTCTGGAGGAAGCGGAAGCACACAGTTGTTCCCTCAA
 TTTTAAACCTCTGATGATGTCGATCCTGAGCTCAATAAAATCGGAGA
 25 AGAAATTGTAAGAAGTGTGAGACTACCCATTGCTATCAAAACCATGG
 CCTGAACCTTCTGAGATGATGTCGATCCTGAGCTCAATAAAATCGGAGA
 CGTTTACAACACCATGACATTAACACAATTGCGTCTACTGTTTCCAAAC
 TAGCTATGACAATCTCGAAGACGAGGTGACTAAAGCTACTTTTGCTTT
 GTGGTTATTCCGGAGGACTTCAATATTCTACCGAGGACCTATTGAGG
 30 TATGGATGGGATTGAAGTTATTCAAGGAAGTAGATACTATACGAGAAGC
 AAGATCCAAGTTGAAAGCCTGCATTGAGCGGCTCATGCATACCAATTGT
 TGATCGAAGGTGATGATGTTAGGTACGTTAAGATGCATGATCTGGTGCCT
 GCTTTGTTGGATATGTTCTAAAGCCGAGCATGCATCTATTGTCAA
 CCATGGTAGTAGTAAGCCAAGGTGCCCTGAAACTGAAAGTGATGTGAGCT
 CCTCTGCAAAAGAATTCAACATGCAAGGGTNTG

RG2U deduced polypeptide sequence (SEQ ID NO:129)

ALCGMGGVGKTTVMKKLKEVVVGKKLFNHYVEAVIGEKTDPPIAIQQAVAELGLIS
 LTETTKPARTDKLRTWFANNNSNGGKKKFLVILDDVVQPVLDIGLSRFPNQDVD
 FKVLITSRDQSVCTEMGVKADLVLKVSVLEEAEAHSLFLQFLEPSDDVDPELNKIGE
 EIVKKCCRLPIAIKTMA.TLRSKSKDWTKNALSRLQHHDINTIASTVFQTSYDNLEDE
 40 VTKATFLLCGLFPEDFNIPTEDLLRYGWGLKLFKEVDTIREARSKLKACIERLMHTN

LLIEGDDVRYVKMHDLVRAFVLDMSKAEHASIVNHSSKPRWPETESDVSSSCKR.
ISLTCKG?

RG2V polynucleotide sequence (SEQ ID NO:130)

5 CTGTGGAAGACACGAATGATSAAGAAGCTGAAGGAGGTCGTGGAACAAAAA
GAAAATGTTCAATATTATTGTTCAAGTGGTCATAGGAGAGAAGACAAACC
CTATTGCTATTCAAGCTGTAGCAGATTACCTCTATTGAGCTGAAA
GAAAACACTAAAGAAGCAAGAGCTGATAAGCTCGTNAATGGTCGAGGA
CGATGGAGGAAAGAATAAGTTCTTGTAACTTGATGATGTATGGCAGT
10 TTGTCGATCTGAAGATATTGGTTAACGCTCTGCCAAATAAAGGTGTC
AACTTCAAGGTCTTGTGACGTTAAGAGATTACATGTTGCACTCTGAT
GGGAGCTGAAGCCAATTCAATTCTCAATATAAAAGTTAAAAGATGTTN
AAGGACAAAGTTCCGCCAGTTGCTAAAATGCAGGTGATGATGAC
CTGGATCCTGCTTCAATGGGATAGCAGATAGTATTGCAAGTAGATGTCA
15 AGGTTGCCATTGCCATCAAAACCATTGCCTTAAGTCTAAAGGTAGAA
GCAAGCCTGCGTGGGACCATGCGCTTCTCGTTGGAGAACATAAGATT
GGTAGTGAAGAAGTTGTGCGTGAAGTTAAAATTAGCTATGACAATCT
CCAAGATGAGGTTACTAAATCTATTTTWTACTTGTGCTTATTCCTG
AAGATTTGATATTCTATTGAGGAGTTGGTGAAGGTATGGTGGGCTTG
20 AAATTATTTATAGAACAAAAACTATAAGAGAACAGAAACAGGCTCAA
CACCTGCACTGAGCGGCTTAGGGAGACAAATTGTTATTGGAAGTGATG
ACATTGGATGCGTCAAGATGCACGATGTGGTGCCTGATTGTTGGTAT
ATATTCTAGAACAGTCCAGCACGCTCAATTGCAACCAGTAATGTGTC
AGAGTGGCTAGAGGAAATCATAGCATCTACTCTTGTAAAAGAATTTCAT
25 TAACATGCAAGGGTATGTCTGAGTTCCCAAAGACCTCAAATTCAAAC
CTTCAATTGAAACTATGCATGGAGATAAGTCGNTGAGCTTCCCTGA
AGACTTTATGGAAAGATGGAAAAGGTTAGGTAAATATCATATGATAAAAT
TGATGTATCCATTGCTCCCTCATCACTTGAATGCTCCACTAACGTTCGA
GTGCTTCATCTCATTATTGTCATTAAGGATGTTGATTGCTCTCAAT
30 TGGTAATCTCTCAACATGGAAGTGCTCAGCTTGTAAATTCTAACATTG
AATGGTTACCATCTACAATTGAAATTGAAAGAACAGCTAAGGCTACTAGAT
TTGACAAATTGTAAGAGCTTATATGGGTGTTAATGTCCGTATGGACCAGG
CCGT
35

RG2V deduced polypeptide sequence (SEQ ID NO:131)

LWKTRM?KKLKEVVEQKKMFNIIVQVVGKIEKTNPIAIQQAVADYLSIELKENTKEAR
ADKLR?WFEDDGKKNKFLVILDDVWQFVDLEDIGLSPLPNKGVNFKVLLLRDSH
VCTLMGAEANSILNIKVLKD?GQSLFRQFAKNAGDDLDPAFNGIADSIASRCQGL
40 PIAIKTIALSLKGRSKPAWDHALSRLENHKIGSEEVVREVFKISYDNLQDEVTKSIF?L
CALFPEDFDIPIEELVRYGWGLKLFIEAKTIREARNRLNTTERLRETNLLFGSDDIG

CVKMHDVVRDFVWYIFSEVQHASIVNHGNVSEWLEENHSIYSCKRISLTCKGMSEF
 PKDLKFPNLSILKLMHGDKS?SFPEDFYGKMEKVQVISYDKLMPPLLSSLECSTNV
 RVLHLHYCSLRMFDCSSIGNLLNMEVLSFANSNIEWLPSTIGNLKKLRLLDLTNCKG
 LRIDNGVLKNLVKLEELYMGVNVRMDQAV

5

RG2W polynucleotide sequence (SEQ ID NO:132)

TTGGGAAAGAGACAATGATGAAGAATTGAAAGAGGTTGTGGTTGAAAAGA
 AAATGTTAACATTATGTGGAGGCGGTATAGGGGAGAAGACGGACCCC
 ATTGCTATTCAAGCAAGCCGTTGCAGAGTACCTGGTATAATTCTAACAGA
 AACCACTAAGGCAGCAAGAACCGATAAGCTACGTGCATGGCTTCTGACA
 ATTCAAGATGGAGGAAGAAGAAGTTCCTAGTAATACTAGACGATGTATGG
 CATCCGGTTGATATGGAAGATATTGGTTAACGTGTTCCCAAATCAAGG
 TGTCGACTTCAAGGTCTGATTACATCACGGGACCAAGCTGTTGCACTG
 AGATGGGAGTTAAAGCTGATTCAAGGTGAGTGTCTAGAGGAA
 10 GCTGAAGCACAAAGCTTATTCTGCCAACCTTGGAACCTCTGATGATGT
 CGATCCTGAGCTCCATCAGATTGGAGAAGAAATTGTAAGGAAGTGTG
 GTTACCCATTGCAATAAAACCATGGCCTGCACTCTAGAAAGTAAAAGC
 AAGGATACATGGAAGAATGCACTTCTCGTTACAACACCATGACATTAA
 CACAGTCGCGCCTACTGTTTCAAACCATGCTATGACAATCTCAAGATG
 15 AGGTGACTGGAGATACTTTTGCTATGTGGTTGTTCCGGAGGACTTC
 GATATTCTACTGAAGACTTATTGAAGTATGGATGGGGCTAAAATTATT
 CAAGGGAGTGGATTCTGTAAGAGAACAGATACCAAGTGAACGCGCTGCA
 TTGAGCGGCTCGTCGACATACCAATTGTTGATTGAAAGTGTGTTGGG
 TGCGTCAAGTTGCACGATCTGGTGCCTGCTTTATTGGATATGTTG
 20 TAAAGCGGAGCATGCTCGATTGTCACCATGGTAGTAGTAAGCCTGGGT
 GGCCTGAAACTGAAAATGATGTGATCAGGACCTCCTGCAAAAGAACATCTCA
 TTAACATGCAAGGGTATGATTGAGTTCTAGTGACCTCAAGTTCCAAA
 TGTCTGATTTAAAACCTATGCATGGAGATAAGTCGCTAAGGTT
 25

20

RG2W deduced polypeptide sequence (SEQ ID NO:133)

WERDNDEELKEVVVEKKMFNHYVEAVIGEKTDPIAIQQA
 VAEYLGILTE
 TDKLRAWLSDNSDGGRKFLVILDDVWHPVDMEDIGLSRFPNQGVDFKVLITSRD
 QAVCTEMGVKADSVIKVS
 VLEEAEAQSLFCQLWEPSDDVDPELHQIGEEIVRKCCG
 LPIAIKTMACTLRSKSKDTWKNALSR
 LQHHDINTVAPTVFQTSYDNLQDEV
 TGDTF
 30 LLCGLFPEDFDIPTEDLLKYWG
 GLKLFKGVD
 SVREARYQLNACIERL
 VHTNLLIESD
 VVGCVKLHD
 LVRAFILDMFCKAE
 HASIVNHGSS
 KPGWPETEND
 VIRT
 SCKRISLTCK
 GMIEFSSDLKFPNV
 LILKLMHGDKSLRF

25

RG5 polynucleotide sequence (SEQ ID NO:134)

40 GGGGGGGTGGGAAGNC
 GACTCTAG
 CCCAGAAGNTCTATAATGACCATAA
 AATAAAAGGAAGCTT
 TAGTAAACAAAGCATGGATCTGT
 GTTTCTCAACAAAT

ATTCTGATATTCAGTTTGAAGAAGTCCTCGGAACATCGGTGTTGAT
TATAAGCATGATGAAACTGTTGGAGAACTTAGCAGAAGGCTTGCACATAGC
TGTGAAAATGCAAGTTCTTCTTGTGGATGATATTGGCAACATG
AGGTGTGGACTAATTACTCAGAGCCCCATTAAACACTGCAGCTACAGGA
5 ATAATTCTAGTAACAACCTCGTAATGATAACAGTTGCACGAGCAATTGGGGT
GGAAGATATTCATCGAGTAGAATTGATGTCAGATGAAGTAGGATGGAAAT
TGCTTTGAAGAGTATGAACATTAGCAAAGAAAGTGAAGTAGAAAACCTA
CGAGTTTAGGGGTTGACATTGTCGTTGTGGTGGCCTCCCCCTAGC
CTT

10

RG5 deduced polypeptide sequence (SEQ ID NO:135)

GGVGKTTLAQK?YNDHKIKGSFSKQAWICVSQQYSDISVLKEVRNIGVDYKHDET
VGELSRRLAIAVENASFFLVLDIWIQHEVWTNLLRAPLNTAATGIIIVTTRNDTVA
RAIGVEDIHRVELMSDEVGWKLKSMNISKESEVENLRVLGVDIVRLCGGLPLAL

15

RG7 polynucleotide sequence (SEQ ID NO:136)

GGTGGGGTTGGGAAGACAAACGGGCACAAGGAGGCAGTCCAATACCC
GACTTTTATTCA TAGAGAGATGACGAGTCTTATTTCTACTACTATAGGGA
GGATATTGGTTGCGCGAGACGATTCA TTGCGCGAAGGGATTCTATCCTT
20 CTTTTTTCCCGCGAAGACTTCGTTCCGGAGGACGGCTATATTCCCTTA
ATATTAGTCTAGCCCAGTCTAGGCCAACCATATGGCGATGCGGTAGACCT
CCCAGAGATAGATACTTGATCTTAGAGGATTACACGTTCAATGGTGGAA
ACTTAAGGAACCGGCTAAGAGTGACTAAACGGAAAAACCTATTCA
ATAGCCTCATCCGGTCGAGGCATTAAACAATCCATCCAATCCTTTCC
25 TTTGGTCTACTCTAATGATGTGCCCGTTGTTGGAATATCTCTTAT
ACCGACGATTATATGGGGATTGCCACTAGCGTTG

The above examples are provided to illustrate the invention but not to limit its scope. Other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference.

30

WHAT IS CLAIMED IS:

1. An isolated nucleic acid construct comprising an RG polynucleotide which encodes an RG polypeptide having at least 60% sequence identity to an RG polypeptide from an RG family selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, an RG4 polypeptide, an RG5 polypeptide, and an RG7 polypeptide.

5 2. The nucleic acid construct of claim 1, wherein the RG polynucleotide encodes an RG polypeptide comprising an leucine rich region (LRR).

10

3. The nucleic acid construct of claim 1, wherein the RG polynucleotide encodes an RG polypeptide comprising a nucleotide binding site (NBS).

15

4. The nucleic acid construct of claim 1, wherein the polynucleotide is a full length gene.

20

5. The nucleic acid construct of claim 1, wherein the further encodes a fusion protein.

25

6. The nucleic acid construct of claim 1, wherein the RG1 polypeptide is encoded by an RG1 polynucleotide sequence.

30

7. The nucleic acid construct of claim 6, wherein the RG1 polypeptide is encoded by a polynucleotide sequence selected from the group consisting of SEQ ID NO:1 (RG1A), SEQ ID NO:2 (RG1B), SEQ ID NO: 3 (RG1C), SEQ ID NO:4 (RG1D), SEQ ID NO:5 (RG1E), SEQ ID NO:6 (RG1F), SEQ ID NO:7 (RG1G), SEQ ID NO:8 (RG1H), SEQ ID NO:9 (RG1I), and SEQ ID NO:10 (RG1J).

35

8. The nucleic acid construct of claim 1, wherein the RG2 polypeptide is encoded by an RG2 polynucleotide sequence.

9. The nucleic acid construct of claim 8, wherein the RG2 polypeptide is encoded by a polynucleotide sequence selected from the group consisting of: SEQ ID NO:21 (RG2A);

SEQ ID NO:23 (RG2B); SEQ ID NO:25 (RG2C); SEQ ID NO:27 (RG2D); SEQ ID NO:29 (RG2E); SEQ ID NO:31 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:35 (RG2H); SEQ ID NO:37 (RG2I); SEQ ID NO:39 (RG2J); SEQ ID NO:41 (RG2K); SEQ ID NO:43 (RG2L); SEQ ID NO:45 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104 (RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W).

10. The nucleic acid construct of claim 1, wherein the RG3 polypeptide is encoded by
15 an RG3 polynucleotide sequence.

11. The nucleic acid construct of claim 10, wherein the RG3 polypeptide is encoded by
a polynucleotide sequence as set forth in SEQ ID NO:68.

20 12. The nucleic acid construct of claim 1, wherein the RG4 polypeptide is encoded by
an RG4 polynucleotide sequence.

13. The nucleic acid construct of claim 12, wherein the RG4 polypeptide is encoded by
a polynucleotide sequence as set forth in SEQ ID NO:69.

25 14. The nucleic acid construct of claim 1, wherein the RG5 polypeptide is encoded by
an RG5 polynucleotide sequence.

15. The nucleic acid construct of claim 14, wherein the RG5 polypeptide is encoded by
30 a polynucleotide sequence as set forth in SEQ ID NO:134.

16. The nucleic acid construct of claim 1, wherein the RG7 polypeptide is encoded by an RG7 polynucleotide sequence.

5 17. The nucleic acid construct of claim 16, wherein the RG7 polypeptide is encoded by a polynucleotide sequence as set forth in SEQ ID NO:136.

18. The nucleic acid construct of claim 1, further comprising a promoter operably linked to the RG polynucleotide.

10 19. The nucleic acid construct of claim 18, wherein the promoter is a plant promoter.

20. The nucleic acid construct of of claim 19, wherein the plant promoter is a disease resistance promoter.

15 21. The nucleic acid construct of claim 19, wherein the plant promoter is a lettuce promoter.

22. The nucleic acid construct of claim 18, wherein the promoter is a constitutive promoter.

20 23. The nucleic acid construct of claim 18, wherein the promoter is an inducible promoter.

25 24. The nucleic acid construct of claim 18, wherein the promoter is a tissue-specific promoter.

25. A nucleic acid construct comprising a promoter sequence from an RG gene linked to a heterologous polynucleotide.

30 26. A transgenic plant comprising a recombinant expression cassette comprising a promoter operably linked to an RG polynucleotide.

27. The transgenic plant of claim 26, wherein the plant promoter is a plant promoter.

28. The transgenic plant of claim 26, wherein the plant promoter is a viral promoter.

5 29. The transgenic plant of claim 26, wherein the plant promoter is a heterologous promoter.

30. The transgenic plant of claim 26, wherein the plant is lettuce.

10 31. The transgenic plant of claim 26, wherein the RG polynucleotide is selected from the group consisting of SEQ ID NO:1 (RG1A), SEQ ID NO:2 (RG1B), SEQ ID NO: 3 (RG1C), SEQ ID NO:4 (RG1D), SEQ ID NO:5 (RG1E), SEQ ID NO:6 (RG1F), SEQ ID NO:7 (RG1G), SEQ ID NO:8 (RG1H), SEQ ID NO:9 (RG1I), and SEQ ID NO:10 (RG1J).

15 32. The transgenic plant of claim 26, wherein the RG polynucleotide is selected from the group consisting of SEQ ID NO:21 (RG2A); SEQ ID NO:23 (RG2B); SEQ ID NO:25 (RG2C); SEQ ID NO:27 (RG2D); SEQ ID NO:29 (RG2E); SEQ ID NO:31 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:35 (RG2H); SEQ ID NO:37 (RG2I); SEQ ID NO:39 (RG2J); SEQ ID NO:41 (RG2K); SEQ ID NO:43 (RG2L); SEQ ID NO:45 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104 (RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W).

30 33. The transgenic plant of claim 26, wherein the RG polynucleotide is selected from the group consisting of SEQ ID NO:68 (RG3) and SEQ ID NO:69 (RG4).

34. The transgenic plant of claim 26, wherein the RG polynucleotide comprises a sequence as set forth in SEQ ID NO:134 (RG5).

5 35. The transgenic plant of claim 26, wherein the RG polynucleotide comprises a sequence as set forth in SEQ ID NO:136 (RG7).

10 36. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG1 polypeptide selected from the group consisting of SEQ ID NO:11 (RG1A), SEQ ID NO:12 (RG1B), SEQ ID NO: 13 (RG1C), SEQ ID NO:14 (RG1D), SEQ ID NO:15 (RG1E), SEQ ID NO:16 (RG1F), SEQ ID NO:17 (RG1G), SEQ ID NO:18 (RG1H), SEQ ID NO:19 (RG1I), and SEQ ID NO:20 (RG1J).

15 37. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG2 polypeptide selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W).

25 38. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG3 polypeptide with a sequence as set forth by SEQ ID NO:138.

30 39. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG4 polypeptide with a sequence as set forth by SEQ ID NO:139.

40. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG5 polypeptide with a sequence as set forth by SEQ ID NO:135.

5 41. A method of enhancing disease resistance in a plant, the method comprising introducing into the plant a recombinant expression cassette comprising a promoter functional in the plant and operably linked to an RG polynucleotide sequence.

42. The method of claim 41, wherein the plant is a lettuce plant.

10 43. The method of claim 41, wherein the RG polynucleotide encodes an RG polypeptide selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); 15 SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W).

20 44. The method of claim 41, wherein the RG polynucleotide encodes an RG polypeptide selected from the group consisting of SEQ ID NO:138 (RG3); SEQ ID NO:139 (RG4); and SEQ ID NO:135 (RG5).

45. The method of claim 41, wherein the promoter is a tissue-specific promoter or a plant disease resistance promoter.

46. The method of claim 41, wherein the promoter is a constitutive promoter or an inducible promoter.

5 47. A method of detecting RG resistance genes in a nucleic acid sample, the method comprising:

contacting the nucleic acid sample with an RG polynucleotide to form a hybridization complex; and,

wherein the formation of the hybridization complex is used to detect the RG resistance gene in the nucleic acid sample.

10

48. The method of claim 47, wherein the RG polynucleotide is an RG1 polynucleotide.

49. The method of claim 47, wherein the RG polynucleotide is an RG2 polynucleotide.

15

50. The method of claim 47, wherein the RG polynucleotide is an RG3 polynucleotide, an RG4 polynucleotide, an RG5 polynucleotide or an RG7 polynucleotide.

51. The method of claim 47, wherein the RG resistance gene is amplified prior to the step of contacting the nucleic acid sample with the RG polynucleotide.

20

52. The method of claim 51, where the RG resistance gene is amplified by the polymerase chain reaction.

53. The method of claim 47, wherein the RG polynucleotide is labeled.

25

54. An RG polypeptide having at least 60% sequence identity to a polypeptide selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, an RG4 polypeptide, an RG5 polypeptide, and an RG7 polypeptide.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/00615

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :Please See Extra Sheet.

US CL :435/6, 91.2, 418, 419; 530/350; 536/23.1, 23.6, 24.1; 800/205

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 91.2, 418, 419; 530/350; 536/23.1, 23.6, 24.1; 800/205

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PARAN et al. Development of Reliable PCR-Based Markers Linked to Downy Mildew Resistance Genes in Lettuce. Theor. Appl. Genet. 1993. Vol. 85, No. 8, pages 985-993, see entire article.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54
Y	KESSELI et al. Analysis of a Detailed Genetic Linkage Map of <i>Lactuca sativa</i> (Lettuce) Constructed From RFLP and RAPD Markers. Genetics. April 1994. Vol. 136, No. 4, pages 1435-1446, see entire document.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54
Y	MICHELMORE, RW. Isolation of Disease Resistance Genes from Crop Plants. Current Opinion in Biotechnology. 1995. Vol. 6, No. 2, pages 145-152, see entire document.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54

Further documents are listed in the continuation of Box C. See patent family annex.

•	Special categories of cited documents:	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A	document defining the general state of the art which is not considered to be of particular relevance		
B	earlier document published on or after the international filing date	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O	document referring to an oral disclosure, use, exhibition or other means	*A*	document member of the same patent family
P	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

14 MARCH 1998

Date of mailing of the international search report

13 APR 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PHUONG BUI

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/00615

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim N .
Y	PARAN et al. Recent Amplification of Triose Phosphate Isomerase Related Sequences in Lettuce. Genome. 1992. Vol. 35, No. 4, pages 627-635, see entire document.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54
Y	PARAN et al. Identification of Restriction Fragment Length Polymorphism and Random Amplified Polymorphic DNA markers linked to Downy Mildew Resistance Genes in Lettuce, Using Near-Isogenic Lines. Genome. 1991. Vol. 34, No. 6, pages 1021-1027, see entire document.	1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/00615

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: 7, 9, 11, 13, 15, 17, 31-40, 43-44 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

these claims are drawn to numerous sequences identified by SEQ ID NOs. However, since no computer readable form was submitted, no meaningful search could be carried out.

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application N .

PCT/US98/00615

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A01H 1/00; C07H 21/04; C07K 14/00; C12N 5/04, 5/10; C12P 19/34; C12Q 1/68